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ABSTRACT	  
	  
Expression	   of	   the	   cellular	   prion	   protein	   (PrPC)	   from	   the	  PRNP	   gene	   is	   crucial	   for	   the	  
development	   of	   a	   group	   of	   fatal	   neurodegenerative	   disorders	   called	   prion	   diseases.	  
During	   prion	   infection	   a	   misfolded	   protein	   homologue	   of	   PrPC,	   PrPSc	   causes	   further	  
misfolding	   on	   interaction	   with	   native	   PrPC	   molecules.	   PrPSc	   is	   highly	   resistant	   to	  
proteinase	   K	   and	   aggregation	   of	   this	   protein	   is	   considered	   a	   hallmark	   of	   infection.	  
Sheep	  are	  considered	  a	  model	  of	  natural	  infection	  and	  susceptibility	  to	  scrapie	  in	  sheep	  
is	  defined	  by	  polymorphisms	  in	  the	  PRNP	  gene.	  It	  is	  still	  not	  fully	  understood	  how	  these	  
polymorphisms	  regulate	  the	  conversion	  process	  or	  which	  other	  co-­‐factors	  are	  involved.	  
One	  such	  factor	  may	  be	  the	  truncation	  of	  PrPC	  via	  proteolytic	  processing	  in	  the	  form	  of	  
two	  main	   cleavage	   events,	   known	   as	  α-­‐	   and	  β-­‐cleavage.	   	   In	   sheep	  α-­‐cleavage	   cuts	   at	  
amino	  acid	  115,	   creating	   two	   truncated	  proteins	  C1	  and	  N1	  and	   represents	   the	  main	  
cleavage	   event	   in	   healthy	   brain.	  β-­‐Cleavage	   creates	   a	   longer	   C-­‐terminal	   fragment,	   C2	  
and	   corresponding	   N-­‐terminal	   fragment	   N2,	   cutting	   around	   amino	   acid	   92	   in	   sheep.	  
Truncated	  forms	  of	  PrPC	  have	  been	  shown	  to	  represent	  around	  50	  %	  of	  total	  residual	  
PrP	  in	  brain	  and	  may	  be	  an	  important	  determinant	  of	  disease	  through	  both	  decreasing	  
the	   amount	   of	   full	   length	   PrPC	   available	   for	   conversion	   and	   through	   functions	  
associated	   with	   the	   truncated	   fragments.	   The	   research	   presented	   has	   shown	   that	  
increased	   production	   of	   an	   α-­‐cleavage	   fragment	   C1	   in	   brain	   is	   associated	   with	   TSE	  
resistant	   genotype	   ARR/ARR,	   while	   the	   presence	   of	   C2	   fragment	   is	   affiliated	   with	  
scrapie	  susceptible	  PRNP	   genotypes	   in	  brain.	  There	  was	  no	  difference	   in	   the	   levels	  of	  
full	   length	   PrPC	   in	   these	   genotypes	   suggesting	   that	   PrP	   expression	   does	   not	   directly	  
correlate	   to	   susceptibility	   in	   this	  model.	   To	   assess	   if	   PrPC	   fragments	   could	   affect	   the	  
conversion	   during	   disease	   in-­‐vitro	   fibrillisation	   assays	   were	   performed	   using	   novel	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truncated	   recombinant	   proteins.	   These	   truncated	   proteins,	   although	   not	   thought	   to	  
convert	   to	  PK	  resistant	  PrPSc	  during	  disease,	  can	  form	  amyloid	   fibrils.	  However,	   these	  
fibrils	   appear	   to	  be	   less	  neurotoxic	  when	   compared	   to	   fibrils	  produced	  by	   full	   length	  
PrPC.	   Only	   the	   truncated	   fragments	   derived	   from	   the	   ARR	   allele	   inhibit	   in-­‐vitro	  
fibrillisation	  of	   other	   allelic	  PrPC	   variants.	   Furthermore,	   treatment	  of	   infected	   cells	   in	  
culture	  with	  recombinant	  C1ARR	  led	  to	  a	  decrease	  in	  the	  formation	  of	  disease	  associated	  
PrPSc.	  In	  conclusion,	  genetic	  variations	  in	  levels	  of	  PrP	  truncated	  fragments	  may	  add	  to	  
the	   complexity	   of	   genetic	   determinants	   of	   prion	   disease.	   In	   parallel	   with	  
polymorphism-­‐dependant	   conversion	   abilities,	   varying	   α-­‐cleavage	   of	   ovine	   PrPC	  may	  
help	  to	  explain	  genetic	  resistance	   in	  sheep.	  The	   inhibitory	  effects	  of	  C1,	   illustrated	   in-­‐
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ROS	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SD	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   Tris	  Borate	  EDTA,	  
TBS	  (T)	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   Variant	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CHAPTER	  1	  	  
INTRODUCTION	  
	  
1.1	  AN	  OVERVIEW	  OF	  TSE	  DISEASE	  
1.1.1	  General	  Introduction	  to	  TSE	  diseases	  
TSE's	   (transmissible	   spongiform	   encephalopathy)	   or	   prion	   diseases	   are	   a	   group	   of	  
neurodegenerative	  disorders,	  which	  are	  incurable	  and	  eventually	  fatal.	  	  The	  first	  TSE	  to	  be	  
identified	  around	  250	  years	  ago	  was	  scrapie	  in	  sheep	  (also	  known	  as	  classical	  scrapie),	  but	  
these	   diseases	   are	   now	   known	   to	   affect	   a	   wide	   range	   of	   mammals	   from	   ruminants	   to	  
humans	   in	   the	   form	   of	   BSE	   (bovine	   spongiform	   encephalopathy)	   in	   cattle,	   CJD	  
(Creutzfeldt-­‐Jakob	  disease)	  in	  humans	  (Harris	  1999)	  and	  CWD	  (chronic	  wasting	  disease)	  
in	  deer	  and	  elk	  (Williams	  and	  Young	  1992)	  (Table	  1.1)	  Genetic,	  sporadic	  or	   infectious	   in	  
nature,	   these	  diseases	  have	  characteristically	   long	  preclinical	   incubation	  periods	  ranging	  
from	   months	   to	   years.	   Symptoms	   vary	   from	   animal	   to	   animal	   and	   also	   depend	   on	   the	  
strain	  of	  infectious	  agent	  but	  generally	  include	  ataxia	  and	  loss	  of	  neuronal	  function,	  which	  
lead	   to	   impairment	   in	   behavior	   (Crozet,	   Beranger	   et	   al.	   2008).	   The	  BSE	   epidemic	   in	  UK	  
cattle	   of	   the	   late	   1980’s-­‐1990’s	   highlighted	   the	   potential	   for	   these	   diseases	   to	   cross	   the	  
species	   barrier	   and	   emphasised	   the	   threat	   to	   human	   health	   in	   the	   form	   of	   variant	   CJD	  
(vCJD).	  The	  realisation	  that	  little	  was	  known	  about	  the	  agent	  of	  the	  disease,	  transmission,	  
pathogenesis	  and	  hence	  how	  best	   to	   implement	  preventative	  strategies	   led	   to	  a	  surge	   in	  
scientific	   research.	   Now	   with	   a	   potential	   threat	   of	   CWD	   in	   North	   America	   and	   Canada	  
nearly	  30	  years	  on,	  there	  are	  still	  unknowns	  and	  questions	  to	  be	  answered	  regarding	  the	  
prion	  protein	  along	  with	  mechanisms	  involved	  in	  disease	  development.	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Table	  1.1	  –	  Summary	  of	  TSE	  diseases,	  including	  clinical	  symptoms,	  characteristic	  pathology	  and	  
molecular	  PrPSc	  profiles	  (Pearson,	  Wyatt	  et	  al.	  1992,	  Cardone,	  Liu	  et	  al.	  1999,	  Collins,	  McLean	  
et	  al.	  2001,	  Casalone,	  Zanusso	  et	  al.	  2004,	  Haïk,	  Peoc'h	  et	  al.	  2004,	  Williams	  2005,	  Capobianco,	  
Casalone	   et	   al.	   2007,	   Konold,	   Davis	   et	   al.	   2007,	   Martin,	   Jeffrey	   et	   al.	   2009,	   Balkema-­‐
Buschmann,	  Fast	  et	  al.	  2011). 
	  
1.1.2	  The	  prion	  hypothesis	  and	  conversion	  
There	   are	   two	   main	   conflicting	   opinions	   as	   to	   the	   nature	   of	   the	   infectious	   agent	  
responsible	  for	  the	  spread	  of	  TSEs.	  Initially	  it	  was	  thought	  to	  be	  a	  small,	  ‘slow	  virus’	  due	  to	  
features	  such	  as	  long	  incubation	  periods	  and	  resistance	  to	  high	  temperatures	  and	  extreme	  
pH	  conditions.	  This	  resistance	  to	  harsh	  conditions	  was	  specifically	  associated	  with	  a	  small	  
amount	   of	   purified	   infective	   agent,	   which	   for	   instance	   could	   represent	   a	   bacteriophage	  
(Chesebro	  2003).	  However,	   this	   ‘virus’	  was	   also	   resistant	   to	   ionizing	   radiation	  and	  ultra	  
violet	   light,	  which	  would	   suggest	   a	   lack	   of	   nucleic	   acids.	  Moreover,	   the	   extremely	   small	  
predicted	   molecular	   weight	   would	   render	   the	   ‘virus’	   unable	   to	   carry	   the	   coding	  
information	  required	  for	  replication	  (Alper,	  Haig	  et	  al.	  1966).	  	  Continued	  attempts	  to	  view	  
the	  infectious	  agent	  by	  microscopy	  were	  unsuccessful	  leading	  to	  the	  development	  of	  novel	  
hypotheses	  for	  the	  nature	  of	  the	  agent	  (Gibbons	  and	  Hunter	  1967).	  	  
	  
The	  now	  widely	  accepted	  prion	  or	  ‘protein	  only’	  hypothesis	  states	  that	  the	  agent	  is	  void	  of	  
nucleic	   acids	   and	   is	   instead	   a	   protein-­‐like	   particle	   inactivated	   by	   Proteinase	   K	   (PK),	  
phenol,	  formalin	  and	  urea	  (Pattison	  1965,	  Prusiner,	  McKinley	  et	  al.	  1981,	  Prusiner	  1998)	  
This	   prion,	   also	   known	   as	   PrPSc	  is	   a	   conversion	   product	   of	   a	   cellular	   form	   of	   the	   prion	  
protein	  (PrPC),	  which	  is	  encoded	  by	  the	  PRNP	  gene.	  PrPC	  is	  normally	  expressed	  in	  the	  brain	  
and	   other	   parts	   of	   the	   central	   nervous	   system	   (CNS)	   and	   at	   lower	   levels	   in	   peripheral	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tissues.	   	   It	   is	   thought	   that,	   on	   contact	   with	   cellular	   PrPC,	   misfolded	   PrPSc	   induces	   a	  
structural	  shift	  from	  a	  primarily	  alpha	  helical	  PrPC	  structure	  to	  one	  rich	  in	  beta	  sheet,	  the	  
latter	   forming	   aggregates	   that	   accumulate	   in	   the	   brain	   over	   the	   course	   of	   the	   disease	  
(Linden,	  Martins	  et	  al.	  2008).	  It	  has	  been	  concluded	  from	  experiments	  with	  PrPC	  null	  mice	  
that	  the	  presence	  of	  cellular	  PrP	  is	  essential	  to	  propagate	  PrPSc	  (Weissmann,	  Bueler	  et	  al.	  
1993).	  	  The	  conversion	  of	  PrPC	  to	  PrPSc	  as	  a	  process	  is	  still	  not	  fully	  understood	  although,	  it	  
is	   thought	   to	   involve	   distinct	   chronological	   steps,	   starting	   with	   oligomerisation	   of	   PrPC	  
(Rigter,	  Priem	  et	  al.	  2009).	  	  
	  
Other	   factors	  may	   be	   involved	   in	   the	   conversion	   of	   PrPC	   to	   PrPSc,	   including	   the	   cellular	  
localisation	  of	  PrPC	  such	  as	  an	  increased	  concentration	  of	  PrPC	  at	  the	  cell	  membrane.	  High	  
concentrations	   of	   PrPC	   at	   the	   cell	  membrane	   can	   cause	   the	   protein	   to	   form	   dimers	   and	  
activate	  a	  structural	   shift	   towards	   the	   formation	  of	  β-­‐sheet	   (Elfrink,	  Ollesch	  et	  al.	  2008).	  
Reduction	  in	  pH	  and	  increased	  salt	  concentration	  can	  also	  cause	  spontaneous	  conversion	  
of	  recombinant	  PrPC	  from	  a	  predominantly	  alpha	  helix	  structure	  to	  one	  rich	  in	  β-­‐sheet	  –	  a	  
process	  which	   is	  reversible	  when	  conditions	  are	  returned	  to	  normal	  (Zhou	  2009).	  There	  
are	   two	   main	   accepted	   models	   of	   conversion:	   the	   nucleation	   model	   and	   the	   template	  
assisted	  model.	   The	   first	   suggests	   that	   both	   PrPC	   and	   PrPSc	   exist	   side	   by	   side	  while,	   the	  
latter	   indicates	   that	   PrPC	   and	   PrPSc	   can	   form	   heterodimers	   that	   go	   on	   to	   convert	   into	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1.1.3	  Acquisition	  of	  disease	  
TSEs	  can	  be	  transmitted	  from	  animal	  to	  animal	  or	  from	  the	  environment	  by	  direct	  feeding	  
of	   infected	   animal	   matter,	   by	   ingesting	   the	   infectious	   agent	   from	   the	   environment,	   by	  
uptake	   through	   broken	   or	   damaged	   skin	   (van	   Keulen,	   Bossers	   et	   al.	   2008),	   maternally	  
(Foster,	  McKelvey	  et	  al.	  1992)	  and	  by	  iatrogenic	  route	  for	  example,	  by	  the	  transfer	  of	  blood	  
products,	   transplanted	   tissue	   and	   peptide	   hormones	   (Mabbott,	   Farquhar	   et	   al.	   1998).	  	  
Infection	   can	   also	   be	   experimentally	   transmitted	   by	   inoculation	   with	   tissue	   from	   an	  
affected	  host	  (CHANDLER	  and	  FISHER	  1963).	  However,	  sporadic	  diseases	  are	  considered	  
the	   most	   common	   in	   humans,	   such	   as	   CJD	   with	   no	   exposure	   to	   known	   risk	   factors	  
(Harries-­‐Jones,	   Knight	   et	   al.	   1988,	   Will	   1993).	   Inherited	   forms	   in	   humans	   include	  
Gerstmann-­‐Straüssler-­‐Scheinker	  syndrome	  (GSS),	   familial	  CJD	  and	  fatal	  familial	   insomnia	  
(FFI).	  By	  definition	  these	  prion	  diseases	  are	  associated	  with	  mutations	   in	  the	  PRNP	  gene	  
but	  perhaps	  also	  involve	  further	  unknown	  genetic	  risk	  factors	  (Hsiao,	  Baker	  et	  al.	  1989).	  
	  
1.1.4	  The	  species	  barrier	  and	  strains	  
	  There	  is	  often	  a	  species	  barrier	  effect	  when	  infectious	  PrPSc	  from	  one	  species	  is	  introduced	  
to	   another	   both	   in	   nature	   and	   under	   experimental	   conditions.	   For	   example,	   there	   have	  
been	  no	  reported	  cases	  of	  scrapie	   transmission	   to	  humans	  (Moore,	  Vorberg	  et	  al.	  2005).	  
Furthermore,	   although	   the	   feeding	   of	   BSE	   contaminated	   meat	   and	   bone	   meal	   led	   to	  
infection	   of	   cats	   and	   the	   development	   of	   feline	   spongiform	   encephalopathy	   (FSE),	   there	  
has	  been	  no	   reported	   infection	  of	   dogs	   fed	  on	   a	   very	   similar	  diet.	   In	   early	   experimental	  
transmission	   experiments	   rabbits	  were	   shown	   to	   be	   resistant	   to	   intracranial	   challenges	  
with	   scrapie	   and	  murine	   adapted	   scrapie	   strains	   (Gibbs	   and	   Gajdusek	   1973).	   However,	  
recently	   adaptation	   of	   scrapie	   using	   in	   vitro	   conversion	   assays	   has	   led	   to	   successful	  
infection	   of	   rabbits	   (Chianini,	   Fernandez-­‐Borges	   et	   al.	   2012).	   Along	   with	   complete	  
resistance	   experimental	   transmission	   experiments	   have	   shown	   that	   the	   species	   barrier	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can	   also	   lead	   to	   disease	   adaptations	   such	   as	   longer	   incubation	   periods,	   altered	  
presentation	  of	   clinical	   symptoms	  and	  different	  pathogenesis	   (Bruce,	  Chree	  et	   al.	   1994).	  
This	  barrier	  may	  be	  explained	  by	  differences	  in	  the	  conformation	  or	  sequence	  of	  the	  host	  
PrPC	  protein,	   which	  may	   inhibit	   or	   alter	   interactions	   with	   the	   infecting	   PrPSc	  molecules.	  
Amino	  acid	  polymorphisms	  in	  the	  host	  PrPC	  can	  also	  create	  a	  barrier-­‐like	  effect	  within	  in	  
the	   same	   species,	   best	   illustrated	   by	   genetic	   resistance	   to	   classical	   scrapie	   in	   sheep	  
(discussed	  in	  more	  detail	  in	  section	  1.2.2).	  	  
On	   transmission	   of	   naturally	   occurring	   scrapie	   isolates	   to	   laboratory	   mice,	   numerous	  
different	  strains	  of	  scrapie	  have	  been	  identified	  which	  present	  with	  different	  clinical	  signs	  
or	  pathologies,	   varying	   incubation	   times	   and	   sometimes	  distinct	  PrP	  glycoform	  patterns	  
created	  by	  different	   ratios	  of	   un-­‐,	  mono-­‐	  or	  di-­‐glycosylated	   forms	  of	  PrPSc	  or	   sizes	  of	  PK	  
resistant	   fragments	   (Somerville	   1999,	   Somerville	   2002).	   	   Along	   with	   different	  
characteristics	   on	   transmission,	   strains	   also	   display	   varying	   stability	   and	   resistance	   to	  
heat	   and	   pH	   (Somerville	   2002).	   Strain	   characteristics	   may	   be	   influenced	   both	   by	   the	  
infectious	  agent	  and	  the	  host	  protein	  and	  as	  a	  result	  strains	  can	  present	  with	  contrasting	  
phenotypes	   in	  different	   laboratory	  mouse	   lines	  or	   the	  phenotype	  can	  alter	  on	  continued	  
passage.	   One	   explanation	   for	   changes	   in	   strain	   phenotype	   is	   the	   presence	   of	   multiple	  
stains	   or	   co-­‐infections,	   such	   as	   classical	   scrapie	   and	   atypical	   scrapie	   (Mazza,	   Iulini	   et	   al.	  
2010).	  	  This	  hypothesis	  assumes	  that	  under	  diverse	  conditions,	  for	  example	  in	  a	  host	  with	  
different	  template	  PrPC	  protein	  and	  cellular	  co-­‐factors,	  different	  strains	  become	  dominant	  
or	  progress	  at	  a	  faster	  rate	  (Somerville	  2002).	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1.1.5	  Atypical	  scrapie	  
Atypical	  scrapie	  strain	  primarily	  causes	  disease	  in	  sheep	  of	  classically	  resistant	  genotypes	  
(discussed	  in	  section	  1.2.2),	  such	  as	  ARR/ARR.	  This	  strain	  was	  identified	  through	  a	  distinct	  
pathology	  (Benestad,	  Sarradin	  et	  al.	  2003)	  and	  biochemical	  signature	  by	  immunoblotting.	  
Atypical	   scrapie	  has	  been	   shown	   to	  be	   infectious	  under	  experimental	   conditions,	  having	  
been	   successfully	   transmitted	   to	   sheep	   and	   porcine	   and	   ovine	   transgenic	   mice	   on	  
intracerebral	   and	   oral	   inoculation	   (Simmons,	   Konold	   et	   al.	   2007,	   Espinosa,	   Herva	   et	   al.	  
2009,	   Andréoletti,	   Orge	   et	   al.	   2011,	   Simmons,	   Moore	   et	   al.	   2011).	   However,	   natural	  
acquisition	   of	   the	   agent	   is	   still	   under	   debate.	   The	   relatively	   small	   number	   of	   isolated	  
natural	  cases	  has	  led	  some	  to	  believe	  that	  atypical	  scrapie	  is	  a	  sporadic	  disease,	  similar	  to	  
CJD	  in	  humans,	  only	  now	  recognised	  due	  to	  the	  large	  scale	  genetic	  screening	  of	  sheep	  and	  
wide	  spread	  recognition	  of	  typical	  clinical	  signs.	  
	  
1.1.6	  Pathogenesis	  and	  pathology	  
Oral	  ingestion	  is	  thought	  to	  be	  the	  most	  common	  natural	  route	  of	  infection	  of	  sheep	  with	  
natural	   scrapie.	   The	   infectious	   agent	   is	   thought	   to	   be	   transported	   though	   the	   intestinal	  
epithelia	  at	   the	  Peyer’s	  patches,	  via	  M	  cell	  or	  dendritic	   cells	   to	   lymphoid	   follicles,	  where	  
PrPSc	  accumulates	  on	  follicular	  dendritic	  cells	  (Sales	  2006,	  van	  Keulen,	  Bossers	  et	  al.	  2008).	  
In	  mice	   follicular	   dendritic	   cells	   play	   an	   important	   role	   in	   the	   replication	   of	   PrPSc	  in	   the	  
lymphoid	   tissue	   (Bruce,	   Brown	   et	   al.	   2000).	   From	   the	   lymph	   reticular	   system	   the	  
infectious	   agent	   is	   transported	   to	   the	   enteric	   nervous	   system	   and	   finally	   the	   central	  
nervous	   system,	  where	   PrPSc	  again	   accumulates,	   evading	   clearance	   by	   the	   host	   immune	  
system	  throughout	  (van	  Keulen,	  Bossers	  et	  al.	  2008).	  	  
	  
CHAPTER 1 - INTRODUCTION 
	   8	  
PrPSc	   protein	   aggregation	   in	   the	   brain	   is	   considered	   the	   hallmark	   of	   prion	   disease,	  
illustrated	   in	  Figure	  1.1.	  However,	   levels	   of	  PrPSc	  are	  not	   always	   correlated	  with	  disease	  
pathogenesis	   (Piccardo,	   Manson	   et	   al.	   2007).	   Histology	   at	   post	   mortem	   also	   normally	  
reveals	   vacuolation	   (Figure	   1.1)	   and	   astrogliosis	   in	   the	   CNS	   (Kuczius,	   Koch	   et	   al.	   2007,	  
Linden,	   Martins	   et	   al.	   2008).	   The	   pattern	   of	   pathology	   is	   often	   strain	   and	   species	  
dependent	   (Ligios,	   Jeffrey	   et	   al.	   2002).	   Symptoms	   are	   also	   host	   dependent	   and	   vary	  
according	  to	  species	  and	  strain	  of	  disease	  (Crozet,	  Beranger	  et	  al.	  2008).	  
 







1.1.7	  Biochemical	  PrPSc	  profiles	  in	  scrapie	  
Although,	   PrPSc	  detection	   in	   the	   brain	   by	   IHC	   is	   though	   to	   be	   one	   of	   the	  most	   sensitive	  
methods	   (Grassi	  2002)	   it	   is	  normally	  used	   in	   conjunction	  with	   immunoblotting	   to	   allow	  
for	  molecular	  profiling	  of	  PrPSc.	  	  Detection	  of	  PrPSc	  by	  immunoblotting	  relies	  on	  the	  use	  of	  
PK	   which	   degrades	   cellular	   PrPC	   and	   cleaves	   misfolded	   PrPSc	   to	   leave	   a	   remaining	   PK	  
resistant	  core	  fragment.	  	  As	  PrPC	  and	  hence	  PrPSc	  are	  present	  in	  the	  brain	  in	  three	  different	  
Infected	  Uninfected	  
Figure	   1.1	   –	   PrPSc	   deposition	   and	   vacuolation	   in	   clinical	   scrapie	   infection	   shown	   by	  
immunohistochemistry.	   Magnification	   of	   the	   thalamus	   from	   an	   uninfected	   and	  
experimentally	   scrapie	   (SSBP/1)	   infected	   sheep	   at	   the	   clinical	   stage	   of	   disease.	   PrPSc	  
deposition	  (brown	  staining,	  black	  arrows)	  and	  vacuolation	  (red	  arrows)	  are	  highlighted.	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forms,	  un-­‐,	  mono-­‐	  and	  di-­‐glycosylated	  (see	  section	  	  1.3.1)	  this	  creates	  a	  three	  band	  pattern	  
in	   classical	   scrapie	   (Figure	   1.2).	   	   Atypical	   scrapie	   can	   be	   distinguished	   from	   classical	  
scrapie	  by	  a	  distinct	  biochemical	  signature of two additional lower molecular weight bands of 





1.1.7	  Prion	  therapeutics	  
There	  is	  currently	  no	  preventative	  therapy,	  treatment	  or	  cure	  for	  prion	  diseases.	  Although	  
the	   spread	  of	   disease	  within	   the	  periphery	   could	  be	  prevented	  using	   immunoregulatory	  
mechanisms,	   this	   approach	   is	   ineffective	   after	   the	   onset	   of	   clinical	   symptoms	   and	   once	  
infection	   has	   passed	   through	   the	   blood-­‐brain	   barrier	   (Wisniewski,	   Prelli	   et	   al.	   2007,	  
Wisniewski	  and	  Goni	  2012).	   	   Some	  pharmaceuticals,	  which	  showed	  promising	   results	   in	  
initial	  cell	  culture	  and	  animal	  studies	  such	  as	  the	  anticoagulant	  Pentosan	  polysulfate,	  did	  
not	  have	  desired	  effects	  in	  clinical	  trials	  (Dealler	  and	  Rainov	  2003,	  Stewart,	  Rydzewska	  et	  
al.	   2008).	   Newer	   potential	   therapeutics	   such	   as	   Astemizole,	   currently	   used	   in	   the	  
treatment	  of	  rheumatoid	  arthritis	  and	  monocationic	  phenyl-­‐furan-­‐benzimidazole	  (DB772)	  
decrease	  PrPSc	  accumulation	  in	  both	  cell	  culture	  and	  mouse	  models	  and	  increase	  survival	  
time	   in	   the	   latter	   (Stanton,	   Schneider	   et	   al.	   2012,	  Karapetyan,	   Sferrazza	   et	   al.	   2013)	  but	  
Figure	  1.2.	  –	  Typical	  biochemical	  profile	  of	  PK	  
resistant	  PrPSc	  in	   scrapie	  by	   immunoblotting.	  
Diagrammatic	  representation	  of	  Western	  blot	  
profile	  of	  PrPSc	  in	  the	  brain	  after	  PK	  treatment	  
in	  both	  classical	  and	  atypical	  scrapie.	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have	  yet	  to	  be	  taken	  to	  clinical	  trials.	  Anti-­‐PrP	  antibodies	  have	  also	  been	  shown	  to	  block	  
infection	   and	   reduce	   PrPSc	   accumulation	   in	   cell	   culture	   when	   treated	   post	   infection	  
(Perrier,	  Solassol	  et	  al.	  2004,	  Pankiewicz,	  Prelli	  et	  al.	  2006).	  Treatment	  with	  antibody	  post	  
infection	   in	   murine	   models	   also	   had	   a	   positive	   effect	   on	   survival	   times	   and	   PrPSc	  
accumulation,	   both	   in	   the	   CNS	   and	   in	   peripheral	   tissues.	   However,	   this	   effect	   was	   not	  
observed	   if	   treatment	  was	   started	   after	   the	   onset	   of	   clinical	   signs	   (White,	   Enever	   et	   al.	  
2003).	   This	   illustrates	   what	   could	   be	   considered	   the	   biggest	   challenge	   in	   regard	   to	   the	  
therapeutic	  treatment	  of	  disease.	  Without	  an	  early	  screening	  and	  detection	  systems	  these	  
diseases	  will	  go	  unnoticed	  until	  the	  onset	  of	  neurological	  clinical	  symptoms,	  at	  which	  point	  
infection	  is	  systemic	  and	  without	  doubt	  more	  difficult	  to	  treat.	  
	  
1.1.8	  In-­‐vitro	  models	  of	  conversion	  
Animal	  infection	  experiments	  and	  bioassays	  are	  considered	  the	  most	  sensitive	  method	  to	  
study	   infectivity,	   TSE	   strains	   and	   susceptibility	   but	   these	   experiments	   are	   long	   and	  
therefore	  costly.	   It	   is	  also	  difficult	   to	   identify	  changes	  and	   interactions	   involving	   the	  PrP	  
protein	   on	   a	  molecular	   level.	   For	   these	   reasons,	   in	  vitro	   conversion	   reactions	  have	  been	  
developed,	   which	  monitor	   the	   formation	   of	   either	   amyloid	   fibrils	   or	   PK	   resistant	   PrPSc.	  
These	   reactions	   usually	   use	   a	   small	   amount	   of	   PrPSc	   as	   a	   seed	   along	   with	   either	  
recombinant	   PrP	   protein	   or	   the	   PrPC	   contained	   in	   uninfected	   brain	   homogenate	   as	   a	  
template,	   which	   is	   then	   converted	   on	   interaction	   with	   the	   PrPSc	   seed.	   In	   in	   vitro	  
fibrillisation	  reactions	  amyloid	  fibrils	  can	  be	  formed	  spontaneously	  from	  recombinant	  PrP	  
in	   the	   absence	   of	   a	   PrPSc	  seed.	   These	   fibrillisation	   reactions	   are	   performed	   under	   semi-­‐
denaturing	  conditions	  to	  aid	  structural	  unfolding/refolding,	  with	  continuous	  shaking	  and	  
in	  the	  presence	  of	  Thioflavin	  T	  (ThT),	  an	  amyloid-­‐binding	  fluorescent	  dye.	  The	  inclusion	  of	  
ThT	   allows	   for	   the	   real-­‐time	   kinetics	   of	   the	   reaction	   to	   be	  monitored	   in	   addition	   to	   the	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analysis	  of	  the	  fibrils	  formed	  during	  the	  reaction,	  such	  as	  their	  toxicity	  to	  cells	   in	  culture	  
(Novitskaya,	  Bocharova	  et	  al.	  2006).	  	  
	  
The	   cell-­‐free	   conversion	   assay	   has	   been	   shown	   to	   mimic	   polymorphism	   dependent	  
resistance	  to	  classical	  scrapie	  and	  BSE	  as	  well	  as	  the	  species	  barrier	  and	  is	  considered	  to	  
simulate	  in	  vivo	  conversion	  efficiencies	  (Kocisko,	  Priola	  et	  al.	  1995,	  Kirby,	  Goldmann	  et	  al.	  
2006,	   Eiden,	   Soto	   et	   al.	   2011).	   This	   reaction	   uses	   radio	   labelled	   recombinant	   PrP	   as	   a	  
template	  and	  a	  brain	  derived,	  purified	  PrPSc	  seed	  and	  measures	  the	  levels	  of	  PK	  resistant	  
template	  through	  autoradiography	  (Kocisko,	  Come	  et	  al.	  1994).	  
	  
While	   both	   these	   assays	   strive	   to	   shed	   light	   on	   the	   mechanisms	   of	   conversion	   and	   the	  
importance	  of	  PRNP	  sequence,	  recently	  other	  assays	  have	  been	  developed	  with	  the	  goal	  of	  
replacing	  costly	  bioassays	  such	  as	  the	  quaking	  induced	  conversion	  (QuIC)	  and	  the	  protein	  
misfolding	  cyclic	  amplification	  (PMCA).	  	  The	  QuIC	  is	  performed	  with	  intermittent	  shaking	  
in	   the	  presence	  of	  ThT	  and	  recombinant	  PrP	  template.	  The	  PMCA	  uses	  similar	  repetitive	  
cycling	  although	  the	  shaking	  step	  is	  replaced	  with	  sonication	  to	  break	  up	  large	  aggregates.	  
These	  assays	  measure	  the	  conversion	  of	  healthy	  brain	  homogenate	  or	  recombinant	  PrP	  to	  
PK	  resistant	  PrPSc	  in	  the	  presence	  of	  a	  small	  amount	  of	  PrPSc	  seed.	  Both	  PMCA	  and	  QuIC	  are	  
highly	  sensitive,	  amplifying	  small	  amounts	  of	  PrPSc	  from	  bodily	  fluids	  such	  as	  blood,	  saliva,	  
cerebral	   spinal	   fluid	   and	   urine	   and	   represent	   possible	   future	   large-­‐scale	   screening	   and	  
monitoring	  strategies	  (Wilham,	  Orrú	  et	  al.	  2010,	  Bucalossi,	  Cosseddu	  et	  al.	  2011).	  
	  
1.1.9	  Transgenic	  mouse	  models	  	  
Due	   to	   the	  dominant	  genetic	   influence	  of	   the	  Prnp	   gene	  on	  TSE	  susceptibility	   transgenic	  
mouse	  models	  have	  been	  used	  extensively	   in	  replacement	  of	  costly	   large	  animal	  models,	  
CHAPTER 1 - INTRODUCTION 
	   12	  
such	  as	  sheep	  and	  cattle.	   In	   these	  models,	   the	  murine	  Prnp	  gene	   is	  replaced	  with	   that	  of	  
ovine	   or	   bovine	   Prnp	   through	   transgenesis	   or	   by	   gene	   replacement	   using	   homologous	  
recombination	  (Weissmann	  and	  Flechsig,	  2003).	  These	  models	  are	  often	  more	  susceptible	  
to	  TSE	   infection	   than	  wild	   type	  mice	  and	  through	  the	  creation	  of	  overexpressing	  models	  
such	  as	   tg338	  and	  tg20	  the	  role	  of	  PrP	  expression	   in	  disease	  development	  has	  also	  been	  
studied	   (Vilotte	   et	   al.,	   2001).	   These	   overexpressing	   models	   display	   shorter	   incubation	  
times	  and	  higher	  susceptibility	  to	  disease	  compared	  to	  lower	  expressing	  models	  (Crozet	  et	  
al.,	   2001).	   The	   Tg338	   line	   is	   homozygous	   for	   the	   ovine	   VRQ	   allele,	   created	   through	   a	  
bacterial	  artificial	  chromosome	  (BAC)	  insert	  comprised	  of	  125	  kb	  of	  sheep	  DNA	  which	  was	  
introduced	  on	  a	  mouse	  PrP0/0	  background	  (Vilotte	  et.al,	  2001).	  
	  
1.2	  PRION	  GENETICS	  AND	  DISEASE	  
1.2.1	  The	  prion	  gene	  family	  	  
The	   prion	   gene	   family	   consists	   of	   three	  members;	  PRNP	   encoding	   PrPC,	  PRND	   encoding	  
Doppel	  and	  SPRN,	  encoding	  Shadoo	  (Shadow	  of	  the	  prion	  protein).	  In	  sheep	  the	  PRNP	  gene	  
is	  located	  on	  chromosome	  13	  and	  consists	  of	  two	  untranslated	  exons	  with	  the	  entire	  open	  
reading	   frame	   located	  within	  a	   third	   long	  exon	   (Goldmann,	  Hunter	  et	  al.	  1990,	   Iannuzzi,	  
Palomba	  et	  al.	  1998).	  This	  gene	  is	  highly	  conserved	  among	  mammals	  with	  variations	  seen	  
only	   in	   the	   size	   or	   number	   of	   exons	   and	   introns	   (Baylis	   and	   Goldmann	   2004).	  PRND	   is	  
located	   within	   15kb	   downstream	   of	   PRNP	   (Moore,	   Lee	   et	   al.	   1999).	   In	   contrast	   to	   PrP,	  
Doppel	  protein	  is	  prominent	  in	  the	  male	  reproductive	  system	  but	  normally	  absent	  in	  the	  
brain	   and	   CNS	   where	   it	   has	   been	   shown	   to	   be	   neurotoxic	   in	   transgenic	   mouse	   models	  
(Genoud,	   Behrens	   et	   al.	   2003).	   In	   sheep	   the	   SPRN	   gene	   is	   located	   on	   chromosome	   22	  
(Lampo,	  Van	  Poucke	  et	  al.	  2007)	  and	   is	  widely	  conserved	  throughout	  different	  genomes,	  
from	  mammals	   to	   fish	  (Premzl,	  Gready	  et	  al.	  2004,	  Stewart,	  Shen	  et	  al.	  2009).	  SPRN,	   like	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PRNP,	   encodes	   the	   entire	   open	   reading	   frame	   on	   one	   exon	   but	   unlike	   PRNP,	   SPRN	  
expression	  appears	  to	  be	  limited	  to	  the	  brain	  (Lampo,	  Van	  Poucke	  et	  al.	  2007).	  	  
	  
1.2.2	  Genetic	  factors	  in	  scrapie	  
In	  sheep,	  polymorphisms	  occurring	  in	  the	  PRNP	  open	  reading	  frame	  specifically	  at	  amino	  
acid	   positions	   136	   (valine/alanine),	   154	   (arginine/histidine)	   and	   171	  
(glutamine/arginine/histidine)	   predominate	   in	   the	   control	   of	   susceptibility	   and	   greatly	  
influence	   incubation	  period	   of	   classical	   scrapie	   infection	   (Goldmann,	  Hunter	   et	   al.	   1990,	  
Goldmann	   1993,	   Clouscard,	   Beaudry	   et	   al.	   1995).	   Genotypes	  with	   at	   least	   one	   valine	   at	  
codon	  136	  (136V)	  are	  associated	  with	  shorter	  incubation	  periods	  of	  scrapie	  infected	  sheep	  
and	  an	   increased	  risk	  of	  acquiring	  natural	   infection	  compared	  to	  genotypes	  homozygous	  
for	  alanine	  at	  the	  codon	  136	  (136A)	  (Goldmann,	  Hunter	  et	  al.	  1991,	  Laplanche,	  Chatelain	  
et	   al.	   1993,	   Hunter,	   Goldmann	   et	   al.	   1994,	   Bossers,	   Schreuder	   et	   al.	   1996).	   There	   is	   an	  
association	   between	   glutamine	   at	   position	   171	   (171Q)	   and	   susceptibility	   to	   natural	  
scrapie	  in	  both	  Suffolk	  sheep	  (Westaway,	  Zuliani	  et	  al.	  1994)	  and	  Romanov	  flocks	  whereas	  
animals	   with	   homozygosity	   or	   heterozygosity	   for	   arginine	   at	   position	   171	   (171R)	  
remained	  healthy	   (Clouscard,	   Beaudry	   et	   al.	   1995).	   171R	   encoded	  by	   at	   least	   one	  PRNP	  
gene	   allele	  prolonged	   survival	   of	  Cheviot	   sheep	  experimentally	   challenged	  with	  CH1641	  
and	   BSE	   by	   four	   fold	   and	   six	   fold	   respectively	   with	   many	   sheep	   showing	   no	   signs	   of	  
infection	  (Goldmann,	  Hunter	  et	  al.	  1994).	  More	  recently,	  a	  polymorphism	  at	  position	  141	  
(phenylalanine/leucine)	  has	  been	  associated	  with	  length	  of	  incubation	  period	  in	  BSE	  and	  
susceptibility	   to	   atypical	   scrapie	   (Moum,	   Olsaker	   et	   al.	   2005,	   Tan,	   Blanco	   et	   al.	   2012).	  
Many	   more	   polymorphisms	   exist	   in	   sheep	   PRNP	   and	   additional	   associations	   have	   also	  
been	  established	  (Goldmann	  2008)	  but	  for	  brevity	  they	  are	  not	  presented	  in	  this	  thesis.	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Sheep	  genotypes	  are	  usually	  described	  in	  terms	  of	  three	  codons	  and	  combinations	  of	  these	  
main	  resistance	  associated	  polymorphisms	  (codons	  136,	  154,	  171)	  result	  in	  five	  common	  
alleles:	   ARR,	   ARQ,	   VRQ,	   AHQ	   and	   ARH.	   These	   can	   be	   categorized	   depending	   on	   their	  
resistance	  to	  classical	  scrapie	  (Figure	  1.3),	  with	  genotype	  VRQ/VRQ	  being	  considered	  the	  
most	  susceptible	  and	  ARR/ARR	  the	  most	  resistant	  (Hunter	  2007).	   	  Heterozygote	  animals	  
with	  one	  ARR	  allele	  can	  have	  a	  lower	  frequency	  of	  scrapie	  infection	  (Baylis	  and	  Goldmann	  
2004)	   and	   greatly	   extended	   incubation	   times	   when	   compared	   to	   heterozygotes	   of	   the	  
other	  alleles	   (Houston,	  Halliday	  et	   al.	   2004).	  There	   could	  be	   several	   reasons	  behind	   this	  
allele	   dependent	   susceptibility,	   for	   example,	   differences	   in	   the	   gene	   expression	   of	   the	  
alleles.	  However,	  studies	  investigating	  gene	  expression	  in	  different	  sheep	  genotypes	  have	  
not	  found	  any	  evidence	  that	  this	  is	  the	  case	  (Caplazi,	  O'Rourke	  et	  al.	  2004).	  In	  vitro	  studies	  
indicate	   that	   PrPARR	  is	   impossible	   or	   difficult	   to	   convert	   to	   PrPSc	   therefore	   heterozygous	  
sheep	   with	   one	   ARR	   allele	  may	   simply	   have	   less	   readily	   convertible	   PrPC.	   In	   ARR/ARQ	  
sheep	  infected	  with	  natural	  scrapie,	  the	  majority	  of	  PK	  resistant	  PrPSc	  was	  found	  to	  be	  that	  
of	   ARQ	   allotype	   (Jacobs,	   Bossers	   et	   al.	   2011).	   PrPARR	   is	   not	   completely	   resistant	   to	  
conversion	   and	   under	   some	   conditions	   PrPARR	   protein	   can	   be	   converted	   to	   PK	   resistant	  
forms,	   for	   example,	   intracerebral	   inoculation	   with	   BSE	   has	   produced	   TSE	   disease	   in	  
ARR/ARR	  genotype	  sheep	  (Houston,	  Goldmann	  et	  al.	  2003).	  
 
Resistant	  	  	  	  	  	  	   	  	  	  	  	  	  Partial	  Resistance	  	  	  	   	   Susceptible	  	   	  	  	  	  	  	  	  	  Highly	  Susceptible	  
ARR/ARR	  
Figure	  1.3	   -­‐	  PRNP	  Genotype	  and	   spectrum	  of	   resistance/susceptibility	   to	  natural	   scrapie.	  
Susceptibility	   of	   sheep	   of	   different	   PRNP	   genotypes	   to	   natural	   scrapie,	   ranging	   from	   the	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1.2.3	  In-­‐vitro	  studies	  of	  PRNP	  polymorphisms	  in	  sheep	  and	  disease	  
In	  order	  to	  study	  the	  importance	  of	  these	  polymorphisms	  on	  the	  ability	  of	  the	  PrPC	  protein	  
to	  convert	  during	  disease	   the	  use	  of	  recombinant	  proteins	  and	  cell	  culture	  systems	  have	  
been	  adopted.	  Sabuncu	  et	  al	  (Sabuncu,	  Petit	  et	  al.	  2003)	  used	  transfected	  rabbit	  epithelial	  
cells	  expressing	  ovine	  PrPARR	  and	  PrPVRQ	  	  (known	  as	  Rov	  cells)	  and	  exposed	  them	  to	  scrapie	  
isolated	  from	  the	  brains	  of	  terminally	  infected	  mice.	  These	  cells	  showed	  no	  differences	  in	  
expression	   levels,	  glycoform	  patterns	  or	  proteolytic	  processing	  of	  PrPC	  prior	   to	   infection.	  
No	  PrPSc	  was	  detected	  in	  the	  cell	  line	  expressing	  PrPARR	  whereas	  a	  substantial	  PK	  resistant	  
band	  was	  seen	  in	  the	  PrPVRQ	  expressing	  cells	  (Sabuncu,	  Petit	  et	  al.	  2003).	  Further	  studies	  
by	  Sabuncu	  and	  colleagues	  have	  highlighted	  the	  possible	  importance	  of	  varying	  detergent	  
solubility	  of	  PrP	  variants	  and	  the	  ability	  of	  these	  amino	  acid	  changes	  to	  cause	  targeting	  to	  
different	  cellular	  compartments	  (Sabuncu,	  Petit	  et	  al.	  2003).	  	  Recombinant	  ovine	  PrP	  171A	  
and	   154H	   have	   limited	   ability	   to	   convert	   to	   PK	   resistant	   PrPSc	  in	   a	   cell-­‐free	   conversion	  
assay,	   seeded	   with	   scrapie	   when	   compared	   to	   136A.	   When	   added	   to	   an	   the	   assay	  
containing	   136A	   these	   proteins	   had	   an	   inhibitory	   effect,	   reducing	   the	   amount	   of	   PrPSc	  
formed	   (Eiden,	   Soto	   et	   al.	   2011).	   These	   results	   support	   findings	   from	   earlier	   studies	   in	  
which	  recombinant	  PrPARR	  showed	  reduced	  conversion	  ability	   in	   the	  cell	   free	  conversion	  
assay	  seeded	  with	  both	  PrPSc	  ARQ	  and	  PrPSc	  VRQ	  (Bossers,	  Belt	  et	  al.	  1997,	  Bossers,	  de	  Vries	  et	  
al.	  2000).	  Using	  PMCA	  (Protein	  Misfolding	  Cyclic	  Amplification)	   the	  conversion	  ability	  of	  
PrPARR	  and	   PrPARQ	  were	   compared	   with	   calculated	   amplification	   factors	   of	   1.4	   and	   10.1	  
respectively	   (Bucalossi,	   Cosseddu	   et	   al.	   2011).	   These	   polymorphisms,	   specifically	   171R,	  
have	  the	  ability	  to	  not	  only	  influence	  the	  susceptibly	  of	  the	  animal	  but	  also	  affect	  the	  direct	  
ability	  of	  PrPC	  to	  convert	  to	  PrPSc	  on	  a	  molecular	  level.	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1.2.4	  Genetic	  factors	  in	  other	  TSE	  diseases	  
Genetic	  predisposition	  to	  prion	  disease	  is	  not	  a	  phenomenon	  specifically	  seen	  in	  sheep,	  but	  
also	  observed	  in	  goats,	  deer	  and	  man.	  Higher	  risk	  of	  vCJD	  transmission	  is	  associated	  with	  
the	  human	  PRNP	  polymorphism	  129M	  and	  until	  2004	  all	  recorded	  cases	  had	  occurred	  in	  
patients	   homozygous	   at	   this	   codon.	   However,	   more	   recently,	   PrPSc	  deposition	   has	   been	  
reported	   in	  heterozygotes	  after	   iatrogenic	   transmission	   (Peden,	  Head	  et	  al.	  2004).	  Using	  
transgenic	  mouse	  models	  of	  human	  disease	  Bishop	  et	  al	  2006	  have	  shown	  irrespective	  of	  
the	  amino	  acid	  at	  position	  129	  all	  animals	  are	  susceptible	  to	  disease,	  although	  differences	  
in	  characteristics	  were	  reported	  (Bishop,	  Hart	  et	  al.	  2006).	  In	  goats	  142M,	  146S	  and	  222K	  
are	   polymorphisms	   associated	   with	   increased	   incubation	   periods	   and	   reduced	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Sheep MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSR 
Goat     ---------------------------------------- 
Cattle   ---------------------------------------- 




.        .         .         .         . 
Sheep YPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPH 
Goat  ---------------------------------------- 
Cattle   ---------------------------------------- 




.        .         .         .         . 
Sheep GGGWGQPHGGGGWGQGG.SHSQWNKPSKPKTNMKHVAGAA 
Goat     -----------------.---------------------- 
Cattle   -----------------.T-G------------------- 




.        .         .         .         . 
Sheep AAGAVVGGLGGYMLGSAMSRPLIHFGNDYEDRYYRENMYR 
Goat  ---------------------------------------- 
Cattle  --------------------------S-----------H- 




.        .         .         .         . 
Sheep YPNQVYYRPVDQYSNQNNFVHDCVNITVKQHTVTTTTKGE 
Goat  ---------------------------------------- 
Cattle -----------------------------E---------- 




.        .         .         .         . 
Sheep NFTETDIKIMERVVEQMCITQYQRESQAYYQ..RGASVIL 
Goat  -------------------------------..------- 
Cattle --------M----------------------..------- 




.        . 
Sheep FSSPPVILLISFLIFLIVG 
Goat  ------------------- 
Cattle ------------------- 
Deer  ------------------- 
Human ------------------- 
Mouse ------------------- 
Figure	   1.4	   –	   PRNP	   sequence	  
alignment	   –	  A	  comparison	  of	  
ovine	   PRNP	   sequence	   with	  
that	   of	   bovine,	  murine,	   goat,	  
deer	   and	   human.	   Matching	  
amino	   acids	   are	   represented	  
by	  a	  dashed	  line.	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1.3	  CELLULAR	  BIOLOGY	  OF	  PrPC	  
1.3.1	  Structure	  and	  Synthesis	  of	  the	  cellular	  prion	  protein	  
PrPC	   features	   an	   unstructured,	   flexible	   N-­‐	   terminal	   region	  with	   a	   stretch	   of	   octapeptide	  
repeats	  (PHGGGWGQ)	  and	  a	  structured,	  globular	  C-­‐terminal	  domain	  with	  one	  disulphide	  
bond	   (Figure	   1.5A).	   PrPC	   is	   attached	   to	   the	   plasma	   membrane	   by	   a	   GPI	  
(glycophosphotidylinositol)–anchor	   (Harris	   1999,	   Linden,	   Martins	   et	   al.	   2008)	   and	   has	  
two	   N-­‐glycosylation	   sites,	   existing	   in	   unglycosylated,	   mono-­‐glycosylated	   and	   di-­‐
glycosylated	   forms	   (Figure	   1.8).	   Glycosylation	  may	   influence	   the	   stability	   of	   the	   protein	  
and	   alter	   protein	   trafficking	   but	   it	   is	   not	   required	   for	   the	   conversion	   of	   PrPC	   to	   PrPSc	  
(Lawson,	  Collins	  et	  al.	  2005).	  Unlike	  other	  transmembrane	  proteins,	  PrP	  is	  not	  synthesised	  
in	  a	   single	  orientation.	  Two	  distinct	   forms	  of	  PrP	  have	  been	   identified,	  PrPsec	   –	   the	   form	  
which	  becomes	  the	  GPI-­‐anchored,	  cell	  membrane	  associated	  protein	  known	  as	  full	  length	  
PrPC	  and	  a	   transmembrane	   form	   (Brockes	  1999).	  This	   transmembrane	   form	  of	  PrPC	   can	  
occur	  in	  two	  different	  topographies	  both	  spanning	  the	  membrane	  at	  position	  112-­‐135,	  C-­‐
transmembrane	   (PrPctm)	   and	  N-­‐	   transmembrane	   (PrPntm)	  which	   are	   named	   according	   to	  
the	  domain	  of	  the	  protein	  in	  the	  ER	  lumen	  (Figure	  1.5B).	  
	  
1.3.2	  Trafficking	  	  
The	  trafficking	  of	  membrane	  associated	  PrPC	  is	  still	  not	  fully	  understood.	  There	  is	  evidence	  
that	  PrP	  can	  be	  internalised	  by	  several	  routes	  of	  endocytosis.	  Shyng	  et	  al	  (Shyng,	  Heuser	  et	  
al.	  1994)	  reported	  that	  in	  N2a	  cells	  PrPC	  is	  internalised	  via	  copper	  dependent	  mechanisms	  
involving	  clathrin	  coated	  vesicles	  (Figure	  1.5B)	   -­‐	  a	  process	   for	  which	  the	  copper	  binding	  
octapeptide	   repeats	   in	   the	   N-­‐terminal	   are	   essential	   (Shyng,	   Heuser	   et	   al.	   1994,	   Shyng,	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Moulder	  et	  al.	  1995).	  However,	  depletion	  of	  these	  clathrin	  coated	  pits	  in	  N2a	  cells	  by	  way	  
of	   siRNA	   resulted	   in	   no	   decrease	   in	   PrPC	   internalisation,	   indicating	   there	   may	   be	   an	  
alternative	   mechanism	   involved	   (Kang,	   Zhao	   et	   al.	   2009).	   Alternative	   candidate	  
mechanisms	  include	  the	  Arf6	  associated	  pathway	  or	  a	  caveolae	  mediated	  pathway	  (Peters,	  
Mironov	  et	  al.	  2003,	  Kang,	  Zhao	  et	  al.	  2009).	  Much	  of	  the	  cellular	  PrPC	  produced	  is	  recycled	  
as	   full	   length	  protein	  although	  a	  percentage	  undergoes	  endoproteolytic	   cleavage	  at	  both	  
the	  N	  and	  C	  terminals.	  It	  is	  reported	  that	  PrPC	  is	  continually	  recycled	  in	  this	  manner,	  taking	  
around	  60	  minutes	  to	  travel	  between	  the	  cell	  surface	  and	  endolytic	  compartments	  (Shyng,	  
Huber	  et	  al.	  1993,	  Harris	  2003)	  but	  whether	  this	  applies	  to	  all	  different	  forms	  of	  the	  PrPC	  
protein	  remains	  to	  be	  established.	  
	  
1.3.3	  Proteolytic	  processing	  of	  PrP	  –	  Extreme	  C-­‐terminal	  cleavage	  and	  shedding	  
Although	   the	  majority	  of	   cell	  associated	  PrPC	   is	  membrane	  bound	  and	   is	   recycled	  within	  
the	   cell,	   some	   may	   be	   released	   from	   the	   cell	   by	   shedding	   either	   through	   the	   action	   of	  
phospolipases	  on	  the	  GPI-­‐anchor	  or	  through	  the	  proteolysis	  in	  the	  protein	  C-­‐terminus.	  The	  
cleavage	  site	  which	  releases	  secreted	  PrPC	  has	  been	   identified	  at	  around	  amino	  acid	  231	  
(murine)	  and	  has	  been	  shown	   to	  be	   the	   result	  of	  action	  by	  ADAM	  proteases,	   specifically	  
ADAM	  9	  and	  ADAM10	  (Endres,	  Mitteregger	  et	   al.	  2009,	  Taylor,	  Parkin	  et	   al.	  2009).	   	  The	  
shed	  protein	  has	  been	  identified	  in	  cell	  culture,	  human	  cerebral	  spinal	  fluid	  and	  in	  Syrian	  
hamster	   brain	   and	   is	   thought	   to	   have	   physiological	   significance	   (Tagliavini,	   Prelli	   et	   al.	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Figure	  1.5	  -­‐	  PrP	  structure	  and	  trafficking.	  A)	  Linear	  representation	  of	  PrPC	  showing	  N-­‐terminal	  
signal	   sequence,	   followed	   by	   a	   basic	   region,	   the	   central	   domain	   consisting	   of	   octapeptide	  
repeats	  Arg/Gly	  rich	  and	  the	  hydrophobic	  tract.	  Structured	  C-­‐terminal	  with	  α	  and	  β	  chains,	  N-­‐
glycosylation	  sites	  and	  GPI-­‐anchor.	  B)	  Summary	  of	  PrPC	  trafficking.	  Full	   length	  PrPC	  is	   located	  
on	  cholesterol	  rich	  lipid	  rafts	  on	  the	  cell	  surface	  where	  it	  interacts	  with	  LRP	  (laminin	  receptor	  
precursor)	   and	   undergoes	   copper	   mediated	   endocytosis	   by	  way	   of	   the	   clathrin	   coated	   pit.	  
Once	  endocytosed	  it	  can	  either	  be	  degraded	  or	  recycled	  back	  to	  the	  cell	  surface.	  Immediately	  
after	   synthesis	   in	   the	  nuclease	  and	   transport	   through	  the	  ER	  and	  Golgi.	   .	  Diagram	  produced	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1.3.4	  Proteolytic	  processing	  of	  PrP	  –	  α-­‐cleavage	  
Proteolytic	  processing	   is	   a	   common	  occurrence	  amongst	  membrane	  bound	  proteins	  and	  
acts	  as	  a	  mechanism	  with	  which	  to	  alter	  biological	   function	  or	   inactivate	  proteins.	   In	  the	  
case	  of	  the	  cellular	  prion	  protein	  ‘normal’	  cellular	  processing	  includes	  an	  α-­‐cleavage	  event,	  
severing	  the	  peptide	  bond	  between	  114H	  and	  115V	  (ovine	  PrPC).	  This	  cleavage	  shortens	  
the	  so-­‐called	  neurotoxic	  region	  (Mange,	  Beranger	  et	  al.	  2004,	  Tveit,	  Lund	  et	  al.	  2005).	  	  PrPC	  
fragments	  equivalent	  to	  this	  α-­‐cleavage	  have	  been	  reported	  in	  the	  brains	  of	  a	  large	  variety	  
of	   mammals	   with	   diverse	   susceptibility	   to	   TSE	   diseases	   including	   human,	   mouse,	  
hamsters,	  rat,	  marmoset,	  dog,	  horse,	  pig,	  cow,	  seal,	  cat	  and	  bear	  (Jimenez-­‐Huete,	  Lievens	  et	  
al.	   1998,	   Laffont-­‐Proust,	   Faucheux	   et	   al.	   2005,	   Diaz-­‐San	   Segundo,	   Salguero	   et	   al.	   2006,	  
Kuczius,	  Grassi	  et	  al.	  2007,	  Kuczius,	  Koch	  et	  al.	  2007,	  Stewart,	  Campbell	  et	  al.	  2012).	  The	  
conserved	  nature	  of	  this	  event	   lends	  to	  the	  hypothesis	  that	   it	   is	  of	   functional	   importance	  
within	  the	  CNS.	  α-­‐Cleavage	  has	  also	  been	  well	  studied	  within	  cell	  culture	  systems,	  allowing	  
further	   analysis	   and	   insight	   into	   its	   functional	   significance	   (Vincent,	   Paitel	   et	   al.	   2000,	  
Yadavalli,	  Guttmann	  et	  al.	  2004,	  Tveit,	  Lund	  et	  al.	  2005,	  Zhao,	  Klingeborn	  et	  al.	  2006).	  	  
	  
α-­‐Cleavage	   creates	   two	   truncated	   proteins.	  Membrane	   bound	   C1	   (Figure	   1.5B)	   is	   the	   C-­‐
terminal	   fragment	  with	   an	   apparent	  molecular	  weight	   of	   17	   kDa,	   which	   like	   full	   length	  
PrPC	   can	   be	   unglycosylated,	   mono-­‐glycosylated	   or	   di-­‐glycosylated,	   shown	   in	   Figure	   1.7	  
(Chen,	   Teplow	   et	   al.	   1995,	   Laffont-­‐Proust,	   Faucheux	   et	   al.	   2005,	   Kuczius,	   Grassi	   et	   al.	  
2007).	  Secreted	  N1	  is	  the	  corresponding	  N-­‐terminal	  fragment	  with	  an	  apparent	  molecular	  
weight	   of	   9	   kDa	   (Vincent,	   Paitel	   et	   al.	   2000).	   These	   truncated	   proteins	   were	   identified	  
through	   both	   epitope	   mapping	   and	   sequencing.	   It	   has	   been	   shown	   that	   C1	   remains	  
attached	   to	   the	   plasma	   membrane	   residing	   alongside	   full	   length	   PrPC	   (Laffont-­‐Proust,	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Hassig	  et	  al.	  2006),	  whereas	  N1	  is	  released	  from	  the	  cell	  (Vincent,	  Paitel	  et	  al.	  2000).	  The	  
lack	   of	   cell	   associated	  N1	   along	  with	   its	   low	  molecular	  weight	  make	   it	   difficult	   to	   study	  
within	   the	   brain	   and	   for	   this	   reason	  most	   observations	   regarding	   α-­‐cleavage	   have	   been	  
made	   by	  measuring	   the	   C1	   fragment.	   This	   said,	   in	   cell	   culture	   the	   use	   of	   GFP-­‐N1	   fusion	  
proteins	   has	   allowed	   the	   fate	   of	   N1	   to	   be	   documented	   (Tveit,	   Lund	   et	   al.	   2005).	   The	  
cellular	   location	  of	   the	  α-­‐cleavage	   event	   is	   still	   undefined	  but	   recent	  work	  published	  by	  
Walmsley	  et	  al.	   shows	   that,	  by	  blocking	  exit	  of	  proteins	   from	  the	  endoplasmic	   reticulum	  
the	  amount	  of	  C1	  isoform	  produced	  was	  decreased.	  This	  indicates	  that	  α-­‐cleavage	  occurs	  
in	   a	   late	   compartment	   of	   the	   secretary	   pathway,	   most	   likely	   the	   Golgi	   apparatus	  





































Figure	   1.6	   -­‐	   Linear	   depiction	   of	   truncated	   C-­‐terminal	   fragments.	   Diagrammatic	  
representation	   of	   C2	   and	   C1,	   produced	   by	   cleavage	   at	   position	   91/92	   and	   114/115	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α-­‐Cleavage	  levels	  are	  reported	  to	  represent	  around	  50	  %	  of	  total	  PrP	  but	  may	  be	  variable	  
both	  within	   species	   groups	   and	   between	   species	   (Table	   1.2).	   It	   is	   unknown	  what	   effect	  
cleavage	   levels	  may	  have	  on	   incubation	  times	  and	  subgroups	  of	  resistance/susceptibility	  
to	  TSE	  disease	   (Laffont-­‐Proust,	  Hassig	   et	   al.	   2006).	   In	   sheep	  usually	  10-­‐60	  %	  of	   cellular	  
PrP	  in	  brain	  undergoes	  α-­‐cleavage	  (Charmaine	  Love,	  PhD	  Thesis,	  University	  of	  Edinburgh,	  
2010)	  and	  we	  hypothesize	  that	  this	  may	  vary	  between	  PRNP	  genotype	  groups,	  with	  higher	  
levels	  of	  cleavage	  being	  associated	  with	  resistance	  to	  disease.	  Data	  on	  levels	  of	  α-­‐cleavage	  
in	  different	  brain	  regions	  are	  limited	  but	  variation	  has	  been	  reported	  in	  both	  murine	  and	  
human	  brain.	   In	  the	  human	  brain	  higher	  C1	   levels	  were	  found	  in	  the	  cerebellum	  and	  the	  
pons,	   when	   compared	   to	   the	   cortex,	   nucleus	   lentiformis,	   thalamus,	   hippocampus	   and	  
medulla.	   (Kuczius,	   Koch	   et	   al.	   2007).	   In	   the	  mouse	   the	   cerebellum	  was	   also	   reported	   to	  
have	  higher	  C1	  levels	  than	  the	  cerebrum	  (Beringue,	  Mallinson	  et	  al.	  2003)	  but	  this	  was	  not	  
confirmed	  by	  others	  (Kayleigh	  Iremonger,	  Ph.D.	  thesis,	  University	  of	  Edinburgh,	  2013).	  
	  
SPECIES	   C1	  (as	  a	  percentage	  of	  total	  
PrP)	  
REFERENCE	  
Human	   30-­‐50%	   (Chen	  et	  al.,	  1995)	  
Human	   >	  50%	   (Jimenez-­‐Huete	  et	  al.,	  1998)	  
Human	  	  (with	  active	  ADAM10)	   42	  %	  (35-­‐50)	   (Laffont-­‐Proust	  et	  al.,	  2005)	  
Human	  (without	  active	  
ADAM10)	  
17	  %	  (15-­‐20)	   (Laffont-­‐Proust	  et	  al.,	  2005)	  
Human	   >	  50	  %	   (Kuczius	  et	  al.,	  2007b)	  
Sheep	   >	  50	  %	   (Kuczius	  et	  al.,	  2007a)	  
Cattle	   >	  50	  %	   (Kuczius	  et	  al.,	  2007a)	  
Mouse	   <	  50%	   (Kuczius	  et	  al.,	  2007a)	  
Mouse	   <	  50%	   (Laffont-­‐Proust	  et	  al.,	  2006)	  
Rat	   ~	  30	  %	   (Laffont-­‐Proust	  et	  al.,	  2006)	  
Hamster	   ~	  30	  %	   (Laffont-­‐Proust	  et	  al.,	  2006)	  
Marmoset	   ~/<	  50%	   (Laffont-­‐Proust	  et	  al.,	  2006)	  
Baboon	   ~	  80	  %	   (Laffont-­‐Proust	  et	  al.,	  2006)	  
 
Table	  1.2	  -­‐	  A	  comparison	  of	  published	  C1	  levels	  in	  different	  species	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1.3.5	  Proteolytic	  processing	  of	  PrP	  –	  β-­‐cleavage	  
Although	   α-­‐cleavage	   accounts	   for	   the	   majority	   of	   proteolytic	   processing,	   a	   second	  
alternative	  cleavage	  event	  does	  occur	  at	  low	  levels	  in	  healthy	  brain,	  known	  as	  β-­‐cleavage.	  
The	  cut	  occurs	  around	  position	  92	  in	  the	  octapeptide	  repeat	  region	  of	  the	  ovine	  PrP	  and	  
creates	  C2	  (Figure	  1.6A),	  the	  slightly	  longer	  C-­‐terminal	  fragment	  with	  apparent	  molecular	  
weight	  of	  21	  kDa	  and	   the	   corresponding	   fragment	  N2	  of	   around	  7	  kDa	   in	   sheep	   (Figure	  
1.7)	  (Mange,	  Beranger	  et	  al.	  2004).	  In	  human	  brain	  the	  C2	  fragment	  accounts	  for	  around	  5	  
%	  of	   total	  PrP	   (Chen,	  Teplow	  et	  al.	  1995)	  and	   there	   is	  evidence	   that	   this	   cleavage	   is	  not	  
specific	  to	  neuronal	  tissue,	  with	  its	  identification	  in	  the	  human	  tonsil	  –	  another	  known	  site	  
of	   PrPSc	  accumulation	   in	   the	   preclinical	   stage	   of	   disease	   (Monleon,	  Monzon	   et	   al.	   2005).	  
Using	  biotinylation	  of	  surface	  PrPC	  in	  cell	  culture	  it	  has	  been	  shown	  that	  β-­‐cleavage,	  unlike	  
α-­‐cleavage	  occurs	  at	  the	  cell	  surface.	  This	  second	  proteolytic	  processing	  event	  is	  mediated	  
by	   reactive	   oxygen	   species	   such	   as	   H2O2,	  which	   on	   exposure	   increase	   the	   amount	   of	   C2	  
produced.	  It	  is	  thought	  that	  β-­‐cleavage	  represents	  a	  mechanism	  to	  protect	  cells	  against	  the	  
build	  up	  of	  free-­‐radicals	  and	  oxidative	  stress	  (Watt	  and	  Hooper	  2005).	  Experiments	  in	  cell	  
culture	   demonstrate	   that	   α-­‐	   and	   β-­‐cleavage	   are	   independent	   events,	   cleaving	   different	  
PrPC	  molecules	  (Sunyach,	  Cisse	  et	  al.	  2007).	  
	  
	  
A	  C2-­‐like	  fragment	  has	  also	  been	  described	  in	  the	  human	  brain	  infected	  with	  sporadic	  CJD	  
and	  familial	  GSS	  and	  scrapie	  infected	  mice	  and	  sheep	  when	  tested	  by	  western	  blot	  in	  the	  
absence	  of	  protease	  K	  (Chen,	  Teplow	  et	  al.	  1995,	  Jimenez-­‐Huete,	  Lievens	  et	  al.	  1998,	  Owen,	  
Rees	   et	   al.	   2007).	   This	   truncated	   form	   was	   purified	   in	   the	   detergent	   insoluble	   fraction	  
along	  with	  the	  PrPSc	  and	  appeared	  of	  similar	  molecular	  weight	  to	  C2	  in	  the	  ‘normal’	  brain.	  
The	  origin	  of	  this	  fragment	  in	  TSE	  infected	  animals	  is	  under	  debate.	  It	  is	  either	  a	  result	  of	  
an	  increase	  in	  production	  of	  the	  cellular	  PrPC	  isoform	  C2	  in	  reaction	  to	  increased	  oxidative	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stress	   during	   neurodegeneration	   or	   a	   result	   of	   a	   similar	   in	   vivo	   cleavage	   of	   PrPSc	  while	  



































Figure	   1.7	   -­‐	   Diagrammatic	   representation	   of	   PrPC	  processing	  within	   the	   cell.	   Full	   length	  
PrPC	  can	  be	  cleaved	  in	  the	  Golgi	  Apparatus	  (a	  process	  known	  as	  α-­‐cleavage).	  The	  products	  
C1	   and	   N1	   are	   transported	   to	   the	   cell	   surface	   where	   C1	   remains	   anchored	   and	   N1	   is	  
secreted	  from	  the	  cell.	  β-­‐cleavage	  occurs	  at	  the	  cell	  surface	  and	  produces	  the	  isoforms	  C2	  
and	  N2.	  	  .	  Diagram	  produced	  using	  Biomedical	  PPT	  toolkit	  (Motifolio).	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1.3.6	  Proposed	  functions	  of	  PrPC	  
The	   normal	   role	   of	   PrPC	   is	   still	   undefined	   although	   there	   is	   evidence	   that	   it	   has	   many	  
contradictory	  cellular	  functions.	  PrP	  null	  mice	  display	  no	  lethal	  phenotype	  indicating	  that	  
PrP	  is	  not	  essential	  for	  survival	  (Bueler,	  Aguzzi	  et	  al.	  1993).	  PRNP	  knockout	  animals	  have	  
also	  been	  generated	  in	  other	  species	  such	  as	  goats	  and	  have	  even	  been	  found	  as	  a	  natural	  
genetic	   variant	   in	   goats	   without	   any	   obvious	   survival	   problems	   (Benestad,	   Ausbo	   et	   al.	  







































































Figure	   1.8	   –	   Schematic	  
representation	   of	   western	  
blot	   profiles	   of	   PrP	   and	  
truncated	   PrP	   proteins.	  
Showing	   apparent	   molecular	  
weights	   of	   all	   forms	   of	   PrP	  
found	   in	   healthy	   brain,	  
including	  glycosylated	  forms	  of	  
PrP,	   unglycosylated	   PrP	   and	  
truncated	   forms	   produced	   by	  
α-­‐	   and	   β-­‐	   cleavage	   and	  
reactivity	  to	  N-­‐	  and	  C-­‐terminal	  
antibodies.	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knockout	  mice	  such	  as	  disturbances	   in	  sleep	  regulation	  (Tobler,	  Gaus	  et	  al.	  1996,	  Huber,	  
Deboer	   et	   al.	   2002),	   decreased	   spatial	   learning	   and	   loss	   of	   both	   short	   and	   long-­‐term	  
synaptic	   plasticity	   leading	   to	   decreased	   memory	   function	   (Collinge,	   Whittington	   et	   al.	  
1994,	   Criado,	   Sanchez-­‐Alavez	   et	   al.	   2005).	   PrP	   null	   mice	   also	   have	   reduced	   protection	  
against	   oxidative	   stress	   and	   decreased	   recovery	   from	   ischemic	   damage	   (Mitteregger,	  
Vosko	  et	  al.	  2007,	  Nicolas,	  Gavin	  et	  al.	  2009).	  It	  is	  thought	  that	  PrPC	  has	  an	  important	  role	  
in	   copper	   metabolism,	   binding	   Cu2+	   via	   the	   octapeptide	   repeats	   within	   the	   flexible	   N-­‐
terminal	   region	   (Hornshaw,	   McDermott	   et	   al.	   1995,	   Kramer,	   Kratzin	   et	   al.	   2001)	   and	  
enabling	  uptake	   into	   the	  cell.	  There	   is	  a	  positive	  correlation	  between	  copper	  uptake	  and	  
PrP	  expression	  in	  primary	  cerebellar	  cells	  (Brown	  1999,	  Kramer,	  Kratzin	  et	  al.	  2001).	  The	  
cellular	  prion	  protein	  also	  has	  further	  neuroprotective	  functions	  within	  the	  brain.	  Normal	  
expression	  of	  PrPC	  reduces	  Bax	  induced	  cell	  death	  –	  an	  attribute	  for	  which	  the	  octapeptide	  
repeat	   region	   is	  again	  essential	   (Bounhar,	  Zhang	  et	  al.	  2001).	   It	  has	  been	  suggested	   that	  
pathogenesis	   associated	  with	   TSE	   infection	   is	   partly	   due	   to	   the	   loss	   of	   PrPC	  function	   on	  
conversion	  to	  PrPSc	  (Crozet,	  Beranger	  et	  al.	  2008).	  
	  
1.3.7	  Functional	  importance	  of	  truncated	  PrP	  produced	  by	  cleavage	  
Independent	   of	   the	   theory	   that	   cleavage	   is	   important	   in	  TSE	   infection	   as	   it	   represents	   a	  
mechanism	  to	  reduce	  the	  amount	  of	   full	   length	  cellular	  PrPC	  available	  for	  conversion,	  the	  
fragments	   produced	   during	   proteolytic	   processing	   are	   biologically	   active	   in	   vitro	   and	   in	  
vivo.	  As	  seen	  with	  over-­‐expression	  of	  full	  length	  PrP,	  C1	  induces	  staurosporine-­‐stimulated	  
caspase-­‐3	  activity	  in	  several	  cell	  types	  by	  means	  of	  increasing	  p53	  mRNA	  activation.	  P53,	  
or	  tumor	  suppressor	  protein	  p53	  induces	  cell	  death	  through	  apoptosis	  and	  is	  an	  important	  
factor	  in	  the	  cell	  cycle.	  The	  specificity	  of	  C1	  is	  revealed	  by	  the	  fact	  that	  C2,	  longer	  only	  by	  
approximately	  22	  amino	  acids	  displayed	  no	  such	  function	  in	  this	  system	  (Sunyach,	  Cisse	  et	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al.	  2007).	  α-­‐Cleavage	  in	  axons	  has	  been	  linked	  to	  maintenance	  of	  myelin	  sheath	  in	  the	  PNS,	  
suggesting	   a	   role	   for	   C1	   in	   myelin	   maintenance	   and	   cross	   talk	   between	   neurons	   and	  
Schwann	  cells	  (Bremer,	  Baumann	  et	  al.	  2010).	  	  
	  
Recombinant	   N1	   when	   added	   to	   several	   cell	   culture	   systems	   resulted	   in	   a	   significant	  
reduction	   in	   staurosporine-­‐stimulated	   caspase-­‐3	   activation	   by	   down-­‐regulating	   p53	  
transcription,	  in	  normal	  expressing,	  PrPC	  over-­‐expressing	  and	  C1	  over-­‐expressing	  cells.	  N1	  
has	   also	   been	   shown	   to	   protect	   rat	   retinal	   cells	   from	   pressure-­‐induced	   ischemia.	  
Surprisingly,	  N1	  had	  effect	  without	  being	  internalised	  by	  the	  cell	  indicating	  that	  secretion	  
of	  N1	  by	  some	  cells	  may	  have	  wider	  multi-­‐cellular	  neuroprotective	  effects.	  Because	  N1	  has	  
been	  shown	  to	  rescue	  C1	  over-­‐expressing	  cells	   from	  apoptosis,	   it	   is	  concluded	  that	  N1	  is	  
dominant	   over	   C1	   function	   which	   may	   partly	   explain	   the	   neuroprotective	   effects	  
associated	  with	   PrPC.	   Again,	   the	   β-­‐cleavage	   product	   N2	   did	   not	   have	   similar	   properties	  
(Guillot-­‐Sestier,	  Sunyach	  et	  al.	  2009).	  
	  
1.3.8	  ADAM	  proteases	  and	  α-­‐cleavage	  
The	  exact	  mechanisms	  of	  α-­‐cleavage	  are	  still	  undefined	  and	  for	  a	  long	  time	  it	  was	  thought	  
that	  this	  process	   involved	  several	  metalloproteases	  of	   the	  ADAM	  class	  (metalloproteases	  
with	   a	   disintigrin	   domain)	   –	   multifunctional	   transmembrane	   proteins	   which	   when	  
activated	  can	  proteolytically	  cleave	  other	  transmembrane	  proteins	  and	  are	  thought	  to	  be	  
of	  great	  functional	  importance	  within	  the	  brain	  (Novak	  2004).	  There	  is	  also	  contradictory	  
evidence	   in	   which	   these	   ADAM	   proteases	   are	   held	   responsible	   for	   a	   different	   cleavage	  
event,	  involving	  the	  removal	  of	  the	  GPI-­‐	  anchor	  and	  shedding	  of	  PrPC	  from	  the	  cell	  (Endres,	  
Mitteregger	  et	  al.	  2009,	  Taylor,	  Parkin	  et	  al.	  2009,	  Altmeppen,	  Prox	  et	  al.	  2011).	  
	  
CHAPTER 1 - INTRODUCTION 
	   29	  
Specifically,	  ADAM	  proteases	  9,	  10,	  17	  (TACE)	  which	  are	  expressed	  throughout	  the	  body	  
and	  ADAM	  23	  which	  is	  specific	  to	  the	  brain	  (Novak	  2004)	  are	  thought	  to	  be	  involved	  in	  α-­‐
cleavage	   of	   PrP	   and	   the	   amyloid	   precursor	   protein	   (APP)	   (Allinson,	   Parkin	   et	   al.	   2003,	  
Asai,	  Hattori	  et	  al.	  2003).	  	  Although	  prion	  and	  Alzheimer’s	  disease	  have	  distinctly	  different	  
pathologies	   the	   similarities	   in	   proteolytic	   processing	   are	   evident.	   Cleavage	   of	  APP	  by	  α-­‐
secretase	  is	  thought	  to	  occur	  at	  the	  plasma	  membrane	  as	  with	  PrPC	  and	  sAPPα	  a	  product	  of	  
this	   event	   has	   neuroprotective	   functions	   similar	   to	   those	   associated	   with	   N1	   of	   PrPC	  
(Vincent	   2004).	   Cleavage	   of	   PrPC	   like,	   APP	   has	   been	   shown	   to	   occur	   independently	   of	  
sequence	  around	  the	  cleavage	  site	  and	  in	  the	  case	  of	  PrP	  is	   influenced	  by	  the	  distance	  of	  
the	  cleavage	  site	  from	  the	  cell	  membrane	  and	  by	  charge	  around	  the	  cleavage	  site	  (Vincent	  
2004,	  Oliveira-­‐Martins,	  Yusa	  et	  al.	  2010).	  Several	  groups	  have	  used	  general	   inhibitors	  of	  
the	   ADAM	   metalloproteinases	   such	   as	   O-­‐phenanthroline,	   which	   in	   TMS	   neurons	   and	  
HEK293	  cells	  reduced	  N1	  formation	  by	  around	  40-­‐70	  %	  when	  compared	  to	  control	  cells	  
(Vincent,	   Paitel	   et	   al.	   2001,	   Cisse,	   Sunyach	   et	   al.	   2005).	   Inhibition	   by	   use	   of	   protease	  
inhibitors	  does	  not	  completely	  prevent	  the	  formation	  of	  N1.	  
	  
ADAM	  9	   has	   been	   linked	   to	   the	   processing	   of	   the	   cellular	   prion	   protein	   in	   an	  ADAM	  10	  
dependent	  manner,	  where	  over	  expression	  of	  ADAM	  9	  in	  several	  cell	  systems	  expressing	  
ADAM	  10	   has	   led	   to	   an	   increase	   in	   the	   secretion	   of	   N1	   but	   no	   effects	  were	   reported	   in	  
ADAM	  10	  null	  cells	  (Cisse,	  Sunyach	  et	  al.	  2005).	  When	  both	  ADAM	  10	  and	  17	  were	  over-­‐
expressed	   independently	   in	  HEK293	   cells	   production	   of	   the	  N1	   fragment	  was	   increased	  
only	   following	   the	  over-­‐expression	  of	  ADAM	  17.	  ADAM	  17	   is	   thought	   to	   cleave	  PrPC	  in	   a	  
PKC	   (Protein	   Kinase	   C)-­‐mediated	   manner.	   Activation	   of	   PKC	   leads	   to	   the	   increase	   in	  
production	   of	   N1	   isoform,	   but	   not	   in	   ADAM	   17	   null	   fibroblasts	   (Alfa	   Cisse,	   Louis	   et	   al.	  
2008).	  This	  evidence	  indicates	  that	  perhaps	  α-­‐cleavage	  may	  be	  the	  result	  of	  two	  separate	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mechanisms,	  one	  ADAM	  10	  dependent	  and	  the	  other	  ADAM	  17	  and	  PKC	  mediated.	  
	  
Along	  with	  investigation	  into	  the	  role	  of	  ADAMS	  in	  cell	  culture	  the	  ability	  of	  recombinant	  
ADAMS	   to	   cleave	   recombinant	   PrP	   has	   also	   been	   considered.	   ADAMS	   10	   and	   17	   were	  
incubated	   in	   the	   presence	   of	   both	   full-­‐length	   recombinant	   PrP	   and	   PrP	   peptide	  
encompassing	  the	  α-­‐cleavage	  site	  with	  no	  evidence	  of	  α-­‐cleavage	  occurring.	  Finally	  it	  has	  
been	   shown	   that	   there	   is	   a	   positive	   correlation	   between	   higher	   C1	   levels	   in	   the	   human	  
brain	   and	   presence	   of	   active	  ADAM	  10	   (Laffont-­‐Proust,	   Faucheux	   et	   al.	   2005).	   Recently,	  
ADAM	   8	   has	   been	   shown	   to	   cleave	   PrPC	   in	   skeletal	   muscle	   but	   as	   this	   protease	   is	   not	  
expressed	  in	  brain	  it	  cannot	  be	  similarly	  involved	  in	  the	  cleavage	  of	  PrPC	  in	  the	  CNS	  (Liang,	  
Wang	  et	  al.	  2012).	  
	  
Despite	   the	  mounting	   evidence	   for	   the	   involvement	   of	   ADAMS	   in	   the	   α-­‐cleavage	   of	   the	  
cellular	  prion	  protein	   there	  has	  been	   recent	   evidence	  which	   contradicts	   this	  hypothesis.	  
Taylor	  et	  al	  2009	  have	  shown	  that	  over	  expression	  of	  ADAMS	  9,	  10	  and	  17	  independently	  
in	  HEK	  cells	  did	  not	  alter	  C1	  levels	  and	  silencing	  of	  the	  same	  candidates	  using	  siRNA	  also	  
proved	  to	  have	  no	  effect	  on	   the	  ratio	  of	   full	   length	  PrP	  and	  C1.	  The	  authors	  suggest	   that	  
this	  difference	  is	  due	  to	  the	  measurement	  of	  the	  cell	  associated	  C1	  and	  not	  the	  N1	  which	  is	  
secreted	   into	   the	  media	   (Taylor,	  Parkin	  et	   al.	   2009).	  This	   evidence	   is	   in	   agreement	  with	  
Altmeppen	  and	  colleagues,	  who	  have	  shown	  that	  C1	  levels	  remain	  high	  in	  ADAM	  10	  knock	  
out	   primary	   neurons	   (Altmeppen,	   Prox	   et	   al.	   2011).	   It	   is	   possible	   that	  measurement	   of	  
secreted	  N1	  may	  be	  a	  misrepresentation	  of	   the	  actual	   levels	  of	  PrPC	  cleaved	  and	   instead	  
represent	  the	  amount	  secreted	  from	  the	  cell	  -­‐	  a	  process	  for	  which	  ADAM	  10	  may	  also	  play	  
a	   role.	   If	   we	   hypothesise	   that	   ADAM	   10	   is	   responsible	   for	   the	   shedding	   of	   N1	   and	   not	  
directly	  involved	  in	  the	  α-­‐cleavage	  event	  then	  it	  could	  explain	  why,	  by	  inhibition	  of	  ADAM	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10,	   a	   reduction	   of	   N1	   is	   reported	   but	   not	   an	   alteration	   in	   C1	   levels.	   LRP1	   (Low-­‐density	  
lipoprotein	  receptor-­‐related	  protein	  1)	   is	  an	  endolytic,	   transmembrane	  receptor	  protein,	  
with	  multiple	   ligand	   binding	   sites	   involved	   in	   the	   endocytosis	   and	   trafficking	   of	   PrPC	  in	  
neuronal	  cells	  and	  it	  binds	  to	  PrPC	  through	  the	  N-­‐terminal	  region	  of	  the	  molecule.	  ADAM	  
proteases	   10	   and	  17	  have	   been	   shown	   to	   result	   in	   shedding	   of	   LRP1	   from	   the	   cell	   (Liu,	  
Zhang	  et	  al.	  2009),	   therefore	   if	  α-­‐cleavage	  occurred	  in	  unison	   	  a	  N1-­‐LRP1	  complex	  could	  
















It	   is	  also	  possible	  that	  these	  proteases	  have	  to	  be	  manipulated	   in	  unison	  as	  cleavage	   is	  a	  
process	  that	  requires	  one	  or	  more	  of	  the	  candidate	  ADAMS	  to	  be	  present.	  ADAM	  10	  over-­‐
Figure	   1.9	   –	   Hypothetical	   model	   of	  
ADAM	  10	   involvement	   in	   the	   shedding	  
of	   N1	   from	   cells.	   Full	   length	   PrP	  bound	  
to	   LRP1	   undergoes	   α-­‐cleavage	   in	   the	  
Golgi.	   C1	   is	   trafficked	   to	   the	   cell	  
membrane	  where	  it	  resides.	  An	  N1-­‐LRP1	  
complex	   is	   trafficked	   to	   the	   cell	  
membrane	  and	  anchored	   through	  LRP1.	  
LRP1	  is	  cleaved	  by	  ADAM	  10,	  releasing	  it	  
from	   the	   membrane	   and	   subsequently	  
releasing	   N1	   from	   the	   cell.	   .	   Diagram	  
produced	   using	   Biomedical	   PPT	   toolkit	  
(Motifolio).	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expressing	  mice	  show	  a	  dose	  dependent	  decrease	  in	  PrPC	  both	  at	  the	  mRNA	  level	  (~70%	  
reduction)	   and	   in	   the	   amount	   of	   protein	   (~30%	   reduction),	   indicating	   that	   over	  
expression	  of	  ADAM	  10	  interferes	  with	  PrP	  gene	  expression.	  This	  decrease	  was	  mimicked	  
in	  C1	  so	  that	  the	  PrP:	  C1	  ratio	  remained	  unchanged	  (Endres,	  Mitteregger	  et	  al.	  2009).	  
	  
1.3.9	  Regulation	  of	  α-­‐cleavage	  by	  Protein	  Kinase	  C	  
Protein	   kinase	   C	   (PKC)	   has	   been	   shown	   to	   be	   an	   important	  mediator	   of	   the	   α-­‐cleavage	  
event.	   Addition	   of	   PKC	   agonists	   PMA	   (phorbol	   12-­‐myristate	   13-­‐acetate)	   and	   PDBu	  
(Phorbol	   12,13-­‐Dibutyrate)	   to	   HEK293	   cells	   and	   TSM1	   primary	   neurons	   led	   to	   an	   dose	  
dependent	  increase	  in	  recovery	  of	  the	  N1	  truncated	  protein	  (Vincent,	  Paitel	  et	  al.	  2000).	  A	  
general	  inhibitor	  of	  PKC,	  GF109203X	  led	  to	  a	  dose	  dependent	  decrease	  in	  N1	  recovery	  in	  
the	  same	  cell	  lines	  (Alfa	  Cisse,	  Louis	  et	  al.	  2008).	  	  It	  has	  also	  been	  shown	  that	  activation	  of	  
PKC	   coupled	  M1/M3	  muscarine	   receptors	   leads	   to	   phosphorylation	   of	  ADAM	  17	   and	   an	  
increase	  in	  levels	  of	  N1	  (Alfa	  Cisse,	  Sunyach	  et	  al.	  2007).	  	  
	  
The	   addition	   of	   PMA	   activates	   PKC	   and	   down-­‐regulates	   LRP1.	   This	   would	   lead	   to	   a	  
decrease	  in	  cell	  associated	  LRP1	  available	  for	  the	  transport	  of	  PrPC	  to	  the	  membrane	  and	  
consequently	  lead	  to	  an	  accumulation	  of	  PrPC	  in	  intracellular	  compartments	  (Amos,	  Mut	  et	  
al.	  2007).	  Hypothetically	  the	  build	  up	  of	  PrPC	  in	  internal	  compartments	  would	  increase	  the	  
chance	   of	   it	   intercepting	   the	   PrP	   α-­‐secretases	   responsible	   for	   α-­‐cleavage	   as	   it	   has	   been	  
shown	  previously	   that	   this	  cleavage	  event	  occurs	   in	  a	   late	  compartment	  of	   the	  secretary	  
pathway	  (Figure	  1.10)	  (Walmsley,	  Watt	  et	  al.	  2009).	  Increases	  in	  ADAM	  10	  and	  17	  which	  
shed	  LRP1	  would	  decrease	  the	  amount	  of	  cell	  associated	  LRP1	  available	  for	  the	  transport	  
of	  PrP	  to	  the	  membrane,	  leading	  to	  an	  increase	  in	  intracellular	  PrPC	  and	  hence	  α-­‐cleavage.	  
This	  model	  could	  explain	  the	  association	  of	  ADAMS	  9,	  10	  and	  17	  and	  α-­‐cleavage	  made	  by	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1.3.10	  PrPC	  cleavage	  and	  its	  potential	  effect	  on	  conversion	  to	  PrPSc	  
From	  a	  therapeutic	  angle,	  it	  is	  important	  to	  understand	  what	  domains	  of	  the	  PrPC	  protein	  
act	  as	  seed	  for	  the	  production	  of	  PrPSc	  	  (Table	  1.3.).	  It	  has	  been	  concluded	  that	  deletion	  of	  
the	   GPI-­‐anchor	   had	   no	   effect	   on	   PrPSc	   replication	   in	   vivo	   (Rogers,	   Yehiely	   et	   al.	   1993).	  
Rigter	  et	  al	  (2009)	  suggest	  that	  the	  octapeptide	  repeat	  region	  of	  the	  protein	  stabilises	  the	  
interaction	  between	  PrPC	  and	  PrPSc.	  When	  added	  to	   the	  PMCA	  (Protein	  Misfolding	  Cyclic	  
Figure	   1.10	   -­‐	   Proposed	   model	   of	   α-­‐cleavage	   regulation	   by	   PKC	   and	   LRP1	   pathway.	  
Activation	  of	  PKC-­‐α	  leads	   to	  a	  down	  regulation	  of	  LRP1,a	  known	  PrP	  receptor	   involved	  in	  
trafficking	  and	  endocytosis.	  The	  down	  regulation	  of	  LRP1	  would	  lead	  to	  an	  increase	  in	  PrP	  
within	  the	  intracellular	  compartments,	  including	  the	  Golgi	  Apparatus	  –	  the	  proposed	  site	  of	  
α-­‐cleavage	  –	   increasing	   the	  chance	  of	   interception	  with	  α-­‐secreatases.	  As	  LRP1	  binds	  PrP	  
via	  the	  N-­‐terminal	  it	  is	  proposed	  that	  the	  C1	  fragment	  is	  transported	  to	  the	  membrane	  by	  
an	   independent	   pathway.	   By	   this	  mechanism	  C1	  would	  be	   the	  prominent	   species	  on	   the	  
cell	  surface.	  Diagram	  produced	  using	  Biomedical	  PPT	  toolkit	  (Motifolio).	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Amplification)	   assay	   this	   peptide	   increased	   formation	   of	   PrPSc.	   The	   same	   authors	   also	  
stressed	  the	  importance	  of	  amino	  acids	  89-­‐107	  in	  PrP	  oligomerisation	  (Rigter,	  Priem	  et	  al.	  
2009).	   From	   several	   studies	   using	   deletion	   mutants	   it	   appears	   that	   essential	   to	   the	  
conversion	   process	   are	   amino	   acids	   34-­‐141,	   deletion	   of	   which	   prevented	   or	   decreased	  
conversion	   (Holscher,	  Delius	  et	   al.	   1998,	  Chabry,	  Priola	   et	   al.	   1999,	  Lawson,	  Priola	   et	   al.	  
2001,	   Lawson,	   Priola	   et	   al.	   2004).	   Furthermore,	   published	  during	   the	  production	  of	   this	  
thesis,	  Westergard	  et	  al	   (2011)	  have	  shown	   that	   transgenic	  mice	  expressing	  only	   the	  C1	  
fragment	  exhibited	  no	  accumulation	  of	  PrPSc	  or	  neurological	  degeneration	  for	  up	  to	  1	  year	  
after	   intracerebral	   inoculation	   with	   scrapie.	   Further	   recent	   work	   also	   indicates	   that	  
expression	  of	  C1	  has	  an	   inhibitory	  effect	  on	  disease	  progression,	   lengthening	   incubation	  
times	  but	  with	  no	  differences	   in	  histology	  or	  PrPSc	   accumulation	   identifiable	   at	   terminal	  
phase	  (Westergard,	  Turnbaugh	  et	  al.	  2011).	  
	  
If	  the	  central	  amyloidogenic	  region	  is	  crucial	  in	  conversion	  of	  PrPC	  to	  PrPSc	  then	  α-­‐cleavage	  
of	  PrPC	  could	  be	  an	  important	  mechanism	  in	  reducing	  the	  amount	  of	  protein	  available	  for	  
conversion	   to	   PrPSc	   during	  TSE	  disease	   because	   it	   cuts	   at	   position	   115	   in	   sheep	   (Figure	  
1.6).	  β-­‐cleavage,	  on	  the	  other	  hand,	  leaves	  the	  central	  region	  of	  PrPC	  intact	  meaning	  C2	  is	  a	  
candidate	  intermediate	  in	  the	  conversion	  of	  PrPC	  to	  PrPSc.	  As	  briefly	  mentioned	  previously	  
there	   is	  evidence	   that	  a	   truncated	  protein	  similar	   to	  C2	  can	  be	  protease	  resistant	   in	  TSE	  
infected	  animals	  but	   it	   is	  unknown	  whether	  this	   is	  a	  product	  of	  normal	  cellular	  PrP	  (C2)	  
which	  is	  then	  converted	  to	  PrPSc,	  or	  the	  result	  of	  cleavage	  of	  PrPSc	  (Yadavalli,	  Guttmann	  et	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Table	  1.3 
DELETION/	  MUTATION	   METHOD	   CONVERSION	  
POTENTIAL	  
REFERENCE	  
34-­‐94	   Cell	  free	  conversion	  
assay	  
Reduced	  by	  35%	   (Lawson	  et	  al.,	  2001)	  
34-­‐113	   Cell	  free	  conversion	  
assay	  
Reduced	  by	  60%	   (Lawson	  et	  al.,	  2001)	  
34-­‐120	   Cell	  free	  conversion	  
assay	  
Reduced	  by	  70%	   (Lawson	  et	  al.,	  2001)	  
34-­‐124	   Cell	  free	  conversion	  
assay	  
Reduced	  by	  70%	   (Lawson	  et	  al.,	  2001)	  
V214I,	  Q218K	   ScN2a	  cells	   No	  conversion	   (Zulianello	  et	  al.,	  2000)	  
Q171R,	  V214I,	  Q218K	   ScN2a	  Cells	   No	  conversion	   (Zulianello	  et	  al.,	  2000)	  
219-­‐232	   Cell	  free	  conversion	  
assay	  
conversion	   (Horiuchi	  &	  Caughey,	  
1999)	  
23-­‐88	   ScN2a	  Cells	   Conversion	   (Supattapone	  et	  al.,	  
1999)	  
23-­‐88	   N2a	  cells	   No	  conversion	   (Supattapone	  et	  al.,	  
1999)	  
23-­‐88,	  141-­‐176	   Tg	  mice	   Conversion	   (Supattapone	  et	  al.,	  
1999)	  
23-­‐88	   ScN2a	  Cells	   Conversion	   (Rogers	  et	  al.,	  1993)	  
231-­‐254	   ScN2a	  Cells	   Conversion	   (Rogers	  et	  al.,	  1993)	  
32-­‐88	   Tg	  mice	   Conversion	   (Fischer	  et	  al.,	  1996)	  
A136V	   Cell	  free	  conversion	  
assay	  
Increased	  conversion	   (Belt	  et	  al.,	  1995)	  
Q171R	   Cell	  free	  conversion	  
assay	  
Decreased	  conversion	   (Belt	  et	  al.,	  1995)	  
114-­‐121	   Sc1-­‐MNB	  cells	   No	  conversion	   (Holscher	  et	  al.,	  1998)	  
Peptide	  109-­‐141	   Cell	  free	  conversion	  
assay	  
Inhibited	  conversion	   (Chabry	  et	  al.,	  1999)	  
Peptide	  119-­‐128	   Cell	  free	  conversion	  
assay	  
Partial	  inhibition	  of	  
conversion	  
(Chabry	  et	  al.,	  1999)	  
Peptide	  119-­‐136	   Cell	  free	  conversion	  
assay	  
Strong	  inhibition	  of	  
conversion	  
(Chabry	  et	  al.,	  1999)	  
34-­‐99	   Cell	  free	  conversion	  
assay	  
Conversion	   (Lawson	  et	  al.,	  2004)	  
34-­‐102	   Cell	  free	  conversion	  
assay	  
Conversion	   (Lawson	  et	  al.,	  2004)	  
34-­‐106	   Cell	  free	  conversion	  
assay	  
Some	  PK	  resistance,	  
different	  conformation	  
(Lawson	  et	  al.,	  2004)	  
34-­‐110	   Cell	  free	  conversion	  
assay	  
Some	  PK	  resistance,	  
different	  conformation	  
(Lawson	  et	  al.,	  2004)	  
34-­‐113	   Cell	  free	  conversion	  
assay	  
Some	  PK	  resistance,	  
different	  conformation	  
(Lawson	  et	  al.,	  2004)	  
34-­‐120	   Cell	  free	  conversion	  
assay	  
Some	  PK	  resistance,	  
different	  conformation	  
(Lawson	  et	  al.,	  2004)	  
34-­‐124	   Cell	  free	  conversion	  
assay	  
Some	  PK	  resistance,	  
different	  conformation	  
(Lawson	  et	  al.,	  2004)	  
136A,	  154H	   Cell	  free	  conversion	  
assay	  
82.5%	  Reduction	   (Eiden	  et	  al.,	  2011)	  
136A,	  171R	   Cell	  free	  conversion	  
assay	  
87.5%	  Reduction	   (Eiden	  et	  al.,	  2011)	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154H	   Cell	  free	  conversion	  
assay	  
>95%	  Reduction	   (Eiden	  et	  al.,	  2011)	  
171R	   Cell	  free	  conversion	  
assay	  
>95%	  Reduction	   (Eiden	  et	  al.,	  2011)	  
23-­‐111	   Tg	  Mice	   No	  PrPSc	  or	  
degeneration	  
(Westergard	  et	  al.,	  
2011)	  




1.4	  THE	  PrPC	  PROTEIN	  AND	  OTHER	  DISEASES	  
1.4.1	  Cancer	  
PrPC	   expression	   in	   the	   periphery	   although	   likely	   pivotal	   to	   the	   development	   of	   prion	  
diseases	  has	  also	  been	  implicated	  in	  progression	  and	  treatment	  of	  other	  diseases	  such	  as	  
gastric	   and	   breast	   cancers	   by	   promoting	   cell	   proliferation	   and	   suppressing	   apoptosis.	  	  
PrPC	   is	   known	   to	   be	   anti-­‐apoptotic	   in	   neuronal	   cells,	   protecting	   against	   Bax	   mediated	  
apoptosis	   (Bounhar,	   Zhang	   et	   al.	   2001).	   PrPC	   expression	   is	   unregulated	   in	   cancerous	  
gastric	  tissue	  in	  comparison	  to	  the	  healthy	  equivalent	  (Du,	  Pan	  et	  al.	  2005)	  and	  silencing	  of	  
PrPC	   expression	   in	   cancerous	   cell	   lines	   reduced	   both	   cellular	   adhesion	   and	   invasive	  
abilities	  (Pan,	  Zhao	  et	  al.	  2006).	  Furthermore,	  PrPC	  expression	  levels	  in	  breast	  cancer	  have	  
been	   suggested	   as	   a	   marker	   of	   treatment	   outcome,	   with	   PrPC	   expression	   in	   tumors	  
associated	  with	  resistance	  to	  chemotherapy	  (Meslin,	  Conforti	  et	  al.	  2007).	  	  
	  
1.4.2	  Alzheimer’s	  Disease	  
Perhaps	  better	  understood	   is	   the	   role(s)	  of	  PrPC	   expression	   in	  Alzheimer’s	  disease.	  PrPC	  
has	   been	   shown	   to	   bind	   BACE1	   (β-­‐site	   APP	   Cleavage	   Enzyme-­‐1),	  which	   has	   a	   knock-­‐on	  
effect	  on	  the	  availability	  of	  BACE	  to	  cleave	  APP.	  	  Reduction	  of	  BACE	  mediated	  cleavage	  of	  
APP	   results	   in	   a	   reduction	   of	   downstream	   shedding	   of	   toxic	   Aβ	   peptides	   Aβ40	  and	   Aβ42	  
(Kellett	  and	  Hooper	  2009).	  This	   relationship	   is	   illustrated	  effectively	  by	   the	   induction	  of	  
PrPC	  expression	  in	  APP	  expressing	  SH-­‐SY5Y	  cells,	  resulting	  in	  reduced	  shedding	  of	  cleaved	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APP.	   Furthermore,	   in	   PrPC	  deficient	  mouse	   lines	   production	   of	   downstream	   products	   of	  
APP	   Aβ40	   and	   Aβ42	   are	   increased	   (Parkin,	   Watt	   et	   al.	   2007).	   This	   would	   suggest	   that	  
expression	   of	   PrPC	  might	   help	   to	   protect	   against	   Alzheimer’s	   pathology	   by	   reducing	   the	  
amount	   of	   toxic	   peptides.	   However,	   PrPC,	   specifically	   amino	   acids	   23-­‐90	   and	   95-­‐110	  
contained	   in	   both	   N1	   and	   N2	   truncated	   fragments	   as	   well	   as	   full	   length	   PrPC	   (murine	  
numbering)	   can	   also	   directly	   bind	   to	   Aβ42	   oligomers,	   the	   most	   neurotoxic	   of	   the	   Aβ	  
peptides	  (Chen,	  Yadav	  et	  al.	  2010).	  In	  vitro	  both	  full	   length	  PrPC	  and	  truncated	  fragments	  
23-­‐126	  and	  91-­‐115	  can	  strongly	  inhibit	  fibril	  formation	  of	  both	  Aβ40	  and	  to	  a	  lesser	  extent	  
Aβ42	  and	  that	  addition	  of	  PrPC	  to	  fully	  formed	  fibrils	  causes	  fibril	  disassembly,	  favoring	  the	  
formation	  of	  Aβ	   oligomeric	   forms.	   	  The	   authors	   further	  demonstrate	   that	   the	  binding	  of	  
PrPC	  to	  Aβ	  peptides	  firstly	  requires	  misfolding	  of	  the	  peptides	  (Younan,	  Sarell	  et	  al.	  2013).	  
It	   is	  Aβ	  oligomers	  which	  are	   though	   to	  be	   the	  most	  neurotoxic	  of	   the	  Aβ	   aggregates,	  not	  
larger	   fibril	   plaques,	   therefore	   PrPC	   expression	   may	   in	   fact	   positively	   correlate	   with	  
Alzheimer’s	  induced	  neuronal	  toxicity.	  	  This	  hypothesis	  is	  supported	  by	  studies	  performed	  
by	  Gimbel	  and	  colleagues	  (Gimbel,	  Nygaard	  et	  al.	  2010)	  who	  show	  that	  in	  the	  absence	  of	  
PrPC	  expression	  (PrP	  null	  murine	  models)	  Aβ	  fibrillar	  plaques	  are	  readily	  formed	  however	  
the	   mice	   show	   no	   behavioral	   abnormalities	   or	   deterioration	   of	   memory	   functions.	  
Revealing	  that	  although	  PrPC	  is	  not	  required	  for	  neuronal	  aggregation	  of	  Aβ,	   it	  appears	  to	  
be	  essential	   for	   the	  production	  of	   small	  neurotoxic	  oligomers	  and	  hence	   the	   subsequent	  
clinical	  symptoms	  associated	  with	  Alzheimer’s	  disease.	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1.6	  AIMS	  
PrPC	   protein	   has	   both	   functional	   importance	   in	   the	   brain	   and	   as	   a	   determinant	   in	   the	  
development	  of	  prion	  diseases.	  While	  cleavage	  of	  PrPC	  has	  been	  well	  characterised	  its	  role,	  
if	  any	  in	  prion	  susceptibility	  is	  still	  inadequately	  understood.	  Primarily,	  this	  thesis	  aims	  to	  
investigate	  cleavage	  of	  PrPC	  in	  the	  sheep	  model	  with	  the	  goal	  of	  understanding	  if	  this	  could	  
be	   a	   contributing	   factor	   in	   the	   resistance/susceptibility	   to	   prion	   disease	   and	   if	   so,	  
determine	  the	  mechanisms	  behind	  such	  effects	  and	  how	  it	  could	  influence	  the	  outcome	  of	  
infection.	  
	  	  
1.	  Investigate	  the	  proteolytic	  processing	  and	  expression	  of	  PrPC	  in	  sheep	  of	  different	  
PRNP	   genotypes	  and	  assess	  whether	   this	  may	  contribute	  susceptibility	   to	   classical	  
scrapie.	  	  
A.	  Establish	  if	  PrPC	  expression	  and	  processing	  is	  uniform	  throughout	  brain	  regions.	  
B.	  Determine	  if	  PrPC	  expression	  in	  the	  ovine	  brain	  correlates	  with	  susceptibility	  to	  scrapie.	  
C.	  Establish	  if	  the	  common	  polymorphisms	  in	  the	  PRNP	  gene	  have	  an	  effect	  on	  proteolytic	  
processing	  of	  PrPC.	  
	  
2.	  	  Determine	  whether	  proteolytic	  cleavage	  of	  PrPC	  could	  have	  a	  role	  in	  fibrillisation	  
and	  in	  the	  conversion	  of	  PrPC	  to	  PrPSc	  during	  TSE	  disease.	  
A.	  	  Establish	  an	  approach	  to	  isolate	  or	  produce	  truncated	  PrPC	  fragments	  in	  vitro.	  	  
B.	  	  Determine	  if	  truncated	  PrPC	  fragments	  can	  misfold.	  
C.	  Investigate	  if	  truncated	  fragments	  can	  alter	  conversion	  of	  full	  length	  PrPC.	  	  
D.	   Investigate	   if	   truncated	   fragments	   can	   alter	   TSE	   susceptibility	   of	   cultured	   cells	   and	  
hence	  evaluate	  the	  future	  use	  of	  these	  fragments	  as	  therapeutics	  in	  the	  treatment	  of	  prion	  
disease.
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CHAPTER	  2	  
GENERAL	  MATERIALS	  AND	  METHODS	  
	  
2.1	  ANIMALS	  AND	  TISSUES	  
2.1.1	  Sheep	  and	  goats	  
Sheep	  used	  in	  this	  study	  were	  obtained	  from	  the	  Roslin	  Institute	  Cheviot	   flock	  (formerly	  
known	   as	   the	   NPU	   Cheviot	   flock)	   and	   from	   a	   scrapie	   free	   flock	   (Animal	   health	   and	  
Veterinary	  Laboratory	  Agency).	  All	  scrapie-­‐infected	  tissues	  were	  selected	  from	  the	  Roslin	  
frozen	   tissue	   archive	   and	   included	   both	   naturally	   and	   experimentally	   infected	   sheep.	  
Following	  post-­‐mortem	  all	  tissue	  had	  been	  immediately	  stored	  at	  -­‐70°C.	  	  Goat	  tissues	  were	  
obtained	  from	  The	  Roslin	  Institute	  goatherd	  and	  were	  uninfected	  negative	  control	  animals	  
from	  other	  TSE	  infection	  experiments.	  
	  
2.1.2	  Other	  species	  
Transgenic	  mice	  lines	  gtARQ	  (The	  Roslin	  Institute,	  unpublished)	  and	  Tg338	  (Laude	  2001)	  
were	   used	   for	   the	   creation	   of	   primary	   neuronal	   cultures.	   Heads	   of	   17-­‐day-­‐old	   embryos	  
were	   provided	   in	   Hanks	   balanced	   salt	   solution	   (HBSS)	   by	   The	   Roslin	   Institute	   animal	  
facility,	   as	   were	   rat	   tissues.	   The	   cat	   brain	   sample	   was	   taken	   from	   The	   Roslin	   Institute	  
tissue	  archive	  where	  it	  had	  been	  stored	  at	  -­‐70	  to	  -­‐90°C.	  
	  
2.2	  PROTEIN	  EXTRACTION	  FROM	  BRAIN	  
2.2.1	  Extraction	  of	  PrPC	  from	  brain	  tissue	  
Lysis	  buffer	  (5	  %	  NP-­‐40	  (v/v),	  12.1	  mM	  Sodium	  deoxycholate	  in	  PBS)	  was	  prepared	  on	  ice	  
and	  stored	  at	  4°C	  for	  up	  to	  a	  month.	  Directly	  before	  use	  protease	  inhibitors	  PMSF	  and	  NEM	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were	   added	   (10	   µM	   PMSF,	   10	   µM	   NEM	   final	   concentration).	   To	   make	   a	   10%	   (w/v)	  
homogenate	   tissues	   (100mg)	   were	   manually	   homogenised	   in	   1ml	   of	   lysis	   buffer	   with	  
protease	   inhibitors	  The	  homogenate	  was	  clarified	  by	  centrifugation	  at	  2000	  rpm	  at	  4	   ºC	  
for	   10	   minutes,	   the	   supernatant	   was	   collected	   in	   100μl	   aliquots,	   flash	   frozen	   in	   liquid	  
nitrogen	  and	  stored	  at	  -­‐20	  °C.	  Aliquots	  were	  subjected	  to	  only	  one	  freeze	  thaw	  cycle.	  
	  
2.2.2	  Deglycosylation	  of	  PrPC	  	  
Deglycosylation	   was	   performed	   using	   a	   PNGase	   F	   kit,	   New	   England	   Biolabs.	   Brain	  
homogenate	   (100μl)	  produced	   as	   described	   in	   section	   2.2.1	   (10	  %	  w/v)	  was	   denatured	  
with	  10μl	  of	  denaturing	  buffer	  at	  100	  ºC	  for	  10	  minutes.	  NP40	  and	  G7	  reaction	  buffer	  (both	  
10μl)	   were	   added	   and	   two	   25μl	   aliquots	   removed	   from	   both	   +PNGase	   and	   –PNGase	  
reactions.	   	   +PNGase	   reactions	   were	   incubated	   with	   0.125	   U	   of	   peptide	   N-­‐glycoside	   F	  
(PNGase	   F	   kit,	   New	   England	   Biolabs)	   for	   2	   hours	   at	   37	   ºC.	   -­‐PNGase	   reactions	   were	  
incubated	  with	  2μl	  of	  pefa	  bloc	  (100mM)	  for	  2	  hours	  at	  37	  ºC	  Protein	  was	  isolated	  using	  
methanol	   or	   acetone	   precipitation	   and	   stored	   at	   -­‐20	   ºC.	   Before	   immunoblotting,	   the	  
protein	  was	  pelleted	  by	  centrifugation	  at	  10,400	  g	  for	  10	  minutes.	  Prior	  to	  electrophoresis,	  
samples	  were	  boiled	  directly	  in	  NuPAGE	  (Invitrogen)	  sample	  buffer	  supplemented	  with	  a	  
reducing	  agent	  (Invitrogen).	  	  
	  
2.3	  PROTEIN	  ANALYSIS	  BY	  SDS-­‐PAGE	  
2.3.1	  Western	  blot	  immunoassay	  for	  detection	  of	  PrPC	  
Protein	   was	   denatured	   in	   NuPAGE	   (Invitrogen)	   sample	   buffer	   supplemented	   with	   a	  
reducing	  agent	   (Invitrogen)	  at	  70	  ºC	   for	  10	  minutes	  and	  separated	  by	  12%	  NuPAGE	  Bis-­‐
Tris	   gels	   (Invitrogen).	   Molecular	   markers	   spanning	   20-­‐220	   kDa	   were	   used	   for	   size	  
reference	   (MagicMarker	   XP	   Western	   protein	   Standard,	   Invitrogen)	   and	   electrophoresis	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was	   performed	   in	   an	   Xcell	   SureLock	   tank	   at	   150	   V	   for	   1	   hour	   using	   a	   NuPAGE	   kit	  
(Invitrogen).	   Proteins	   were	   transferred	   onto	   poly	   (vinylidenedifluoride)	   membranes	  
(Millipore	  or	  GE	  Healthcare)	  using	  wet	   transfer	   in	   the	  Xcell	   SureLock	   tank	  at	  25	  V	   for	  1	  
hour,	  after	  which	  the	  membranes	  were	  washed	  with	  TBS	  (50	  mM	  Tris,	  150	  mM	  NaCl,	  pH	  
7.5).	  The	  membranes	  were	  blocked	  using	  0.1	  %	  (v/v)	  blocking	  solution	  (Roche)	  for	  1	  hour	  
at	  room	  temperature	  with	  agitation	  followed	  by	  incubation	  with	  anti-­‐PrP	  antibodies	  (Table	  
2.1)	  diluted	  in	  0.5	  %	  (v/v)	  blocking	  solution	  under	  the	  same	  conditions.	  	  Membranes	  were	  
washed	  with	  TBST	   (0.1	  %	  Tween	  20	   in	  TBS)	   followed	  by	  0.5	  %	   (v/v)	  blocking	   solution.	  
The	  membranes	  were	  incubated	  in	  horseradish-­‐peroxidase-­‐conjugated	  rabbit	  anti-­‐mouse	  
antibody	   (Stratech,	   UK)	   diluted	   at	   1:10000	   in	   0.5	   %	   (v/v)	   block	   for	   75	   minutes.	   The	  
membranes	   were	   washed	   in	   TBST	   and	   proteins	   were	   visualized	   using	   activated	  
chemiluminescence	   (SuperSignal	   West	   Dura	   Extended	   Duration	   Substrate,	   Thermo	  
Scientific)	  and	  Chemiluminescent	  Detection	  Film	  (Lumi-­‐Film,	  Roche).	  	  
	  
2.3.2	  Anti-­‐PrP	  monoclonal	  antibodies	  for	  western	  blot	  immunoassay	  
	  PrP	   specific	  monoclonal	   antibodies	   and	   conditions	   used	   unless	   otherwise	   stated	   in	   text	  
are	  summarised	   in	  Table	  2.1.	  Murine	  α-­‐tubulin	   (NeoMarkers,	  Fisher)	  was	  used	  at	  a	   final	  
concentration	  of	  0.01µg/ml	  in	  0.5%	  blocking	  reagent.	  
	  
2.3.3	  Stripping	  and	  re-­‐probing	  of	  PDVF	  membrane	  	  
To	  allow	  a	  western	  blot	  membrane	  to	  be	  re-­‐probed	  with	  a	  second	  monoclonal	  antibody	  it	  
was	  twice	  washed	  in	  TBST,	   followed	  by	  TBS	  and	  incubated	  in	  25mLs	  of	  Restore	  western	  
stripping	  reagent	  (Roche)	  for	  60	  minutes.	  It	  was	  then	  incubated	  in	  fresh	  Restore	  overnight	  
with	   agitation	   and	  washed	   in	   TBS	   and	   TBST.	  Monoclonal	   antibody	  was	   then	   applied	   as	  
previously	  described	  in	  section	  2.3.1)	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Dilution	  in	  0.5%	  
blocking	  solution	  
Source	  
BC6	   144-­‐154	   0.3	   1:10000	   Sandra	  
McCutcheon,	  
Roslin	  Institute	  
6H4	   144-­‐152	   0.1	   1:1000	   Biopharm	  Rhone	  
Ltd	  
FH10	   202-­‐210	   0.5	   1:500	   Sandra	  
McCutcheon,	  
Roslin	  Institute	  
JB10	   216-­‐225	   3.1	   1:3000	   Sandra	  
McCutcheon,	  
Roslin	  Institute	  




P4	   89-­‐104	   0.2	   1:5000	   Biopharm	  Rhone	  
Ltd	  
Table	  2.1	  –	  PrP	  specific	  monoclonal	  antibodies	  as	  used	  for	  western	  blotting.	  
	  
2.3.4	  Densitometry	  analysis	  
For	   quantitative	   analysis,	   blots	  were	   scanned	   and	   the	   net	   intensity	   of	  manually	   selected	  
protein	  bands	  representative	  of	  full	  length	  PrPC,	  C1	  and	  C2	  were	  measured	  by	  use	  of	  Kodak	  
MI	   software.	   The	   combined	   signal	   of	   all	   bands	   for	   each	   sample	  was	   taken	   as	   100%	  and	  
each	  band	  calculated	  as	  a	  percentage	  of	  the	  total	  signal.	  For	  each	  animal	  deglycosylation,	  
immunoblotting	  and	  densitometry	  were	  performed	  at	  least	  twice	  and	  any	  further	  analysis	  
was	   based	   on	   the	   average	   C1	   value.	   For	   analysis	   of	   total	   PrP	   protein	   densitometry	  
measurements	   of	   the	   alpha	   tubulin	   loading	   control	   were	   performed.	   Using	   these	  
measurements	   loading	  was	  calculated	  as	  a	   factor	  of	   the	   least	  concentrated	   lane	  and	  PrPC	  
densitometry	  values	  were	  normalized	  accordingly.	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2.3.5	  Protein	  staining	  by	  Instant	  Blue	  
Protein	  samples	  were	  denatured	  at	  70	  ºC	  for	  10	  minutes	  in	  a	  heat	  block	  and	  separated	  by	  
12	   %	   NuPAGE	   Bis-­‐Tris	   gels	   (Invitrogen).	   Electrophoresis	   was	   performed	   in	   an	   Xcell	  
SureLock	  tank	  at	  150	  V	  for	  1	  hour	  using	  a	  NuPAGE	  kit	  (Invitrogen).	  Gels	  were	  incubated	  
with	  agitation	  in	  20mls	  of	  Novexin	  Instant	  Blue	  stain	  (Gentaur)	  for	  1	  hour,	  allowing	  blue	  
staining	  to	  develop.	  After	  which	  gels	  were	  stored	  in	  dH20.	  
	  
2.3.6	  Protein	  staining	  by	  Silver	  Staining	  
After	  electrophoresis	  12	  %	  NuPAGE	  Bis-­‐Tris	  gels	  (Invitrogen)	  were	  soaked	  in	  25mls	  fixing	  
solution	  (30	  %	  v/v	  ethanol,	  10%	  v/v	  acetic	  acid)	   for	  1	  hour	  or	  overnight	  and	  were	  then	  
incubated	   for	   1	   hour	   in	   25mls	   sensitizing	   solution	   (30	  %	   ethanol	   v/v,	   4mls	   5%	   sodium	  
thiosulphate	   (w/v),	   sodium	   acetate	   0.84M,	   0.5mls	   25	  %	   glutaraldehyde)	   and	  washed	   in	  
H2O.	   Gels	   were	   stained	   with	   25mls	   silver	   nitrate	   (0.25	   %	   w/v)	   in	   ddH2O	   with	  
Formaldehyde	   (0.1	  %	  v/v)	   for	   1	   hour	   and	  developed	   in	   25mls	   2.5	  %	   sodium	   carbonate	  
(w/v)	  with	  Formaldehyde	  (0.04	  %	  v/v)	  until	  bands	  were	  clear.	  Gels	  were	  then	  transferred	  
to	  25mls	  stopping	  solution	  (1.46	  %	  w/v	  EDTA).	  
	  
2.4.	  IMMUNOHISTOCHEMISTRY/IMMUNOCYTOCHEMISTRY	  
2.4.1	  Haematoxylin	  and	  Eosin	  staining	  of	  cultured	  cells	  
Cells	  adhered	   to	  glass	  cover	  slips	  were	  washed	   twice	   in	  PBS	  (x1)	  pH	  7.8.	  The	  cells	  were	  
fixed	   in	  a	  4	  %	  paraformaldehyde/0.25	  %	  glutaraldehyde/PBS	  solution	   for	  10	  minutes	  at	  
room	  temperature.	  	  	  This	  step	  was	  followed	  by	  three	  five-­‐minute	  washes	  in	  PBS.	  The	  slides	  
were	   then	   washed	   with	   water	   (2	   x	   1	   minute)	   and	   stained	   with	   haematoxylin	   for	   2.5	  
minutes,	  washed	   three	   times	  with	  water	   (1	  minute),	   stained	  with	   eosin	   for	   1.5	  minutes	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and	  washed	  again	  with	  water.	  The	  cover	  slips	  were	  mounted	  with	  Vectasheild®	  hard	  set	  
(Vector	  laboratories).	  
 





BC6	   PrP	  (144-­‐154)	   Monoclonal	  IgG1	   0.05	   Sandra	  
McCutcheon,	  
Roslin	  Institute	  
MAP-­‐2	   Microtubule	  
associated	  
protein	  2	  
Monoclonal	  IgG1	   5.0	   Abcam	  
BE12	   PrP	  (23-­‐90)	   Monoclonal	  IgG1	   	   The	  Roslin	  
Institute,	  TSE	  
Resource	  Centre	  
6H4	   PrP	  (144-­‐152)	   Monoclonal	  IgG1	   0.1	   Biopharm	  Rhone	  
Ltd	  
FH10	   PrP	  (202-­‐210)	   Monoclonal	  
IgG2a	  
0.5	   Sandra	  
McCutcheon,	  
Roslin	  Institute	  
FH11	   PrP	  (54-­‐58)	   Monoclonal	  
IgG2b	  
	   	  
Anti-­‐Syntaxin	  6	   Syntaxin	  6	   Monoclonal	  IgG	   1:100	   Cell	  Signaling	  
Technology	  
Table	  2.2	  –	  Primary	  antibodies	  used	  for	  IHC/ICC.	  
	  
 







Alexa	  fluor®	  488	   Rabbit	  Anti-­‐
Mouse	  
IgG	  (H+L)	   10	   Invitrogen	  
Alexa	  fluor®	  594	   Goat	  Anti-­‐Rabbit	   IgG	  (H+L)	   10	   Invitrogen	  
Table	  2.3	  –	  Secondary	  antibodies	  used	  for	  ICC	  
	  
2.4.2	  Immunocytochemistry	  of	  cultured	  neurons	  
Cells	  adhered	   to	  glass	  cover	  slips	  were	  washed	   twice	   in	  PBS	  (x1)	  pH	  7.8.	  The	  cells	  were	  
fixed	  in	  4	  %	  paraformaldehyde	  (w/v)/0.25	  %	  glutaraldehyde	  (v/v)	  in	  PBS	  for	  10	  minutes	  
at	   room	   temperature.	   	   	   This	   step	  was	   followed	   by	   three	   five-­‐minute	  washes	   in	   PBS.	   To	  
permeabilise	  the	  cells,	  coverslips	  were	  submerged	  in	  0.1	  %	  Tritron	  X-­‐100	  in	  PBS	  (v/v)	  and	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washed	  a	  further	  three	  times	  in	  PBS	  as	  above.	  Block	  (3	  %	  BSA	  (w/v)	  in	  PBS)	  was	  applied	  
and	   left	   for	   30	   minutes.	   The	   cells	   were	   incubated	   in	   monoclonal	   antibody	   in	   a	   humid	  
chamber	   at	  4	   ˚C	  overnight.	  Monoclonal	   antibodies	  used	   for	   ICC	  are	   summarised	   in	   table	  
3.2.	  Following	  the	  application	  of	  primary	  antibody	  the	  cells	  were	  washed	  in	  PBS	  as	  above	  
and	   incubated	   in	  secondary	  alexa	   fluor	  conjugated	  antibody	  (Table	  2.3)	   in	  a	  dark	  humid	  
chamber	   at	   room	   temperature	   for	   1	   hour.	   Again	   PBS	  washes	  were	   performed	   and	   cells	  
were	   incubated	   in	   Hoechst	   33342	   3μg/ml	   (Sigma)	   in	   water	   for	   10	   minutes.	   This	   was	  
removed	  by	  washing	  in	  water	  twice	  and	  the	  cover	  slips	  were	  mounted	  with	  Vectasheild®	  
hard	  set.	  
 
2.5	  DNA	  EXTRACTION	  AND	  SEQUENCING	  
	  2.5.1	  DNA	  extraction	  from	  brain	  tissues	  
Genomic	  DNA	  was	  extracted	  from	  small	  sections	  of	  tissues	  (~25mg)	  using	  the	  Qiagen	  DNA	  
Easy	  kit	  according	  to	  manufacturers	  instructions.	  All	  solutions	  were	  supplied	  with	  the	  kit	  
unless	  otherwise	  indicated.	  DNA	  was	  eluted	  in	  sterile	  dH20	  by	  centrifugation	  at	  13,000rpm	  
for	   3	   minutes.	   Concentration	   was	   determined	   by	   Nanodrop	   spectrophotometry	   and	  
genomic	  DNA	  was	  stored	  at	  4ºC.	  	  
	  
2.5.2	  PRNP	  Polymerase	  chain	  reaction	  (PCR)	  
	  Amplification	   of	   the	   PrP	   gene	   from	   genomic	   DNA	   was	   performed	   by	   PCR	   using	   Taq	  
polymerase	  kit	  (HotStarTaq	  polymerase	  (Qiagen))	  was	  performed	  with	  oligos	  forward	  (5’	  
to	   3’)’	   CAAGAGAGAAGCAAGAAATGAGAGACA	   and	   reverse	  
GGAATGTGAAGAACATTTATGACCTAGAAT	  (5’	  to	  3’)	  (Sigma,	  UK).	  Reactions	  were	  set	  up	  as	  
shown	  in	  table	  2.4.	  PCR	  conditions	  were	  95ºC	  for	  10mins,	  followed	  by	  40	  repeats	  of	  95ºC	  
for	  1	  min,	  61ºC	  for	  30	  seconds	  and	  72ºC	  for	  1	  minute,	  with	  a	  final	  extension	  of	  72ºC	  for	  10	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Table	  2.4	  -­‐	  PRNP	  PCR	  reaction	  
 
2.5.3	  Activated	  charcoal	  purification	  of	  PCR	  products	  
To	   PCR	   reactions,	   30	  %	   (v/v)	   activated	   charcoal	   (1.6	  %	   (w/v)	   charcoal	   in	   ddH2O)	  was	  
added,	  mixed	  by	  vortexing	  and	  incubated	  for	  20	  minutes.	  The	  reaction	  was	  centrifuged	  at	  
13,000	  rpm	  for	  15	  minutes,	  supernatant	  removed	  and	  stored	  at	  4ºC.	  
	  
2.5.4.	  Agarose	  gel	  electrophoresis	  
To	  visualise	  PCR	  products,	  reactions	  were	  separated	  on	  1.5	  %	  agarose	  gels	  (1.5	  %	  agarose,	  
TBE	  X1	  (diluted	  from	  10X	  stock	  solution,	  0.89M	  Tris,	  0.89M	  orthoboric	  acid,	  0.2M	  EDTA)	  
and	   SYBRsafe®	   (0.1μl/1ml	   of	   agarose/TBE)	   (Life	   Technologies).	   Molecular	   marker	   IV	  
(Invitrogen)	   was	   used	   to	   identify	   the	   molecular	   weights	   of	   DNA	   bands.	   Gel	   was	   run	   at	  
10V/cm	  for	  approximately	  1.5	  hours	  and	  viewed	  under	  U.V.	  light.	  	  
	  
REAGENT	   VOLUME	  (μl)	  
ddH2O	   41.1	  
X10	  Buffer,	  with	  25	  mM	  MgCl2	   5.0	  
Forward	  and	  Reverse	  oligos	  (100	  μM)	   0.2	  
dNTPs	  (10mM)	   1.0	  
Taq	  Polymerase	  (5U/μl)	   0.5	  
Genomic	  DNA	   2.0	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2.5.5	  Sequencing	  of	  PRNP	  	  
	  The	  PRNP	  sequencing	  reaction	  was	  set	  up	  as	  shown	  in	  table	  2.5,	  using	  BigDye	  Terminator	  
v3.1	  kit,	  with	  supplied	  BigDye	  terminator	  and	  x5	  sequencing	  buffer	  (Applied	  Biosystems)	  
(Oligonucleotide	   reverse	   CCCCCAACCTGGCAAAGATTAAGA	   (3’	   to	   5’)	   (Sigma	   UK),	   was	  
diluted	  1	  to	  20	  in	  ddH2O.	  Reactions	  conditions	  were	  as	  follows:	  25	  repeats	  of	  96ºC	  for	  10	  
seconds,	  53ºC	  for	  15	  seconds	  and	  60ºC	  for	  4	  minutes.	  Reactions	  were	  purified	  by	  adding	  
EDTA	  (pH	  7.5,	  final	  concentration	  11.3mM)	  followed	  by	  60µL	  100%	  ethanol,	  incubated	  at	  
room	  temperature	  for	  15	  minutes.	  DNA	  was	  pelleted	  by	  centrifugation	  at	  2750	  rpm	  for	  30	  
minutes,	   after	   which	   the	   tubes	   were	   inverted	   and	   pulse	   spun	   upside	   down	   to	   remove	  
residual	   ethanol	   from	   the	   pellet.	   The	   pellet	  was	  washed	  with	   60µL	   of	   70%	   ethanol	   and	  
centrifugation	   repeated.	   Pellets	   were	   air-­‐dried,	   resuspended	   in	   12μl	   of	   formamide	   and	  








	  Table	  2.5	  –	  Sequencing	  reaction	  
 
2.6	  CELL	  CULTURE	  
2.6.1	  Cell	  lines	  
Cell	   lines	   used	   during	   this	   study	  were	   kindly	   gifted	   as	   follows;	  N2a	   cell	   line	  Dr	  Herbert	  
Baybutt,	  The	  Roslin	  institute;	  SMB-­‐PS	  cell	  line,	  Dr	  Rona	  Wilson,	  The	  Roslin	  Institute;	  Rov9	  
REAGENT	   VOLUME	  (μl)	  
ddH2O	   11.0	  
X5	  Sequencing	  Buffer	   3.0	  
F	  and	  R	  Oligos	  (5μM)	   0.2	  
Big	  Dye	  terminator	   2.0	  
Purified	  PCR	  reaction	   3.0	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cell	   line,	   Didier	   Vilette,	   (National	   Institute	   for	   Agricultural	   Research,	   France);	   CHOVRQ,	  
CHOARQ	  and	  CHOARR	  cell	  lines,	  Alex	  Bossers	  (Wageningen	  University,	  The	  Netherlands).	  
	  
2.6.2	  Establishing	  primary	  neuronal	  cultures	  
The	   following	  procedure	  was	  performed	  under	  aseptic	   conditions.	  The	  heads	  of	  17-­‐day-­‐
old	   freshly	  killed	  mouse	  embryos	  (transgenic	   lines	   tg338	  and	  tgARQ)	   in	  Hanks	  Balanced	  
Salt	  Solution	  (HBSS)	  were	  placed	  on	  ice.	  The	  brain	  tissue	  was	  removed	  by	  carefully	  peeling	  
back	  the	  skin	  and	  skull	  tissue	  and	  placed	  in	  fresh	  HBSS.	  0.3mLs	  of	  TrpyLE™	  (GIBCO®)	  was	  
added	  per	  brain	  and	  incubated	  for	  15	  minutes	  at	  37˚C.	  TrpyLE™	  was	  removed	  by	  pipetting	  
and	  the	  brains	  were	  washed	  in	  HBSS,	  which	  was	  subsequently	  removed	  by	  pipetting.	  The	  
brains	  were	   incubated	   for	   10	  minutes	   in	   neuronal	  media	   (Neurobasal	  media,	   2	  %	  B-­‐27	  
supplement	   (v/v),	   Penicillin	   (100U/ml),	   Streptomycin	   (100μg/ml),	   2mM	   L-­‐glutamine)	  
1mL	   per	   brain	   and	   the	   tissue	   was	   dissociated	   by	   repeated	   pipetting	   using	   a	   electronic	  
10ml	  serological	  pipette	  (PipetteBoy,	  INTEGRA).	  At	  this	  point	  the	  cells	  were	  counted	  using	  
a	   heamocytometer.	   For	   the	   differentiation	   of	   primary	   neurons,	   cells	   were	   plated	   at	   a	  
density	  of	  2.3	  x	  104	  cells/mL	  on	   cell	   culture	  plates	  or	  glass	   cover	   slips	   coated	   in	  poly-­‐D-­‐
lysine	  hydrobromide	  (Sigma)	  and	  incubated	  at	  37˚C,	  0.5	  %	  C02.	  	  	  
	  
2.6.3	  Establishing	  neurosphere	  cultures	  
To	   establish	   long-­‐term	   cultures	   and	   reduce	   the	   numbers	   of	   animals	   required,	  
neurospheres	  were	  created.	  These	  are	  precursor	  cells,	  which	  readily	  divide	  in	  culture	  and	  
can	   be	   later	   differentiated	   into	   neurons.	   For	   the	   production	   of	   neurospheres	   around	  
5.0x106	   cells	   were	   plated	   in	   a	   25cm2	   flask	   along	   with	   8mLs	   of	   growth	   medium	   with	  
addition	   of	   10	   nM	   epidermal	   growth	   factor	   (EGF)	   and	   10	   nM	   fibroblast	   growth	   factor	  
(FGF)	   and	   incubated	   at	   37˚C	   for	   >20	   days.	   The	   morphology	   was	   monitored	   and	  
CHAPTER 2 – GENERAL MATERIALS AND METHODS 
	   49	  
neurospheres	  were	  identified	  as	  large	  round	  floating	  aggregates	  of	  undifferentiated	  cells.	  
The	   suspension	   was	   centrifuged	   at	   500rpm	   for	   2	   minutes	   and	   the	   supernatant	   was	  
discarded.	  	  For	  long	  term	  storage	  of	  neurospheres	  the	  pellet	  was	  resuspended	  in	  modified	  
freezing	  media	   (Growth	  media,	   10	  %	   (v/v)	  DMSO),	   then	   frozen	   at	   -­‐70˚C	   for	  24	  hours	   in	  
Nalgene®	  Cryol˚C	  container,	  after	  which	  they	  were	  moved	  to	  -­‐180˚C	  for	  long-­‐term	  storage.	  
For	   direct	   differentiation	   into	   primary	   neurons	   neurospheres	   were	   pelleted	   by	  
centrifugation	   at	   500rpm	   and	   incubated	   in	   TrpyLE™	   (GIBCO®)	   at	   37°C	   for	   5	   minutes.	  	  
Cells	  were	  transferred	  to	  fresh	  neuronal	  media,	  in	  the	  absence	  of	  EGF	  and	  disassociated	  by	  
pipetting.	  Cells	  were	  plated	  and	  cultured	  as	  section	  2.6.4.	  
	  
Cell	  line	   Growth	  media	   Reference	  
N2a	   44.5%	   DMEM	   (v/v),	   45%	   Opti-­‐MEM	   (v/v),	   10%	   FCS,	   Penicillin	  
(100U/ml),	  Streptomycin	  (100μg/ml).	  
Available	  commercially	  
SMB-­‐PS	   Media	   199,	   10	   %	   FCS	   (v/v),	   Penicillin	   (100U/ml),	   Streptomycin	  
(100μg/ml).	  
Clarke	  and	  Haig,	  1970	  
CHO	   EMEM,	   10%	   FCS	   (v/v),	   Penicillin	   (100U/ml),	   Streptomycin	  
(100μg/ml),	  Hygromycin	  B	  (Sigma)	  (500μg/ml).	  
Rigter	  and	  Bossers,	  2005	  
Rov9	   Opti-­‐MEM,	   10%	   FCS	   (v/v),	   Penicillin	   (100U/ml),	   Streptomycin	  
(100μg/ml).	   For	   PrP	   expression	   Doxycycline	   (Sigma)	   to	   final	  
concentration	  of	  (1μg/ml).	  
Vilette	  et	  al,	  2000	  
Table	  2.6	  -­‐	  Cell	  line	  specific	  growth	  media	  and	  supplements.	  
	  
2.6.4	  Maintenance	  of	  immortalised	  cell	  lines	  
All	  cell	  culture	  was	  performed	  under	  aseptic	  conditions.	  Cells	  were	  thawed	  quickly	  at	  37°C	  
and	   slowly	   introduced	   to	   preheated	   specific	   growth	   media,	   indicated	   in	   Table	   2.6	   (All	  
purchased	   from	   Invitrogen	   unless	   otherwise	   stated).	   Cultures	  were	  maintained	   at	   37˚C,	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0.5	  %	  CO2	  and	  at	  around	  80	  %	  confluence	  unless	  otherwise	  stated	  in	  text.	  	  Cells	  were	  split	  
when	   required	   by	   removing	   culture	   media	   and	   washing	   twice	   with	   HBSS.	   Cells	   were	  
dislodged	   from	   culture	   flasks	   by	   addition	   of	   Trypsin-­‐EDTA	   (X1)	   and	   incubating	   for	   10	  
minutes	   at	   37˚C.	   An	   equal	   volume	   of	   growth	   media	   was	   added	   and	   cells	   pelleted	   by	  
centrifugation	  at	  500rpm	  for	  5	  minutes.	  The	  cell	  pellet	  was	  resuspended	  in	  growth	  media	  
and	   plated	   at	   desired	   concentration,	   approximately	   calculated	   by	   cell	   counting	   using	   a	  
hemocytometer. 
	  
2.6.5	  Freezing	  of	  immortalised	  cell	  lines	  
Cell	   lines	   were	   frozen	   to	   create	   working	   cell	   banks.	   Cells	   were	   dislodged	   from	   culture	  
flasks	  by	  addition	  of	  Tripsin-­‐EDTA	  (X1)	  and	  incubating	  for	  10	  minutes	  at	  37	  ˚C.	  An	  equal	  
volume	  of	  growth	  media	  was	  added	  and	  cells	  pelleted	  by	  centrifugation	  at	  500rpm	  for	  5	  
minutes.	   The	   cell	   pellet	   was	   resuspended	   in	   modified	   freezing	   medium	   (45	   %	   (v/v)	  
growth	  medium,	  45	  %	  (v/v)	  FCS	  and	  10	  %	  (v/v)	  DMSO)	  and	  frozen	  at	  -­‐70˚C	  for	  24	  hours	  
in	  a	  Nalgene®	  Cryol	  ˚C	  container.	  Cell	  banks	  were	  stored	  at	  -­‐170˚C.	  
	  
2.6.6	  Lysis	  of	  cultured	  cells	  	  
Media	  was	  removed	  from	  plates	  and	  stored	  at	  4	  ˚C.	  Wells	  were	  washed	  with	  cold	  PBS	  (X1)	  
and	  250	  µL	  of	   lysis	  buffer	  (5	  %	  NP-­‐40	  (v/v),	  12.1	  mM	  Sodium	  deoxycholate	   in	  PBS	  with	  
protease	   inhibitors	  10	  µM	  PMSF,	  10	  µM	  NEM)	  was	  added	  per	  well	  of	  a	  6	  well	  plate.	  The	  
cells	  were	  scraped	  from	  the	  surface	  and	  suspension	  was	  syringed	  repeatedly	  to	  manually	  
lyse	  the	  cells.	  The	  suspension	  was	  clarified	  by	  centrifugation	  at	  500rpm	  for	  3	  minutes	  and	  
supernatant	  collected,	  flash	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐20˚C.	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2.6.7	  Estimation	  of	  total	  protein	  concentration	  in	  cell	  lysates	  by	  bicinchoninic	  acid	  
assay	  (BCA)	  
As	  a	  result	  of	  differences	   in	  the	  confluence	  of	  cell	  cultures	   it	  was	  necessary	  to	  normailse	  
the	  protein	   concentration	   in	   cell	   lysates	  using	   the	  BCA	  assay	   (Pierce).	  All	   reagents	  were	  
provided	  with	  the	  kit	  and	  the	  protocol	  was	  followed	  from	  the	  manufacturers	  instructions.	  
Briefly,	  BSA	  protein	  standards	  were	  diluted	   in	  ddH2O,	  ranging	  from	  2	  mg/ml	  –	  0	  mg/ml.	  
BSA	  standard	  or	  cell	  lysate	  (25	  µl)	  was	  aliquoted	  into	  a	  96	  well	  plate	  and	  diluted	  with	  200	  
μl	   of	   activated	   reagent	   (50:1,	   A:	   B)	   per	  well.	   The	   protein	   concentration	   of	   samples	  was	  
calculated	  using	  the	  BSA	  standard	  curve.	  
	  
2.7	  STATISTICAL	  ANALYSIS	  
The	   two-­‐tailed	   T	   test	   was	   used	   to	   test	   for	   statistically	   significant	   differences	   between	  
means	   from	   two	   data	   sets.	   Errors	   bars	   for	   in	   vivo	   data	   represent	   calculated	   standard	  
deviation	  (SD)	  from	  the	  mean,	  while	  for	  in	  vitro	  data	  error	  bars	  are	  representative	  of	  the	  
standard	  error	  of	  the	  mean	  (SEM).	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CHAPTER	  3	  
PRODUCTION	  AND	  EVALUATION	  OF	  ANTIBODIES	  FOR	  THE	  STUDY	  




Many	   conventional	   methods	   of	   PrPC	   analysis	   relevant	   for	   this	   study,	   such	   as	   western	  
blotting	   depend	   highly	   on	   the	   use	   of	   monoclonal	   antibodies.	   For	   example,	   differential	  
binding	   efficiencies	   of	   antibodies	   to	   cellular	   PrPC	   may	   result	   from	   sequence	  
polymorphisms	   around	   their	   epitopes,	   such	   as	   SAF84	  which,	   specifically	   binds	   to	   171Q	  
allotypes	   and	   shows	   little	   or	   no	   reactivity	   with	   171R	   or	   recombinant	   PrPARR	   (Jacobs,	  
Bossers	   et	   al.	   2011).	   There	   are	   PrPC	   specific	   antibodies	   which	   were	   thought	   to	   display	  
different	   binding	   affinities	   to	   di-­‐,	  mono-­‐,	   and	   un-­‐glycosylated	   PrPC	   but	   these	   differences	  
have	   since	  been	   shown	   to	   rise	   from	   the	   ability	   of	   C-­‐terminal	   antibodies	   to	   recognise	  di-­‐	  
and	  mono-­‐glycosylated	   truncated	  proteins	  C1	  and	  C2	  which	   in	   the	  absence	  of	  PNGase	  F,	  
are	   similar	   in	   size	   to	   un	   and	  mono-­‐glycosylated	   PrPC	   (Figure	   1.7)	   (Kuczius,	   Grassi	   et	   al.	  
2007).	   To	   ensure	   correct	   comparisons	   of	   both	   full	   length	   protein	   and	   truncated	   protein	  
between	  samples	  from	  sheep	  of	  different	  PRNP	  genotypes	  antibodies	  are	  required	  which	  
show	  minimal	  variability	  in	  their	  affinities.	  	  
	  
3.2	  AIMS	  AND	  OBJECTIVES	  
The	  aim	  of	  this	  chapter	  was	  to	  assess	  and	  select	  the	  most	  sensitive	  anti-­‐PrP	  antibody	  for	  
which	  affinity	  was	  not	  affected	  by	  the	  most	  important	  ovine	  PRNP	  polymorphisms.	  Firstly,	  
to	   ensure	   that	   PrPC	   protein	   levels	   could	   be	   accurately	  measured	   throughout	   this	   thesis	  
several	   new	   in-­‐house	   anti-­‐PrP	   monoclonal	   antibodies	   were	   purified	   and	   compared	   for	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binding	   to	   both	   full-­‐length	   PrPC	   and	   truncated	   forms	   isolated	   from	   brain	   tissue.	  
Additionally,	  protocols	  were	  optimised	  and	  assessed	  for	  reproducibility.	  	  
	  
3.3	  MATERIALS	  AND	  METHODS	  
3.3.1	  Harvesting	  and	  purification	  of	  monoclonal	  antibodies	  
	  Working	   cell	   bank	   stocks	   of	   hybridoma	   cell	   lines	   JB10	   (773/2/7-­‐	   10/03/10),	   FH10	  
(772/2/6	  4403)	   and	  BC6	   (F782/2/7)	  were	   kindly	  donated	  by	   Sandra	  McCutcheon	   (The	  
Roslin	   Institute).	   	  Cells	  were	  thawed	  quickly	  and	  slowly	   introduced	  to	  preheated	  growth	  
media	   (RPMI	   +	   L-­‐glutamine,	   10	   %	   FCS	   (v/v),	   2%	   HT	   supplement	   (v/v)	   and	   1%	  
penicillin/streptomycin	   (v/v,	   Penicillin	   (100U/ml),	   Streptomycin	   (100μg/ml)).	   These	  
were	  cultured	  until	  confluent	  and	  left	  for	  10	  days	  to	  die	  and	  release	  intracellular	  antibody.	  
The	   suspension	   was	   clarified	   by	   centrifugation	   at	   4000	   rpm	   for	   10mins	   and	   the	  
supernatant	   was	   concentrated	   to	   10%	   of	   initial	   volume	   using	   Vivaflow	   50	   (Sartorius	  
Mechatronics)	   according	   to	   manufactures	   instructions.	   Monoclonal	   antibodies	   were	  
purified	  by	  using	  a	  HiTrap	  protein	  G	  column	  by	  FPLC	  and	  dialysed	  in	  PBS	  (pH	  7.5).	  	  
	  
3.3.2	  Storage	  of	  hybridoma	  cell	  lines	  
Hybridoma	  cell	   lines	  were	   frozen	  when	  cultures	  were	  around	  60%	  confluent.	  Cells	  were	  
dislodged	  from	  the	  surface	  of	  the	  flask	  and	  pelleted	  by	  centrifugation	  at	  1200rpm	  for	  10	  
minutes.	   The	   cell	   pellet	   was	   re-­‐suspended	   in	   modified	   freezing	   medium	   (45%	   (v/v)	  
growth	  medium,	  45	  %	  (v/v)	  FCS	  and	  10	  %	  (v/v)	  DMSO)	  and	  frozen	  at	  -­‐70˚C	  for	  24	  hours	  
in	  a	  Nalgene®	  Cryol˚C	  container.	  Cells	  were	  stored	  at	  -­‐170˚C.	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3.4	  RESULTS	  
3.4.1	  Regrowth,	  purification	  and	  testing	  of	  PrP	  monoclonal	  antibodies	  
Monoclonal	   antibodies	   BC6,	   JB10	   and	   FH10	   were	   quality	   tested	   to	   ensure	   conserved	  
binding	  efficiencies	  with	  previous	  batches	  of	  antibodies.	  FH10	  and	  JB10	  show	  reactivity	  to	  
sheep	  PrPC	  -­‐	  both	  cellular	  and	  PK	  resistant	  -­‐	  but	  with	  greatly	  reduced	  binding	  efficiency	  to	  
murine	  PrPC	  whereas	  BC6	  shows	  strong	  affinity	   to	  both	  murine	  and	  ovine	  PrPC.	  None	  of	  
the	  three	  antibodies	  show	  any	  non-­‐specific	  reactivity	  to	  PrPC	  null	  mouse	  tissue,	  indicating	  















	   	  
	  
	  
	   	  






Figure	  3.1	  –	  Testing	  of	  monoclonal	  antibodies.	  Mouse	  and	  sheep	  brain	  homogenate	  (10	  %)	  
was	  subjected	  to	  western	  blotting	  and	  probed	  with	  newly	  produced	  batches	  of	  monoclonal	  
antibodies	   FH10,	   JB10	   and	   BC6.	  Di-­‐glycosylated	   PrP	   	   (★★),	   Mono-­‐glycosylated	   PrP	   (★	  ),	  
Unglycosylated	  PrP	  (*),	  unglycosylated	  C1	  (***).	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3.4.2	  Antibody	  binding	  to	  PrPC	  in	  sheep	  
A	  panel	   of	   four	  monoclonal	   antibodies	  were	   compared	   for	  binding	   efficacy	   to	  PrPC	   from	  
sheep	  of	  four	  common	  PRNP	  genotypes.	  It	  was	  important	  that	  the	  antibody	  chosen	  would	  
consistently	  reflect	   the	   levels	  of	  both	   full	   length	  and	  truncated	  PrP	   in	  all	   samples	   tested.	  
This	  panel	   included	  commercially	  available	  6H4	  (Prionics)	  and	   those	  produced	   in-­‐house	  
BC6,	  FH10	  and	  JB10	  (sections	  3.3.1	  and	  3.4.1).	  The	  individual	  epitopes	  for	  each	  antibody	  
used	  are	  shown	  in	  Figure	  3.3A.	  As	  both	  6H4	  and	  BC6	  share	  very	  similar	  binding	  epitopes	  
the	  sensitivity	  of	  these	  antibodies	  to	  PrPC	  from	  sheep	  brain	  was	  firstly	  compared	  (Figure	  
3.2).	  Homogenate	  (10	  %w/v)	  from	  the	  ovine	  cortex	  was	  diluted	  to	  0.0625	  %	  homogenate	  
in	   lysis	   buffer	   and	   treated	   with	   PNGase	   F	   (as	   described	   in	   section	   2.2.2).	   The	   diluted	  
samples	  were	  subjected	  to	  western	  blotting	  with	  both	  6H4	  and	  BC6	  antibodies.	  6H4	  could	  
detect	  PrPC	  in	  100	  µg	  of	  ovine	  brain	  but	  not	  at	  lower	  dilutions	  whereas	  BC6	  identified	  both	  
















	  	  	  1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  6	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Figure	   3.2	   –	   Comparison	   of	   PrPC	  detection	   limit	   in	   ovine	  brain	   tissue	   using	  BC6	   and	  
6H4	   monoclonal	   antibodies.	   Cortex	   was	   sampled	   from	   an	   ARQ/ARR	   (61X13)	   sheep	  
brain.	   A	   10	  %	   homogenate	   (w/v)	  was	   prepared	   and	   a	   range	   of	   dilutions	  were	  made	  
from	   neat	   to	   0.625	   %.	   Samples	   were	   treated	   with	   PNGase	   F,	   subjected	   to	   western	  
blotting	   as	   described	   in	   section	   2.3.1	   with	   monoclonal	   antibodies	   6H4	   and	   BC6	   and	  
images	  were	  exposed	  for	  1	  minute.	  Lane	  1	  (400	  µg),	  Lane	  2	  (300	  µg),	  Lane	  3	  (200	  µg),	  
Lane	  4	  (100	  µg),	  Lane	  5	  (50	  µg),	  Lane	  6	  (25	  µg).	  Full	  length	  PrPC	  (*),	  C1	  (***).	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Figure	   3.3	   –	   Comparison	   of	   monoclonal	   antibody	   binding	   to	   ovine	   PrPC	  of	   various	   PRNP	  
genotypes	   by	   western	   blotting.	   A)	   Linear	   diagram	   of	   the	   PrPC	   protein,	   with	   epitopes	   for	  
monoclonal	   antibodies	   6H4,	   BC6,	   FH10	   and	   JB10.	   Showing	   the	   site	   of	  α-­‐cleavage,	   areas	   of	  
helical	  structure	   (αA-­‐C),	  areas	  of	  beta	  sheet	   structure	  (βA-­‐B))	  and	   two	  glycosylation	  sites.	  B)	  
Western	   blotting	   of	   one	   animal	   from	   each	   PRNP	   genotype	   was	   performed	   as	   described	   in	  
section	   2.3.1	   and	   probed	   with	   the	   four	   selected	   antibodies.	   These	   blots	  were	   subjected	   to	  
densitometry	  measurements	  and	  C1	  levels	  calculated.	  Full	  length	  PrPC	  (*),	  C2	  (**),	  C1	  (***).	  C)	  
Graph	  representing	  densitometry	  results	  for	  western	  blots	  shown	  in	  Figure	  3.2B.	  The	  average	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Brain	   tissue	   homogenate	   from	   one	   animal	   of	   each	   of	   the	   following	   PRNP	   genotypes:	  
ARR/ARR,	  ARQ/ARQ,	  AHQ/AHQ	  and	  VRQ/VRQ	  was	  tested	  by	  western	  blot	  and	  probed	  as	  
described	   in	   section	   2.3.1.	   The	   level	   of	   C1	  was	   calculated	   as	   a	   percentage	   of	   total	   PrPC,	  
measured	   by	   densitometry.	   An	   average	   value	   was	   calculated	   for	   each	   animal	   from	   two	  
replicate	   experiments	   shown	   in	   Figure	   3.3C	  with	   the	   average	   C1	   value	   calculated	   as	   an	  
average	  of	  results	  from	  all	  antibodies	  tested,	  represented	  by	  the	  dashed	  line	  (Figure	  3.3C).	  
The	   BC6	   antibody	   epitope	   has	   been	   mapped	   using	   peptide	   scanning	   (Dr	   Sandra	  
McCutcheon,	  personal	  communication,	  The	  Roslin	  Institute),	  which	  defined	  the	  epitope	  in	  
sheep	  PrPC	  as	  encompassing	  amino	  acids	  144-­‐154	  and	  figure	  3.3B	  indicates	  that	  BC6	  has	  
reduced	   binding	   to	   PrPC	   and	   C1	   with	   the	   154H	   allele.	   To	   further	   investigate	   this	  
observation	  total	  protein	  levels	  of	  10	  %	  brain	  homogenate	  from	  ARQ/ARQ,	  ARQ/AHQ	  and	  
AHQ/AHQ	   sheep	   were	   measured	   by	   BCA	   assay,	   loading	   normalised	   and	   subjected	   to	  
western	   blotting	   with	   both	   BC6	   and	   anti-­‐α	   tubulin	   antibodies	   (Figure	   3.4).	   BC6	   shows	  
strong	   reactivity	   to	   PrPARQ/ARQ,	   decreased	   reactivity	   to	   PrPARQ/AHQ	   and	   no	   binding	   to	  
PrPAHQ/AHQ	  with	  equal	  amounts	  of	  brain	  homogenate	  loaded	  per	  well.	  
	  
It	   is	   also	   apparent	   from	   both	   comparing	   data	   collected	   previously	   using	   6H4	   antibody	  
(Charmaine	  Love,	  Ph.D.	  Thesis,	  University	  of	  Edinburgh,	   2010)	   and	   from	  Figure	  3.5	   that	  
monoclonal	   antibody	  6H4	  binds	   less	   efficiently	   to	   the	  C1	   truncated	  protein	   in	  ARR/ARR	  
animals	  compared	  to	  the	  other	  three	  antibodies	  tested.	  To	  further	  investigate	  the	  reduced	  
binding	  of	  6H4	  to	  C1ARR,	  10	  %	  brain	  homogenate	  from	  gene	  targeted	  (gt)	  transgenic	  mice	  
expressing	   the	   same	   level	   of	   either	   sheep	   PrPARR	  or	   sheep	   PrPARQ	   	  (The	   Roslin	   Institute,	  
unpublished)	   were	   subjected	   to	   western	   blotting	   with	   both	   6H4	   and	   BC6	   antibodies	  
(Figure	  3.5).	  Using	  densitometry,	  C1	  was	  calculated	  as	  a	  percentage	  of	   total	  PrPC	  and	  an	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average	   taken	   from	   two	   repeat	   experiments.	   With	   BC6	   antibody	   C1	   was	   calculated	   in	  
gtARR	  mice	  to	  represent	  42	  %	  of	  total	  PrPC	  whereas	  with	  6H4	  C1	  was	  calculated	  as	  20	  %	  
of	  total	  PrPC.	  In	  contrast	  in	  gtARQ	  mice	  C1	  was	  calculated	  as	  40	  %	  of	  total	  PrPC	  with	  BC6	  













    
 










Figure	  3.5	  –	  6H4	  has	  reduced	  binding	  to	  truncated	  PrPARR	  produced	  in	  in	  transgenic	  mice.	  10	  
%	  brain	  homogenate	  from	  gtARQ	  (Lanes	  1	  and	  3)	  and	  gtARR	  (Lanes	  2	  and	  4)	  were	  treated	  with	  
PNGase	   F	   and	   subjected	   to	   western	   blotting	   with	   6H4	   and	   BC6	   monoclonal	   antibodies,	   as	  
described	  in	  section	  2.3.1.	  Full	  length	  PrP	  (*),	  C2	  (**),	  C1	  (***).	  
6H4	  BC6	  













Figure	   3.4	   –	   BC6	   has	   reduced	   binding	   to	   PrPAHQ.	   Equal	   concentrations	   of	   10	   %	   brain	  
homogenate	   from	   sheep	   of	   genotypes	   AHQ/AHQ	   (Lanes	   1	   and	   2),	   ARQ/AHQ	   (Lane	   3)	   and	  
ARQ/ARQ	  (Lane	  4),	  were	   treated	  with	  PNGase	  F	  and	  subjected	  to	  western	  blotting	  with	  BC6	  
monoclonal	  antibody	  and	  anti-­‐α	   tubulin	  as	  described	   in	  section	  2.3.1.	  Full	   length	  PrP	   (*),	  C2	  
(**),	  C1	  (***)	  and	  -­‐α	  tubulin	  (T).	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To	  allow	  comparison	  of	  the	  data	  presented	  in	  this	  thesis	  with	  other	  results	  from	  scientific	  
collaborators,	   C1	   levels	   calculated	   from	   western	   blotting	   in	   sheep	   brain	   with	   Bar224	  
monoclonal	   antibody	  were	   compared	   to	   those	   calculated	   from	  BC6	   (Figure	   3.6).	   In	   four	  
out	  of	  five	  sheep	  use	  of	  Bar224	  resulted	  in	  slightly	  higher	  C1	  levels	  compared	  to	  BC6	  but	  
































ARR/ARR	  	  	  	  	  ARR/ARR	  	  	  	  	  	  ARR/ARR	  	  	  	  ARQ/ARQ	  	  	  	  ARQ/ARQ	  
	  
Figure	   3.6	   –	   Comparison	   of	   C1	   levels	   in	   the	   cortex	  of	   ARR/ARR	   and	  ARQ/ARQ	   sheep	   using	  
different	   monoclonal	   antibodies	   A)	   Western	   blots	   of	   ovine	   cortex	   probed	   with	   monoclonal	  
antibody	  Barr	  224	  as	  described	  in	  section	  2.3.1;	  Lane	  1(O22,	  ARR/ARR),	  Lane	  2	  (O30,	  ARR/ARR),	  
Lane	   3	   (61x04,	   ARR/ARR),	   Lane	   4(Pg0443,	   ARQ/ARQ),	   Lane	   5	   (Pg0877,	   ARQ/ARQ).	   B)	   Graph	  
showing	  C1	  levels	  calculated	  for	  each	  animal	  when	  probed	  with	  each	  monoclonal	  antibody.	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3.4.3	  Quantification	  of	  western	  blotting	  analysis	  by	  densitometry	  
To	  semi-­‐quantify	  protein	  levels	  from	  western	  blots,	  gel	  images	  were	  scanned	  and	  analysed	  
by	  densitometry	  using	  the	  Kodak	  IM	  software.	  The	  method	  of	  manual	  band	  selection	  was	  
chosen	   to	   take	   into	   account	   irregularities	   in	   shape,	   size	   and	   spacing	  of	  bands	  and	   lanes.	  
The	   net	   intensity	   was	   taken	   for	   bands	   of	   full	   length	   PrPC,	   C2	   and	   C1	   and	   levels	   of	   the	  
truncated	  isoforms	  were	  calculated	  as	  a	  percentage	  of	  total	  PrPC	  (100	  %).	  It	  was	  important	  
to	  ensure	  that	  selection	  of	  western	  blot	  bands	  using	  this	  manual	  region	  of	  interest	  setting	  
was	   reproducible	  and	  was	  not	   subject	   to	  human	  error.	  To	   test	   reproducibility,	   the	   same	  
gel	  image	  (Figure	  3.7A)	  was	  subjected	  to	  four	  separate	  analyses	  on	  non-­‐consecutive	  days.	  
Figure	   3.7B	   shows	   the	   calculated	   C1	   levels	   for	   each	   repeat.	   	   The	   largest	   margin	   of	  











Figure	   3.7	   -­‐	   Reproducibility	   of	   densitometry	   method	   for	   analysis	   of	   western	   blots.	   A)	  
Sheep	  cortex	  from	  four	  animals	  (Lane	  1-­‐4)	  treated	  with	  PNGase	  F,	  tested	  by	  western	  blot,	  
and	  probed	  with	  monoclonal	  antibody	  BC6	  as	  described	   in	   section	  2.3.1.	  Full	   length	  PrPC	  
(*),	  C2	  (**),	  C1	  (***).	  B)	  C1	  levels	  calculated	  as	  a	  percentage	  of	  total	  PrPC.	  Each	  marker	  is	  
representational	  of	  an	  independent	  single	  reading	  taken	  on	  consecutive	  days.	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As	   pre-­‐loading	   total	   protein	   assays	   were	   not	   performed	   before	   western	   blotting	   it	   was	  
accepted	  that	  loading	  concentrations	  would	  vary	  slightly	  between	  samples.	  Although	  care	  
was	  taken	  to	  accurately	  prepare	  10	  %	  (w/v)	  homogenates	  for	  each	  sample	  the	  brain	  tissue	  
in	  some	  cases	  was	  taken	  from	  a	  frozen	  tissue	  archive.	  As	  a	  result,	  over	  time	  this	  may	  have	  
been	   subjected	   to	   desiccation,	   increasing	   the	   protein	   concentration/mg.	   A	   dilution	  
experiment	  was	   performed	   to	   assess	   if	   changes	   in	   the	  mass	   of	   protein	   loaded	   per	   lane	  
would	  have	  an	  effect	  on	  antibody	  binding	  or	  densitometry	  analyses.	  Dilutions	  of	  the	  same	  
sample	  were	  made	   in	   lysis	  buffer	   ranging	   from	  undiluted	  (10	  %	  w/v)	   to	  1	  %	  (w/v)	  and	  
subjected	   to	   western	   blotting	   and	   densitometry.	   In	   this	   specific	   case	   the	   C1	   level	   was	  
calculated	   to	   be	   52	  %	   of	   total	   PrPC	   in	   the	   10	  %	   (w/v)	   sample,	   57	  %	   in	   the	   5	  %	   (w/v)	  
sample,	  59	  %	  in	  the	  2	  %	  (w/v)	  sample	  and	  52	  %	  in	  the	  1	  %	  (w/v)	  sample.	  This	  finding	  was	  
important	   as	   it	   showed	   that	   C1	   levels	   calculated	   using	   this	   methodology	   were	   not	  
influenced	   by	   the	   amount	   of	   homogenate	   loaded	   onto	   a	   gel.	   These	   four	   measurements	  
resulted	  in	  a	  standard	  deviation	  of	  	  ±	  3.55	  from	  the	  mean	  of	  55	  %	  (Figure	  3.8).	  Therefore,	  
the	   standard	   variation	   of	   this	   method	   exclusive	   of	   biological	   and	   sample	   preparation	  

































Lane	  of	  gel	  
	  
Figure	  3.8	  -­‐	  The	  effects	  of	  protein	  loading	  on	  calculated	  C1	  levels.	  A)	  Western	  blot	  of	  sheep	  
cortex	  sample	  diluted	  and	  probed	  with	  BC6	  antibody	  as	  described	  in	  section	  2.3.1.	  Full	  length	  
PrPC	  (*),	  C1	  (***).	  Lane	  1	  (Undiluted,	  10	  %	  w/v),	  Lane	  2	  (5	  %	  w/v),	  Lane	  3	  (2	  %	  w/v),	  Lane	  4	  (1	  
%	  w/v).	  Densitometry	  was	  performed	  and	  C1	  levels	  calculated	  as	  a	  percentage	  of	  total	  PrPC.	  
B)	  Graph	  of	  densitometry	  results	  for	  each	  lane.	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3.5	  DISCUSSION	  
3.5.1	  The	  selection	  of	  an	  antibody	  for	  detection	  of	  PrPC	  in	  brain	  by	  immunoblotting	  
The	   antibodies	   newly	   assessed	   for	   their	   binding	   to	  PrPC	  were	   created	  within	  The	  Roslin	  
Institute	   (BC6,	   FH10,	   JB10),	   reviewed	   by	   McCutcheon	   (2014)	   and	   new	   batches	   were	  
produced	   for	   the	   purpose	   of	   this	   thesis.	   This	   ensured	   that	   all	   immuno-­‐blotting	   was	  
performed	   using	   one	   batch	   to	   avoid	   variation	   in	   concentration	   or	   efficacy	   sometimes	  
associated	   with	   batches	   of	   commercially	   available	   antibodies.	   BC6,	   JB10	   and	   FH10	  
represent	   useful	   C-­‐terminal	   antibodies,	   which	   recognise	   both	   full	   length	   PrPC	   and	  
truncated	   proteins	   C1	   and	   C2	   in	   brain	   tissue.	   BC6	   was	   found	   to	   have	   less	   unspecific	  
background	  when	   compared	   to	  both	   JB10	  and	  FH10	  and	  had	  higher	   sensitivity	   to	  ovine	  
PrPC	  and	  truncated	  proteins	  when	  compared	  to	  6H4,	  particularly	  concerning	  ARR/ARR.	  	  It	  
was	  therefore	  preferential	   to	  use	  BC6	  for	  the	  purpose	  of	  studying	  PrPC	  in	  ovine	  brain	  for	  
the	  genotypes	  selected	  for	  this	  study.	  For	  applications	  involving	  cell	  culture	  derived	  PrPC	  
JB10	  has	  the	  advantage	  of	  having	  no	  or	  very	  low	  reactivity	  to	  murine	  or	  hamster	  PrPC.	  For	  
example,	   this	   antibody	   was	   used	   to	   distinguish	   between	   ovine	   and	   hamster	   PrPC	   in	  
transfected	  CHO	  cells	  (data	  not	  shown).	  
	  
3.5.2	  Ovine	  PRNP	  polymorphisms	  and	  antibody	  binding	  
With	  one	  of	   the	  main	   aims	  of	   this	   thesis	   to	   investigate	   the	   levels	   of	   full	   length	  PrPC	   and	  
truncated	   proteins	   in	   sheep	   of	   different	   PRNP	   genotypes	   it	   was	   imperative	   that	   the	  
antibody	  used	  for	  immunoblotting	  showed	  no	  loss	  of	  binding	  as	  a	  result	  of	  PRNP	  sequence	  
polymorphisms.	   PrP:	   C1	   ratios	   were	   compared	   in	   the	   cortex	   of	   sheep	   of	   genotypes	  
ARR/ARR,	  AHQ/AHQ,	  ARQ/ARQ	  and	  VRQ/VRQ	  by	  probing	  with	  6H4,	  BC6,	  FH10	  and	  JB10	  
antibodies.	  BC6	  showed	  reduced	  immunoreactivity	  to	  PrPC	  from	  AHQ/AHQ	  sheep	  brain.	  It	  
is	   likely	  that	  the	  variation	  (arginine	  or	  histidine)	  of	  the	  amino	  acid	  at	  position	  154	  alters	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the	   affinity	   of	   BC6.	   Binding	   may	   be	   disrupted	   by	   variation	   in	   charges	   at	   the	   antibody	  
epitope	  for	  example,	  arginine	  is	  fully	  positively	  charged	  at	  cellular	  pH	  whereas	  only	  50	  %	  
of	  histidine	  will	  be	  charged.	  Secondly,	  arginine	  and	  histidine	  differ	  structurally.	  Histidine	  is	  
both	   smaller	   in	   size	   compared	   to	   arginine	   and	   has	   an	   aliphatic	   ring	   which	   could	   affect	  
antibody	  binding	  to	  proteins	  with	  154H.	  This	   is	  an	   important	   finding	   if	  we	  consider	  that	  
BC6	  has	  previously	  been	  used	  for	  the	  detection	  of	  PrPSc	  (Tan,	  Blanco	  et	  al.	  2012)	  and	  may	  
also	   fail	   to	   recognise	   PrPSc	   from	   AHQ	   carriers.	   This	   data	   suggests	   that	   ovine	   genotype	  
should	   be	   considered	   before	   immunological	   detection	   of	   PrPSc/PrPC	   in	   ovine	   tissues.	  
Moreover,	   it	  would	  be	  advised	  that	  new	  antibodies	  should	  be	  tested	  on	  all	  known	  alleles	  
or	  as	  new	  alleles	  become	  of	  interest	  in	  prion	  research	  they	  be	  screened	  with	  a	  selection	  of	  
available	  antibodies.	  
	  
Antibody	  6H4	  which	  is	  used	  for	  rodent	  and	  ruminant	  prion	  protein	  studies	  has	  a	  light	  but	  
consistent	  reduction	  of	  binding	  affinity	  to	  the	  truncated	  C1	  171R	  (C1ARR)	  compared	  to	  C1	  
171Q	  	  (C1ARQ	  or	  C1VRQ)	  which	  does	  not	  appear	  to	  affect	  the	  full-­‐length	  protein	  affinity.	  This	  
is	  difficult	   to	  understand	  as	   the	  epitope	  of	  6H4	  DYEDRYYRE	   in	  helix	  1	   (codon	  147-­‐155)	  
should	   not	   be	   directly	   affected	   by	   the	   truncation	   of	   the	   protein	   at	   amino	   acid	   115.	  
Although,	   the	  mechanism	   of	   this	   altered	   binding	   cannot	   yet	   be	   explained	   this	   antibody	  
should	  not	  be	  used	  for	  the	  study	  of	  PrPC	  processing	  in	  sheep	  with	  171R.	  
	  	  
3.5.3	  Evaluation	  of	  densitometry	  as	  a	  method	  to	  calculate	  PrP:C1	  ratio	  in	  brain	  tissue	  
To	  allow	  quantification	  of	   relative	   levels	  of	   truncated	  proteins	   in	  brain	  samples	  western	  
blot	   images	   were	   subjected	   to	   densitometry.	   Using	   manual	   band	   selection,	   which	  
accounted	   for	   abnormalities	   in	   band	   shape,	   there	  was	   little	   variation	   between	   separate	  
readings,	   henceforth	   it	  was	   thought	   sufficient	   to	   analyse	   gel	   images	   only	   once	  with	   this	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technique.	  These	  experiments	  have	  also	  shown	  that	  amount	  of	  protein	   loaded	  onto	  a	  gel	  
has	  little	  influence	  on	  C1	  level	  when	  calculated	  relative	  to	  the	  amount	  of	  total	  PrPC	  using	  
this	  method.	  This	  method	  was	  used	   throughout	   this	   thesis	   to	  maintain	   consistency	  with	  
results	  however	   it	   is	  envisaged	   that	   in	   the	   future	  direct	  detection	  based	  on	   fluorescence	  
will	  be	  employed.	  
	  
3.5.6	  Conclusions	  
The	  aim	  of	  this	  chapter	  was	  to	  assess	  and	  select	  a	  sensitive	  anti-­‐PrP	  antibody	  with	  which	  
affinity	   was	   not	   affected	   by	   ovine	   PRNP	   polymorphisms.	   The	   selection	   of	   appropriate	  
antibodies	   for	   the	   study	   of	   protein	   expression	   is	   pivotal	   to	   ensuring	   findings	   accurately	  
represent	  the	  in	  vivo	  situation.	  In	  the	  case	  of	  PrPC,	  BC6	  was	  selected	  to	  use	  for	  all	  further	  
western	   blotting.	   This	   antibody	   has	   high	   sensitivity	   and	   specificity	   to	   ovine	   PrPC	   and	  
truncated	  PrPC	  C-­‐terminal	  fragments	  within	  brain	  tissue	  -­‐	  an	  important	  factor	  as	  some	  of	  
the	   truncated	   PrPC	   proteins,	   such	   as	   C2	   are	   present	   at	   very	   low	   concentrations.	   The	  
inability	   of	   BC6	   to	   bind	   154H	   was	   not	   considered	   to	   hinder	   this	   study	   as	   the	   animals	  
selected	  were	  all	  homozygous	  154R.	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CHAPTER	  4	  
	  EXPRESSION	  AND	  PROTEOLYTIC	  PROCESSING	  OF	  THE	  CELLULAR	  




As	   described	   in	   section	   1.3.4	   and	   1.3.5	   cellular	   processing	   of	   PrPC	   involves	   two	   well-­‐
documented	   proteolytic	   cleavage	   events	   (Mange,	   Beranger	   et	   al.	   2004,	  Tveit,	   Lund	   et	   al.	  
2005).	   In	   the	   case	   of	   α-­‐cleavage	   both	   cleavage	   fragments,	   C1	   and	   N1,	   appear	   to	   have	  
additional	  or	  possibly	  supplementary	  functions	  to	  those	  of	  full	  length	  PrPC.	  	  It	  is	  a	  long	  held	  
view	   that	  prion	  disease	   incubation	  periods	  are	   correlated	  with	   the	  amount	  of	  PrPC.	   This	  
has	  been	  demonstrated	   in	  various	  transgenic	  mouse	  models	   in	  which	   incubation	  periods	  
of	   experimentally	   induced	   prion	   diseases	   are	   inversely	   correlated	  with	   the	   PrPC	  protein	  
expression	  (Manson,	  Clarke	  et	  al.	  1994,	  Weissmann,	  Bueler	  et	  al.	  1994).	  However,	  often	  in	  
these	   studies	   the	   levels	   of	   full-­‐length	   PrPC	   and	   its	   proteolytic	   fragments	   have	   not	   been	  
differentiated.	  Recently	  it	  was	  shown	  conclusively	  that	  the	  murine	  C1	  fragment	  itself	  does	  
not	   convert	   into	   a	   protease-­‐resistant	   isoform	   in	   scrapie	   challenged	   transgenic	   mice	  
expressing	  only	  C1.	  Furthermore,	  when	  the	  C1	  fragment	  was	  co-­‐expressed	  with	  full-­‐length	  
PrPC	   incubation	  periods	  were	   extended	   (Westergard,	  Turnbaugh	   et	   al.	   2011).	   It	   has	   also	  
been	   shown	   that	   cell	   lines	   with	   naturally	   higher	   levels	   of	   α-­‐cleavage	   show	   enhanced	  
resistance	  to	  prion	  infection	  (Lewis,	  Hill	  et	  al.	  2009).	  This	  raises	  the	  possibility	  that	  PrPC	  
cleavage	  may	  control	  disease	  by	  either	   reducing	   the	  amount	  of	   full	   length	  PrPC	  available	  
for	   conversion	   or	   by	   producing	   different	   levels	   of	   the	   C1	   fragment,	   which	  would	   act	   as	  
inhibitory	   modulators	   of	   conversion.	   Additionally,	   in	   sheep	   the	   natural	   host	   of	   scrapie,	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highly	   complex	   genetic	   variation	   and	   disease	   association	   of	  PRNP	   could	   be	   the	   result	   of	  
processing	  differences	  of	  the	  many	  PrPC	  protein	  variants.	  
	  
Experimental	  considerations	  
During	   this	   study	   it	   was	   vital	   that	   the	   tissues	   tested	   were	   scrapie	   free	   to	   allow	   for	  
investigations	   into	   ‘normal’	   cellular	   process	   to	   be	   made.	   In	   the	   Roslin	   Institute	   flock	  
scrapie	   is	   endemic	   producing	   disease	   in	   VRQ/VRQ	   and	   VRQ/ARQ	   sheep	   generally	   over	  
two	  years	  of	  age.	  As	  a	  result	  healthy	  sheep	  tissue	  of	  the	  most	  susceptible	  PRNP	  genotype,	  
VRQ/VRQ	  was	  sourced	  from	  a	  scrapie	  free	  sheep	  flock	  (AHVLA).	  For	  this	  reason	  numbers	  
of	  sheep	  in	  this	  group	  are	  lower	  than	  in	  other	  genotype	  groups.	  It	  was	  also	  imperative	  that	  
the	  animals	  used	  were	  homozygous	  for	  the	  resistance/susceptibility	  haplotype	  in	  order	  to	  
generate	  clear	  results,	  reducing	  sample	  size	  considerably.	  Low	  sample	  size	  was	  considered	  
to	   be	   of	   secondary	   importance	   to	   the	   benefits	   of	   using	   a	   large	   animal	   model,	   naturally	  
infected	  with	  scrapie	  over	  ovine	  transgenic	  mouse	  models.	  
	  
It	   was	   previously	   thought	   that	   PrPC	   cleavage	   products	   may	   accumulate	   after	   death,	  
representing	  an	  artifact	  produced	  on	   tissue	  degradation	  or	   fragmentation	  of	   the	  protein	  
on	   storage	   and	   freeze/thaw	   cycles.	   However,	   this	   has	   been	   investigated	   by	   several	  
research	  groups	  through	  the	   incubating	  of	   tissue	  samples	  at	  different	  temperatures	  over	  
increasing	  time	  periods	  in	  the	  absence	  of	  protease	  inhibitors,	  with	  no	  differences	  in	  levels	  
of	  C1	  isoform	  observed	  (Laffont-­‐Proust,	  Hassig	  et	  al.	  2006)	  (Charmaine	  Love,	  PhD	  Thesis,	  
University	   of	   Edinburgh).	   It	   has	   also	  been	   shown	   that	   there	   is	   no	   significant	   correlation	  
between	  α-­‐cleavage	  and	  age	  at	  death	  or	  time	  of	  post-­‐mortem	  interval	  in	  humans	  (Laffont-­‐
Proust,	   Faucheux	   et	   al.	   2005).	   	   To	   distinguish	   these	   cleavage	   fragments	   from	   full	   length	  
PrPC	  PNGase	  F	  was	  used	   to	   remove	   the	  N-­‐glycans.	  This	   assay	   involves	   the	   incubation	  of	  
CHAPTER 4 – EXPRESSION AND PROTEOLYTIC PROCESSING OF THE CELLULAR PRION PROTIEN IN 
BRAIN 
	   67	  
homogenates	  at	  37°C	  for	  2	  hours,	  which	  could	  induce	  degradation	  of	  PrPC	  and	  affect	  levels	  
of	  truncated	  proteins.	  In	  previous	  experiments	  within	  our	  laboratory	  10	  %	  homogenates	  
were	  incubated	  with	  PNGase	  F	  for	  up	  to	  24	  hours	  at	  37	  °C	  without	  any	  effects	  on	  the	  PrP:	  
C1	   ratio	   (Kayleigh	   Iremonger,	   PhD	   Thesis,	   University	   of	   Edinburgh,	   2013).	   Despite	   the	  
indication	   that	   tissue	   storage	   has	   little	   effect	   on	   C1	   levels	   relative	   to	   PrPC	   several	  
precautions	   were	   taken	   to	   minimize	   tissue	   degradation.	   These	   included	   the	   freezing	   of	  
tissue	  at	  -­‐70°C	  at	  the	  time	  of	  post	  mortem,	  followed	  by	  removal	  of	  tissue	  which	  was	  used	  
to	  prepare	  10	  %	  homogenate.	  This	  homogenate	  was	   aliquoted	   into	   small	   volumes,	   flash	  
frozen	  in	  liquid	  nitrogen	  and	  thawed	  only	  once	  immediately	  before	  use.	  
	  
4.2	  AIMS	  AND	  OBJECTIVES	  
This	  chapter	  presents	  data	  with	  the	  aim	  of	  exploring	  both	  the	  expression	  and	  proteolytic	  
processing	  of	  PrPC	   throughout	   the	   sheep	  brain,	   in	   animals	  with	  varying	   susceptibility	   to	  
TSE	  disease	  defined	  by	  PRNP	  genotype.	  Both	  expression	  and	  proteolytic	  processing	  of	  PrPC	  
were	   compared	   in	   seven	  ovine	  brain	   areas	   and	  proteolytic	   processing	  was	   compared	   in	  
the	  cortex	  of	  sheep	  of	  ARR/ARR,	  ARQ/ARQ	  and	  VRQ/VRQ	  genotypes.	  To	  assess	  if	  levels	  of	  
PrPC	  cleavage	   in	   sheep	   brain	   was	   comparable	   with	   other	   species,	   several	   species	   were	  
tested,	   along	   with	   transgenic	   mouse	  models	   expressing	   ovine	   PrP	   alleles.	   Furthermore,	  
manipulation	  of	  α-­‐cleavage	   in	  cell	   lines	  was	  attempted	  to	  produce	  an	   inducible	  model	  of	  
PrPC	  processing.	  
4.3	  MATERIALS	  AND	  METHODS	  
4.3.1	  Sectioning	  of	  ovine	  brain	  
For	   a	   small	   selection	   of	   sheep	   1cm	   sections	   were	   cut	   from	   the	   left	   side	   of	   ovine	   brain	  
midsection	   at	   post	  mortem	   (Wim	  Bosma,	   Roslin	  NPD	   farm).	   Cores	  were	   removed	   using	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Harris	   Unicore	   3mm	   (Ted	   Pella	   Inc.)	   from	   the	   cortex,	   cerebellum,	   medulla,	   thalamus,	  








4.4.1	  Levels	  of	  PrPC	  fragments	  in	  different	  areas	  of	  ovine	  brain	  
During	   TSE	   disease	   PrPSc	   selectively	   accumulates	   in	   certain	   brain	   areas	   and	   displays	  
varying	   rate	   of	   spread	  within	   the	   brain	   (van	   Keulen,	   Schreuder	   et	   al.	   1995,	  Wemheuer,	  
Benestad	  et	  al.	  2011).	  It	  was	  hypothesised	  that	  this	  may	  be	  influenced	  by	  varying	  levels	  of	  
α-­‐cleavage	   throughout	   the	  ovine	  brain	  as	  a	  mechanism,	  which	   inadvertently	  reduces	   the	  
amount	   of	   PrPC	  available	   for	   conversion	  during	  TSE	  disease.	   Variation	   in	   cleavage	   levels	  
between	  brain	  areas	  may	  also	  indicate	  a	  change	  in	  expression	  of	  the	  protease(s)	  involved	  
in	  cleavage,	  of	  which	  there	  remain	  several	  candidates.	  
	  








Figure	  4.1	  –	  Coring	  from	  the	  ovine	  brain.	  Photograph	  of	  section	  from	  ovine	  brain,	  taken	  
before	   sampling.	   Circles	   indicate	   areas	   where	   3mm	   cores	   were	   removed	   for	   protein	  
extraction.	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Animals	   were	   re-­‐genotyped	   as	   described	   in	   section	   2.5.2	   to	   section	   2.5.5	   prior	   to	  
experimental	  use	   for	  confirmation	  of	  ARR/ARR,	  ARQ/ARQ	  and	  VRQ/VRQ	  carriers	  and	  to	  
exclude	  any	  of	  AHQ/AHQ	  genotype	  (see	  antibody	  reactivity,	  section	  3.4.2).	  The	  removal	  of	  
brain	  slices	  at	  post	  mortem	  to	  extract	  tissue	  samples	  from	  specific	  brain	  areas	  was	  a	  new	  
procedure	  and	  as	  a	   result	   the	  number	  of	   sheep	  available	   to	  be	  culled	   for	   this	   thesis	  was	  
limited.	  These	   included	   three	  ARQ/ARQ,	   two	  ARR/ARR	  and	   two	  ARQ/ARR	   sheep.	   Seven	  
brain	   areas	   were	   selected;	   cortex,	   cerebellum,	   medulla,	   thalamus,	   hypothalamus,	   mid	  
brain	   and	   pons	   to	   give	   coverage	   throughout	   the	   whole	   brain.	   These	   samples	   were	  
removed	  from	  specific	  areas	  by	  coring	  and	  tested	  by	  western	  blot	  using	  BC6	  antibody	  and	  
α-­‐tubulin	   as	   a	   loading	   control.	   To	   visualise	   the	   cleavage	   products	   of	   PrPC,	   the	   samples	  
were	   treated	   with	   PNGase	   F	   to	   remove	   N-­‐glycosylated	   sugars.	   This	   produced	   three	  
characteristic	   bands,	   one	   representing	   full-­‐length	  unglycosylated	  PrPC	  of	   around	  27	  kDa,	  
truncated	  C1	  17kDa	  and	  in	  some	  of	  the	  animals	  tested	  a	  faint	  band	  of	  around	  21	  kDa	  was	  
also	  evident	  which	  most	  likely	  represented	  C2,	  the	  product	  of	  β	  cleavage	  –	  known	  to	  occur	  
at	  lower	  levels	  in	  healthy	  animals	  (Jimenez-­‐Huete,	  Lievens	  et	  al.	  1998).	  	  	  
	  
An	   example	   of	   PrPC	  banding	   patterns	   in	   each	   area	   from	  ARR/ARR	   and	   ARQ/ARQ	   sheep	  
when	  visualised	  by	   immunoblotting	  are	  shown	  in	  Figure	  4.1.	   In	  all	  sheep	  α-­‐cleavage	  was	  
observed	  in	  all	  brain	  areas	  tested	  (Figure	  4.2).	  The	  average	  C1	  levels	  for	  all	  animals	  tested	  
were	  as	  follows;	  hypothalamus	  36.3	  %	  (SD	  ±	  9.7),	  thalamus	  36.3	  %	  (SD	  ±	  9.9),	  cortex	  34.5	  
%	  (SD	  ±	  7.1),	  mid	  brain	  33.1	  %	  (SD	  ±	  9.6),	  medulla	  28.5	  %	  (SD	  ±	  13),	  cerebellum	  25.1	  %	  
(SD	   ±	   11.4),	   and	   pons	   18.5	   %	   (SD	   ±	   8.1),	   	   (Figure	   4.3A).	   Relative	   C1	   levels	   varied	  
considerably	  between	  animals	  (e.g.	  levels	  of	  C1	  in	  the	  cortex	  ranged	  from	  12-­‐48	  %).	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Figure	   4.2	   –	   PrPC	   and	   C-­‐terminal	  
fragments	   in	   seven	   brain	   areas	   from	  
ARR/ARR	   and	   ARQ/ARQ	   sheep.	   Cores	  
were	  removed	  from	  specific	  areas	  and	  10	  
%	   homogenates	  were	  made	   and	   treated	  
with	   PNGase	   F.	   Samples	   were	   subjected	  
to	   western	   blotting	   with	   monoclonal	  
antibody	   BC6	   as	   described	   in	   section	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Figure	  4.3	  –	  Levels	  of	  C1	  throughout	  the	  ovine	  brain.	  A)	  Average	  C1	  levels	  in	  seven	  brain	  
areas	  of	   sheep	  of	  mixed	  PRNP	   genotypes	   (ARR/ARR,	  ARQ/ARQ	  and	  ARQ/ARR,	  n	  =	   7).	  B)	  
Average	  C1	  levels	   in	  seven	  brain	  areas	  of	  ARR/ARR	  sheep	  (n	  =	  2).	  C)	  Average	  C1	  levels	   in	  
seven	   brain	   areas	   of	   ARQ/ARQ	   genotype	   sheep	   (n	   =	   3).	   Error	   bars	   represent	   standard	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We	  normalised	  C1	  levels	  for	  all	  brain	  areas	  against	  the	  cortex	  (cortex	  =	  1)	  for	  each	  animal	  
and	   for	   a	   further	   four	   unrelated	   homozygote	   Norwegian	   sheep.	   C1	   levels	   in	   cerebellum	  
(0.78	  ±	  0.23)	  and	  brainstem	  (0.9	  ±	  0.54),	  relative	  to	  cortex	  in	  the	  Norwegian	  sheep,	  did	  not	  
differ	   significantly	   from	   the	  Roslin	   sheep	   (Figure	  4.4).	  Overall,	  we	   found	   that	   relative	  C1	  
levels	  were	  similar	  across	  different	  brain	  regions	  for	  individual	  animals.	  
	  
The	  ARQ/ARQ	  (n	  =	  3)	  and	  ARR/ARR	  (n	  =	  2)	  genotype	  animals	  were	  assessed	  separately	  
(Figure	  4.3B	  and	  4.3C).	  Brain	  areas	  were	  ranked	  by	  the	  percentage	  of	  C1	  as	  a	  percentage	  of	  
total	  PrPC.	  In	  sheep	  of	  ARQ/ARQ	  genotype	  the	  mid	  brain	  had	  the	  highest	  average	  level	  of	  
C1	  with	  36.7%	  of	  total	  PrPC,	   followed	  by	  hypothalamus	  (29.3	  %),	  the	  thalamus	  (27.0	  %),	  
the	   pons	   (24.0	  %),	   the	   cortex	   (21.3	  %)	   and	   the	   cerebellum	   (19.0	  %).	   For	   the	  ARR/ARR	  
animals	  average	  C1	  levels	  ranged	  from	  high	  to	   low	  as	  follows;	  thalamus	  (45.0	  %),	  cortex	  
(41.0	  %),	  medulla	  (39.5	  %),	  mid	  brain	  (38.0	  %),	  cerebellum	  (37.0	  %),	  hypothalamus	  (36.0	  
%)	  and	  pons	  (32.2	  %).	  The	  ARR	  homozygote	  group	  showed	  less	  variation	  in	  C1	  levels	   in	  






































Figure	   4.4	   –	   Comparison	   of	   C1	   levels	   in	   three	   brain	   areas	   from	   sheep	   taken	   from	   two	  
unrelated	   flocks.	   Brain	   tissue	   was	   treated	   with	   PNGase	   F	   and	  western	   blotted	  with	   either	  
antibody	   BC6	   (Roslin)	   or	   Barr	   224	   (Norwegian).	   C1	   levels	   calculated	   by	   densitometry	   were	  
normalised	  against	   the	  cortex	  for	  each	  animal	  and	  averages	  calculated.	  Error	  bars	  represent	  
standard	  deviation	  from	  the	  mean.	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As	  there	  were	  no	  significant	  differences	  in	  cleavage	  levels	  between	  the	  brain	  areas	  levels	  
of	  full	   length	  PrPC	  were	  measured	  in	  the	  same	  brain	  areas	  of	  three	  sheep	  (one	  ARQ/ARQ	  
and	   two	  ARR/ARR).	  For	  each	  brain	   (n	  =	  3)	  PrPC	  levels	  were	  normalized	   to	   the	   cortex	   to	  
allow	  for	  relative	  expression	  levels	  to	  be	  compared.	  The	  cortex	  had	  significantly	  	  (p	  ≤	  0.02)	  
higher	   average	   levels	   of	   full	   length	   PrPC	   when	   compared	   to	   the	   mid	   brain	   (48.4	   %	   of	  
cortex,	   SD	   ±	   5.3)	   and	   pons	   (42.6	   %	   of	   cortex,	   SD	   ±	   3.6)	   but	   there	   was	   no	   significant	  
difference	  between	  any	  of	  the	  other	  areas	  tested	  (Figure	  4.5E).	  To	  investigate	  if	  there	  was	  
a	   relationship	   between	  C1	   levels	   and	   full	   length	  PrPC	   the	   net	   intensity	   of	   the	   full	   length	  
band	  as	  a	  percentage	  of	  the	  highest	  value	  was	  plotted	  against	  C1	  levels	  as	  a	  percentage	  of	  
total	   PrPC	   for	   two	   sheep.	   	   In	   the	   ARR/ARR	   animal	   there	   was	   a	   significant	   positive	  
correlation	  (p	  ≤	  0.02),	  indicating	  higher	  PrPC	  levels	  are	  associated	  with	  higher	  α-­‐cleavage	  
levels	   in	   this	   animal.	   However,	   in	   the	   ARQ/ARQ	   animal	   there	  was	   no	   such	   relationship	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Figure	   4.5–	  Comparison	   of	   full	   length	  PrPC	  throughout	   the	  ovine	  brain.	  A)	  Western	  blot	  of	  
seven	  brain	  areas	  from	  an	  ARR/ARR	  genotype	  animal,	  probed	  with	  BC6	  and	  α-­‐tubulin	  (T)	  as	  
described	  in	  section	  2.3.1.	  Full	  length	  *PrPC,	  **C2,***C1.	  B)	  Western	  blot	  of	  seven	  brain	  areas	  
from	  an	  ARQ/ARQ	  genotype	  animal,	  probed	  with	  BC6	  and	  α-­‐tubulin.	  C)	  Net	   intensity	  of	   full	  
length	  PrPC	  plotted	  against	  C1	  levels	  throughout	  the	  ovine	  brain	  for	  the	  ARR/ARR	  animal.	  D)	  
Net	   intensity	  of	   full	   length	  PrPC	  plotted	  against	  C1	   levels	   throughout	   the	  ovine	  brain	  for	  the	  
ARQ/ARQ	  animal.	  E)	  Average	  levels	  of	  full	  length	  PrPC	  in	  seven	  brain	  areas	  from	  three	  sheep	  (2	  
of	  ARR/ARR	  and	  1	  ARQ/ARQ).	  Normalized	  to	  PrP	  level	  in	  the	  cortex	  (100	  %).	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  4	  	  	  	  	  	  	  	  5	  	  	  	  	  	  	  6	  	  	  	  	  	  	  7	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4.4.2	  Polymorphisims	  in	  the	  PRNP	  gene	  and	  α-­‐cleavage	  of	  PrPC	  in	  the	  ovine	  cortex	  
It	   appeared	   that	   the	   ARR/ARR	   animals	   tested	   during	   the	   brain	   areas	   study	   had	   higher	  
levels	  of	  truncated	  C1	  than	  ARQ/ARQ	  sheep,	  which	  supported	  the	  hypothesis	  of	  a	  genetic	  
association	  between	  α-­‐cleavage	  and	  PRNP	   genotype.	  To	  verify	   the	  putative	   link	  between	  
PRNP	  genotype	  and	  PrP	  processing	  a	  more	  detailed	  investigation	  was	  carried	  out.	  A	  larger	  
number	   of	   ovine	   brain	   samples	   were	   taken	   from	   homozygous	   sheep	   of	   the	   following	  
genotype	   groups	   ARR/ARR,	   ARQ/ARQ	   and	   VRQ/VRQ	   with	   varying	  
resistance/susceptibility	  to	  natural	  scrapie.	  	  
	  
Cortex	  samples	  were	   treated	  with	  PNGase	  F	  and	  subjected	   to	  western	  blotting	  with	  BC6	  
antibody.	   Sheep	   of	   ARR/ARR	   genotype	   –	   associated	  with	   resistance	   to	   natural	   scrapie	   -­‐	  
have	   significantly	   higher	   levels	   of	   C1	   in	   cortex	   when	   calculated	   as	   a	   percentage	   of	   full	  
length	  PrPC	  when	  compared	  to	  sheep	  of	  ARQ/ARQ	  (p	  ≤	  0.0001)	  and	  VRQ/VRQ	  (p	  ≤	  0.002)	  
genotypes,	  with	  an	  average	  of	  52.6	  %	  (SD	  ±	  11.9)	  (Figure	  4.6B).	  Figure	  4.6A	  illustrates	  the	  
different	  western	  blot	  profiles	  seen	  when	  comparing	  an	  ARR/ARR	  sheep	  in	  which	  a	  more	  
pronounced	   band	   of	   C1	   was	   detected	   in	   comparison	   to	   examples	   of	   the	   other	   PRNP	  
genotypes.	   There	   was	   no	   significant	   difference	   between	   C1	   levels	   in	   the	   remaining	  
genotypes,	  which	  have	  varying	  levels	  of	  susceptibility	  to	  natural	  scrapie.	  For	  these	  groups	  
the	  average	  C1	  values	  were	  as	  follows:	  ARQ/ARQ	  27.7	  %	  (SD	  ±	  14.5)	  and	  VRQ/VRQ	  32.6	  %	  
(SD	  ±	  8.8).	  The	  standard	  deviation	  from	  the	  mean	  was	  higher	  than	  the	  calculated	  range	  for	  
experiential	  variation	  	  (10-­‐15	  	  %),	  indicating	  that	  this	  represents	  natural	  animal-­‐to-­‐animal	  
variation,	  which	  appears	  to	  be	  larger	  in	  the	  ARQ/ARQ	  genotypes.	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To	   further	   investigate	   this	   correlation	   the	   effects	   of	   one	   ARR	   allele	  was	   investigated	   by	  
comparing	  C1	   levels	   in	  ARR	  homozygotes	   and	  ARR	  heterozygotes	  with	  other	  genotypes.	  
Both	   the	  ARR/VRQ	  (49.5	  %	  SD	  ±	  12.3)	  and	  ARR/ARQ	  (53.4	  %	  SD	  ±	  20.3)	  heterozygotes	  
have	  higher	  C1	  levels	  than	  homozygotes	  of	  the	  VRQ/VRQ	  (32.6	  %	  SD	  ±	  8.8)	  and	  ARQ/ARQ	  
(27.7	  %	  SD	  ±	  14.5)	  genotypes,	  p	  =	  0.060	  and	  p	  =	  0.039	  respectively	  (Figure	  4.7).	  	  
	  
The	  sheep	  used	  in	  this	  study	  came	  from	  two	  different	  flocks	  as	  explained	  in	  section	  2.1.1.	  
To	  rule	  out	  any	  flock	  specific	  effect	  on	  C1	  levels	  the	  ARQ/ARQ	  and	  VRQ/VRQ	  animals	  were	  
grouped	  depending	  on	  the	  flock	  they	  resided	  in	  and	  average	  C1	  levels	  were	  taken	  for	  each	  
group.	  There	  was	  no	  significant	  difference	  between	  flocks	  with	  average	  C1	  values	  of	  29.9	  
%	  (SD	  ±	  16.4)	  and	  28.4	  %	  (SD	  ±	  10.0).	  	  
Figure	  4.6	  –	  PRNP	  genotype	  and	  C1	  levels	   in	   the	  ovine	  cortex.	  A)	  Examples	  of	  one	  animal	  
from	  each	  PRNP	  genotype	  tested	  by	  western	  blot	  with	  BC6	  antibody	  as	  described	  in	  section	  
2.3.1.	   *Full	   length	   PrP.	   **	   C2,	   ***C1.	   B)	   Graph	   showing	   the	   average	   C1	   values	   as	   a	  



































p	  <	  0.0001	  p	  ≤	  0.002	  
VRQ/VRQ	  	  	  ARR/ARR	  	  	  ARQ/ARQ	  
	  	  	  	  	  VRQ/VRQ	  	  	  	  	  	  	  	  ARR/ARR	  	  	  	  	  	  	  	  	  ARQ/ARQ	  
A.	   B.	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Alleles	   at	   amino	   acid	   141	   have	   been	   shown	   to	   influence	   susceptibility	   to	   BSE	   in	   sheep	  
inoculated	   intravenously.	   LL141	   was	   associated	   with	   shorter	   incubation	   periods,	   while	  
both	   LF141	   and	   FF141	   were	   associated	   with	   prolonged	   incubation	   periods	   when	  
inoculated	   intravenously	   (Tan,	   Blanco	   et	   al.	   2012).	   It	  was	   investigated	   if	   there	  was	   any	  
association	  of	  incubation	  period	  length	  and	  C1	  levels	  within	  the	  ARQ/ARQ	  genotype	  with	  a	  
polymorphic	  codon	  141.	  Illustrated	  in	  Figure	  4.8,	  there	  was	  a	  trend	  but	  no	  significance	  (p	  
=	  0.06,	  in	  both	  cases)	  towards	  higher	  levels	  of	  C1	  in	  LF141	  heterozygotes	  with	  an	  average	  
C1	   level	   of	   44	  %	   (SD	   ±	   14.5,	   n	   =	   3),	   compared	   to	   the	   LL141	   and	   FF141	   animals,	   with	  
average	  C1	  levels	  of	  24.1	  %	  (SD	  ±	  10.8,	  n	  =	  4)	  and	  23.5	  %	  (SD	  ±	  12.9,	  n	  =	  4)	  respectively.	  	  
Figure	   4.7	   –	   Effects	   of	   one	   ARR	  
allele	  on	   levels	  of	  C1	  in	  the	  ovine	  
cortex.	   A)	   Histogram	   comparing	  
average	   C1	   levels	   in	   ARR/ARR	  
homozygotes	   ARR/VRQ	  
heterozygotes	   and	   VRQ/VRQ	  
homozygotes.	   B)	   Histogram	  
comparing	   average	   C1	   levels	   in	  
ARR/ARR	   homozygotes	   ARR/ARQ	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This	  trend	  could	  explain	  the	  larger	  varaiation	  in	  C1	  levels	  seem	  in	  the	  ARQ/ARQ	  genotype	  







4.4.3	  Polymorphisims	  in	  the	  PRNP	  gene	  and	  β-­‐cleavage	  of	  PrPC	  in	  the	  ovine	  cortex.	  
While	  collecting	  C1	  data	   from	  these	  animals	   it	  was	  observed	  that	  some	  but	  not	  all	  had	  a	  
second	   C-­‐terminal	   truncated	   protein	   C2.	   Therefore	   levels	   of	   C2	   were	   calculated	   as	   a	  
percentage	   of	   total	   PrPC	   in	   the	   genotype	   groups.	   Using	   the	   densitometry	   method	   as	  
described	   in	   section	   2.3.4	   detection	   of	   bands	   as	   low	   as	   1	   %	   of	   the	   total	   PrP	   can	   be	  
identified.	   In	   the	   animals	   in	   which	   no	   C2	   band	   could	   be	   visualised,	   even	   after	   over	  
exposure	  the	  levels	  of	  C2	  were	  taken	  as	  0	  %.	  	  
Across	  sheep	  of	  all	  genotypes,	  the	  mean	  C2	  level	  (for	  C2	  ≠	  0)	  was	  7.8	  %	  (SD	  ±	  4.8)	  of	  total	  
PrPC	  (n	  =	  11),	  but	  17	  samples	  had	  no	  detectable	  C2	  (defined	  here	  as	  ≥	  1%	  of	  total	  PrPC).	  A	  
single	  ARR/ARR	  sample	  out	  of	  11	  showed	  detectable	  C2,	  representing	  3	  %	  of	  total	  PrPC.	  Of	  





























Figure	   4.8	   –Alleles	   at	   position	   141	   and	   levels	   of	   C1	   in	   ovine	   cortex	  of	   ARQ/ARQ	   sheep.	  
Histogram	  showing	  average	  C1	  levels	  in	  the	  cortex	  of	  ARQ/ARQ	  sheep	  with	  alleles	  at	  amino	  
acid	  141.	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(SD	  ±	  4.3)	  C2	  was	  produced	  more	  frequently	  in	  the	  VRQ/VRQ	  group,	  within	  which	  80	  %	  of	  
animals	   had	   a	   visible	   C2	   band	   with	   an	   average	   value	   of	   8.9	  %	   (SD	   ±	   6.2)	   (Figure	   4.9).	  
Although	  the	  production	  of	  C1	  and	  C2	  is	  thought	  to	  be	  unrelated	  it	  was	  investigated	  if	  there	  
was	  any	  link	  between	  levels	  of	  production	  of	  either	  truncated	  protein.	  Average	  C1	  and	  C2	  
levels	   were	   plotted	   for	   all	   animals,	   independent	   of	   genotype	   with	   no	   correlation	   found	  
(Figure	  4.10A).	  When	  C2	  levels	  were	  plotted	  against	  levels	  of	  full	  length	  PrPC	  there	  was	  a	  
significant	  negative	  correlation	  (p	  =	  0.01),	   indicating	  that	  as	  expected	  higher	   levels	  of	  C2	  
























Figure	   4.9	   -­‐	   PRNP	   genotype	   and	   levels	   of	   C2	   in	   the	   ovine	   brain.	   Graph	   showing	   the	  
percentage	   of	   animals	   in	   each	   genotype	   group	  with	   visible	   C2	   band	   and	   comparing	   the	  
average	  levels	  of	  C2	  as	  a	  percentage	  of	  total	  PrP	   in	  the	  cortex	  from	  each	  of	  the	  genotype	  





















































C2	  as	  a	  percentage	  of	  total	  PrP	   Percentage	  of	  animals	  with	  visible	  C2	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Figure	   4.10	   –	   The	   relationship	   between	   C2	   levels	   and	   other	   forms	   of	   PrP	   in	   the	   ovine	  
cortex	   n=11.	   A)	   Average	   levels	   of	   C2	   for	   each	   animal	   were	   plotted	   against	   C1	   as	   a	  
percentage	  of	   total	   PrP.	   B)	  Average	   levels	   of	   C2	   for	   each	  animal	  were	  plotted	   against	   full	  
length	  PrP	  as	  a	  percentage	  of	  total	  PrP.	  	  
	  
	  
A.	   B.	  



























Full	  length	  PrP	  as	  a	  percentage	  of	  total	  PrP	  



























C1	  as	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  percentage	  of	  total	  PrP	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Figure	   4.11	   –	   Differential	   PrPC	  
processing	   in	   PRNP	   genotypes	   A)	  
Examples	   of	  PrP	   banding	  patterns	   from	  
samples	   of	   the	   cortex	   of	   two	   ARR/ARR	  
animals,	   subjected	   to	   western	   blotting	  
as	  described	  in	  section	  2.3.1	  and	  probed	  
with	   BC6.	   The	   densitometry	   readings	  
are	   represented	   in	   the	   opposing	   bar	  
chart.	  B)	  ARQ/ARQ	  animals	  as	  described	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Genotype	   C1	  (%)	  
	  
Average	  C1	   C2	  (%)	   Average	  C2	  
66x48	   ARR/ARR	   38,	  31,	  45	   38	   0,	  0,	  9	   3	  
O14	   ARR/ARR	   53,	  55	   54	   0,	  0,	   0	  
O22	   ARR/ARR	   51,	  52	   51.5	   0,	  0	   0	  
O30	   ARR/ARR	   64,	  57	   60.5	   0,	  0	   0	  
O51	   ARR/ARR	   48,	  38	   43	   0,	  0	   0	  
77x94	   ARR/ARR	   53,	  32	   42.5	   0,	  0	   0	  
75x49	   ARR/ARR	   45,	  35	   40	   0,0	   0	  
O17	   ARR/ARR	   85,	  47	   65	   0,	  0	   0	  
81X28	   ARR/ARR	   72,	  82	   77	   0,	  0	   0	  
82X77	   ARR/ARR	   47,	  50	   48.5	   0,	  0	   0	  
61X04	   ARR/ARR	   62,	  56	   58.75	   0,	  0	   0	  
PG0443/03	   ARQ/ARQ	   11,	  11	   11	   0,	  0	   0	  
PG0854/03	   ARQ/ARQ	   20,	  13	   16.5	   0,	  0	   0	  
PG0856/03	   ARQ/ARQ	   27,	  27	   27	   3,	  7	   5	  
75X68	   ARQ/ARQ	   25,	  9	   17	   0,	  0	   0	  
69X67	   ARQ/ARQ	   10,	  18	   14	   0,	  0	   0	  
83X13	   ARQ/ARQ	   58,	  60	   59	   0,	  0	   0	  
72X75	   ARQ/ARQ	   42,	  43	   42.5	   14,	  13	   13.5	  
67x79	   ARQ/ARQ	   45,	  38	   41.5	   0,	  0	   0	  
79x99	   ARQ/ARQ	   19,	  9,	  15	   14.3	   0,	  0	   0	  
78x80	   ARQ/ARQ	   12,	  28	   20	   0,	  4	   2	  
78x74	   ARQ/ARQ	   25,	  37	   31	   12,	  0	   6	  
PG0877/03	  
85	  
ARQ/ARQ	   31,	  23	   27	   11,	  11	   11	  
PG0416/03	   ARQ/ARQ	   40,	  38	   39	   10,	  10	   10	  
PG0216/04	   VRQ/VRQ	   43,	  30	   36.5	   4,	  0	   2	  
PG0109/08	   VRQ/VRQ	   39,	  34	   36.5	   12,	  22	   17	  
PG0224/04	   VRQ/VRQ	   14,	  36	   25	   0,0	   0	  
PG0225/04	   VRQ/VRQ	   33,	  14	   23.5	   16,	  0	   8	  
PG0114/08	  
85	  
VRQ/VRQ	   39,	  44	   41.5	   8,	  9	   8.5	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Genotype	   C1	  (%)	  
	  
Average	  C1	   C2	  (%)	   Average	  C2	  
61x13	   ARR/ARQ	   62,	  51.9	   57	   0,	  3.5	   1.5	  
72x38	   ARR/ARQ	   41.3	   41.3	   0,0	   0	  
74x00	   ARR/ARQ	   37.6	   37.6	   0,0	   0	  
63x51	   ARR/ARQ	   76.7,	  88.3	   82.5	   0,0	   0	  
60x68	   ARR/VRQ	   63.5,	  55.4	   59.5	   0,0	   0	  
67x26	   ARR/VRQ	   64.6,	  58	   61.3	   0,0	   0	  
73x23	   ARR/VRQ	   41.1,	  33.1	   37.1	   0,0	   0	  
Table	   4.2	   –	   Summary	   of	   C1	   and	   C2	   levels	   in	   all	   heterozygote	   sheep	   included	   in	  
analyses.  
 
4.3.4	  Proteolytic	  processing	  in	  other	  species	  
Although	   data	   on	   C1	   levels	   has	   been	   previously	   published	   for	   a	   range	   of	   species	   often	  
these	   are	   simply	   reported	   as	   over/under	   50	  %	   total	   PrPC	  (Table	   1.2).	   For	  more	   specific	  
values	   allowing	   for	   a	   direct	   comparison	   to	   our	   sheep	   data	   goat,	   rat	   and	   cat	   cortex	  was	  
extracted,	  treated	  with	  PNGase	  F	  and	  subjected	  to	  western	  blotting	  as	  with	  previous	  ovine	  
samples	   (Figure	   4.12).	   Five	   goats	   of	   ARQ/ARQ	   genotype	   all	   showed	   visible	   bands	   of	   C1	  
with	  an	  average	  C1	  level	  of	  29.1	  %	  (SEM	  ±	  4.6).	  This	  value,	  when	  compared	  to	  ARQ/ARQ	  
sheep	   (average	   of	   27.7	   %	   SEM	   ±	   4.0)	   was	   found	   to	   be	   very	   similar.	   Samples	   from	   the	  
cortex	  of	   five	  rats	  were	  also	   tested.	  C1	  values	  ranged	   from	  between	  16.4	  %	  and	  25.0	  %,	  
with	  an	  average	  of	  18.8	  %	  (SEM	  ±	  1.63),	  this	  was	  significantly	  lower	  than	  ARQ/ARQ	  sheep	  
(p	  =	  0.03)	  and	  goats	  (p	  =	  0.04).	  The	  one	  cat	  sample	  was	  found	  to	  have	  a	  C1	  level	  of	  47.2	  %	  
which	  has	  been	   compared	   to	   a	   second	  by	   Stewart	  et	  al	   2012,	  with	   very	   similar	  western	  
blotting	  profiles	  (Stewart,	  Campbell	  et	  al.	  2012).	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Ovine	   transgenic	   mouse	   models	   express	   ovine	   PrPC	   with	   the	   purpose	   of	   modeling	   the	  
genotype	   specific	   incubation	   times	   and	   disease	   profiles	   seen	   in	   sheep.	   	   In	   these	  models	  
ovine	   PrPC	  is	   produced	   under	   the	  murine	   gene	   expression	   control,	   therefore	   there	   is	   no	  
evidence	  that	  levels	  of	  genotype	  specific	  expression	  seen	  in	  sheep	  will	  be	  mimicked.	  Two-­‐
day-­‐old	  Tg338	  transgenic	  mice,	  expressing	  PrPVRQ	  reportedly	  around	  6-­‐8	  times	  that	  seen	  in	  
sheep	  (Le	  Dur,	  Beringue.	  et	  al	  2005)	  showed	  very	  similar	  levels	  of	  truncated	  C2	  protein	  as	  
seen	  in	  VRQ/VRQ	  sheep	  (13.9	  %,	  SEM	  ±	  7.2)	  	  (Figure	  4.13B).	  The	  average	  C1	  level	  of	  21.8	  








































Figure	  4.12	  -­‐	  C1	  levels	  in	  other	  species.	  A)	  Western	  blot	  of	  goat,	  cat	  and	  rat	  probed	  with	  BC6	  
monoclonal	   antibody.	   B)	   Graph	   comparing	   average	   C1	   levels	   for	   ARQ/ARQ	   sheep	   with	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C2	  are	  similar,	  meaning	  that	  relative	  levels	  of	  full	  length	  PrPC	  protein	  are	  higher	  in	  Tg338	  
mice.	  	  
 
Gene	   targeted	   gtARR	   and	   gtARQ	   transgenic	  mice	  were	   also	   tested.	   These	   express	   ovine	  
PrPARR	  or	  PrPARQ	  at	  levels	  comparable	  to	  that	  in	  sheep.	  Although	  only	  one	  brain	  of	  each	  line	  
could	  be	  sourced	  PrPC	  expression	  and	  processing	  appeared	  to	  be	  almost	  identical	  in	  both	  
models	   and	   no	   genotype	   effect	   was	   observed	   (Figure	   4.13).	   GtARQ	  mice	   and	   ARQ/ARQ	  
sheep	  produce	  strikingly	  similar	  levels	  of	  C1	  protein,	  while	  gtARR	  mice	  have	  lower	  levels	  
compared	   to	   ARR/ARR	   sheep.	   C2	   is	   present	   in	   both	  models	   at	   higher	   levels	   than	   ovine	  
equivalents,	  9.8	  %	  in	  gtARQ	  and	  14.1	  %	  in	  gtARR.	  In	  ovine	  brain	  this	  fragment	  was	  found	  




















Figure	   4.13	   –	   Proteolytic	   processing	   in	   ovine	   transgenic	   mice.	   A)	   10	   %	   whole	   brain	  
homogenate	  from	  3	  Tg338	  (Lanes	  1,3	  and	  5),	  gtARQ	  (Lane	  6)	  and	  gtARR	  (Lane	  7)	  was	  treated	  
with	  PNGase	  F	  and	  subjected	  to	  western	  blotting	  with	  BC6	  antibody,	  as	  described	  in	  section	  
2.3.1.	   B)	   Graph	   comparing	   levels	   of	   PrP	   truncated	   proteins	   in	   transgenic	   mice	   to	   sheep	  
expressing	   corresponding	   allotype	   of	   PrP.	   For	   transgenic	   analysis	   densitometry	   was	  
performed	   on	   western	   blots	   and	   average	   levels	   of	   both	   C1	   and	   C2	   were	   calculated	   as	   a	  
percentage	  of	  total	  PrPC.	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4.4.5	  Levels	  of	  PrPC	  in	  the	  ovine	  cortex	  and	  polymorphisms	  in	  the	  PRNP	  gene.	  
In	  parallel	  to	  measuring	  PrPC	  processing,	  levels	  of	  total	  PrPC	  were	  also	  measured	  as	  it	  was	  
hypothesised	  that	  varying	  levels	  of	  PrPC	  	  	  protein	  in	  the	  brain	  may	  influence	  the	  amount	  of	  
PrPSc	   accumulation	   and	   susceptibility	   to	   disease.	   This	   was	   based	   on	   evidence	   that	   in	  
PrP0/0,	  PrP+/0	  and	  PrP+/+	  mouse	  models	  disease	  susceptibility	  and	  incubation	  period	  was	  
inversely	  correlated	  with	  PrPC	  expression	  (Bueler,	  Aguzzi	  et	  al.	  1993).	  Homozygotes	  from	  
genotype	  groups	  ARR/ARR,	  ARQ/ARQ	  and	  VRQ/VRQ	  were	  used	  in	  this	  study	  and	  both	  full	  
length	  PrPC	  levels	  and	  total	  PrPC	  levels	  (taken	  as	  a	  sum	  of	  all	  bands	  visible)	  were	  measured.	  
To	   compare	   the	  bands	  of	   full	   length	  PrP	   the	  net	   intensity	  of	   the	   loading	   control	  band	  of	  
alpha	  tubulin	  was	  measured	  by	  densitometry.	  All	  values	  were	  calculated	  as	  a	  factor	  of	  the	  
lowest	  net	  intensity	  and	  this	  was	  used	  to	  determine	  the	  level	  of	  full	  length	  PrPC	  if	  loading	  
was	  exactly	  equal	  between	  all	  samples.	  This	  method	  allowed	  for	  all	  samples	  in	  a	  gel	  to	  be	  
included	   for	  measurement	   despite	   varied	   loading.	   Shown	   in	   Figure	   4.14,	   animals	   of	   the	  
VRQ/VRQ	  genotype	  have	  significantly	  higher	  levels	  of	  full	  length	  PrPC	  than	  animals	  of	  the	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p=0.033	  	  	  	  p=0.012	  
A.
Figure	  4.14	  –	   Full	   length	  PrPC	  expression	   in	  PRNP	   genotype	   groups.	  A)	  10	  %	  homogenate	  
from	   homozygous	   animals	   of	   the	   following	   PRNP	   genotypes	   VRQ/VRQ,	   ARQ/ARQ	   and	  
ARR/ARR,	   treated	   with	   PNGase	   F	   and	   subjected	   to	   western	   blotting	   with	   BC6	   and	   alpha	  
tubulin	  antibodies.	  Full	  length	  PrP*,	  C1***,	  alpha	  tubulin	  T.	  B)	  Average	  full	  length	  PrPC	  levels	  
(calculated	  from	  net	  intensity)	  for	  each	  PRNP	  genotype	  (n=3)	  when	  probed	  with	  monoclonal	  
antibody	  BC6.	  
	  	  	  
T 
VRQ/VRQ	  
55kDa-­‐	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The	   total	   PrPC	   level	   in	   the	   cortex	   of	   each	   sheep	   was	   determined	   by	   measuring	  
densitometry	  of	  all	  bands	  and	  calculating	  an	  average	  for	  each	  genotype	  group.	  There	  is	  a	  
significant	  difference	  between	  the	  average	  levels	  of	  total	  PrPC	  in	  VRQ/VRQ	  and	  ARQ/ARQ	  
sheep	  (p	  =	  0.006).	  PrPC	  levels	  in	  animals	  of	  the	  ARR/ARR	  genotype	  were	  also	  found	  to	  be	  
significantly	  higher	  than	  those	  of	  the	  ARQ/ARQ	  genotype	  (p	  =	  0.009),	  representing	  around	  











4.4.6	  PrPC	  expression	  in	  peripheral	  lymphoid	  tissues	  
Due	  to	  the	   involvement	  of	   lymphoid	  organs	  such	  as	  the	  tonsils	  and	  spleen	   in	  early	  prion	  
infection	  it	  was	  of	   interest	  to	  study	  both	  PrPC	  expression	  and	  processing	  in	  these	  tissues.	  
Any	   variation	   in	   levels	   of	   either	   full	   length	   PrPC	   or	   truncated	   C1	   fragment	   could	   have	  
influence	  over	  the	   initial	  stages	  of	   infection	  and	  explain	  the	   lack	  of	  PrPSc	  accumulation	   in	  
resistant	  animals	  before	  nervous	  system	  involvement.	  10	  %	  (w/v)	  homogenates	  of	  tonsil,	  
mesenteric	  lymph	  node	  (MLN)	  and	  popliteal	  lymph	  node	  (PLN)	  were	  produced	  from	  one	  
ARR/ARR	   sheep	   and	   subjected	   to	   western	   blotting.	   PrPC	   expression	   levels	   in	   the	  
peripheral	   lymphoid	   organs	  were	   expected	   to	   be	   around	  100	   times	   lower	   than	   in	   brain	  
Figure	  4.15	  –	  PRNP	  genotype	  and	  levels	  of	  total	  PrPC	  in	  the	  ovine	  brain	  Average	  total	  PrP	  levels	  
for	  each	  PRNP	  genotype	  (n=3)	  when	  probed	  with	  monoclonal	  antibody	  BC6.	  Highest	   levels	  are	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(Moudjou,	  Frobert	  et	  al.	  2001).	  After	  extended	  exposure	  a	  band	  of	  ~	  27	  kDa,	   thought	   to	  
represent	  full	  length	  unglycosylated	  PrPC,	  can	  be	  seen	  in	  the	  tonsil	  sample	  (Figure	  4.16A),	  
which	   becomes	   more	   defined	   on	   increased	   concentration	   of	   homogenate.	   At	   higher	  
concentration	   of	   homogenate	   the	   lanes	   become	   overloaded	   and	   smearing	   occurs.	  
Examples	  from	  MLN	  and	  PLN	  are	  shown	  in	  Figure	  4.16B,	  after	  treatment	  with	  PNGase	  F.	  
Again,	  there	  is	  a	  band	  of	  possible	  unglycosylated	  PrPC,	  but	  no	  smaller	  truncated	  fragments.	  
This	   sheep	   is	   of	   ARR/ARR	   genotype	  which	   has	   around	   50	  %	   C1	   in	   brain	   tissue.	   As	   full	  
length	  PrPC	  is	  visible	  but	  no	  C1	  we	  can	  surmise	  that	  levels	  of	  α-­‐cleavage	  are	  lower	  in	  these	  








4.4.7	  	  ADAM	  protease	  inhibition	  and	  α-­‐cleavage	  in	  Tg338	  derived	  primary	  neuronal	  
cells	  
Although	  there	  are	  many	  immortalised	  cell	   lines	  that	  express	  ovine	  PrP,	  few	  of	  these	  are	  













Figure	  4.16	  –	  Visualisation	  of	  PrPC	  in	  peripheral	  lymphoid	  tissues	  by	  western	  blotting.	  A)	  10	  
%	  homogenate	  of	  brain	  (Lane	  1)	  and	  tonsil	   (Lanes	  2-­‐4)	  from	  sheep	  O51,	  were	  subjected	  to	  
western	  blotting	  with	   antibody	  BC6	   as	   described	   in	   section	   2.3.1.	  Three	   concentrations	   of	  
tonsil	  homogenate	  were	  tested.	  10	  %	  homogenate	  (Lane	  2),	  20	  %	  homogenate	  (Lane	  3)	  and	  
50	  %	  homogenate	  (Lane	  4).	  B)	  20	  %	  homogenates	  from	  MLN	  (Lane	  1)	  and	  PLN	  (Lane	  2)	  from	  
sheep	   O51,	   were	   treated	   with	   PNGase	   F	   and	   subjected	   to	   western	   blotting	   with	   BC6	  
antibody.	  Dashed	  box	  highlights	  possible	  band	  of	  full	  length	  unglycosylated	  PrPC.	  
	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	   	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	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characteristics	  to	  cells	  in	  vivo	  and	  therefore	  represent	  a	  more	  attractive	  in	  vitro	  model	  for	  
the	   study	   of	   cellular	   processing.	   Primary	   neuronal	   cultures	   were	   established	   under	  
selection	  of	  growth	  factor	  B-­‐27	  from	  embryonic	  stem	  cells	  derived	  from	  mouse	  line	  Tg338,	  
which	  has	  truncated	  PrPC	  fragments	  at	  similar	  levels	  to	  VRQ/VRQ	  sheep	  and	  from	  gtARQ,	  
which	  are	  thought	  to	  express	  PrPC	  at	  levels	  comparable	  to	  that	  in	  sheep.	  
	  
Neuronal	  differentiation	  in	  cell	  cultures	  were	  identified	  by	  characterisation	  of	  morphology	  
and	   ICC	   with	   an	   antibody	   against	   microtubule	   associated	   protein-­‐2	   (MAP-­‐2),	   a	   neuron	  
specific	   marker	   (Figure	   4.17).	   	   Axons	   and	   dendrites	   can	   clearly	   be	   seen	   indicating	   that	  
most	   cells	   have	   fully	   differentiated	   into	   neuronal	   cells.	   Differentiated	   cells	   from	   these	  
cultures	  were	  lysed	  7	  days	  post	  plating,	  treated	  with	  PNGase	  F	  and	  immuno-­‐blotted	  with	  
BC6	  antibody	  to	  assess	  PrPC	  expression	  (Figure	  4.18A).	  Tg338-­‐derived	  cells	  had	  around	  40	  
%	   C1,	   slightly	   lower	   than	   the	   Tg338-­‐derived	   line	   created	   by	   Cronier	   and	   colleagues	   in	  
which	  C1	  represented	  around	  60	  %	  of	   total	  PrPC	  (Cronier,	  Laude	  et	  al.	  2004).	  Total	  PrPC	  
expression	   was	   around	   4-­‐fold	   higher	   in	   Tg338-­‐derived	   primary	   neurons	   compared	   to	  
gtARQ-­‐derived	  cells	  (Figure	  4.18B).	  Expression	  of	  full	  length	  PrPC	  was	  only	  2.5-­‐fold	  higher	  
in	   Tg338	   primary	   neurons	   compared	   to	   gtARQ-­‐derived	   cells.	   It	   has	   previously	   been	  
reported	  that	  Tg338	  mice	  express	  PrPC	  at	  a	  level	  of	  6	  x	  higher	  than	  found	  in	  sheep	  brain	  
(Laude,	   Vilette	   et	   al.	   2002).	   However,	   it	   is	   important	   to	   note	   that	   PrPC	   expression	   in	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As	  PrPC	  glycosylation	  has	  been	  shown	  to	  influence	  both	  susceptibility	  to	  TSEs	  and	  cellular	  
localisation	   and	   trafficking	   (Cancellotti,	   Wiseman	   et	   al.	   2005,	   Cancellotti,	   Mahal	   et	   al.	  
2013)	  we	  compared	  PrPC	  glyco-­‐profiles	  from	  Tg338	  derived	  neuronal	  cell	  lysates	  to	  whole	  
brain	  lysate	  of	  a	  2-­‐day-­‐old	  Tg338	  mouse	  and	  found	  them	  to	  be	  very	  similar	  (Figure	  4.18C),	  
with	  di-­‐glycosylated	  PrPC	  as	  the	  most	  prominent	  band.	  	  
Figure	  4.17	  –	  Morphology	  of	  primary	  neuronal	  cells	  Tg338	  and	  gtARQ.	  A)	  Primary	  neurons	  
extracted	   and	   differentiated	   from	   the	   brains	   of	   17d	   embryos,	   cultured	   on	   poly-­‐ornithine	  
treated	  glass	  slides	  at	  37˚C	  for	  around	  14	  days	  as	  described	  in	  section	  2.6.2.	  Haemolysin	  and	  
Eosin	  staining	  performed	  as	  described	  in	  section	  2.4.1	  shows	  typical	  neuronal	  morphology.	  
Images	   were	   taken	   on	   a	   Nikon	   800E	   B)	   Anti-­‐MAP-­‐2	   is	   specific	   for	   microtubule-­‐associated	  
protein-­‐2,	   a	   marker	   for	   neurons.	   IHC	   was	   performed	   as	   described	   in	   section	   2.4.4Visible	  
staining	  of	  neuronal	  bodies	  and	  dendrites.	  Images	  were	  taken	  on	  a	  Zeiss	  LSM	  Pascal	  confocal	  
microscope.	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ICC	  was	  performed	  as	  described	  in	  section	  2.4.2	  to	  establish	  the	  localisation	  of	  both	  PrPC	  
and	   truncated	   C1	   on	   primary	   neuronal	   cell	   lines	   using	   a	   panel	   of	   specific	   monoclonal	  
antibodies	  with	  epitopes	  in	  both	  the	  C-­‐terminal	  (BC6,	  FH10),	  reactive	  with	  C1,	  C2	  and	  full	  













	  	  1	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  	  
Figure	  4.18	  –	  Comparison	  of	  PrPC	  expression	  in	  primary	  neurons	  by	  western	  blot	  A)	  Cell	  
lysates	  were	  prepared	  day	  7	  post	  plating	  as	  described	  in	  section	  2.6.2	  and	  samples	  were	  
treated	  with	  PNGase	  F.	  Alpha	  tubulin	  was	  used	  as	  a	  loading	  control	  (T)	  and	  the	  blot	  was	  
probed	  with	  BC6	  antibody,	  as	  described	  in	  section	  2.3.1;	  Lane	  1	  and	  2	  (cell	  lysate	  gtARQ);	  
Lane	   3	   and	   4	   (cell	   lysate	   Tg338).	   B)	   PrP	   bands	   were	   measured	   by	   densitometry	   and	  
loading	  was	  normalised	  to	  the	  alpha	  tubulin	  loading	  control.	  C)	  Tg338-­‐derived	  cell	  lysate	  
as	  A)	  and	  brain	  homogenate	  from	  a	  2	  day	  old	  Tg338	  mouse,	  in	  absence	  of	  PNGase	  F	  were	  
probed	  with	  two	  monoclonal	  antibodies	  P4	  and	  BE12.	  Lanes	  1	  and	  5	  (10	  μg	  total	  protein,	  
Tg338	   cell	   lysate),	   Lanes	   2	   and	  6	   (25	  μg	   total	   protein,	   Tg338	   cell	   lysate),	   Lane	   3	   and	  7	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length	   PrPC	   and	   the	   N-­‐terminal	   (BE12,	   FH11),	   specific	   to	   full	   length	   PrPC	   (Figure	   4.19,	  
Table	  2.2).	   	  All	   antibodies	   showed	   reactivity	   to	   these	  primary	  neurons,	   shown	   in	  Figure	  
4.18	   but	   the	   patterns	   of	   expression	   varied	   considerably	   depending	   on	   the	   primary	  
antibody	  used.	  	  N-­‐terminal	  antibody	  BE12	  showed	  strong	  immuno-­‐reactivity	  with	  the	  cell	  
body	   alone	   and	   less	   pronounced	   staining	   along	   projections	   while	   FH11	   shows	   less	   cell	  
body	   specific	   reactivity	   and	   has	   strong	   tropism	  with	   the	   nucleus.	   C-­‐terminal	   antibodies	  
BC6	  and	  FH10	  both	  stained	  projections	  strongly	  and	  showed	  deposition	   in	   the	  cell	  body	  






	   	  
FH10	  
Figure	  4.19	  –	  Expression	  of	  PrPC	   in	  gtARQ	  derived	  primary	  neurons	  using	  a	  panel	  of	  PrP	  
specific	   antibodies.	  Primary	  neurons	  extracted	  and	  differentiated	  from	  the	  brains	  of	  17d	  
gtARQ	  embryos,	  cultured	  on	  poly-­‐ornithine	  treated	  glass	  slides	  at	  37˚C	  for	  around	  14	  days	  
as	   described	   in	   section	  2.6.2	   ICC	  was	   performed	  using	   a	  panel	   of	   PrP	   specific	   antibodies	  
(see	   section	   2.4.2),	   to	   both	   the	  C-­‐terminal	   and	   the	  N-­‐terminal.	   Images	  were	   taken	   on	   a	  
Zeiss	  LSM	  Pascal	  confocal	  microscope,	  with	  LSM	  image	  analysis	  software.	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It	   has	   been	   reported	   that	   general	   inhibitors	   of	   the	   ADAM	  metalloproteinase	   such	   as	   O-­‐
phenanthroline	  (OPH)	  reduced	  N1	  formation	  by	  around	  40	  %	  -­‐	  70	  %	  in	  TMS	  neurons	  and	  
HEK293	   cells	   (Vincent,	   Paitel	   et	   al.	   2001,	   Cisse,	   Sunyach	   et	   al.	   2005).	   However,	   the	  
involvement	   of	   the	   ADAM	   proteases	   in	   α-­‐cleavage	   is	   still	   under	   debate.	   A	   cell	   line	  with	  
manipulative	  levels	  of	  C1	  could	  also	  act	  as	  a	  model	  to	  study	  the	  mechanisms	  linking	  C1	  to	  
TSE	  pathology.	  In	  an	  attempt	  to	  create	  such	  a	  system	  a	  general	  ADAM	  protease	  inhibitor	  
OPH	  (10	  µM	  –	  1	  mM)	  was	  added	  to	  the	  Tg338	  primary	  neuronal	  cell	  line	  at	  day	  23,	  when	  
full	   differentiation	  was	   observed	   and	   incubated	   for	   24	   hours.	   The	   cells	  were	   then	   lysed	  
and	  subjected	  to	  western	  blotting	  with	  monoclonal	  antibodies	  BC6	  and	  anti-­‐ADAM	  10	  with	  
α-­‐tubulin	  as	  a	  loading	  control	  (Figure	  4.20A	  and	  4.21A).	  Three	  wells	  (12	  well	  plate	  format)	  
were	  set	  up	  for	  each	  of	  conditions	  tested	  and	  the	  experiment	  was	  repeated	  twice.	  All	  C1	  
values	  calculated	  are	  averaged	  from	  both	  experiments.	  	  
	  
To	   confirm	   inhibition	   of	   ADAM	   proteases	   the	   levels	   of	   ADAM	   10	   were	   measured	   by	  
western	   blotting	   with	   ADAM	   10	   specific	   monoclonal	   antibody	   (Abcam	   UK)	   and	   anti-­‐α-­‐
tubulin	  as	  a	   loading	  control.	  OPH	   is	  a	   zinc	  metalloproteinase	   inhibitor,	  which	  means	   the	  
mechanism	  of	   inhibition	   involves	   the	   removal	   of	   a	   zinc	   ion	  which	   inactivates	   the	  ADAM	  
protease	   but	   does	   not	   destroy	   it.	   Figure	   4.20	   illustrates	   the	   build	   up	   of	   this	   inactivated	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Addition	  of	  OPH	  at	  1mM	  concentration	  appeared	  toxic	  to	  cells,	  indicated	  both	  from	  visible	  
cell	   death	   and	   morphological	   change.	   Therefore	   no	   further	   analysis	   was	   performed	   for	  
that	   concentration.	  The	  control	   cells	  had	  an	  average	  C1	   level	  of	  26.0	  %	  (SEM	  ±	  2.2)	  and	  
10µM	  and	  100µM	  OPH	  treated	  cells	  had	  levels	  of	  29.0	  %	  (SEM	  ±	  2.4)	  and	  34.1	  %	  (SEM	  ±	  
2.6)	  respectively	  (Figure	  4.21).	  Addition	  of	  OPH	  at	  a	  concentration	  of	  100	  µM	  therefore	  led	  
to	   s	   small	   but	   significant	   increase	   of	   C1	   (p	   =	   0.03),	   suggesting	   that	   inhibition	   of	   ADAM	  
proteases	  does	  not	  prevent	  or	  reduce	  α-­‐cleavage	  as	  reported	  for	  other	  cell	  lines.	  It	  has	  also	  
been	  suggested	  that	  ADAMs	  may	  be	  directly	  involved	  in	  the	  extreme	  C-­‐terminal	  shedding	  
of	  PrPC	   therefore	   levels	  of	   total	  PrP	  were	  measured	  using	  α-­‐tubulin	  as	  a	   loading	  control.	  
Addition	  of	  10	  µM	  OPH	  significantly	   increases	  the	   levels	  of	   total	  PrP	  to	  170	  %	  of	  control	  
cells	   (p	   =	   0.027).	   With	   the	   higher	   concentration	   100µM	   OPH	   the	   increase	   (140	   %	   of	  











Anti	  -­‐ADAM	  10	  +	  α-­‐Tubulin	  
Figure	  4.20	  –	  Levels	  of	  ADAM	  10	  after	  addition	  of	  O-­‐phenanthroline.	  A)	  Western	  blot	  of	  
cell	   lysate,	   produced	   as	  described	   in	   section	  2.6.6,	   probed	  with	   anti	   ADAM	  10	   and	   anti-­‐
alpha	  tubulin	  antibodies.	  Lanes	  1	  and	  2,	  control;	  lanes	  3-­‐5,	  O-­‐phenanthroline	  10µM;	  Lanes	  
6-­‐8,	  O-­‐phenanthroline	  100µM.	  Mature	  ADAM	  10	  *,	  Inactivated	  ADAM	  10**,	  alpha	  tubulin	  
T.	   B)	   Graph	   illustrating	   relative	   levels	   of	  mature	   ADAM	   10	   in	   O-­‐phenanthroline	   treated	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4.4.11	  PrPC	  processing	  in	  the	  cortex	  of	  scrapie-­‐positive	  sheep 
	  
It	  has	  been	  shown	  that	  N1	  the	  corresponding	  product	  of	  α-­‐cleavage	  has	  neuroprotective	  
functions	   by	   inhibition	   of	   staurosporine	   induced	   caspase-­‐3	   activation	   through	   the	   p53	  
pathway	  and	   that	   this	   function	   is	  dominant	  over	  any	  pro-­‐apoptotic	  C1	   function	   (Guillot-­‐
Sestier,	  Sunyach	  et	  al.	  2009).	  	  It	  can	  therefore	  be	  supposed	  that	  any	  decrease	  in	  production	  
of	  this	  fragment	  could	  have	  negative	  effects	  and	  may	  aid	  the	  neurodegeneration	  associated	  


































BC6	  +	  α-­‐Tubulin	  
1	  	  	  	  2	  	  	  	  3	  	  	  	  4	  	  	  	  	  5	  	  	  	  	  6	  	  	  	  7	  	  	  	  	  8	  	  	  	  	  
Figure	  4.21	  –	  PrPC	  and	  α-­‐cleavage	  levels	  on	  addition	  of	  O-­‐phenanthroline.	  A)	  Western	  blot	  
of	  cell	  lysate	  taken	  after	  24	  hour	  incubation,	  performed	  as	  described	  in	  section	  2.3.1	  with	  0	  
(Lanes	   1-­‐2),	   10µM	   (Lanes	   3-­‐5),	   or	   100µM	   	   (Lanes	   6-­‐8)	   O-­‐phenanthroline,	   treated	   with	  
PNGase	  F	  and	  probed	  with	  BC6	  and	  α-­‐tubulin	  antibodies.	  B)	  Graph	  of	  average	  C1	  levels	  as	  a	  
percentage	  of	  total	  PrP	  by	  densitometry	  for	  each	  concentration.	  C)	  Graph	  of	  average	  total	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was	   extracted	   and	   subjected	   to	   western	   blotting	   using	   BC6	   antibody	   as	   previously	  
described.	   	   All	   scrapie	   cases	   had	   been	   confirmed	   as	   PrPSc	  positive	   in	   the	   brain	   (Angie	  
Chong,	  The	  Roslin	  Institute).	  PK,	  which	  would	  normally	  be	  used	  for	  the	  analysis	  of	  scrapie	  
infected	  tissue	  was	  omitted	  as	  this	  would	  cause	  degradation	  of	  cellular	  PrPC,	  C1	  and	  C2.	  It	  
can	   therefore	   be	   noted	   that,	   the	   detected	   bands	   on	   the	   immunoblot	   may	   include	   both	  
cellular	   and	   disease-­‐associated	   forms	   of	   the	   protein.	   	   	   However,	   PrPSc	   isolated	   from	  
classical	  scrapie	  cases	  does	  not	  normally	  contain	  PrP	  fragments	  of	  the	  size	  range	  in	  which	  
C1	  is	  detected	  even	  after	  PK	  digestion.	  Specific	  genotypes	  were	  not	  considered	  here	  but	  all	  








In	  all	   infected	  animals	   tested	  (n	  =	  17)	  there	  was	  a	  visible	  band	  of	  C1	  protein,	  running	  at	  
the	   same	  molecular	  weight	   as	  C1	   isolated	   from	  uninfected	  brain	   (Figure	  4.22A).	  Normal	  
Figure	  4.22	  –	   C1	   is	   present	   in	  scrapie	   infected	  sheep	  brain	  at	   similar	   levels	  as	   in	   uninfected	  
brain.	   A)	   Western	   blots	   of	   animals	   of	   VRQ/ARQ	   and	   VRQ/ARR	   genotypes,	   uninfected	   and	  
infected	   with	   SSBP/1,	   treated	   with	   PNGase	   F	   and	   probed	   with	   BC6	   monoclonal	   antibody	  
(section	   2.3.1)	   Full	   length	   PrP/PrPSc	   (*),	   C2(**)	   and	   C1(***).	   B)	   Average	   C1	   values	   were	  
calculated	  as	  a	  percentage	  of	  total	  PrP	  for	  SSBP/1	  and	  classical	  scrapie	  infected	  sheep	  and	  these	  
values	  were	  compared	  to	  average	  C1	  levels	  in	  uninfected	  sheep,	  omitting	  ARR/ARR	  genotype.	  	  
	  	  	  U
ninfected	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  U
ninfected	  
	  	  	  SSBP/1	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loading	  controls	  such	  as	  alpha	  tubulin	  cannot	  be	  used	  to	  compare	  the	  loading	  of	  samples	  
from	  healthy	  and	  brains	  undergoing	  neurodegeneration,	  as	  neuronal	  death	  will	  alter	  levels	  
of	   housekeeping	   proteins	   (Dr	   Barry	   McColl,	   The	   Roslin	   Institute,	   personal	  
communication).	  Total	  PrP	  includes	  both	  cellular	  PrPC	  and	  PrPSc	  as	  at	   the	  present	  we	  had	  
no	  means	  to	  accurately	  separate	  the	  two	  forms	  of	  the	  protein	  from	  tissue.	  However,	  it	  was	  
calculated	  from	  SSBP/1	  infected	  sheep	  brain	  by	  blotting	  with	  a	  standard	  curve	  dilution	  of	  
recombinant	   PrP	   protein	   (Data	   not	   shown)	   that	   there	   is	   around	   2µg	   of	   SAF/g	   of	   sheep	  
brain.	  Using	  this	  calculation	  we	  can	  assume	  there	  will	  only	  be	  around	  0.5ng	  of	  SAF	  loaded	  
per	  lane	  of	  gel,	  which	  is	  unlikely	  to	  present	  a	  visible	  change	  in	  the	  density	  of	  the	  full	  length	  
PrP	  band.	  	  
Omitting	  ARR	  carriers	  as	  we	  have	  shown	  the	  presence	  of	  one	  ARR	  allele	  is	  associated	  with	  
higher	   level	  of	  C1,	  ARQ/ARQ	  and	  VRQ/VRQ	  uninfected	   sheep	  were	   compared	   to	   scrapie	  
infected	   sheep.	   There	   was	   no	   significant	   difference	   in	   C1	   levels	   in	   scrapie	   infected	   and	  
uninfected	  ovine	  brain	  (Figure	  4.22B),	  indicating	  that	  at	  clinical	  stage	  of	  disease	  C1	  is	  not	  
reduced	  at	  measureable	  levels.	  
In	  the	  SSBP/1	  and	  classical	  scrapie	  	  infected	  animals	  there	  is	  an	  increase	  or	  appearance	  of	  
C2,	   with	   an	   apparent	   molecular	   weight	   of	   20-­‐21	   kDa	   (Figure	   4.22).	   It	   is	   unknown	   at	  
present	  whether	   this	   protein	   represents	   an	   increase	   in	   production	   of	   	   the	   cellular	   form	  
seen	  at	  low	  levels	  in	  healthy	  animals	  (Chen,	  Teplow	  et	  al.	  1995,	  Jimenez-­‐Huete,	  Lievens	  et	  
al.	   1998,	   Mange,	   Beranger	   et	   al.	   2004)	   mediated	   by	   reactive	   oxygen	   species	   (Watt	   and	  
Hooper	  2005,	  Watt,	  Taylor	  et	  al.	  2005)	  or	  a	  cleavage	  product	  of	  disease	  related	  PrPSc.	  	  This	  
C2	  protein	  was	  observed	  at	  a	  higher	   frequency	   in	   infected	  sheep	  with	  100	  %	  of	  SSBP/1	  
infected	  animals	  and	  66.7	  %	  of	  classical	  scrapie	  infected	  animals	  with	  visible	  bands	  of	  C2,	  
compared	   to	   37.9	   %	   of	   uninfected.	   To	   characterise	   the	   C1	   and	   C2	   proteins	   in	   infected	  
tissue	  western	  blots	  were	  performed	  with	  N-­‐terminal	  antibody	  P4	  (Table	  2.1).	  	  P4	  showed	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no	   reactivity	   to	   C1,	   confirming	   this	   is	   N-­‐terminally	   truncated,	   while	   both	   BC6	   and	   P4	  
antibodies	  bound	  the	  C2	  fragment	  as	  shown	  in	  Figure	  4.23.	  
 







4.5.1	  Distribution	  of	  PrPC	  and	  truncated	  fragments	  in	  the	  ovine	  brain	  
It	  was	   speculated	   that	   different	   ovine	   brain	   regions	  would	   have	   different	   levels	   of	   PrPC	  
expression	  as	  a	  result	  of	  both	  physiological	  and	  functional	  regional	  variation	  and	  the	  high	  
diversity	   of	   cell	   types.	   PrP	  mRNA	  expression	   levels	   in	  neurons	   in	  mice	   are	  higher	  when	  
compared	   to	   glial	   cells	   (Ford,	   Burton	   et	   al.	   2002).	   Although	   protein	   levels	   may	   not	  
correlate	   directly	   with	  mRNA	   expression	  we	   can	   speculate	   that	   areas	   known	   to	   have	   a	  
relatively	   high	   density	   of	   neurons,	   such	   as	   the	   cerebellum,	   would	   have	   higher	   levels	   of	  
PrPC	  expression,	  compared	  to	  areas	  where	  neurons	  are	  thought	  to	  represent	  less	  than	  1	  %	  
of	   cells,	   such	   as	   the	  mid	   brain	   and	  pons	   (Azevedo,	   Carvalho	   et	   al.	   2009).	  Our	   data	   from	  
sheep	   partially	   complies	   with	   this	   model,	   with	   very	   low	   relative	   levels	   of	   residual	   full	  
length	  PrPC	  in	  the	  mid	  brain	  and	  pons.	  However,	  in	  the	  three	  sheep	  tested	  average	  levels	  of	  
full	   length	   PrPC	   were	   highest	   in	   the	   cortex	   and	   thalamus	   and	   relatively	   low	   in	   the	  
cerebellum.	   If	   we	   consider	   the	   cellular	   composition	   of	   ovine	   brain	   to	   resemble	   that	   of	  
Figure	  4.23	  –Antibody	  binding	  to	  truncated	  fragments	  in	   infected	  brain.	  A)	  A	  western	  blot	  of	  
SSBP/1	  infected	  brain	  first	  probed	  with	  BC6,	  stripped	  and	  then	  probed	  with	  P4	  as	  described	  in	  
section	  2.3.3	  (Full	  length	  PrP*,	  C2**,	  C1*).	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primates	  this	  finding	  would	  suggest	  that	  neuronal	  density	  is	  not	  associated	  with	  high	  PrPC	  
expression,	  illustrated	  by	  low	  levels	  of	  PrPC	  in	  the	  cerebellum.	  This	  also	  suggests	  that	  glial	  
cells	  express	  measureable	  PrPC,	  confirming	  in	  sheep	  that	  mRNA	  levels	  in	  glia	  and	  neurons	  
do	  not	  directly	   correlate	   to	  PrPC	  expression	   in	   the	  brain,	  or	   that	  not	  all	  neuronal	   cells	   in	  
areas	  such	  as	  the	  cerebellum	  express	  PrPC	  measureable	  by	  western	  blotting.	  
	  
Furthermore,	  it	  was	  thought	  that	  regional	  variations	  in	  PrPC	  expression	  may	  partly	  explain	  
the	   distinct	   phenotypes	   and	   regions	   of	   PrPSc	   accumulation	   in	   scrapie	   (Spiropoulos,	  
Casalone	  et	  al.	  2007).	  However,	  low	  average	  levels	  of	  residual	  full	  length	  PrPC	  were	  found	  
in	   the	   pons	   and	  midbrain	  which	   are	   primary	   sites	   of	   PrPSc	   accumulation	   during	   disease	  
(Wemheuer,	   Benestad	   et	   al.	   2011).	   This	   indicates	   that	   PrPC	  expression	   levels,	   although	  
important	   in	   the	  development	  of	   scrapie	   in	  murine	   transgenic	  models	  are	  unlikely	   to	  be	  
the	  only	  defining	   factor	   in	  PrPSc	  deposition	   throughout	   the	  ovine	  brain.	   In	   the	  periphery,	  
PrPC	  expression	   in	   tissues	   and	   organs	   alone	   is	   not	   correlated	  with	   ability	   to	   accumulate	  
PrPSc	  or	  involvement	  in	  infection.	  PrPC	  expression	  is	  relatively	  low	  in	  the	  spleen	  and	  tonsil	  
when	  compared	  to	  areas	   thought	   to	  be	  absent	  of	  PrPSc	  accumulation,	  such	  as	   lung,	  heart	  
and	  skeletal	  muscle	  (Moudjou,	  Frobert	  et	  al.	  2001,	  Komolka,	  Ponsuksili	  et	  al.	  2013).	  
	  
To	   further	   understand	   the	   discrepancies	   with	   regional	   PrPC	   expression	   and	   PrPSc	  
accumulation	  proteolytic	  processing	  was	  investigated	  in	  these	  seven	  brain	  areas	  -­‐	  the	  first	  
most	  detailed	  study	  of	  PrP	  processing	  in	  a	  ruminant	  brain.	  It	  was	  hypothesised	  that	  areas	  
with	  higher	   levels	  of	  C1	  would	  be	   less	   likely	  to	  accumulate	  PrPSc	  as	  C1	   is	  not	  a	  sufficient	  
substrate	  for	  conversion	  and	  may	  act	  as	  a	  dominant	  inhibitor	  of	  conversion,	  as	  illustrated	  
in	  murine	  models	  (Westergard,	  Turnbaugh	  et	  al.	  2011).	  α-­‐Cleavage,	  represented	  by	  steady	  
state	  levels	  of	  C1	  protein,	  was	  evident	  in	  all	  of	  the	  seven	  brain	  areas	  tested	  and	  there	  were	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no	  significant	  differences	  in	  C1	  levels	  between	  these	  areas.	  Firstly,	  this	   indicates	  that	  the	  
unknown	  protease(s)	  responsible	  for	  cleavage	  is	  (are)	  ubiquitously	  expressed	  throughout	  
the	   brain.	   	   Additionally,	   the	   possibility	   cannot	   be	   excluded	   that	   different	   proteases	   are	  
responsible	   for	  cleavage	   in	  different	  cell	   types.	  For	  example,	   in	   skeletal	  muscle,	  ADAM	  8	  
has	   been	   linked	   to	   α-­‐cleavage	   (Liang,	   Wang	   et	   al.	   2012)	   but	   there	   is	   no	   evidence	   that	  
ADAM	   8	   is	   directly	   involved	   in	   α-­‐cleavage	   in	   brain	   tissue.	   Even	   CNS	   specific	   ADAM	  
proteases	  are	  more	  likely	  to	  be	  involved	  in	  cleaving	  at	  the	  extreme	  C-­‐terminus,	  shedding	  
PrPC	   from	   the	   cell	   surface	   (Parkin,	   Watt	   et	   al.	   2004).	   Secondly,	   this	   suggests	   that	   the	  
function	  of	  C1	   is	  not	   area	   specific	  or	   that	  C1	  may	  play	   several	  different	   roles	  within	   the	  
brain	  as	  the	  range	  of	  brain	  areas	  tested	  are	  both	  structurally	  and	  functional	  diverse.	  	  
	  
C1	  levels	  have	  been	  previously	  investigated	  throughout	  both	  the	  murine	  and	  human	  brain.	  
In	  agreement	  with	  our	   findings,	  C1	  distribution	   in	  wild	   type	  mice	   showed	  no	   significant	  
regional	   differences	   when	   measured	   by	   western	   blotting	   (Kayleigh	   Iremonger,	   Ph.D	  
Thesis,	   University	   of	   Edinburgh,	   2013).	   However,	   in	   human	   brain	   C1	   levels	   were	  
reportedly	  highest	  in	  the	  cerebellum	  and	  pons	  (Kuczius,	  Koch	  et	  al.	  2007).	  Whether	  this	  is	  
a	  true	  difference	  between	  species	  or	  due	  to	  differences	  in	  preparations	  and	  measurements	  
remains	   to	   be	   shown.	   It	   is	   likely	   that	   ovine	   brain,	   like	   that	   of	   primates	   has	   distinctly	  
different	   regional	   cell	   populations.	   As	   levels	   of	   proteolytic	   processing	   in	   ovine	   brain	  
regions	   are	   remarkably	   similar	   despite	   their	   cellular	   composition	  we	   can	   postulate	   that	  
neurons	  and	  glial	  cells	  may	  have	  comparable	  levels	  of	  PrPC	  processing.	  This	  would	  indicate	  
that	  processing	  of	  PrPC	  is	  an	   important	   feature	  of	  cellular	   function	  in	  general	  rather	  than	  
specifically	  neuronal.	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4.5.2	  PrPC	  expression	  in	  the	  ovine	  brain	  and	  susceptibility	  to	  scrapie	  
It	  is	  currently	  very	  difficult	  to	  measure	  PrPC	  expression	  and	  cleavage	  in	  the	  brain	  prior	  to	  
infection	  with	  scrapie	  and	  during	  scrapie	  infection,	  due	  to	  the	  physiology	  of	  the	  brain	  and	  
the	  difficulties	  involved	  with	  sampling	  from	  this	  organ.	  	  Hence	  it	  is	  not	  possible	  to	  directly	  
correlate	   these	   variables	   with	   susceptibility	   and	   incubation	   of	   disease.	   PrPC	   expression	  
and	   processing	   was	   therefore	   investigated	   in	   known	   models	   of	   resistance	   and	  
susceptibility,	  determined	  by	  PRNP	  genotype.	  	  Although	  there	  was	  a	  trend	  for	  average	  full-­‐
length	  PrPC	  levels	  in	  VRQ/VRQ	  sheep	  to	  be	  slightly	  higher,	  both	  ARR/ARR	  and	  VRQ/VRQ	  
animals	  had	  similar	   levels,	  while	  expression	   in	  ARQ/ARQ	  animals	  was	   lower.	  A	  separate	  
study	  which	   looked	   at	   PrPC	  expression	   in	   brain	   from	   two	   sheep	   of	   each	  PRNP	   genotype	  
(ARR/ARR,	   ARQ/ARQ	   and	   VRQ/VRQ)	   reported	   no	   significant	   differences	   in	   total	   PrPC	  
expression	  (Thackray,	  Fitzmaurice	  et	  al.	  2006).	  We	  know	  from	  in	  vitro	  studies	  that	  PrPARR	  
cannot	  be	  easily	  converted	  to	  PrPSc	  therefore	  perhaps	  small	  variations	  in	  PrPC	  expression	  
between	  VRQ/VRQ	  and	  ARQ/ARQ	  can	  go	  someway	  to	  explaining	  the	  varying	  susceptibility	  
to	  scrapie	  (Bossers,	  Belt	  et	  al.	  1997,	  Kirby,	  Agarwal	  et	  al.	  2010).	  	  
	  
This	  study	  has	  primarily	   looked	  at	  PrPC	  expression	  and	  processing	  in	  the	  brain.	  Although	  
the	  brain	   is	   the	  major	   site	  of	  PrPSc	  accumulation	  and	  pathology	   it	   is	  not	   the	  main	  site	  of	  
PrPSc	  conversion	  during	  scrapie	  infection	  via	  the	  natural	  oral	  route.	  PrPSc	  can	  accumulate	  in	  
the	   digestive	   tract,	   lymphoid	   organs,	   (Andreoletti,	   Berthon	   et	   al.	   2000)	   and	   circulating	  
blood	  prior	  to	  the	  onset	  of	  clinical	  disease	  (Terry,	  Howells	  et	  al.	  2009).	  It	  is	  the	  latter,	  along	  
with	  PrPSc	  presentation	  on	  migrating	  immune	  cells,	  which	  is	  though	  to	  promote	  the	  spread	  
of	   prion	   infection	   throughout	   the	   body.	   PrPC	   expression	   and	   processing	   as	   a	   factor	   of	  
susceptibility/resistance	  may	  be	  more	  important	  in	  these	  early	  sites	  of	  conversion	  rather	  
than	   in	   the	   brain.	   During	   this	   study	   attempts	   were	   made	   at	   visualising	   PrPC	   truncated	  
fragments	  from	  tonsil	  and	  lymph	  node	  (section	  4.4.6).	  The	  sheep	  used	  for	  this	  study	  had	  an	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average	  C1	   level	   of	   43	  %	   in	   brain	   therefore	  we	   can	   surmise	   that	   although	  C1	   cannot	   be	  
measured	  it	  represents	  sufficiently	  less	  than	  50	  %.	  This	  suggests	  that	  α-­‐cleavage	  levels	  in	  
the	  lymphoid	  organs	  may	  be	  lower	  compared	  to	  levels	  seen	  in	  ovine	  brain.	  PrPC	  expression	  
was	  too	  low	  in	  these	  tissues	  to	  allow	  for	  clear	  visualisation	  of	  PrPC	  truncated	  forms	  using	  
conventional	   blotting	   methods.	   Using	   immunoprecipitation	   or	   similar	   enrichment	  
techniques	   analysis	   of	   PrPC	   and	   truncated	   proteins	   in	   these	   tissues	   may	   be	   possible,	  
however	  at	  the	  time	  of	  completing	  this	  work	  the	  importance	  of	  C1	  in	  scrapie	  susceptibility	  
was	   unknown	   and	   hence	   the	   time	   was	   not	   spent	   to	   develop	   these	   techniques.	   PrPC	  
expression	   has	   been	   compared	   on	   ovine	   blood	   cells	   of	   varying	   PRNP	   genotypes.	   Total	  
expression	   of	   PrPVRQ	  was	   found	   to	   be	   higher	   than	   both	   PrPARR	  and	  PrPARQ,	   while	   surface	  
expression	  of	  PrP	  was	  found	  to	  be	  similar	  in	  all	  genotypes	  (Halliday,	  Houston	  et	  al.	  2005,	  
Thackray,	   Fitzmaurice	   et	   al.	   2006),	   indicating	   that	   there	   may	   be	   PRNP	   genotypic	  
differences	  in	  the	  periphery,	  which	  needs	  to	  be	  further	  explored.	  
	  
Although,	   we	   have	   found	   no	   direct	   association	   between	   levels	   of	   PrPC	   expression	   and	  
scrapie	  susceptible	  genotypes,	   if	  we	  postulate	  that	  ovine	  C1	  may	  be	  a	  dominant	  negative	  
inhibitor	   of	   conversion	   of	   PrPSc	   as	   suggested	   for	  mice	   by	  Westergard	   et	   al	   (Westergard,	  
Turnbaugh	  et	  al.	  2011)	  more	  relative	  C1	  in	  the	  brain	  of	  ARR/ARR	  sheep	  could	  negate	  or	  
prevent	  much	   of	   the	   full	   length	   PrP	   converting	   to	   PrPSc	  during	   TSE	   disease.	   Figure	   4.24	  
models	  such	  an	  effect	  in	  a	  deliberately	  simplified	  linear	  manner.	  Convertible	  forms	  of	  PrP	  
(full	   length	  PrPC	  and	  C2)	  are	  shown	  in	  black	  for	  each	  PRNP	  genotype.	  If	  C1	  (white)	  could	  
inhibit	   conversion	   at	   a	   1:1	   molecule:	   molecule	   ratio	   the	   level	   of	   convertible	   PrP	   in	  
ARR/ARR	  sheep	  is	  greatly	  reduced	  compared	  to	  VRQ/VRQ.	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4.5.3	  PrPC	  processing	  in	  the	  ovine	  brain	  and	  susceptibility	  to	  scrapie	  
ARR/ARR	   sheep,	   which	   are	   naturally	   resistant	   to	   classical	   scrapie,	   have	   significantly	  
higher	  average	  levels	  of	  C1	  fragment	  in	  the	  cortex	  than	  ARQ/ARQ	  and	  VRQ/VRQ	  sheep.	  In	  
heterozygous	   sheep	   the	   presence	   of	   one	   ARR	   allele	   led	   to	   higher	   C1	   levels	   in	   the	   ovine	  
brain	  which	  could	  be	  attributed	  to	  an	  increased	  susceptibility	  of	  more	  PrPARR	  to	  take	  part	  
in	  α-­‐cleavage.	  In	  sheep	  the	  presence	  of	  one	  ARR	  allele	  greatly	  reduces	  the	  risk	  of	  acquiring	  
natural	   scrapie	   and	   increases	   incubation	  period	  of	   infection	   (Baylis,	   Chihota	   et	   al.	   2004,	  
Hunter	  2007).	  If	  antibodies	  specific	  to	  PrPC	  variants	  were	  available	  these	  could	  have	  been	  
used	   to	   determine	   if	   the	   C1	   present	   in	   the	   brains	   of	   heterozygotes	   is	   predominantly	  
produced	  from	  PrPARR.	  	  
	  
Figure	   4.24	   –	   The	   hypothetical	   effect	   of	   C1	   as	   inhibitor	   of	   conversion	   on	   levels	   of	  
convertible	  PrP	  in	  PRNP	  genotype	  groups	  with	  varying	  susceptibility	  to	  scrapie.	  Levels	  of	  
full	  length	  PrP,	  C2	  and	  C1	  were	  taken	  from	  average	  levels	  as	  shown	  in	  Figure	  3.19A,	  using	  
BC6	  antibody.	  1:1	   inhibition	  assumes	  that	  every	  molecule	  of	  C1	  can	  inhibit	  one	  molecule	  
of	  PrP	  or	  C2,	  shown	  in	  grey.	  
 VRQ/VRQ	    	  VRQ/VRQ	  
inhibited	  1:1	  
















PrP	  full	  length	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The	   correlation	  between	  a	  high	  C1	   levels	   and	   scrapie	   resistance	   is	   supported	  by	   similar	  
evidence	  from	  cell	  culture	  assays	  and	  transgenic	  mouse	  models.	  Lewis	  et	  al	  (Lewis,	  Hill	  et	  
al.	   2009)	   showed	   that	   neuronal	   and	   non-­‐neuronal	   cell	   lines	   with	   higher	   levels	   of	   α-­‐
cleavage	  show	  more	  resistance	  to	  prion	   infection	  and	  concluded	  that	  this	  cleavage	   is	   the	  
most	   important	   factor	   in	   the	   selective	   vulnerability	   to	   prions	   (Lewis,	   Hill	   et	   al.	   2009).	  
Scrapie	  challenges	  in	  transgenic	  mice	  expressing	  only	  C1	  protein	  (Westergard,	  Turnbaugh	  
et	  al.	  2011)	  have	  shown	  that	  C1	  alone	  does	  not	  act	  as	  a	  substrate	  for	  conversion	  to	  PrPSc.	  
Over-­‐expression	  of	  C1	  in	  the	  presence	  of	  full	  length	  PrPC	  slowed	  accumulation	  of	  PrPSc	  and	  
extended	   the	   incubation	  period	  of	  disease	   in	   these	   transgenic	  mice,	   supporting	   the	  view	  
that	   C1	   may	   inhibit	   some	   unknown	   pathway	   in	   the	   conversion	   of	   PrPC	   to	   PrPSc	  
(Westergard,	  Turnbaugh	  et	  al.	  2011).	  
	  
Although	   N1	   levels	   were	   not	   measured	   in	   sheep	   brain	   samples,	   its	   production	   can	   be	  
inferred	  from	  the	   levels	  of	   the	  corresponding	  C1	  fragment	  and	  it	   is	   likely,	   therefore,	   that	  
the	   increased	   levels	   of	   this	   fragment	   in	   disease-­‐resistant	   animals	   will	   represent	   an	  
additional	   benefit	   in	   protection	   against	   the	   neurodegeneration	   associated	   with	   prion	  
disease.	  For	  example,	  N1	  can	   inhibit	  staurosporine	   induced	  caspase-­‐3	  activation	  through	  
the	  p53	  pathway	   (Sunyach,	  Cisse	  et	   al.	   2007).	  Addition	  of	   a	   recombinant	  N1	   to	   cultured	  
cells	   also	   shows	   dose	   dependent	   neuroprotective	   effects	   (Guillot-­‐Sestier,	   Sunyach	   et	   al.	  
2009).	  N1	  has	  also	  been	  shown	  to	  bind	  to	  early	  stage	  Aβ	  oligomers	  which	  may	  inhibit	  the	  
formation	  of	  amyloid	  fibril	   formation	  and	  reduce	  fibril	  associated	  toxicity	  and	  associated	  
effects	  in	  both	  neuronal	  cell	  culture	  and	  in	  murine	  Alzheimer’s	  models	  (Tagliavini,	  Prelli	  et	  
al.	  1992).	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In	  TSE	  infected	  mice	  it	   is	  reported	  that	  there	  is	  a	  decrease	  in	  C1	  (Nicot	  and	  Baron	  2010)	  
which	  could	  be	  indicative	  of	  an	  alteration	  in	  cellular	  homeostasis,	  disrupting	  an	  upstream	  
signaling	  pathway	  such	  as	  protein	  kinase	  C.	  It	  could	  also	  signify	  increased	  degradation	  of	  
C1,	  possibly	  due	   to	  attempts	  by	   the	  cell	   to	  clear	  misfolded	  PrPSc.	   In	  contrast,	   all	   infected	  
sheep	   brain	   tested	   had	   C1	   present	   and	   levels	   of	   C1	   were	   relatively	   similar	   to	   those	   in	  
uninfected	   ovine	   brain	   of	   susceptible	   PRNP	   genotypes.	   Although	   the	   amount	   of	   PrPSc	  
accumulation	   in	   the	   brain	   changes	   during	   disease	   and	   varies	   from	   sheep-­‐to-­‐sheep,	  
affecting	  the	  total	  PrP	  levels,	  PrPSc	  was	  not	  thought	  to	  be	  present	  at	  sufficient	  levels	  to	  alter	  
the	   appearance	   of	   PrP	   by	   conventional	   immunoblotting.	   The	   use	   of	   α-­‐tubulin	   loading	  
control,	   as	   used	   in	   other	   aspects	   of	   this	   thesis,	   was	   explored.	   However,	   this	   and	   other	  
similar	  ‘house-­‐keeping’	  markers	  can	  decrease	  with	  neuronal	  loss	  (Barry	  McColl,	  personal	  
communication),	  a	  key	  feature	  of	  scrapie	  infection.	  	  
	  
Although	   C1	   represented	   the	   major	   truncated	   fragment	   in	   ovine	   brain,	   C2	   was	   also	  
observed	   in	   some	   samples.	   It	   is	   though	   that	   C2	   may	   be	   an	   intermediate	   which	   is	  
subsequently	  converted	  to	  PrPSc	  and	  there	  were	  clearly	  more	  infected	  sheep	   in	  this	  study	  
that	   showed	   C2	   compared	   to	   uninfected	   sheep.	   Rather	   unexpectedly,	  ARR/ARR	   animals	  
had	   both	   a	   significantly	   lower	   average	   C2	   level	   and	   were	   much	   less	   likely	   to	   have	  
detectable	   C2	   than	   the	   more	   susceptible	   genotypes.	   Truncated	   recombinant	   PrP	   90-­‐231,	  
representing	   truncated	   C2	   protein	   have	   similar	   ability	   to	   aggregate	   and	   form	   amyloid	  
fibrils	   as	   full	   length	   recombinant	   PrP23-­‐231	   (Stohr,	   Elfrink	   et	   al.	   2011)	   indicating	   C2	  may	  
represent	  an	  alternative	  substrate	   for	  conversion	  to	  PK	  resistant	  PrPSc.	   It	   is	  possible	   that	  
this	  increase	  in	  production	  of	  C2	  during	  disease	  is	  specific	  to	  the	  brain	  region	  tested	  –	  the	  
cortex	   –	   as	   cell	   culture	   experiments	   have	   show	   production	   of	   this	   fragment	   to	   be	  
dependent	  on	  cell	  type,	  finding	  higher	  levels	  of	  C2	  produced	  in	  scrapie	  infected	  astrocytes	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when	  compared	  to	  neurons	  (Dron,	  Moudjou	  et	  al.	  2010).	  However,	  ovine	  PrPC	  expressing	  
neuronal	  and	  non-­‐neuronal	  cell	   lines	   tested	  during	   this	   thesis	  showed	  no	  evidence	  of	  C2	  
fragment.	  
	  
4.5.4	  Potential	  mechanisms	  of	  PRNP	  polymorphism	  dependent	  PrPC	  processing	  
The	  C1	  fragment	  is	  produced	  by	  the	  action	  of	  an	  unknown	  PrP-­‐secretase	  (as	  discussed	  in	  
section	   1.3.8)	   and	   high	   C1	   levels	   in	   ARR/ARR	   sheep	   may	   result	   from	   an	   increased	  
proteolytic	   processing	   of	   PrPARR	  compared	   to	  PrPARQ	  or	  PrPVRQ.	  This	  may	  be	   explained	  by	  
conformational	   differences	   leading	   to	   increased	  presentation	   of	   the	   cleavage	   site	   for	   the	  
PrP	   secretase	   or	   by	   the	   extended	   presence	   of	   PrPARR	  within	   intracellular	   compartments	  
increasing	   the	   chance	   of	   interacting	   with	   the	   PrP	   secretase.	   Slight	   conformational	  
variations	  could	   lead	  to	  differences	   in	   the	  half-­‐lives	  of	   the	  C1	   fragments,	  as	  suggested	  by	  
Thackray	   et	   al	   in	   the	   case	   of	   full	   length	   PrP	   (Thackray,	   Yang	   et	   al.	   2004).	   Furthermore,	  
PrPARR	  may	  have	  a	  higher	  propensity	  to	   form	  homodimers,	  compared	  to	  other	  variants	  of	  
PrPC.	  It	  has	  been	  shown	  that	  forced	  homodimerisation	  of	  PrPC	  in	  cell	  culture	  increased	  α-­‐
cleavage	  levels	  and	  it	  may	  be	  the	  case	  that	  PrPC	  homodimerisation	  is	  required	  for	  binding	  
to	   or	   recognition	   by	   the	   unknown	   PrP	   secretase	   (Tagliavini,	   Prelli	   et	   al.	   1992,	   Béland,	  
Motard	   et	   al.	   2012).	   In	   agreement	   with	   this	   hypothesis,	   mutations	   within	   the	   dimer	  
binding	   site	   (amino	   acids	   112-­‐133,	   murine)	   but	   not	   directly	   at	   the	   alpha	   cleavage	   site	  
(111/112,	  murine)	  have	  been	  shown	  to	  reduce	  production	  of	  C1	  (Oliveira-­‐Martins,	  Yusa	  et	  
al.	  2010).	  	  
	  
It	  is	  yet	  unknown	  if	  the	  formation	  of	  homodimers	  containing	  two	  variants	  of	  PrPC	  (for	  the	  
purposes	   of	   this	   discussion	   from	   now	   on	   referred	   to	   as	   heterodimers)	   have	   the	   same	  
effects	  on	  levels	  of	  α-­‐cleavage	  as	  the	  formation	  of	  homodimers	  of	  the	  same	  PrPC	  variants.	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However,	   if	   this	   increase	   in	   cleavage	  was	   homodimer	   specific	   it	  would	   be	   expected	   that	  
levels	   of	  α-­‐cleavage	   in	   heterozygote	   sheep	   would	   be	   much	   lower	   than	   in	   homozygotes,	  
which	  was	  not	  the	  case	  in	  the	  sheep	  tested.	  Polymorphisms	  at	  position	  136,	  154	  and	  171	  
are	  out	  with	   the	  dimer	  binding	  site	  and	   therefore	  dimerisation	  should	  be	   irrespective	  of	  
polymorphisms	  at	   these	  positions.	  However,	   if	  we	  speculate	   that	  PrPARR	  has	  an	   increased	  
propensity	   to	   form	   dimers	   other	   factors	   may	   be	   involved,	   such	   as	   conformational	  
differences	  which	  would	  affect	  outward	  facing	  regions	  for	  binding.	  It	  has	  been	  shown	  that	  
polymorphisms	   at	   positions	   136	   and	  171	   can	  have	   an	   effect	   on	   the	   secondary	   structure	  
and	  stability	  of	  PrPC.	  On	  comparison	  of	  171Q	  to	  171R	  it	  was	  found	  that	  the	  latter	  results	  in	  
a	  more	  flexible	  structure	  and	  as	  a	  result	  PrPARQ	  and	  PrPVRQ	  are	  more	  compact,	  ridged	  and	  
stable	  (Rezaei,	  Choiset	  et	  al.	  2002,	  Wong,	  Thackray	  et	  al.	  2004,	  Bujdoso,	  Burke	  et	  al.	  2005).	  
If	  PrPARR	  is	  more	  flexible	  we	  can	  surmise	  that	  perhaps	  the	  dimer	  binding	  regions	  are	  more	  
likely	  to	  intercept	  when	  compared	  to	  other	  PrPC	  variants.	  
	  
It	  also	  has	   to	  be	  considered	  that	   the	  high	   levels	  of	  α-­‐cleavage	  associated	  with	   the	  Roslin	  
Institute	  ARR	  carriers	  may	  be	  a	  result	  of	  inbreeding	  within	  a	  closed	  flock.	  If	  high	  levels	  of	  
C1	  are	  a	  result	  of	  a	  separate	  genetic	  factor	  such	  as	  mutation	  of	  another	  gene,	  perhaps	  the	  
unknown	  PrP-­‐secretase,	  high	  levels	   in	  these	  animals	  may	  in	  fact	  be	   inadvertently	  passed	  
from	   generation	   to	   generation	   in	   parallel	   with	   the	   R171	   polymorphism.	   This	   would	  
explain	  the	  lack	  of	  a	  strong	  association	  of	  higher	  levels	  of	  C1	  in	  ARR-­‐heterozygotes	  in	  the	  
Norwegian	  sheep,	  clearly	  seen	  within	  the	  Rosin	  sheep	  flock	  (Michael	  Tranulis	  and	  Wilfred	  
Goldmann,	  personal	  communication),	  while	  there	  was	  little	  difference	  when	  we	  compared	  
ARQ/ARQ	  sheep	  in	  both	  flocks.	  Unfortunately,	  we	  have	  not	  yet	  been	  able	  to	  obtain	  brain	  
tissue	   from	   any	   ARR/ARR	   homozygote	   sheep	   from	   the	   Norwegian	   flock	   to	   directly	  
compare	  to	  ARR/ARR	  homozygotes	  from	  Roslin.	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4.5.5	  Levels	  of	  α-­‐cleavage	  fragments	  in	  sheep	  relative	  to	  other	  species.	  
C1	  levels	  account	  for	  around	  50	  %	  of	  the	  total	  PrP	  in	  brain	  of	  several	  other	  species,	  such	  as	  
humans,	  cats,	  brown	  bear	  and	  primates,	  indicating	  that	  the	  ARR/ARR	  sheep	  tested	  in	  this	  
thesis	   do	   not	   have	   abnormally	   high	   levels	  of	  α-­‐cleavage	   	   (table	   1.2,	   Chapter	   1)(Stewart,	  
Campbell	  et	  al.	  2012).	  In	  particular,	  baboon	  brain	  shows	  very	  high	  levels	  of	  C1,	  of	  ~	  80	  %	  
(Laffont-­‐Proust,	  Hassig	  et	  al.	  2006),	  similar	  to	  the	  highest	  levels	  found	  in	  ARR/ARR	  sheep,	  
whereas	   C1	   levels	   found	   in	  ARQ/ARQ	   and	  VRQ/VRQ	   sheep	   are	  more	   similar	   to	   those	   in	  
rats,	   mice	   and	   goats	   (Laffont-­‐Proust,	   Hassig	   et	   al.	   2006).	   These	   data	   suggest	   that	   high	  
levels	  of	  α-­‐cleavage	  is	  not	  an	  anomaly	  associated	  with	  the	  ARR/ARR	  genotype	  of	  sheep	  but	  
it	  may	  be	  unusual	  to	  have	  such	  variation	  within	  a	  species	  and	  I	  am	  currently	  unaware	  of	  
other	   studies	   in	   which	   α-­‐cleavage	   levels	   have	   been	   investigated	   in	   a	   large	   number	   of	  
animals	  out	  with	  transgenic	  or	  laboratory	  mice	  populations.	  	  
	  
4.5.6	  Cell	  culture	  models	  of	  PrPC	  processing	  
Although	  sheep	  represent	  excellent	  large	  animal	  models	  of	  disease	  it	  was	  advantageous	  to	  
identify	   a	  model	   of	   ovine	   PrPC	   expression	   that	  would	   accurately	  mimic	   proteolytic	   PrPC	  
processing	  observed	  in	  ovine	  brain,	  as	  it	  would	  be	  open	  for	  manipulation.	  Therefore	  PrPC	  
expression	  and	  processing	  were	  investigated	  in	  cell	  culture	  models	  expressing	  ovine	  PrPC.	  
Primary	  neuronal	   cell	   lines	  were	  derived	   from	  ovine	   transgenic	  mice	  Tg338	  and	  gtARQ.	  
PrPC	   expression	   in	   gtARQ	   derived	   primary	   neuronal	   cells	   was	   lower	   in	   comparison	   to	  
Tg338	   and	   truncated	   fragments	   were	   not	   visible	   by	   western	   blotting	   of	   cell	   lysates.	  
Primary	  neurons	  derived	   from	  the	  PrPC	  overexpressing	  Tg338	   line	  had	  measureable	   full	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length	  PrPC	  protein	  and	   truncated	   fragment	  C1	  at	   levels	  comparable	  with	  Tg338	  murine	  
brain	  and	  VRQ/VRQ	  ovine	  brain.	  	  With	  the	  goal	  of	  using	  Tg338	  derived	  neuronal	  cells	  as	  a	  
basis	   to	   create	   an	   inducible	   model	   of	   α-­‐cleavage	   to	   study	   conversion	   ADAM	   proteases	  
were	  inhibited	  by	  addition	  of	  OPH.	  This	  had	  no	  inhibitory	  effect	  on	  the	  levels	  of	  α-­‐cleavage	  
and	   at	   the	   highest	   concentration	   resulted	   in	   a	   significant	   increase	   in	   cell	   associated,	  
truncated	  C1.	  In	  agreement	  with	  these	  findings	  Taylor	  et	  al	  (2009)	  have	  shown	  that	  over	  
expression	  of	  ADAMS	  9,	  10	  and	  17	  independently	  in	  HEK	  cells	  did	  not	  alter	  C1	  levels	  and	  
silencing	  of	  the	  same	  candidates	  using	  siRNA	  also	  proved	  to	  have	  no	  effect	  on	  the	  levels	  of	  
C1.	  Altmeppen	  and	  colleagues	  also	  show	  that	  C1	  levels	  remain	  high	  in	  ADAM	  10	  knock	  out	  
primary	  neurons	   (Altmeppen,	   Prox	   et	   al.	   2011).	   In	   contrast,	   in	   cultures	   of	  TMS	  neurons	  
and	  HEK293	  cells	  addition	  of	  OPH	  resulted	  in	  a	  significant	  reduction	  in	  N1	  secretion	  by	  40	  
-­‐70	  %	  when	  compared	  to	  untreated	  cells	  (Vincent,	  Paitel	  et	  al.	  2001,	  Cisse,	  Sunyach	  et	  al.	  
2005).	  It	  is	  possible	  that	  this	  difference	  is	  due	  to	  the	  measurement	  of	  secreted	  N1	  and	  not	  
the	   cell	   associated	   C1	   and	   can	   be	   explained	   using	   our	   hypothetical	   model	   of	   ADAM	   10	  
involvement	  in	  the	  shedding	  of	  N1	  through	  the	  cleavage	  and	  shedding	  of	  LRP1	  and	  not	  the	  
direct	   cleavage	   of	   PrPC	   (Chapter	   1,	   Figure	   1.9).	   Further	   attempts	   at	   manipulating	   the	  
processing	   of	   PrPC	   in	   the	  Tg338	   derived	   primary	   cell	  model	  were	   hindered	   both	   by	   the	  
availability	   of	   embryonic	   tissues	   as	   a	   result	   of	   low	   mating	   success	   and	   problems	   with	  
reproducibility	  in	  production	  of	  primary	  neuronal	  cultures.	  	  
	  
Interestingly,	   there	  was	  no	  measureable	  band	  of	  C2	   found	   in	   any	  of	   the	   cell	   lines	   tested	  
throughout	  this	  study.	  This	  may	  indicate	  that	  production	  of	  C2	  is	  specific	  to	  some	  neuronal	  
cells	  or	  the	  conditions	  in	  which	  the	  cells	  are	  grown	  suppress	  C2	  production.	  This	  could	  be	  
investigated	  by	  inducing	  oxidative	  stress	  or	  by	  addition	  of	  reactive	  oxygen	  species	  to	  these	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cells	   in	   culture	   and	  measuring	   effects	   on	   C2	   production,	   as	   described	   by	  Watt	   et	   al	   for	  
neuronal	  cells	  (Watt,	  Taylor	  et	  al.	  2005).	  	  
	  
4.5.7	  Conclusions	  
This	  chapter	  firstly	  aimed	  to	  investigate	  the	  proteolytic	  processing	  and	  expression	  of	  PrPC	  
in	  the	  ovine	  brain.	  Regional	  differences	  in	  residual	  full	  length	  PrPC	  levels	  could	  be	  further	  
understood	   by	   investigating	   PrPC	   protein	   expression	   in	   different	   neuronal	   cell	   types.	  
However,	   the	   lack	   of	   an	   association	   between	   high	   PrPC	  expression	   and	  areas	   of	   known	  
PrPSc	  accumulation	  during	  scrapie	  disease	  led	  us	  to	  conclude	  that	  regional	  PrPC	  expression	  
in	  the	  ovine	  brain	  is	  not	  a	  defining	  factor	  in	  the	  pattern	  of	  spread.	  Perhaps,	  the	  ability	  of	  
different	  cell	  types	  to	  support	  and	  accumulate	  PrPSc	  or	  variable	  susceptibility	  of	  neuronal	  
cell	  types	  to	  PrPSc	  related	  neurotoxicity	  might	  better	  explain	  the	  characteristic	  pathologies.	  
Contrastingly,	   there	  was	  no	  major	   regional	   variation	   in	   the	   levels	  of	   residual	  C1	  protein	  
throughout	  the	  ovine	  brain	  which	  may	  reflect	  the	  functional	  importance	  of	  this	  fragment.	  
However,	  levels	  of	  C1	  in	  the	  cortex	  were	  found	  to	  vary	  extensively	  between	  sheep,	  which	  
may	  have	  consequences	  on	  normal	  cellular/brain	  function.	  
	  
Secondly,	   this	   chapter	   aimed	   to	   assess	   whether	   variations	   in	   PrPC	   expression	   and	  
processing	   could	   contribute	   to	   scrapie	   disease	   susceptibility	   in	   sheep.	   	  We	   identified	   an	  
association	   of	   high	   levels	   of	   α-­‐cleavage	   fragment	   C1	   with	   scrapie	   resistant	   genotype	  
ARR/ARR	  although,	  it	  is	  unknown	  if	  this	  is	  a	  result	  of	  an	  altered	  ability	  of	  the	  PrP	  secretase	  
to	   cleave	   PrPARR,	   higher	   stability	   of	   C1ARR	   or	   of	   another	   heritable	   genetic	   factor.	   The	  
development	  of	  in	  vitro	  assays	  of	  conversion	  with	  C1	  will	  be	  essential	  to	  fully	  understand	  
the	  role	  of	  C1	  in	  the	  conversion	  of	  PrPC	  to	  PrPSc.	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As	  discussed	   in	  great	  detail	   in	   sections	  1.3.2,	  1.3.8	   and	  1.3.10	   there	   is	   growing	  evidence	  
that	   C1	   cannot	   be	   converted	   to	  PrPSc	  and	   that	   the	  presence	   of	   C1	  may	   lead	   to	   increased	  
resistance	   to	   TSE	   infection.	   This	   raises	   the	   possibility	   that	   PrPC	   cleavage	   may	   control	  
disease	  by	   either	   reducing	   the	   amount	  of	   full	   length	  PrPC	   available	   for	   conversion	  or	  by	  
producing	  different	  levels	  of	  the	  C1	  fragment,	  which	  would	  act	  as	  an	  inhibitory	  modulator	  
of	  conversion.	  In	  sheep,	  this	  control	  may	  be	  associated	  with	  PRNP	  genotype.	  To	  investigate	  
the	  conversion	  potential	  of	  ovine	  C1	  in	  vitro	  fibrillisation	  assays	  were	  performed.	  
	  
Experimental	  considerations	  
Recombinant	   proteins	   have	   been	   extensively	   used	   to	   represent	   cellular	   PrPC	   in	   prion	  
research;	   hence	   a	   system	   was	   developed	   here	   to	   produce	   bacterially	   expressed	  
recombinant	  proteins	   representing	   truncated	  C1	  and	  C2	  proteins	  with	  various	   sequence	  
variations.	   Ideally,	   these	  experiments	  using	   recombinant	  C1	  would	  be	   followed	  by	  using	  
C1	   purified	   either	   from	   the	   ovine	   brain	   or	  mammalian	   cells	   in	   culture	   as	   this	  would	   be	  
both	   glycosylated,	   carry	   the	   GPI-­‐anchor	   and	   be	   naturally	   folded.	   However,	   using	  
unglycosylated	   recombinant	   PrPC	   is	   not	   entirely	   artificial	   as	   a	   fraction	   of	   cellular	   PrPC	  
isolated	  from	  tissue	  is	  unglycosylated	  and	  can	  be	  found	  in	  PrPSc	  preparations	  supported	  by	  
in	   vivo	   studies	   also	   showing	   that	   glycosylation	   is	   not	   essential	   for	   conversion	   (Tuzi,	  
Cancellotti	  et	  al.	  2008).	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In	   vitro	   fibrillisation	   assays	   are	   discussed	   in	   detail	   in	   section	   1.1.8.	   They	   allow	   for	   the	  
kinetics	   of	   conversion	   to	   be	   monitored	   through	   the	   use	   of	   ThT,	   a	   fluorescent	   dye	   that	  
specifically	  binds	  to	  amyloid	  and	  which	  can	  be	  used	  to	   follow	  the	  conversion	  reaction	   in	  
real	   time.	   Furthermore,	   this	   assay	   has	   been	   well	   characterised	   for	   PrP	   and	   does	   not	  
involve	  a	  PrPSc	  seed.	   	   Fibrillisation	   reactions	  have	  been	   shown	   to	  mimic	   the	   interspecies	  
barrier	   (Panza,	   Luers	   et	   al.	   2010)	   and	  may,	   as	   reported	   from	   other	   in	   vitro	   conversion	  
assays,	   display	   variation	   in	   fibrillisation	   abilities	   associated	   with	   resistance	   associated	  
polymorphisms	  (Kirby,	  Agarwal	  et	  al.	  2010,	  Eiden,	  Soto	  et	  al.	  2011).	  
	  
5.2	  AIMS	  AND	  OBJECTIVES	  
Previous	   chapters	   have	   shown	   that	   levels	   of	   truncated	   PrPC	   protein	   in	   ovine	   brain	   are	  
highly	  variable.	  It	  has	  also	  been	  suggested	  that	  murine	  C1	  is	  not	  converted	  to	  PK	  resistant	  
PrPSc.	   This	   chapter	   aimed	   to	   investigate	   whether	   truncated	   ovine	   PrPC	   proteins	   with	  
sequence	   variation	   have	   the	   potential	   to	   misfold	   in	   vitro.	   Recombinant	   proteins	   were	  
produced	  and	  characterised.	  These	  recombinant	  proteins	  were	  subjected	   to	   fibrillisation	  
assays	  to	  assess	  their	  potential	  to	  contribute	  to	  conversion	  during	  disease.	  	  
	  
5.3.	  MATERIALS	  AND	  METHODS	  
5.3.1	  Production	  of	  PET19B/	  C1	  and	  C2	  plasmids	  
To	   produce	   truncated	   recombinant	   PrP	   proteins	   representative	   of	   the	   C1	   fragment	   the	  
open	  reading	  frame	  between	  codons	  115	  and	  234	  of	  the	  ovine	  PRNP	  gene	  alleles	  ARR,	  VRQ	  
and	  ARQ	  was	  amplified	  each	  by	  PCR	   from	  ovine	  genomic	  DNA	   (homozygous	  genotypes)	  
with	   oligonucleotide	   primers	   Nde_C1F	   (CATCATATGGTGGCAGGAGCTGCTG,	   3’	   to	   5’)	   and	  
BamH1_C1R	   (AGTGGATCCTCAACTTGCCCCCCTTTG,	   3’	   to	   5’)	   and	   high	   fidelity	   Taq	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polymerase.	  For	  production	  of	  C2	  fragments	  the	  open	  reading	  frame	  between	  codons	  92	  
and	  234	  of	  ovine	  PRNP	  from	  gene	  alleles	  ARR	  and	  VRQ	  were	  amplified	  each	  by	  PCR	  from	  
genomic	  DNA	  with	  oligonucleotide	  primers	  Nde_C2F	  (CATCATATGGGCTGGGGTCAAGGTG)	  
and	  BamH1_C1R	  (AGTGGATCCTCAACTTGCCCCCCTTTG)	  and	  high	  fidelity	  Taq	  polymerase.	  
The	   PCR	   reactions	   are	   summarised	   in	   Table	   2.4	   and	   conditions	   are	   as	   follows	   95ºC	   for	  
10minutes,	  followed	  by	  40	  repeats	  of	  95ºC	  for	  1	  minute,	  61ºC	  for	  30	  seconds	  and	  72ºC	  for	  
1	   minute,	   with	   a	   final	   extension	   of	   72ºC	   for	   10	   minutes.	   PCR	   products	   and	   PET-­‐19b	  
plasmids	   were	   digested	   with	   Nde	   and	   BamH1	   restriction	   enzymes	   (both	   New	   England	  
Biolabs)	   in	  a	  double	  digest	   reaction	  at	  37°C	   for	  1	  hour.	  Digested	  products	  were	   then	  gel	  
purified	  using	  QIAquick	  gel	  extraction	  kit	  (QIAGEN,	  UK)	  to	  manufacturers	  instructions	  and	  
eluted	  in	  ddH2O.	  PCR	  products	  were	  ligated	  into	  the	  digested	  PET	  19b	  plasmids	  using	  the	  
rapid	  DNA	   ligation	   kit	   (Roche,	  UK)	   at	   a	   ratio	   of	   plasmid:	   insert	   1:3	   as	   to	  manufacturers	  
instructions.	  
	  
5.3.2	  Transformation	  of	  PET-­‐19b	  plasmids	  into	  E.coli	  	  
PET-­‐19b	   plasmids	   with	   inserts	   were	   transformed	   into	   competent	   E.coli	   DHα	   cells	  
(Invitrogen)	  as	  follows;	  40µL	  of	  cells:	  5µL	  of	  ligation	  reaction	  was	  incubated	  on	  ice	  for	  30	  
minutes,	  heat	  shocked	  at	  42ºC	  for	  45	  seconds,	  incubated	  on	  ice	  for	  2	  minutes	  and	  diluted	  
in	  0.9mLs	  of	  SOC	  medium	  (Invitrogen).	  Cells	  were	  grown	  for	  1	  hour	  at	  37	  ºC	  and	  plated	  
onto	   agar/ampicillin	   plates	   (100μg/ml)	   and	   incubated	   at	   37	   ºC.	   Colonies,	   which	   had	  
grown	  overnight,	  were	  picked	  and	  inoculated	  in	  to	  LB	  broth	  (6mls,	  ampicillin	  100μg/ml).	  
These	  were	   again	   grown	   overnight	   and	   the	   plasmids	  were	   purified	   from	   cultures	   using	  
QIAminiprep	  kit	  (Qiagen,	  UK)	  according	  to	  manufacturer’s	  instructions	  and	  eluted	  in	  H2O.	  
For	   protein	   expression	   the	   QIA	   minipreps	   were	   transfected	   into	   competent	   E.coli	  
BL21(DE3)	   competent	   E.coli	   cells	   (Invitrogen)	   under	   the	   same	   conditions	   as	   described	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above.	   The	   sequences	   of	   all	   plasmid	   constructs	   were	   confirmed	   by	   sequencing	  with	   T7	  
oligonucleotide	   (TAATACGACTCACTATAGG)	   on	   an	   AB3130	   Genetic	   Analyser	   with	   the	  
BigDye®	  terminator	  v3.1	  cycle	  sequencing	  kit	  (Applied	  Biosystems,	  USA)	  as	  described	  in	  
section	  2.5.5.	  
	  
5.3.3	  Expression	  of	  recombinant	  proteins	  
For	   expression	   of	   recombinant	   full	   length	   PrP	   variants	   glycerol	   bacterial	   stocks	   were	  
kindly	   provided	   by	  Dr	   Andy	  Gill	   (The	  Roslin	   Institute).	   These	  were	  E.coli	  strain	   Rosetta	  
(DE3)	   with	   pTrcHis	   B	   vector	   containing	   the	   PrP	   open	   reading	   frame	   (codons	   25-­‐233	  
inclusive)	  of	  the	  ARR,	  ARQ,	  and	  VRQ	  alleles	  (Kirby,	  Goldmann	  et	  al.	  2006).	  Individual	  E.coli	  
clones	   were	   cultured	   over	   night	   in	   10mls	   of	   LB/ampicillin	   (100μg/ml)	   at	   37°C	   with	  
shaking.	   	   Overnight	   cultures	   (4ml)	   were	   then	   cultured	   in	   Terrific	   Broth	   (TB,	   400mls)/	  
ampicillin	   (100μg/ml)	   to	   an	   optical	   density	   of	   between	   0.6	   -­‐	   0.8	   and	   PrP	   protein	  
expression	  was	  induced	  by	  addition	  of	  isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  to	  a	  
final	  concentration	  of	  1	  mM	  and	  cultures	  were	  grown	  for	  16-­‐18	  hours.	  To	  harvest	  the	  cells,	  
the	  cultures	  were	  centrifuged	  at	  10,000rpm	  for	  15	  minutes	  and	  pelleted	  E.coli	  were	  frozen	  
at	  -­‐20°C	  to	  aid	  cell	  lysis.	  Pellets	  were	  resuspended	  in	  50	  mM	  Tris-­‐HCl,	  pH	  8.0,	  1	  mM	  EDTA	  
and	  100	  mM	  NaCl,	  (9mls/g	  of	  pellet)	  and	  mixed	  for	  1	  hour.	  Lysozyme	  (20µl/ml)	  and	  PMSF	  
(4mM)	   was	   added	   to	   each	   pellet	   mix	   and	   cultures	   were	   then	   incubated	   at	   4˚C	   with	  
continued	   stirring	   for	   40	  minutes.	   Sodium	  Deoxycholate	  was	   added	   (1mg/ml)	   and	   each	  
mixture	  was	  stirred	   for	  a	   further	  30	  minutes,	   followed	  by	  addition	  of	  DNase	   (10	  μg/ml)	  
and	  stirring	  for	  40	  minutes.	  Inclusion	  bodies	  were	  pelleted	  by	  centrifugation	  at	  15,000rpm	  
for	  15	  minutes	  and	  stored	  at	  -­‐20	  ˚C	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5.3.4	  NI-­‐IMAC	  purification	  
NI-­‐IMAC	   purification	   was	   performed	   as	   described	   in	   Kirby	   et	   al,	   2010.	   Inclusion	   body	  
pellets	   containing	   recombinant	   protein	   were	   resuspended	   in	   a	   urea	   based	   buffer	   NI-­‐A	  
(urea	   8	  M,	   Na2HPO4	   0.1	  M,	   Tris-­‐base	   10	   µM,	   pH8	  with	   2-­‐mercaptoethanol)	   5	  ml/g	   and	  
centrifuged	   at	   15000rpm	   for15	   minutes.	   The	   supernatant	   was	   collected.	   Affinity	  
purification	  was	  performed	  using	  Ni-­‐NTA	   resin	   (QIAGEN)	  equilibrated	   in	  buffer	  NI-­‐A	  by	  
gravity	   flow.	   Proteins	   were	   eluted	   in	   buffer	   NI-­‐B	   (buffer	   NI-­‐A,	   pH	   4	   with	   2-­‐
mercaptoethanol).	  Fractions	  were	  collected	  and	  analysed	  by	  general	  protein	  staining	  with	  









Figure	   5.1	   –	   Ion	   Exchange	   purification.	   Typical	   chromatogram	   of	   the	   purification	   of	  
recombinant	  PrPC	  and	  truncated	  proteins	  using	  a	  Sepharose™	  column.	  The	  sample	  was	  	  
loaded	   (1	   :1	   in	   ION-­‐A)	   and	  unbound	  proteins	  were	   collected	   in	   the	   flow	   through.	   The	  
column	  was	  washed	  in	   ION-­‐A	  and	  when	   the	  U.V.	   returned	   to	  baseline	  bound	  proteins	  
were	   eluted	   with	   a	   graduated	   increase	   of	   ION-­‐B	   from	   0-­‐50	   %	   over	   20	   minutes.	   PrP	  
protein	  was	  eluted	  in	  a	  single	  major	  peak	  (*).	  
	  
* 
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5.3.5	  Ion	  Exchange	  Purification	  
Elutes	   collected	   from	   NI-­‐IMAC	   chromatography	   containing	   the	   protein	   of	   interest	   were	  
subjected	   to	   Ion	   exchange	   chromatography	   using	   a	   Sepharose™	   column	   (GE	   healthcare)	  
and	  FPLC	  machine	  (AKTA,	  GE	  Healthcare)	  equilibrated	  with	  buffer	  ION-­‐A	  (8M	  urea,	  HEPES	  
50μM,	  pH	  8).	  Proteins	  were	  eluted	  in	  buffer	  ION-­‐B	  (buffer	  ION-­‐A	  with	  NaCl	  1.5M)	  over	  a	  
linear	  gradient	  with	  buffer	  ION-­‐A	  of	  0-­‐50%	  and	  UV	  peaks	  were	  collected	  and	  analysed	  and	  
fractions	  containing	  the	  protein	  of	  interest	  were	  pooled.	  
 
5.3.6	  Refolding	  of	  truncated	  PrP	  C1	  
To	   induce	   the	   formation	   of	   the	   di-­‐sulphide	   bond	   in	   recombinant	   protein	   molecules,	  
recombinant	  protein	  was	  diluted	  to	  a	  concentration	  of	  0.1mg/ml	  in	  urea	  (9M).	  CuCl2	  was	  
added	  at	  a	  molar	  ratio	  CuCl2:	  protein	  of	  5:1	  and	  incubated	  at	  4	  ˚C	  with	  stirring	  overnight.	  
The	   protein	   was	   dialysed	   in	   2l	   of	   50mM	   sodium	   acetate,	   10mM	   EDTA,	   pH	   5.5,	   with	   a	  
second	  dialysis	  step	  of	  50mM	  sodium	  acetate	  only,	  pH	  5.5	  and	  then	  stored	  at	  -­‐80°C.	  
	  
5.3.7	  NI-­‐IMAC	  purification	  for	  fibrillisation	  
For	  the	  use	  in	  fibrillisation	  reactions	  an	  alternative	  protocol	  was	  used	  for	  the	  purification	  
of	  recombinant	  proteins.	  Inclusion	  body	  pellets	  containing	  protein	  were	  resuspended	  in	  a	  
urea	  based	  buffer	  NIF-­‐A	  (urea	  8	  M,	  Na2HPO4	  0.1	  M,	  Tris-­‐base	  10	  µM,	  reduced	  glutathione,	  
12mM,	  pH8)	  10mL/g	  for	  1	  hour	  and	  centrifuged	  15000rpm,	  15	  minutes.	  The	  supernatant	  
was	  collected	  and	  Ni-­‐NTA	  resin	  (QIAGEN)	  equilibrated	   in	  buffer	  NIF-­‐A	  was	  added	  (10	  %	  
v/v)	  and	  incubated	  with	  stirring	  for	  1	  hour.	  Affinity	  purification	  was	  performed	  by	  gravity	  
flow	   using	   disposable	   polypropylene	   10	  ml	   columns	   (Pierce),	   purifying	   around	   50ml	   of	  
supernatant/resin	  suspension	  per	  column.	  Proteins	  were	  eluted	  in	  buffer	  NIF-­‐B	  (buffer	  A,	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pH	  4)	  and	  5ml	  fractions	  were	  collected	  with	  addition	  of	  50µl	  EGTA	  (5mM),	  pH	  8.	  Fractions	  
were	   analysed	   by	   NuPAGE	   electrophoresis	   with	   gels	   either	   stained	   with	   instant	   blue	  












5.3.8	  Desalting	  purification	  for	  fibrillisation	  
Fractions	  containing	  the	  protein	  of	  interest	  after	  NI-­‐IMAC	  purification	  were	  pooled.	  Using	  
an	  FPLC	  machine	  (AKTA,	  GE	  Healthcare)	  the	  desalting	  column	  (HiPrep)	  was	  equilibrated	  
with	  desalting	  buffer	   (urea	  6M,	  Tris	  100mM,	  pH	  7.5).	  Pooled	   fractions	  were	   loaded	  onto	  
the	  column	  at	  a	  rate	  of	  1ml/minute.	  Fractions	  were	  collected	  when	  the	  U.V.	  strated	  to	  rise	  
as	  illustrated	  in	  Figure	  5.2.	  Fractions	  were	  analysed	  by	  NuPAGE	  electrophoresis	  with	  gels	  
Figure	   5.2	   –	   Desalting	   purification.	   A	   characteristic	   chromatogram	   of	   desalting	  
purification	  of	  recombinant	  PrPC	  and	  truncated	  PrPC	  with	  a	  HiPrep	  Desalting	  column.	  The	  
sample	  was	  loaded	  1:1	  in	  desalting	  buffer	  and	  fractions	  (10mls)	  were	  collected	  when	  the	  
U.V.	   started	   to	   rise	   above	  base	   line,	   indicating	   that	   protein	   had	  been	  eluted.	  Once	   the	  
sample	  had	  been	   loaded	  Desalting	   buffer	   is	   continually	   rinsed	   through	   the	   column	  and	  
fractions	  are	  collected	  until	  the	  U.V.	  returned	  to	  base	  line.	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either	  stained	  with	   instant	  blue	  (Section	  2.3.1)	  or	  western	  blot	   (Section	  2.3.3).	  Fractions	  
containing	   the	   protein	   of	   interest	   were	   pooled,	   the	   concentration	   was	   determined	   by	  
nanodrop	  spectrophotometry	  as	  described	  in	  section	  5.3.10	  and	  the	  protein	  was	  diluted	  to	  
0.3mg/ml	   in	   desalting	   buffer,	   EGTA	   (5mM)	   and	   oxidised	   glutathione	   (0.2µM)	   and	  
incubated	  overnight,	  at	  4°C,	  with	  stirring.	  	  
	  
5.3.9	  Reverse	  Phase	  purification	  for	  fibrillisation	  
After	   desalting	   the	   protein	   was	   purified	   further	   using	   a	   reverse	   phase	   HPLC	   (Ultimate	  
3000,	  Dionex)	  with	  a	  Vydac	  HPLC	  column	  #4	  protein	  (GRACE)	  equilibrated	  in	  H2O	  with	  0.1	  
%	  (v/v)	  Trifluoroacetic	  Acid	   (TFA).	  Prior	   to	   loading	  purified	  protein	   from	  desalting	  was	  
diluted	  to	  0.1mg/ml	  in	  H2O	  0.1	  %	  (v/v)	  TFA	  and	  loaded	  onto	  the	  column	  at	  a	  rate	  of	  3ml/	  
minute.	   	  After	   loading	   the	   column	  was	  washed	  with	  H2O	  0.1	  %	   (v/v)	  TFA	  until	  U.V.	  had	  
returned	   to	  baseline	  and	  bound	  proteins	  were	  eluted	  over	  a	  gradient	  with	  acetyl	  nitrate	  
0.1	  %	   TFA	   (v/v),	   as	   illustrated	   in	   figure	   5.3	   the	   gradient	   was	   as	   follows;	   0-­‐20%	   in	   0-­‐5	  
minutes,	  20-­‐50%	   in	  5-­‐45	  minutes	  and	  50-­‐100%	   in	  45-­‐60	  minutes.	  Again,	   fractions	  were	  
analysed	   by	  NuPAGE	   electrophoresis	  with	   gels	   either	   stained	  with	   instant	   blue	   (Section	  
2.3.1)	   or	  western	   blot	   (Section	   2.3.3).	   Fractions	   containing	   the	   protein	   of	   interest	  were	  
pooled,	   the	  concentration	  was	  determined	  by	  nanodrop	  spectrophotometry	  as	  described	  
in	  section	  5.3.10	  and	  the	  protein	  was	  lyophilised	  and	  stored	  at	  -­‐20°C.	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5.3.10	  Measuring	  recombinant	  protein	  concentration	  by	  nanodrop	  spectrophotometry	  
The	   concentration	   of	   recombinant	   protein	   was	   measured	   using	   a	   nanodrop	   (Thermo	  
Scientific).	   	   Readings	   were	   taken	   at	   both	   280nm	   and	   320nm.	   The	   concentration	   of	  
recombinant	  protein	  was	  calculated	  using	  the	  following	  equations;	  
	  	  
𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛  𝑐𝑜 − 𝑒𝑓𝑓𝑖𝑓𝑓𝑖𝑐𝑒𝑛𝑡
= 𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑦𝑠𝑡𝑒𝑖𝑛𝑒  𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠  ×  120
+ 𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑡𝑦𝑟𝑜𝑠𝑖𝑛𝑒  𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠  ×  1280
+ (𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑡𝑟𝑦𝑝𝑡𝑜𝑝ℎ𝑎𝑛  𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠  ×  5690)	  
	  
Figure	  5.3	  –	  Reverse	  Phase	  purification	  of	  recombinant	  proteins.	  Typical	  chromatogram	  
of	   reverse	   phase	   of	   recombinant	   PrPC	  and	   truncated	   proteins.	   The	   sample	  was	   loaded	  
(0.3mgs/ml,	  in	  H2O	  0.1	  %	  TFA)	  and	  the	  column	  was	  washed	  with	  H2O	  0.1	  %	  TFA	  until	  U.V.	  
returned	   to	   baseline.	   Bound	   protein	   was	   eluted	  with	   a	   gradient	   of	   ACN	   0.1	   %	   TFA	   as	  
follows;	  0-­‐20	  %	  in	  5	  minutes,	  20-­‐50	  %	  in	  30	  minutes,	  50-­‐100	  %	  in	  10	  minutes.	  Typically	  
PrP	  (*)	  started	  to	  elute	  around	  35	  %	  ACN	  0.1	  %TFA.	  
	  
*	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𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑚𝑔/𝑚𝑙 = !"  !"#!!"  !"#
!"#$%&#$'%  !"!!""#$#!%&
×  𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟  𝑤𝑒𝑖𝑔ℎ𝑡	  	  
	  
5.3.11	  Circular	  Dichroism	  	  
For	  circular	  dichroism	  studies	  measurements	  of	  purified	  protein	  (~0.5	  mg/ml)	  in	  50	  mM	  
sodium	  acetate	  were	  made	  using	  a	   Jasco	   J-­‐710	   spectropolarimeter	  with	  a	  path	   length	  of	  
0.2	  mm.	  Readings	  were	  collected	  from	  260	  nm	  to	  200	  nm,	  with	  20	  scans	  repeated	  for	  each	  
reading	   at	   a	   rate	   of	   100	   nm/min.	   Observations	   were	   made	   about	   protein	   secondary	  
structure	   by	   comparison	   of	   the	   spectral	   output	   with	   those	   characteristically	   associated	  
with	  proteins	  of	  known	  secondary	  structure.	  
	  
5.3.12	  Mass	  Spectrometry	  
Mass	  spectrometry	  was	  performed	  by	  Dr	  Andy	  Gill,	  (The	  Roslin	  Institute)	  with	  lyophilised	  
protein	  samples,	  purified	  for	  fibrillisation.	  These	  methods	  are	  described	  in	  full	  in	  Campbell	  
et	  al.	  2013.	  
	  
5.3.13	  Fibrillisation	  of	  recombinant	  C1	  and	  C2	  
The	   fibrillisation	   studies	   followed	   a	  method	   previously	   published	   by	   Breydo	   et	  al	   2008	  
(Breydo,	   Makarava	   et	   al.	   2008,	   Graham,	   Agarwal	   et	   al.	   2010).	   In	   summary,	   lyophilised	  
recombinant	  C2	  and	  C1	  and	  full	   length	  PrP	  were	  reconstituted	  in	  6	  M	  guanidine-­‐HCl	  (pH	  
6.0)	   to	   a	   concentration	   of	   3	   mg/ml.	   Reaction	   mixtures	   were	   prepared	   contained	   2	   M	  
guanidine-­‐HCL,	   50	  mM	  MES,	   10	  mM	   thiourea	   and	   100	   µg/ml	   recombinant	   protein.	   For	  
assays	  with	  two	  proteins,	  each	  was	  added	  to	  a	  final	  concentration	  of	  50	  µg/ml.	  To	  account	  
for	  background	  fluorescence,	  fibrillisation	  reactions	  were	  also	  set	  up	  in	  the	  absence	  of	  PrP	  
protein.	  To	  monitor	  fibrillisation	  kinetics,	  Thioflavin	  (ThT)	  was	  added	  (10	  µM).	  T	  reaction	  
CHAPTER 5 – CHARACTERISATION AND MISFOLDING OF PRION PROTEINS IN VITRO 
	   121	  
mix	   (167	   µl)	  was	   dispensed	   into	   each	  well	   of	   a	   96	  well	   plate	   along	  with	   3	   Teflon	   balls	  
(2.381	  mm	  diameter,	  The	  Precision	  Plastic	  Ball	  Company).	  The	  plate	  was	  incubated	  at	  37	  
°C	   with	   shaking	   at	   900rpm	   in	   a	   fluorescent	   plate	   reader	   (Fluoroskan	   Ascent,	   Thermo	  
Scientific).	   ThT	   fluorescence	  was	  measured	   every	   5	  minutes	   for	   24	   hours	   (excitation	   at	  
444	  nm,	  emission	  at	  485	  nm).	  Data	  was	  analysed	  and	   lag	   times	  calculated	  as	  previously	  
described	   (Graham,	   Agarwal	   et	   al.	   2010).	   The	   number	   of	   repeat	   fibrillisation	   assays	   (n)	  
varied	   for	   each	   protein	   variant	   and	   is	   stated	   in	   the	   corresponding	   results	   sections.	   For	  
analysis	   of	   fibrils	   by	   other	  methods,	   separate	   reactions	  were	   set	   up	  without	   ThT.	   Post-­‐
fibrillisation,	  these	  reactions	  were	  dialysed	  into	  10	  mM	  sodium	  acetate	  and	  stored	  at	  4	  °C.	  
	  
5.3.14	  Maturation	  and	  PK	  digestion	  of	  fibrils	  	  
This	   protocol	   was	   followed	   directly	   from	   Breydo	   et	   al	   (Breydo,	   Makarava	   et	   al.	   2008).	  
Proteins	  were	   visualised	   by	   gel	   electrophoresis	   (12	  %	  NuPAGE	  Bis-­‐Tris	   gel,	   Invitrogen)	  
and	  silver	  staining	  (Section	  2.4.2).	  
	  
5.3.15	  Dynamic	  Light	  Scattering	  (DLS)	  
Fibrils	  of	  recombinant	  PrP	  and	  C1	  were	  produced	  as	  described	  in	  5.3.13	  in	  the	  absence	  of	  
ThT	   and	   dialysed	   into	   sodium	   acetate.	   To	   analyse	   smaller	   aggregates	   and	   oligomers	  
dialysed	   fibrillisation	   reactions	   were	   centrifuged	   at	   16,000rpm	   for	   30	   minutes	   and	   the	  
supernatant	  was	  collected.	  A	  sample	  (60μl)	  of	  fibril	  preparation	  (0.5mg/ml)	  was	  loaded	  to	  
a	   384	  well	   plate	   and	   run	   on	   a	   Zetasizer	   APS	   (Malvern)	   at	   10	   °C.	   Between	   readings	   the	  
instrument	  was	  washed	  with	  5	  %	  (v/v)	  Decon	  and	  sodium	  acetate	  buffer	   (pH	  5.5).	  Each	  
sample	   was	   scanned	   ≥	   13	   times	   per	   reading	   and	   5	   repeat	   readings	   were	   performed.	  
Average	  curves	  were	  fitted	  and	  size	  distribution	  by	  mass	  was	  used	  to	  compare	  estimated	  
aggregate	  sizes.	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5.3.16	  Electron	  Microscopy	  	  
Electron	  microscopy	  was	  performed	  by	  Dr	  Gillian	  McGovern	  (AHVLA-­‐Lasswade).	  Formvar	  
coated	  copper	  grids	  were	  placed	  onto	  a	  50	  μl	  drop	  of	   fibril	  preparation	  (60	  µg/ml	   in	  10	  
mM	   sodium	   acetate,	   pH	   5).	   After	   45	   seconds,	   the	   grid	  was	   removed,	   touched	   to	   a	   filter	  
paper	   to	   remove	   excess	   fluid,	   and	   then	   placed	   onto	   a	   drop	   of	   filtered	   2	   %	   aqueous	  
phosphotungstic	   acid	   for	   2	   minutes.	   Grids	   were	   then	   air	   dried	   before	   storage	   and	  
examined	  using	  a	  Jeol	  1200EX	  transmission	  electron	  microscope.	  
	  
5.4.	  RESULTS	  
5.4.1	  Expression	  and	  purification	  of	  recombinant	  C1	  proteins	  
Several	  different	  methods	  of	  separating	  C1	  from	  full	  length	  PrP	  in	  brain	  homogenate	  and	  
cell	  culture	  were	  investigated	  during	  the	  production	  of	  this	  thesis	  for	  example	  exploiting	  
the	   differential	   binding	   affinities	   to	   soil	   and	   the	   purification	   of	   C1	   from	   transfected	   PrP	  
expressing	   CHO	   cells	   (Rigter	   and	   Bossers,	   2005).	   Complete	   separation	   of	   C1	   from	   full	  
length	   PrP	  was	   not	   accomplished	   therefore	   alternatively	   recombinant	   C1	   proteins	  were	  
produced.	   As	   described	   in	   sections	   5.3.1-­‐5.3.9	   the	   PRNP	   open	   reading	   frame	   DNA	   was	  
amplified	  from	  genomic	  DNA	  and	  a	  truncated	  fragment	  covering	  amino	  acids	  115-­‐234	  was	  
inserted	   into	  a	  protein	  expression	  vector	  (PET-­‐19b)	  with	  a	  His-­‐Tag	  to	  aid	  purification	  of	  
the	  protein,	  in	  absence	  of	  the	  charged	  N-­‐terminal.	  As	  these	  proteins	  had	  previously	  never	  
been	   produced	   samples	   were	   harvested	   at	   several	   time	   points	   after	   induction	   to	   check	  
both	   the	   expression	   of	   the	   protein	   and	   for	   bacterial	   degradation.	   Sampling	   at	   1	   hour,	   2	  
hours,	  3	  hours	  and	  4	  hours	  showed	  increased	  production	  of	  a	  16.5	  kDa	  molecular	  weight	  
band	   (predicted	   molecular	   weight	   16.6642	   kDa),	   confirmed	   as	   C1	   by	   western	   blotting	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using	  BC6	  C-­‐terminal	  antibody	  (Figure	  5.5	  and	  5.6).	  C1	  proteins	  were	  purified	  either	  using	  
NI-­‐IMAC	  (Figure	  5.7A)	   followed	  by	   Ion	  exchange	  (Figure	  5.7B)	  and	  dialysed	   into	  sodium	  
acetate,	  or	  for	  fibrillisation,	  by	  NI-­‐IMAC,	  followed	  by	  Desalting	  (Figure	  5.7C)	  and	  Reverse	  
Phase	  chromatography	  (Figure	  5.7D),	  summarised	  in	  Figure	  5.8.	  Both	  methods	  resulted	  in	  
production	  of	  pure	  recombinant	  protein	  as	  shown	  in	  eluted	  fractions.	  
 
  
Figure	  5.4	  –	  Expression	  of	  C1VRQ	  protein	  in	  bacteria.	  Sampling	  of	  bacteria	  after	  induction	  of	  
expression,	  stained	  with	  both	  Instant	  Blue	  as	  described	  in	  section	  2.3.5	  for	  total	  protein	  and	  
BC6	  C-­‐terminal	  antibody	   confirming	   the	  presence	  of	   truncated	  PrP	  species.	   Lane	  1	   (Before	  
induction),	  Lane	  2	  (After	  1	  hour),	  Lane	  3	  (After	  2	  hours),	  Lane	  4	  (After	  3	  hours),	  Lane	  5	  (After	  










	  	  1	  	  	  	  	  	  2	  	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  	  	  5	  	  	  	  	  	  	  	  1	  	  	  	  	  	  2	  	  	  	  	  	  3	  	  	  	  	  	  4	  	  	  	  	  	  5	  	  	  	  	  	  
Instant	  Blue	  
CHAPTER 5 – CHARACTERISATION AND MISFOLDING OF PRION PROTEINS IN VITRO 



























	  	  C1ARR	  	   	  	  C1
ARQ	   	  	  C1VRQ	  	  
Figure	   5.5	   –	   Expression	   of	   C1	   recombinant	   proteins.	   SDS	   –page	   gel	   stained	  with	   instant	  
blue	   as	   described	   in	   section	   2.3.5.	   Bacterial	   cultures	  were	   pelleted	  by	   centrifugation	   and	  
denatured	  in	  sample	  buffer	  and	  reducing	  agent	  at	  90	  °C.	  	  Before	  induction	  (Lane	  1),	  1	  hour	  
post	  induction	  (Lane	  2),	  ~	  18	  hours	  post	  induction	  (Lane	  3).	  





	  L	  	  	  	  	  	  FT	  	  	  	  W	  	  	  	  F1	  	  	  	  F2	  	  	  F3	  	  	  	  F4	  	  	  	  F5	  	  	  F6	  	  	  F7	  	  	  F8	  
Figure	   5.6	   –	   Purification	   of	   recombinant	   C1VRQ	   protein.	   SDS	   –page	   gels	   stained	   with	  
instant	  blue	  as	  described	  in	  section	  2.3.5.	  A)	  NI-­‐IMAC	  purification	  of	  C1	  protein	  by	  gravity	  
flow.	   16.7	   kDa	   protein	   is	   eluted	   in	   fractions	   2-­‐8	   (Lanes	   5-­‐11).	   B)	   Ion	   exchange	  
chromatography	  purification	  of	   C1	  protein	   by	   FPLC.	  C)	  Desalting	   purification	  of	  C1VRQ	   by	  
FPLC.	   D)	   Reverse	   Phase	   purification	   by	   HPLC.	   Load	   (L),	   Flow	   through	   (FT),	   Wash	   (W),	  
Collected	  fractions	  (F1-­‐F10).	  Recombinant	  C1VRQ	  protein	  is	  highlighted	  dashed	  box.	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C.	   D.	  
CHAPTER 5 – CHARACTERISATION AND MISFOLDING OF PRION PROTEINS IN VITRO 



















5.4.2	  Characterisation	  of	  recombinant	  C1	  proteins	  
As	  expected,	  the	  recombinant	  C1	  proteins	  were	  detected	  by	  immuno-­‐blotting	  with	  the	  C-­‐
terminal	  antibody,	  BC6,	  but	  no	  reactivity	  was	  observed	  with	   the	  N-­‐terminal	  antibody	  P4	  
(Figure	  5.9A).	  The	  purity	  of	  protein	  was	  confirmed	  both	  by	  SDS-­‐PAGE	  stained	  with	  Instant	  
Blue	   (Figure	   5.9B)	   and	   by	  mass	   spectrometry.	   Mass	   spectrometry	   revealed	   that	   the	   C1	  
proteins	   had	   been	   correctly	   expressed,	   but	   also	   indicated	   small	   amounts	   of	   the	   protein	  
Figure	   5.7	   –	   Recombinant	   protein	   purification.	  An	  overview	  of	   recombinant	   protein	  
production	   using	   two	   different	   methods.	   Both	   result	   in	   pure	   protein	   suitable	   for	  
different	  applications.	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that	   had	   been	   modified	   causing	   mass	   shifts	   of	   +178Da	   and	   +258Da	   (Figure	   5.8).	   Such	  
modifications	  have	  been	  previously	  documented	  and	  are	  attributed	  to	  spontaneous	  alpha-­‐
N-­‐6-­‐phospho-­‐gluconoylation	   of	   the	   His-­‐tag	   (Geoghegan,	   Dixon	   et	   al.	   1999).	   These	  
modifications	   were	   slightly	   more	   abundant	   in	   the	   C1ARR	  variant,	   but	   since	   the	   levels	   of	  
these	  modifications	   are	   already	   low	   and	   the	  modifications	   are	  within	   the	   octa-­‐histidine	  
tag,	  they	  are	  unlikely	  to	  impact	  on	  protein	  misfolding	  or	  stability.	  To	  check	  this	  secondary	  
structure	   was	   analysed	   using	   circular	   dichroism	   spectra	   (CD)	   for	   the	   three	   C1	   protein	  
variants,	  which	  appeared	   to	   exhibit	   a	  primarily	   alpha-­‐helical	   structure,	   characterized	  by	  
spectra	  showing	  two	  minima	  at	  222	  nm	  and	  208	  nm,	  as	  shown	  in	  Figure	  5.9C.	  
	  
CD	  analysis	  programs	  were	  used	  to	  confirm	  this	  observation.	  Four	  were	  deemed	  suitable	  
for	  this	  data;	  K2D,	  CDSTTR,	  SELCON	  and	  CONTIN	  (Compton	  and	  Johnson	  1986,	  Manavalan	  
and	  Johnson	  1987,	  Sreerama	  and	  Woody	  2000,	  Sreerama	  and	  Woody	  2004,	  Whitmore	  and	  
Wallace	  2004,	  Whitmore	  and	  Wallace	  2008).	  Three	   independent	  readings	  were	  analysed	  
for	  each	  variant	  with	  each	  program	  and	  average	  values	  are	  shown	  in	  Table	  5.1.	  	  Estimation	  
of	   secondary	   structure	   varied	  depending	   on	   the	  program	  used	   therefore	   average	   values	  
for	  all	  four	  programs	  were	  calculated	  for	  comparison.	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  1	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  3	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  2	  	  	  	  	  	  	  	  	  3	  
	  	  	  	  	  	  P4	   	  BC6	  
Figure	  5.8	  –	  Characterisation	  of	  recombinant	  C1	  proteins.	  A)	  Western	  blots	  of	  rC1	  proteins,	  
probed	   with	   monoclonal	   antibodies	   P4	   (epitope	   89-­‐104)	   and	   BC6	   (epitope	   146-­‐154).C1	  
variants	   C1ARR	  (Lane	   1),	   C1ARQ	  (Lane	   2)	   and	   C1VRQ	  (Lane	   3)	   were	   immunoblotted	  with	   both	  
BC6	  and	  P4	  antibodies.	  B)	  All	  variants	  of	  recombinant	  protein	  expressed	  were	  separated	  by	  
SDS-­‐page	   and	  stained	  with	   Instant	   Blue	   to	  confirm	  purity.	  PrPARR	  (Lane	  1),	   PrPARQ	  (Lane	  2),	  
PrPVRQ	   (Lane	   3),	   C1ARR	   (Lane	   4),	   C1ARQ	   (Lane	   5),	   C1VRQ	   (Lane	   6).	   C)	   Circular	   Dichroism	   was	  
performed	  as	  described	  in	  section	  5.3.11	  of	  three	  C1	  variants	  to	  assess	  secondary	  structure.	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Supplementary Figure S1 
(A) Mass spectrum and (inset) deconvoluted mass spectrum of the expressed C1-ARR 
fragment.  
The  spectrum  consists  of  a   single  major  charge   envelope,   labelled  with   ‘A’  along  with   the  
charge state of each of the species (20+, 19+ etc) and the mass/charge ratio at which each 
peak occurs. Deconvolution of the spectrum shows the presence of a single major species 
(labelled Mr(A) 16505.9) which represents the unmodified protein. The measured molecular 
weight of the unmodified protein (16505.9 Da) is in excellent agreement with the theoretical 
molecular weight calculated from the sequence of 16506.1 Da. A second species (labelled 
Mr(B) 16764.1) occurs at a molecular weight of 258 Da higher than the unmodified protein 
whilst a third (labelled Mr (C) 16684.7) is 178 Da higher in mass than the unmodified 
protein. These species are consistent with previously reported modifications within the His 
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(B) Mass spectrum and (inset) deconvoluted mass spectrum of the expressed C1-VRQ 
fragment.  
The  spectrum  consists  of  a  single  major  charge  envelope,  labelled  with  ‘A’  along  with  the  charge  
state of each of the species (20+, 19+ etc) and the mass/charge ratio at which each peak occurs. 
Deconvolution of the spectrum shows the presence of a single major species (labelled Mr(A) 
16505.9) which represents the unmodified protein. The measured molecular weight of the 
unmodified protein (16505.9 Da) is in excellent agreement with the theoretical molecular weight 
calculated from the sequence of 16506.1 Da. A second species (labelled Mr(B) 16763.5) occurs 
at a molecular weight of 258 Da higher than the unmodified protein whilst a third (labelled Mr 
(E) 16684.1) is 178 Da higher in mass than the unmodified protein. These species are consistent 
with previously reported modifications within the His Tag region of the protein, specifically 
attributed to spontaneous alpha-N-6-phospho-gluconoylation. The levels of modifications are 
lower for the VRQ variant than for the ARR variant, but in both cases appear to be present in less 
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Figure	   5.9	   –	   Mass	   Spectrometry	   of	   recombinant	   C1	   proteins.	   A)	   rC1ARR.	   The	   spectrum	  
consists	  of	  a	  single	  major	  charge	  envelope,	  labelled	  with	  ‘A’	  along	  with	  the	  charge	  state	  of	  
each	  of	   the	   species	   (20+,	   19+	   etc)	  and	   the	  mass/charge	   ratio	   at	  which	   each	  peak	  occurs.	  
Deconvolution	   of	   the	   spectrum	   shows	   the	   presence	   of	   a	   single	   major	   species	   (labelled	  
Mr(A)	  16505.9)	  which	  represents	  the	  unmodified	  protein.	  The	  measured	  molecular	  weight	  
of	   the	   unmodified	   protein	   (16505.9	   Da)	   is	   in	   excellent	   agreement	   with	   the	   theoretical	  
molecular	  weight	  calculated	   from	  the	  sequence	  of	  16506.1	  Da.	  A	  second	  species	   (labelled	  
Mr(B)	  16764.1)	  occurs	  at	  a	  molecular	  weight	  of	  258	  Da	  higher	  than	  the	  unmodified	  protein	  
whilst	   a	   third	   (labelled	   Mr	   (C)	   16684.7)	   is	   178	   Da	   higher	   in	   mass	   than	   the	   unmodified	  
protein.	  These	  species	  are	  consistent	  with	  previously	  reported	  modifications	  within	  the	  His	  
Tag	   region	   of	   the	   protein,	   specifically	   attributed	   to	   spontaneous	   alpha-­‐N-­‐6-­‐phospho-­‐
gluconoylation.	  B)	  The	  spectrum	  consists	  of	  a	   single	  major	  charge	  envelope,	   labelled	  with	  
‘A’	  along	  with	   the	  charge	  state	  of	  each	  of	  the	  species	  (20+,	  19+	  etc)	  and	  the	  mass/charge	  
ratio	  at	  which	  each	  peak	  occurs.	  Deconvolution	  of	   the	  spectrum	  shows	   the	  presence	  of	  a	  
single	  major	  species	  (labelled	  Mr(A)	  16505.9)	  which	  represents	  the	  unmodified	  protein.	  The	  
measured	   molecular	   weight	   of	   the	   unmodified	   protein	   (16505.9	   Da)	   is	   in	   excellent	  
agreement	  with	  the	  theoretical	  molecular	  weight	  calculated	  from	  the	  sequence	  of	  16506.1	  
Da.	   A	   second	   species	   (labelled	   Mr(B)	   16763.5)	   occurs	   at	   a	   molecular	   weight	   of	   258	   Da	  
higher	  than	  the	  unmodified	  protein	  whilst	  a	  third	  (labelled	  Mr	  (E)	  16684.1)	  is	  178	  Da	  higher	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Program	   C1	  ARR	   C1	  ARQ	   C1	  VRQ	  
	   α	   β	   Un-­‐
ordered	  
α	   β	   Un-­‐
ordered	  
α	   β	   Un-­‐
ordered	  
K2d	   36	   13	   51	   14	   35	   50	   30	   15	   54	  
CDSTTR	   30	   18	   28	   44	   19	   28	   47	   20	   33	  
SELCON	   28	   21	   51	   28	   16	   58	   42	   13	   46	  
CONTIN	   28	   22	   51	   34	   17	   49	   38	   18	   44	  
Mean	   30.5	   18.5	   45	   30	   22	   47	   39	   16.5	   44	  
Table	  5.1	  –	  Comparison	  of	  CD	  analysis	  of	  recombinant	  C1	  using	  four	  independent	  programs	  
 
 
On	  average	  it	  was	  estimated	  that	  C1ARR	  has	  30.5	  %	  alpha	  helix	  and	  18.5	  %	  beta-­‐sheet,	  C1ARQ	  
has	  30.0	  %	  alpha	  helix	  and	  22.0	  %	  beta-­‐sheet	  and	  C1VRQ	  has	  39%	  alpha	  helix	  and	  16.5	  %	  
beta	  sheet.	  Alpha	  helix	  is	  the	  dominant	  structure	  in	  all	  three	  variants,	  confirming	  that	  most	  
molecules	  have	  been	  refolded	  correctly	  (Haire,	  Whyte	  et	  al.	  2004).	  
	  
5.4.3	  Expression	  and	  purification	  of	  recombinant	  C2	  proteins	  
As	  with	  production	  of	  C1,	  PRNP	  open	  reading	  frame	  DNA	  (encoding	  amino	  acids	  92-­‐234)	  
was	  amplified	  from	  genomic	  DNA	  and	  inserted	  into	  an	  expression	  vector	  (PET-­‐19b)	  with	  a	  
His-­‐Tag	   to	   aid	   purification	   of	   the	   protein	   as	   described	   in	   sections	   5.3.1-­‐5.3.9.	   After	  
induction	  of	  expression	  a	  band	  with	  apparent	  molecular	  weight	  of	  20	  kDa	  was	  produced	  
(Figure	   5.11A),	   this	   was	   similar	   to	   the	   predicted	   molecular	   weight	   of	   19.171	   kDa.	   To	  
confirm	   this	   was	   C2	   these	   bacterial	   samples	   were	   immuno	   blotted	   with	   BC6	   (Figure	  
5.11B).	  C2	   is	   visible	  1	  hour	  post	   induction	  and	   is	   increased	  by	  ~18	  hours.	  The	  bacterial	  
pellet	   sample	   shows	   strong	   staining	   with	   BC6	   and	   smearing	   attributed	   to	   the	   viscous	  




CHAPTER 5 – CHARACTERISATION AND MISFOLDING OF PRION PROTEINS IN VITRO 























	  	  C2ARR	  	   	  	  C2
VRQ	  	  







	  	  	  	  1	  	  	  	  	  	  	  2	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  
Figure	  5.10	  –	  Expression	  of	  recombinant	  C2	  proteins.	  A)	  SDS	  –page	  gel	  stained	  with	  instant	  
blue,	   as	   described	   in	   section	   2.3.5.	   Samples	   of	   bacterial	   cultures	   were	   pelleted	   by	  
centrifugation	   and	   denatured	   in	   sample	   buffer	   and	   reducing	   agent	   at	   90	   °C.	   	   Before	  
induction	   (Lane	  1	  and	  6),	  1	  hour	  post	   induction	  (Lane	  2	  and	  7),	  ~	  18	  hours	  post	   induction	  
(Lane	   3	   and	   8),	   bacterial	   supernatant	   (Lane	   4	   and	   9),	   bacterial	   pellet	   (Lane	   5	   and	   10).	  
Recombinant	  C2	  is	  highlighted	  by	  a	  dashed	  box	  B)	  Western	  blot	  (section	  2.3.2)	  of	  bacterial	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Figure	   5.11	   –	   Purification	   of	   recombinant	   C2	   proteins.	   A)	   SDS	   –page	   gel	   stained	   with	  
instant	  blue,	  as	  described	  in	  section	  2.3.5.	  NI-­‐IMAC	  purification	  of	  C2ARR	  protein	  by	  gravity	  
flow.	   B)	   Ion	   exchange	   chromatography	   purification	   of	   C2ARR	   protein	   by	   FPLC.	   C)	   Reverse	  
phase	  purification	  of	  C)	  Fractions	  F4,	  F5	  and	  F6	  were	  considered	  pure	  and	  were	  pooled	  and	  
lyophilsed.	   D)	   NI-­‐IMAC	   purification	   of	   C2VRQ	   protein	   by	   gravity	   flow.	   E)	   Ion	   exchange	  
chromatography	   purification	   of	   C2VRQ	   protein	   by	   FPLC.	   F)	   Reverse	   phase	   purification	   of	  
C2VRQ.	  Fractions	  F6	  and	  F7	  were	  considered	  pure	  and	  were	  pooled	  and	  lyophilsed.	  Load	  (L),	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5.4.4	  Characterisation	  of	  recombinant	  C2	  proteins	  
To	  assess	  the	  secondary	  structure	  of	  recombinant	  C2	  proteins	  circular	  dichroism	  spectra	  
(CD)	  were	  measured	   for	  each	  variant.	  Both	  appeared	   to	  exhibit	  a	  primarily	  alpha-­‐helical	  
structure	   similar	   to	   the	   recombinant	  C1	  variants.	  However,	   the	   characteristic	  minima	  at	  
222	  nm	  and	  208	  nm	  are	  less	  pronounced,	  as	  shown	  in	  Figure	  5.13.	  The	  same	  panel	  of	  CD	  
analysis	  programs	  were	  used	  to	  estimate	  secondary	  structure	  elements,	  although	  K2d	  was	  
deemed	  unsuitable	  to	  analyse	  this	  data	  as	  resulting	  readings	  reported	  100	  %	  alpha	  helix	  
(Compton	  and	   Johnson	  1986,	  Manavalan	  and	   Johnson	  1987,	  Sreerama	  and	  Woody	  2000,	  
Sreerama	  and	  Woody	  2004,	  Whitmore	  and	  Wallace	  2004,	  Whitmore	  and	  Wallace	  2008).	  
Three	   independent	   readings	   were	   analysed	   for	   each	   variant	   with	   each	   remaining	  
programs	  and	  average	  values	  are	  shown	  in	  Table	  5.2.	   	  Estimation	  of	  secondary	  structure	  
varied	  depending	  on	  the	  program	  used	  therefore	  average	  values	  were	  taken	  from	  all	  three	  






















Figure	   5.12	   –	   Secondary	   structure	   of	   recombinant	   C2	   proteins	   by	   circular	   dichroism.	  
Circular	  Dichroism	  was	  performed	  as	  described	  in	  section	  5.3.11.	  Recombinant	  proteins	  ~	  
0.5mg/ml	  in	  sodium	  acetate.	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Program	   C2	  ARR	   C2	  VRQ	  
	   α	   β	   Un-­‐
ordered	  
α	   β	   Un-­‐
ordered	  
CDSTTR	   63	   13.5	   21.5	   45	   28	   27	  
SELCON	   35	   18	   55	   80	   1	   23	  
CONTIN	   65	   2	   33	   97	   3	   0	  
Mean	   54.3	   11.2	   36.5	   74	   10.7	   16.7	  
	  	  	  	  	  	  	  Table	  5.2	  -­‐	  Comparison	  of	  CD	  analysis	  of	  C2	  using	  three	  independent	  programs	  
 
On	   average	   it	   was	   estimated	   that	   C2ARR	  has	   54.3	   %	   alpha	   helix	   and	   11.2	   %	   beta-­‐sheet,	  
while	  C2VRQ	  has	  74	  %	  alpha	  helix	  and	  10.7	  %	  beta	  sheet.	  Average	  alpha	  helical	  content	  in	  
recombinant	  C2	  VRQ	  appears	  to	  be	  higher	  than	  C2	  ARR,	  although	  in	  both	  proteins	  helix	  is	  the	  
dominant	  secondary	  structure.	  	  It	  should	  be	  noted	  that	  the	  VRQ	  variant	  of	  recombinant	  C1	  
is	   also	   predicted	   to	   have	   slightly	   higher	   alpha	   helical	   content	   when	   compared	   to	   ARR	  
(Table	  5.1).	  
	  
5.4.5	  Amyloid	  fibril	  formation	  of	  recombinant	  C1	  protein	  
The	  mechanisms	  involved	  in	  conversion	  itself	  are	  still	  fairly	  unknown	  as	  is	  the	  role	  of	  C1	  
in	  this	  process.	  C1	  proteins	  were	  assessed	  for	  their	  ability	  to	  form	  amyloid	  fibrils	  in	  vitro	  
and	  to	  investigate	  genotype	  specific	  effects	  associated	  with	  the	  folding	  pathways	  of	  the	  C1	  
fragment.	   For	   comparison,	   truncated	   proteins	   and	   full	   length	   PrPARR	   and	   PrPVRQ	   were	  
expressed	  and	  purified	  from	  bacterial	  glycerol	  stocks	  provided	  by	  Dr	  Andy	  Gill	  (The	  Roslin	  
Institute).	  Using	  these	  full-­‐length	  PrPC	  proteins	  along	  with	  three	  variants	  of	  recombinant	  
C1,	   fibrillisation	  assays	  were	  set	  up	   in	  the	  presence	  of	   thioflavin	  T	  (ThT)	  as	  described	   in	  
section	   5.3.13.	   Fibril	   formation	   kinetics	   were	   measured	   over	   a	   24-­‐hour	   period	   and	   lag	  
times	   were	   calculated	   as	   described	   in	   Graham	   et	   al.	   (Graham,	   Agarwal	   et	   al.	   2010).	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Fibrillisation	   experiments	   were	   repeated	   multiple	   times	   (n)	   and	   typical	   fibrillisation	  
curves	  for	  C1	  fragments	  are	  shown	  in	  Figure	  5.14B,	  whilst	  typical	  curves	  for	  the	  full-­‐length	  
proteins	  PrPVRQ	  and	  PrPARR	  are	  shown	   in	  Figure	  5.14D.	  Fibrillisation	  of	  PrPARR	  and	  PrPVRQ	  
showed	  an	   initial	   lag	  phase	   (nucleation)	   followed	  by	  a	   rapid	   increase	   in	   fluorescence	  on	  
fibril	  growth	  (elongation)	  as	  reported	  previously	  for	  murine	  full	   length	  PrPC	  (Bocharova,	  
Breydo	   et	   al.	   2005,	   Graham,	   Kurian	   et	   al.	   2011)	   and	   human	   full	   length	   PrPC	   (Almstedt,	  
Nystrom	  et	  al.	  2009).	  PrPVRQ	  had	  an	  average	  lag	  time	  of	  5.57	  hours	  (SEM	  +/-­‐	  0.40,	  n	  =16)	  
while	  with	  PrPARR	  the	   lag	   time	  was	  significantly	   longer	  (p	  ≤	  0.002),	  averaging	  8.32	  hours	  
(SEM	  +/-­‐	  0.69,	  n	  =	  16).	  	  Fibrillisation	  of	  C1VRQ	  (n	  =	  24)	  and	  C1ARQ	  (n	  =	  14)	  produced	  curves	  
that	  were	  qualitatively	  similar	  to	  those	  of	  the	  full	  length	  variants,	  with	  shorter	  average	  lag	  
times	  of	   3.98	   (SEM+/-­‐	  0.34)	   and	  3.96	   (SEM	  +/-­‐	  0.22)	  hours	   respectively	   (Figure	  5.12E).	  
Once	   maximum	   fluorescence	   was	   reached,	   ThT	   fluorescence	   curves	   tended	   to	   fall	   to	  
around	  60	  %	  of	  the	  maximum	  (Figure	  5.12D).	  This	  phenomenon	  of	  reducing	  fluorescence	  
signal	   following	   fibril	   formation	  has	  previously	  been	  reported	  during	   the	   fibrillisation	  of	  
human	   PrP90-­‐231.	   The	   reasons	   for	   it	   are	   yet	   to	   be	   fully	   explained,	   but	   Almstedt	   et	   al.	  
suggested	   that	   aggregation	   of	   fibrils	   was	   the	   most	   likely	   cause,	   thereby	   reducing	   the	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Figure	  5.13	  –	  Fibrilisation	  kinetics	  of	  PrP	  and	  C1	  recombinant	  proteins.	  A)	  Expected	  curve	  
representing	   fibril	   formation,	   with	   lag	   time	   or	   nucleation	   phase	   followed	   by	   elongation	  
phase.	  B)	  Typical	  fibrillisation	  curves	  for	  PrP	  variants.	  Background	  ThT	  fluorescence	  from	  no	  
PrP	  controls	  subtracted	  from	  raw	  data.	  C)	  Average	  lag	  time	  of	  fibrillisation	  for	  PrP	  variants	  
in	  reactions	  which	  fibrillisation	  occurred	  within	  the	  time	  frame	  of	  the	  experiment.	  PrPARR	  n	  
=	   18,	   PrPVRQ	  n	   =	  20.	  D)	   Typical	   fibrillisation	   curves	   for	   C1	   variants.	  E)	   Average	   lag	   time	  of	  
fibrillisation	   for	   C1	   variants	   in	   reactions	  which	   fibrillisation	  has	   occurred	  within	   the	   time	  
frame	  of	  the	  experiment.	  C1ARR	  n	  =	  12,	  C1ARQ	  n	  =	  24,	  C1VRQ	  n	  =	  24.	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Compared	   to	   the	   other	   two	   C1	   proteins,	   C1ARR	  (n	   =	   24)	   showed	   a	  modified	   fibrillisation	  
profile	  comprising	  a	  significantly	   longer	   lag	   time	  (taken	  as	  an	  average	  of	  all	   reactions	   in	  
which	   fibrillisation	  had	  occurred	  within	  24	  hours,	  p	  ≤	  2.5	  x	  10-­‐6),	  on	  average	  11.0	  hours	  
(SEM	  +/-­‐	  1.0)	   (Figure	  5.14E)	  and	  a	   longer	  period	  of	   elongation	  after	  nucleation.	   Indeed,	  
complete	   fibrillisation	  did	  not	  occur	   in	  50	  %	  of	   these	   reactions	  within	   the	  24-­‐hour	   time	  
frame	  of	   the	   experiment;	   in	   these	   cases	   the	   lag	   times	   could	  not	   be	   calculated,	   since	   this	  
calculation	  depends	  on	  maximal	   levels	  of	  ThT	   fluorescence	  being	  achieved.	  Figure	  5.14D	  
shows	   an	   example	   of	   two	   C1ARR	   reactions,	   one	   positive	   and	   one	   negative	   for	   complete	  
fibrillisation.	  	  
	  
It	   has	   been	   suggested	   that	   the	  maximum	   level	   of	   fluorescence	   is	   dependent	   on	   protein	  
concentration	  (Biancalana	  and	  Koide	  2010).	  However,	  Alvarez-­‐Martinez	  et	  al	  (2011)	  show	  
that	   structurally	  diverse	   amyloid	   can	  be	   formed	  with	   the	   same	   concentration	  of	   protein	  
under	  the	  same	  conditions	  (Alvarez-­‐Martinez,	  Fontes	  et	  al.	  2011).	  This	  is	  thought	  to	  be	  a	  
factor	  of	  differential	  initial	  conformational	  changes	  at	  the	  nucleation	  stage,	  which	  are	  then	  
propagated	  during	  fibril	  formation.	  The	  resulting	  fibrils	  may	  appear	  to	  differ	  structurally	  
and	  ability	  to	  bind	  ThT	  may	  vary,	  hence	  explaining	  the	  different	  ThT	  fibrillisation	  profiles.	  
When	   protein	   from	   the	   two	   distinct	   pathways	   is	   seeded	   the	   characteristics	   seen	   in	   the	  
unseeded	   reaction	   are	   mimicked	   (Alvarez-­‐Martinez,	   Fontes	   et	   al.	   2011).	   Similar	  
discrepancies	   in	  maximum	   fluorescence	   between	  wells	   have	   been	   observed	   during	   this	  
experiment.	   For	   example	   Figure	   5.15	   represents	   four	   repeat	   wells	   containing	   C1VRQ,	   in	  
which	   two	  wells	   reach	   a	  maximum	   relative	   fluorescence	   of	   double	   the	   other	   two	  wells.	  
There	  is	  little	  variation	  between	  the	  lag	  time	  or	  the	  rate	  of	  elongation	  between	  wells.	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5.4.6	  Characterisation	  of	  C1	  amyloid	  fibrils	  
To	  confirm	  that	  C1	  proteins	  were	  producing	  fibrils	  rather	  than	  non-­‐fibrillar,	  ThT-­‐binding	  
aggregates	  an	  assay	  originally	  described	  by	  Bocharova	  et	  al	   (Bocharova,	  Makarava	  et	   al.	  
2006)	  know	  as	  the	  fibril	  maturation	  assay	  was	  performed.	  Fibrils	  composed	  of	  PrP	  have	  a	  
PK	   resistant	   core	   of	   10-­‐12	   kDa,	   but	   by	   heating	   PrP	   amyloid	   fibrils	   to	   80	   ˚C	   a	   structural	  
change	   is	   initiated	   such	   that	   the	   PK-­‐resistant	   core	   is	   extended	   to	   16	   kDa.	   Protease-­‐
resistant	  PrP	  can	  be	  detected	  by	  SDS-­‐PAGE	  and	  silver	  staining	  (Figure	  5.16).	  For	   the	   full	  
length	  PrP	  samples,	  a	  well-­‐defined	  16	  kDa	  band	  is	  evident	  after	  maturation	  along	  with	  the	  
characteristic	   12	   and	   10	   kDa	   fragments,	   consistent	   with	   previously	   reported	   results	  
(Bocharova,	   Makarava	   et	   al.	   2006,	   Breydo,	   Makarava	   et	   al.	   2008)	   and	   confirming	   the	  
presence	   of	   fibrils.	   In	   C1	   fibrillisation	   reactions,	   along	   with	   the	   three	   bands	   described	  
above	  two	  additional	  PK-­‐resistant	  fragments	  appeared	  after	  maturation,	  one	  of	  the	  similar	  




















Figure	   5.14	   –	   Differential	   fibrillisation	   profiles	  under	   the	   same	   experimental	   conditions.	  
Raw	  data	  of	  C1VRQ	   fibrillisation,	   showing	  ThT	   fluorescence	  obtained	   from	  four	   repeat	  wells.	  
All	   four	   wells	   have	   similar	   lag	   times	   however	   maximal	   fluorescence	   readings	   show	   two	  
patterns.	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intense	   in	  C1	   fibril	   preparations	   compared	   to	   recombinant	  PrP	  preparations,	   suggesting	  
that	  a	  reduced	  amount	  of	  fibrils	  may	  be	  produced	  in	  C1	  fibrillisation	  reactions.	  To	  further	  
characterise	   C1	   amyloid	   fibrils,	   preparations	   were	   analysed	   by	   electron	  microscopy,	   as	  
shown	   in	  Figure	  5.17.	  Fibrils	  were	  observed	   in	  all	  preparations	  and	   there	  were	  no	  clear	  
morphological	  differences	  between	   fibrils	   from	  different	   samples.	   It	   appeared	   that	   there	  
were	  fewer	  fibrils	  in	  the	  C1ARR	  and	  C1ARQ	  preparations	  but	  using	  this	  technique	  it	  was	  not	  














Figure	   5.15	   –	   Maturation	   and	   PK	   digestion	   of	   PrP	   and	   C1	   fibrils.	   Maturation	   and	   PK	  
digestion	  of	   fibrils	   were	  performed	   as	   described	   in	   section	   5.3.14.	   0.5	  µg	  of	   recombinant	  
protein	  was	  untreated	  (Lane	  1),	  PK	  treated	  at	  a	  ratio	  100:1	  of	  PrP:PK	  (Lane	  2),	  or	  matured	  by	  
heating	  to	  80°C	  followed	  by	  PK	  treatment	  (Lane	  3).	  Matured	  fibrils	  (Lane	  3)	  show	  increased	  
PK	   resistance	   relative	   to	   non-­‐matured	   fibrils.	   rPrP	   reactions	   show	   a	   16	   kDa	   band	   after	  
maturation	   which	   confirms	   the	   presence	   of	   fibrils,	   highlighted	   by	   the	   black	   box.	   In	   rC1	  
preparations,	   bands	   with	   increased	   PK	   resistance	   of	   16.6	   kDa,	   16	   kDa	   and	   13	   kDa	   are	  
present,	  highlighted	  by	  the	  dotted	  box.	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Figure	   5.16	   –	   Electron	  
microscopy	  of	  PrP	  and	  C1	  
amyloid	   fibrils.	   	   Electron	  
microscopy	   was	  
performed	  as	  described	  in	  
section	   5.3.16.	   Fibrils	  
were	   produced	   in	   the	  
absence	   of	   ThT	   and	  
dialysed	   into	   sodium	  
acetate.	   Fibrils	   were	  
viewed	  on	   a	   transmission	  
electron	   microscope.	  
Images	   were	   taken	   at	   x	  
5000	   (right	   panel)	   and	   x	  
20000	   (left	   panel).	   A:	  
rPrP
ARR
,	   B:	   rPrP
VRQ
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To	  shed	  some	   light	  on	  both	  the	  numbers	  of	   fibrils	  present	   in	   these	  preparations	  and	  the	  
smaller	   intermediates	   and/or	   aggregates	   dynamic	   light	   scattering	   (DLS)	   was	   used,	   as	  
described	   in	   section	  5.3.13.	  This	   technique	  measures	   the	  amount	  of	   light	   scattered	   from	  
particles	   in	   a	   solution	   and	   predicts	   particle	   size	   and	   distribution	   using	   the	   theory	   of	  
Brownian	  motion.	  C1	  fibrils	  ~0.5mg/ml	  were	  compared	  either	  directly	  to	   full	   length	  PrP	  
fibrils	   	   (Figure	  5.18A)	  or	  preparations	  were	   centrifuged	   to	   remove	   the	   larger	   fibrils	   and	  
aggregates	  to	  allow	  analysis	  of	  the	  smaller	  particles	  (Figure	  5.18B).	  	  The	  size	  estimates	  are	  
based	   in	  a	  globular	  protein	  model	  and	   therefore	  will	  not	  accurately	  represent	   fibril	   size.	  
However,	  the	  predicted	  sizes	  allow	  for	  comparisons	  between	  fibril	  preparations.	   	  Figures	  
5.18A	   and	   B	   represent	   average	   traces	   taken	   from	   5	   separate	   repeats	   of	   13	   or	   more	  
readings	  calculated	  by	  Zetasizer	  software. 
	  
The	  C1	   fibril	  preparations	  appear	   to	  have	   less	   large	  sized	  aggregates	  when	  compared	   to	  
PrP	  preparations	  represented	  by	  the	  lower	  percentage	  volume	  of	  protein	  species	  (Figure	  
5.18A).	  The	  size	  of	  the	  most	  prevalent	  protein	  aggregates	  in	  PrP	  and	  C1	  preparations	  also	  
vary,	  with	  C1	  reactions	  forming	  aggregates	  equivalent	  to	  the	  largest	  of	  full	   length	  PrP.	   In	  
C1ARR	  fibril	  preparations	  the	  dominant	  species	  were	  around	  253.8	  (SD	  ±	  21.12),	  374.6	  (SD	  
±	  46.50)	  and	  602	  (SD	  ±	  72.27)	  d.nm	  and	  in	  C1VRQ	  preparations	  the	  dominant	  species	  are	  
estimated	   at	   422.2	   (SD	   ±	   40.77)	   and	   611.7	   (SD	   ±	   56.77).	   In	   comparison,	   in	   PrPARR	  
preparations	   the	   dominant	   species	   were	   58.72	   (SD	   ±	   5.229),	   115.3	   (SD	   ±	   19.60)	   and	  
480.27	   (SD	  ±	  125.1)	  d.nm	  and	   in	   full	   length	  PrPVRQ	   reactions	   the	  dominant	  species	  were	  
around	  90.23	  (SD	  ±	  9.605)	  and	  365.2	  (SD	  ±	  84.43).	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Size Distribution by Intensity
Record 46: PRPVRQ fibrils  (well B10)
Record 47: prparr FIBRILS  (well B11)
Record 48: C1ARR FIBRILS  (well B12)



















Size Distribution by Volume
Record 46: PRPVRQ fibrils  (well B10)
Record 47: prparr FIBRILS  (well B11)
Record 48: C1ARR FIBRILS  (well B12)
Record 49: C1 VRQ FIBRILS  (well B13)
*The molecular weight reported here is only an estimate, calculated using an empirical mass vs. size calibration curve.
Primary Protein Analysis Report
v1.0
Well Position: 



















C1 VRQ FIBRILS  (well B13)
B 13
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75.8
LAUREN210313.dts
Hydrodynamic Radius Estimated MW (± SD) (KDa): 
Meas Date & Time: 
Polydisperse. Sample Polydispersity: 
Sample Details




































Serial Number : MAL1056310
Zetasizer Ver. 6.34






























Size Distribution by Intensity
Record 114: C1ARR_superC  (well A5)
Record 115: C1VRQ_Super c  (well A6)



















Size Distribution by Volume
Record 114: C1ARR_superC  (well A5)
Record 115: C1VRQ_Super c  (well A6)
Record 116: PRPVRQ_sUPER C  (well A7)
*The molecular weight reported here is only an estimate, calculated using an empirical mass vs. size calibration curve.
Primary Protein Analysis Report
v1.0
Well Position: 



















PRPVRQ_sUPER C  (well A7)
A 7
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40.1
lauren 060313 C1 fibril spin down.dts
Hydrodynamic Radius Estimated MW (± SD) (KDa): 
Meas Date & Time: 
Polydisperse. Sample Polydispersity: 
Sample Details




































Serial Number : MAL1056310
Zetasizer Ver. 6.34
11 Apr 2013 14:29:51
Record Number: 116




Figure	   5.17	   –	   Fibrils	   size	  
distribution	  by	  mass	  using	  DLS.	  As	  
described	   in	   section	   5.3.15,	   C1	  
fibrils	   ~0.5mg/ml	   were	   compared	  
either	   directly	   to	   full	   length	   PrP	  
fibrils	   	   (Figure	   5.16A)	   or	  
preparations	   were	   centrifuged	   to	  
remove	   the	   larger	   fibrils	   and	  
aggregates	  to	  allow	  analysis	  of	  the	  
smaller	  particles	  (Figure	  5.16B)	  
Figures	   5.16A	   and	   B	   represent	  
average	   traces	   taken	   from	   5	  
separate	   repeats	   of	   13	   or	   more	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When	  the	  larger	  aggregates	  were	  removed	  by	  centrifugation	  C1	  preparations	  were	  found	  
to	  be	  very	  similar	   to	  each	  other	  with	  C1ARR	  dominant	   species	  around	  47.74	   (SD	  ±	  8.290)	  
and	  186.2	  (SD	  ±	  75.07)	  and	  C1VRQ	  around	  62.86	  (SD	  ±	  9.278)	  196.7	  (SD	  ±	  71.89)	  (Figure	  
5.18B	  and	  5.19).	  Full	   length	  PrPVRQ	  had	  a	   small	  amount	  of	  48.18	   (SD	  ±	  4.688)	  and	  major	  
species	  of	  157.4	  (SD	  ±	  72.90)	  and	  630	  (SD	  ±	  89.66).	  These	  readings	  indicate	  that	  C1	  fibril	  
preparations	   vary	   from	   full	   length	  PrP	  both	   in	   the	   sizes	  of	   large	   aggregates	   and	   smaller	  
oligomers.	  This	  could	  be	  important	  in	  neuronal	  toxicity	  as	  it	  is	  still	  unknown	  which	  form	  





























Figure	  5.18	  –	  Estimation	  and	  comparison	  of	  average	  particle	  size	   in	   fibril	  preparations.	  
Fibrils	  were	  produced	   in	   the	   absence	  of	   ThT	   at	   ~0.5mg/ml	   and	   analysed	  by	  DLS	  using	   a	  
Zetasizer	  APS	   as	   described	   in	   section	   5.3.15.	   The	   size	   of	   dominant	   protein	   species	  were	  
calculated	   from	   the	   average	   of	   five	   readings	   of	   multiple	   repeats.	   Error	   bars	   represent	  
variations	  in	  size	  around	  each	  peak.	  This	  graph	  combines	  data	  from	  5.18A	  and	  5.18B.	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5.4.7	  Amyloid	  fibril	  formation	  of	  recombinant	  C2	  protein	  
It	  was	  also	  assessed	  if	  recombinant	  C2	  proteins	  could	  form	  amyloid	  fibrils.	  Although	  found	  
at	   low	   levels	   in	   healthy	   animals	   and	   more	   common	   in	   ARQ	   and	   VRQ	   homozygotes	  
compared	  to	  ARR	  homozygotes,	  as	  illustrated	  in	  section	  4.4.3	  (Chapter	  4)	  the	  frequency	  of	  
C2	   is	   increased	   in	   infected	   brain	   tissue	   (section	   4.4.11,	   Chapter	   4).	   C2ARR	   and	   C2VRQ	  
fibrillisation	   assays	   were	   set	   up	   in	   the	   presence	   of	   thioflavin	   T	   (ThT).	   Fibril	   formation	  
kinetics	  were	  measured	  over	  a	  24-­‐hour	  period	  and	  lag	  times	  were	  calculated	  as	  described	  
in	  Graham	  et	  al.	   (Graham,	  Agarwal	  et	  al.	  2010).	  Fibrillisation	  experiments	  were	  repeated	  
multiple	   times	   (n)	  and	   typical	   fibrillisation	  curves	   for	  C2	   fragments	  are	  shown	   in	  Figure	  
5.18.	   C2VRQ	  produced	   curves	   similar	   to	   those	   of	   the	   full-­‐length	   variants,	   C1ARQ	   and	   C1VRQ	  
with	   an	   average	   lag	   time	  of	   4.3	   hours	   (SEM	  +/-­‐	   0.4).	   	   C2ARR	  reactions	  had	   a	   significantly	  
longer	   average	   lag	   time	   of	   9.1	   hours	   (SEM	   +/-­‐	   1.6,	   p	   =	   0.01)	   taken	   from	   only	   7	   repeat	  
reactions	   as	   80	  %	   of	   reactions	   failed	   to	   fibrillise	   within	   the	   24	   hour	   time	   frame	   of	   the	  
experiment.	   Fibrillisation	   curves	   of	   C2ARR	   tended	   to	   mirror	   those	   of	   C1ARR	   with	   slow	  
elongation	   rates	   and	   low	   maximum	   fluorescence	   indicating	   that	   C2ARR,	   like	   C1ARR	   has	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rC2	  VRQ	  n=	  24	   rC2	  ARR	  n	  =	  7	  
Figure	   5.19	   –	   Fibrillisation	   kinetics	   of	   C2	   recombinant	   proteins.	   Fibrillisation	   was	  
performed	   as	   described	   in	   section	   5.3.13	   A)	   Typical	   fibrillisation	   curves	   for	   PrP	   variants.	  
Background	  ThT	   fluorescence	   from	  no	  PrP	  controls	  subtracted	  from	  raw	  data.	  B)	  Average	  
lag	  time	  of	  fibrillisation	  for	  C2	  variants	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To	  confirm	  that	  C2	  proteins	  were	  producing	  fibrils	  rather	  than	  non-­‐fibrillar,	  ThT-­‐binding	  
aggregates,	  a	  fibril	  maturation	  assay	  was	  performed.	  Like	  full	  length	  PrP,	  recombinant	  C2	  
proteins	  display	  a	  16	  kDa	  band	  evident	  after	  maturation	  along	  with	  the	  characteristic	  12	  








5.4.8	  Comparison	  of	  fibril	  formation	  kinetics	  between	  PrP	  and	  truncated	  cleavage	  
fragments	  C1	  and	  C2	  
All	  prior	  fibrillisation	  reactions	  were	  performed	  at	  a	  protein	  concentration	  of	  100	  µg/ml.	  
To	   compare	   fibril	   formation	   kinetics	   between	   proteins	   of	   different	   molecular	   weights,	  
reactions	  were	  set	  up	  at	  a	  single	  molar	  concentration	  of	  4.4nM	  (equal	  to	  100	  µg/ml	  of	  full	  
length	   recombinant	   PrP	   protein)	   ensuring	   the	   same	   numbers	   of	   protein	   particles	   were	  
added	  into	  each	  reaction.	  Full	  length	  PrP	  reactions	  were	  as	  previously	  described	  in	  section	  
5.4.6	  and	  Figure	  5.14.	  For	  both	  C1ARR	  and	  C2ARR	  all	  reactions	  at	  4.4nM	  (both,	  n	  =	  4)	  failed	  to	  
fibrillise	   within	   the	   time	   frame	   of	   the	   experiment,	   therefore	   lag	   times	   could	   not	   be	  
calculated.	  	  The	  higher	  frequency	  of	  failed	  reactions	  compared	  to	  the	  prior	  experiment	  can	  












C2	  ARR	   C2	  VRQ	  
Figure	   5.20	   –	  Maturation	   and	  PK	  digestion	  of	   C2	   fibrils.	  Maturation	  and	  PK	  digestion	  of	  
fibrils	  were	  performed	  as	  described	  in	  section	  5.3.14..	  0.5	  µg	  of	  recombinant	  protein	  was	  
untreated	  (Lane	  1),	  PK	  treated	  at	  a	  ratio	  100:1	  of	  PrP:	  PK	  (Lane	  2),	  or	  matured	  by	  heating	  to	  
80°C	   followed	   by	   PK	   treatment	   (Lane	   3).	   Matured	   fibrils	   (Lane	   3)	   show	   increased	   PK	  
resistance	  relative	  to	  non-­‐matured	  fibrils.	  Reactions	  show	  a	  16	  kDa	  band	  after	  maturation	  
which	  confirms	  the	  presence	  of	  fibrils,	  highlighted	  by	  the	  black	  box.	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be	  explained	  by	  the	  reduction	  in	  molecules	  put	  in	  to	  the	  reaction.	  C1VRQ	  at	  4.4	  nM	  had	  an	  
average	   lag	   time	   of	   2.11	   hours	   (SEM	   ±	   0.27)	   while	   for	   C2VRQ	  the	   average	   lag	   time	   was	  
slightly	  longer	  at	  3.47	  hours	  (SEM	  ±	  0.27).	  Lag	  time	  of	  fibrillisation	  for	  PrP	  and	  truncated	  
PrP	   representing	   the	   VRQ	   allele	   seems	   to	   positively	   correlate	   with	   molecular	   weight	  
(Figure	   5.21A).	   Reactions	   at	   lower	   protein	   concentration	   of	   C1VRQ	   and	   C2VRQ	   also	   have	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Figure	  5.21	  –	  Fibrilisation	  lag	  time	  and	  molar	  concentration.	  A)	  The	  relationship	  between	  
average	  fibrillisation	  lag	  time	  and	  protein	  molecular	  weight	  for	  recombinant	  VRQ	  variants.	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5.5	  DISCUSSION	  
5.5.1	  Generation	  and	  characterisation	  of	  truncated	  PrPC	  recombinant	  proteins	  
A	   number	   of	   in	   vitro	   studies	   investigating	   the	   molecular	   aspects	   of	   scrapie-­‐associated	  
polymorphisms	  in	  the	  PRNP	  gene	  have	  examined	  the	  initial	  binding	  of	  PrPC	  to	  PrPSc	  prior	  
to	  conversion	  (McCutcheon,	  Hunter	  et	  al.	  2005,	  Rigter	  and	  Bossers	  2005)	  and	  the	  relative	  
convertibility	   of	   prion	   protein	   variants	  (Kirby,	   Goldmann	   et	   al.	   2006,	   Eiden,	   Soto	   et	   al.	  
2011).	  Others	  have	  tried	  to	  explain	  disease	  resistance	  by	  allele-­‐specific	  expression	  profiles	  
(McCutcheon,	   Hunter	   et	   al.	   2005,	   Rigter	   and	   Bossers	   2005),	   different	   protein	  
conformations	   or	   different	   characteristics	   of	   fibrillisation	   and	   thermal	   stability	   (Kirby,	  
Agarwal	  et	  al.	  2010).	  These	  studies	  have	  shown	  that	  alterations	  in	  the	  sequence	  of	  PRNP	  
are	   pivotal	   in	   defining	   the	   ability	   of	   the	   PrPC	   protein	   to	   convert.	   However,	   at	   this	   time	  
there	  have	  been	  no	  in	  vitro	  models	  which	  have	  taken	  truncated	  PrPC	  proteins	  into	  account	  
albeit	   levels	   of	   C1	   have	   been	   shown	   to	   be	   an	   important	   determinant	   of	   scrapie	  
susceptibility	  in	  cell	  culture	  (Lewis,	  Hill	  et	  al.	  2009).	  Moreover,	  we	  have	  shown	  that	  levels	  
of	  C1	  and	  C2	  can	  be	  highly	  variable	  in	  ovine	  brain	  and	  can	  account	  for	  a	  large	  proportion	  
of	  cellular	  PrPC	  (sections	  4.4.2	  and	  4.4.3).	  	  
	  
It	   was	   felt	   that	   the	   production	   of	   recombinant	   proteins	   C1	   and	   C2	   and	   consequent	  
fibrillisation	  would	  be	  the	  best	  method	  to	  directly	  determine	  if	  truncated	  PrPC	  proteins	  C1	  
and	   C2	   could	   be	  misfold	   and	  whether	  misfolding	  was	   associated	  with	   protein	   allotypes.	  
Recombinant	  full	  length	  PrPC,	  three	  variants	  of	  C1	  (C1ARR,	  C1ARQ,	  C1VRQ)	  and	  two	  variants	  of	  
C2	   (C2ARR	  and	  C2VRQ)	  were	  produced.	   In	   the	   case	   of	   C1	   variants,	  mass	   spectrometry	  was	  
performed	  which	  confirmed	  high	  purity	  but	  did	  highlight	  slight	  modifications	   in	  the	  His-­‐
tag	  which	   has	   been	   previously	   reported	   (Geoghegan,	   Dixon	   et	   al.	   1999).	   These	   proteins	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were	   primarily	   alpha-­‐helical	   in	   secondary	   structure	   as	   indicated	   by	   CD.	   Interestingly,	  
when	  estimates	  were	   compared	  between	   the	  C1ARR	   and	  C2ARR	   variants	   it	  was	   found	   that	  
the	   C2	   variants	   had	   more	   molecules	   of	  α-­‐helical	   structure.	   The	   same	   was	   observed	   on	  
comparison	  of	  VRQ	  variants.	  Both	  C1VRQ	  and	  C2VRQ	  had	  higher	  estimates	  of	  α-­‐helix	  than	  the	  
corresponding	  ARR	  variants.	  	  It	  is	  unknown	  if	  similar	  structural	  variations	  will	  be	  present	  
in	  vivo.	  These	  findings	  are	  somewhat	  unexpected	  as	  during	  conversion	  α-­‐helices	  undergo	  a	  
structural	   shift	   into	  β-­‐sheet,	   therefore	   it	  would	  be	  assumed	   that	   a	  protein	  with	  a	  higher	  
propensity	  of	  β-­‐sheet	  would	  more	  easily	  undergo	  conversion.	  	  
	  
The	   isolation	   of	   mammalian	   expressed	   truncated	   protein	   from	   full	   length	   PrPC	   would	  
allow	  for	  the	  misfolding	  of	  these	  proteins	  to	  be	  investigated	  using	  in	  vitro	  as	  the	  majority	  
of	  ovine	  C1	  appears	  to	  be	  mono-­‐or	  di-­‐glycosylated,	  as	  indicated	  by	  the	  lack	  of	  substantial	  
17	  kDa	  band	   in	   the	  absence	  of	  PNGase	  F	  by	  western	  blotting.	  Glycosylation	  of	   truncated	  
PrP175-­‐195	  fragment	  has	  been	  shown	  to	  alter	  the	  kinetics	  of	  fibrillisation	  reactions	  (Bosques	  
and	   Imperiali	   2003),	   indicating	   that	   glycosylation	   of	   C1	   and	   C2	   may	   be	   an	   important	  
consideration	   for	   fibrillisation	  studies.	  Furthermore,	   complete	  separation	  of	  C1	   from	   full	  
length	  PrPC	  protein	  in	  brain	  would	  allow	  for	  direct	  quantification	  of	  C1	  levels	  by	  DELFIA,	  
which	   has	   previously	   been	   performed	   for	   total	   PrPC	   (Charmaine	   Love,	   Ph.D.	   Thesis,	  
University	  of	  Edinburgh,	  2010).	  	  
	  
5.5.2	  C1	  and	  C2	  recombinant	  proteins	  can	  form	  amyloid	  fibrils	  in	  vitro	  
The	   pure	   and	   refolded	   recombinant	   proteins	   were	   subjected	   to	   fibrillisation	   assays	   to	  
determine	   if	   they	   had	   the	   potential	   to	   undergo	   structural	  misfolding	   and	   form	   amyloid	  
fibrils	   under	   semi-­‐denaturing	   conditions	   All	   variants	   tested	   had	   the	   ability	   to	   form	  
amyloid	  fibrils,	  confirmed	  by	  the	  presence	  of	  mature	  PK	  resistant	  cores	  after	  fibrillisation	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Full-­‐length	   PrP	   variants	   and	   C2	   variants	   had	   typical	   banding	   after	   maturation	   and	   PK	  
digest	  in	  the	  form	  of	  16	  kDa,	  12	  kDa	  and	  10	  kDa	  bands,	  indicating	  that	  C2	  forms	  the	  same	  
PK	   resistant	   C-­‐terminal	   core	   as	   full	   length	   PrP,	   encompassing	   amino	   acids	   173-­‐224	  
(murine	  numbering)	   (Tycko,	  Savtchenko	  et	  al.	  2010).	   In	  contrast,	   recombinant	  C1	   fibrils	  
had	   additional	   bands	   of	   16.6	   kDa	   and	   13	   kDa.	   The	   presence	   of	   a	   13	   kDa	   band	  was	   also	  
evident	   in	  maturation	   assays	   of	   human	  PrP90-­‐231,	   representative	   of	   the	   C2	   fragment	   (Lu,	  
Wintrode	  et	  al.	  2007)	  and	  may	  indicate	  formation	  of	  disordered	  aggregates	  with	  increased	  
PK	   resistance.	   The	   16.6	   kDa	   band	   could	   represent	   an	   increase	   in	   core	   expansion	   or	   a	  
structural	  change,	  which	  alters	  available	  PK	  digestion	  sites.	  Whether	  this	  fragment	  is	  ovine	  
sequence	   related	  or	   can	   also	  be	   found	   in	   recombinant	  C1	   fibril	   preparations	   from	  other	  
species	   remains	   to	   be	   established.	   The	   fibril	   associated	   16	   kDa	   band	   was	   fainter	   in	   all	  
preparations	   of	   truncated	   PrP	   proteins	   indicating	   that	   less	   fibrils	   were	   being	   formed	  
during	   these	   reactions	   compared	   to	   full-­‐length	   proteins:	   an	   observation	  which	   fitted	   in	  
with	  findings	  from	  both	  electron	  microscopy	  and	  DLS	  of	  recombinant	  C1	  proteins.	  Further	  
discrepancies	   in	   fibrillisation	   reactions	   were	   observed	   and	   hence,	   fibrillisation	   kinetics	  
were	  investigated	  in	  detail	  to	  determine	  if	  there	  were	  allotype	  specific	  differences	  in	  fibril	  
formation	  of	  PrPC	  truncated	  proteins.	  
	  
5.5.3	  Amyloid	  fibril	  formation	  kinetics	  
ARR/ARR	   sheep	   are	   considered	   resistant	   to	   classical	   scrapie	   infection	   and	   do	   not	  
accumulate	  PrPSc,	   although	   they	  can	  do	  so	  after	  BSE	   infection	   (Houston,	  Goldmann	  et	  al.	  
2003).	   In	   vitro	   PrPARR	   has	   the	   ability	   to	   form	   fibrils.	   However,	   longer	   lag	   times,	  
representing	  the	  time	  taken	  for	  protein	  misfolding	  to	  commence,	   indicate	  that	  PrPARR	  has	  
reduced	  potential	  to	  form	  amyloid	  fibrils	  compared	  to	  PrPVRQ	  with	  a	  significantly	  longer	  lag	  
time.	   C1ARR	   and	   C2ARR	   also	   had	   a	   significantly	   longer	   average	   lag	   time	   of	   fibrillisation.	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However	   unlike	   full	   length	   PrPARR	   these	   variants	   also	   showed	   an	   extended	   or	   slowed	  
elongation	   phase	   when	   compared	   to	   other	   allotypic	   forms	   of	   C1	   and	   PrPC.	   Often	   in	  
reactions	  truncated	  ARR	  variants	  would	  fail	  to	  fibrillise	  fully	  within	  the	  time	  frame	  of	  the	  
experiment	   indicating	   that	   these	   proteins	   have	   a	   reduced	   potential	   to	   form	   fibrils.	  
Truncated	   ARR	   variants	  most	   likely	   take	   a	   different	   aggregation	   pathway	   to	   that	   of	   the	  
other	  variants	  tested.	  Previous	  work	  looking	  at	  kinetic	  pathways	  of	  aggregation	  in	  course-­‐
grain	  peptide	  models	  have	  shown	  that	  small	  differences	  in	  sequence	  can	  lead	  to	  extremely	  
different	  structural	  outcomes	  (Bellesia	  and	  Shea	  2009).	  Similar	  polymorphism-­‐dependent	  
differences	  have	  been	   reported	  with	   in	  vitro	   conversion	  of	   recombinant	  human	  PrP90-­‐231	  
(Apetri,	  Vanik	  et	  al.	  2005,	  Baskakov,	  Disterer	  et	  al.	  2005,	  Nystrom,	  Mishra	  et	  al.	  2012).	  It	  
appears	   that	   only	   in	   the	   absence	   of	   the	   N-­‐terminal	   of	   PrP	   does	   the	   inhibitory	   effect	  
associated	  with	  the	  presence	  of	  an	  arginine	  at	  position	  171	  become	  important	  in	  delaying	  
fibril	   formation	   (Figure	  5.28),	  while,	   polymorphisms	   at	   136	   appear	   to	  have	  no	   effect	   on	  
fibrillisation	   of	   PrP.	   The	   primary	   binding	   site	   of	   PrP-­‐to-­‐PrP	   interaction	   is	   likely	   to	   be	  
situated	   on	   the	   N-­‐terminal	   of	   the	   protein	   and	   therefore	   we	   can	   hypotheses	   that	   when	  
proteins	   bind	   via	   this	   site	   under	   specific	   conditions	   the	   structure	   is	   favorable	   to	   fibril	  
formation.	   In	   the	   absence	   of	   this	   binding	   site,	   for	   example,	   in	   truncated	   C1	   and	   C2	   a	  
secondary,	  lower	  affinity	  binding	  site	  must	  be	  adopted.	  If	  this	  site	  is	  in	  close	  proximity	  to	  
amino	   acid	   171,	   then	   polymorphisms	   at	   this	   position	   could	   be	   important	   in	   defining	  
interaction	  and	  binding.	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Figure	   5.22	   –	   Diagrammatic	   illustration	   of	   allele-­‐dependent	   variation	   in	   ability	   to	   form	  
amyloid	  fibrils	  in-­‐vitro.	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It	   has	   been	   previously	   suggested	   that	   lag	   time	   is	   a	   factor	   of	   concentration	   and	   that	   the	  
more	  concentrated	  a	  protein	  the	  shorter	  the	  lag	  time,	  explained	  through	  proteins	  at	  higher	  
density	   having	   more	   chance	   of	   intercepting	   each	   other	   in	   the	   correct	   susceptible	  
conformation.	   To	   understand	   the	   effect	   of	   concentration	   on	   lag	   time,	   fibrillisation	  
reactions	  were	   set	  up	   at	   two	  different	  molar	   concentrations.	  At	   lower	   concentrations	   to	  
that	  originally	  tested	  (100	  µg/ml)	  all	  ARR	  truncated	  variants	  failed	  to	  fibrillise	  within	  the	  
time	   frame	   of	   the	   experiment.	   In	   contrast	   to	  ARR	   and	   against	   expectation,	   lowering	   the	  
concentration	   of	   recombinant	   C1VRQ	  and	   C2VRQ	   proteins	   resulted	   in	   shorter	   lag	   times	   of	  
fibrillisation.	   Furthermore,	   it	   was	   observed	   that	   lag	   times	   of	   PrP	   and	   truncated	   PrP	  
proteins	   representing	   the	   VRQ	   allele	   appeared	   to	   positively	   correlate	   with	   protein	  
molecular	   weight,	   indicating	   that	   the	   shorter	   the	   PrPVRQ	   fragment	   the	   faster	   it	   was	  
misfolded.	  This	  may	  directly	   reflect	   the	  α-­‐helical	   content	  of	   these	  proteins,	  as	  calculated	  
by	  CD,	  of	  which	  C2VRQ	  was	  found	  to	  have	  a	  higher	  proportion	  of	  helically	  folded	  protein	  in	  
comparison	  to	  C1.	  We	  can	  hypotheses	  that	  the	   longer	   lag	  time	  of	   fibrillisation	  associated	  
with	  C2	  may	  reflect	  the	  time	  taken	  for	  a	  more	  helically	  folded	  protein	  to	  fully	  adopt	  a	  beta-­‐
sheet	   formation,	   compared	   to	   a	   protein	   with	   less	   alpha	   helix	   (C1).	   However,	   the	   direct	  
reasons	  for	  this	  remain	  to	  be	  established.	  
	  
5.5.5	  Fibrillisation	  as	  a	  tool	  to	  unravel	  molecular	  mechanisms	  of	  PrP	  conversion	  
The	  formation	  of	  amyloid	  fibrils	  in	  vitro	  has	  been	  important	  in	  shedding	  light	  on	  the	  early	  
stages	  of	  conversion	  at	  a	  molecular	  level.	  Fibrils	  formed	  using	  these	  assays	  have,	  like	  PrPSc,	  
have	   increased	   resistance	   to	   PK	   and	   produce	   characteristic	   truncated	   species	   and	   PK	  
cleavage	  patterns	  (Bocharova,	  Breydo	  et	  al.	  2005,	  Sajnani,	  Pastrana	  et	  al.	  2008).	  Perhaps,	  
most	   importantly	   amyloid	   fibrils	   formed	   in	   vitro	   have	   been	   shown	   to	   generate	   disease	  
(Legname,	   Baskakov	   et	   al.	   2004).	   Although	   in	   vitro	   fibrils	   are	   likely	   to	   be	   formed	   by	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different	  misfolding	  pathways	  and	  misfolded	  proteins	  are	  therefore	  structurally	  different	  
to	  PrPSc	  formed	   in	  vivo,	  structural	   similarities	  must	   be	   sufficient	   to	   bind	  native	  PrPC	   and	  
induce	  misfolding.	  During	   this	  study	   fibrillisation	  was	  performed	  using	  recombinant	  PrP	  
and	   truncated	   proteins.	   Considering	   the	   results	   with	   the	   various	   allotypes,	   it	   may	   be	  
important	   to	  repeat	   these	  misfolding	  assays	  using	  purified	  mammalian	  PrP	  with	   its	  GPI-­‐
anchor	  and/or	  glycosylation	  intact.	  The	  purification	  and	  fibrillisation	  of	  full	  length	  PrPVRQ	  
from	  CHO	  cells	  proved	  to	  produce	  fibrillar	  structures	  morphologically	  different	  from	  that	  
produced	   by	   recombinant	   protein,	   with	   similar	   properties	   to	   PrPSc	   isolated	   from	   brain	  
(Stohr,	  Elfrink	  et	  al.	  2011).	  	  
	  
Fibrillisation	   assays,	   while	   able	   to	   produce	   fibrils	   with	   PrPSc-­‐like	   properties,	   cannot	  
account	  for	  cellular	  conditions	  such	  as	  PrPC	  localisation	  in	  the	  cell	  or	  cellular	  co-­‐factors	  for	  
their	   importance	   in	   conversion.	   These	   assays	   are	   performed	   under	   semi-­‐denaturing	  
conditions	   to	  promote	  protein	  unfolding	  and	  with	   intense	  and	  continuous	  shaking	   these	  
assays	   do	   not	   mimic	   physiological	   conditions,	   limiting	   their	   relevance	   in	   vivo.	  
Furthermore,	  these	  assays	  measure	  the	  formation	  of	  amyloid	  alone	  and	  do	  not	  account	  for	  
the	   formation	  of	   smaller	  oligomers	  and	   intermediates.	  These	   smaller	  aggregates	  may	  be	  
PK	   sensitive,	   infective	   and	   could	   be	   responsible	   for	   prion	   associated	   cellular	   toxicity	  
(Sanghera,	  Wall	  et	  al.	  2008)	  -­‐	  hypothesis	  supported	  by	  transgenic	  models	  with	  little	  or	  no	  
PK	   resistant	   PrPSc	   but	   high	   titers	   of	   infectivity	   (Barron,	   Campbell	   et	   al.	   2007,	   Piccardo,	  
Manson	  et	  al.	  2007).	   	  Despite	   these	   limitations,	   fibrillisation	  represents	  a	  useful	  assay	   to	  
study	  the	  ability	  of	  proteins	  to	  misfold	  and	  can	  be	  used	  as	  an	  indicator	  of	  in	  vivo	  behavior.	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5.5.6	  Conclusions	  
In	  contrast	  to	  previous	  assumptions	  the	  work	  described	  in	  this	  chapter	  has	  shown	  that	  C1	  
and	  C2	  proteins	  have	  the	  potential	  to	  form	  amyloid	  fibrils.	   It	   is	  unknown	  whether	  this	   is	  
strictly	   an	   event	   occurring	   in-­‐vitro	   or	   whether	   this	   can	   also	   occur	   in	   the	   brain	   during	  
disease.	   Moreover,	   it	   is	   unknown	   how	   variation	   in	   the	   potential	   of	   these	   truncated	  
proteins	  to	  misfold	  could	  effect	  the	  conversion	  and	  misfolding	  of	  full	  length	  PrPC.	  To	  fully	  
understand	   the	   role	   of	   these	   proteins	   in	   disease	   it	   is	   essential	   that	   these	   questions	   be	  
answered.	  If	  these	  truncated	  proteins	  of	  TSE	  susceptible	  allotypes	  could	  also	  take	  part	  in	  
conversion	  whereas,	  truncated	  ARR	  variants	  representing	  on	  average	  	  ~50	  %	  of	  total	  PrP	  
could	  not,	  this	  may	  be	  partially	  responsible	  for	  the	  resistance	  effect	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CHAPTER	  6	  	  
A	  ROLE	  FOR	  C1	  IN	  TSE	  DISEASE?	  
6.1.	  INTRODUCTION	  
Recombinant	  ovine	  C1	  can	  form	  amyloid	  fibrils	  in-­‐vitro,	  but	  does	  not	  convert	  into	  PrPSc	  in	  
scrapie	  challenged	  Tg	  mice	  expressing	  only	  C1	  (Westergard,	  Turnbaugh	  et	  al.	  2011).	  I	  have	  
also	  presented	  data	  in	  chapter	  5	  showing	  that	  recombinant	  C1ARR	  has	  reduced	  potential	  to	  
form	   amyloid	   fibrils	   compared	   to	   other	   C1	   variants	   and	   full-­‐length	   PrPC.	   These	   findings	  
leave	  many	  unanswered	  questions	  as	  to	  the	  role	  of	  C1	  during	  scrapie	  disease	  but	  indicate	  
that	  the	  C1	  fragment	  may	  be	  an	  inhibitory	  modulator	  of	  conversion.	  In	  sheep,	  this	  control	  
is	   likely	   to	  be	  associated	  with	  PRNP	  genotype.	   Inclusion	  of	  recombinant	  C1	  proteins	   into	  
well-­‐characterised	   in	   vitro	   fibrillisation	   assays	   may	   shed	   some	   light	   on	   this	   possible	  
inhibitory	  effect.	  If	  C1	  can	  delay	  or	  inhibit	  conversion	  of	  PrPC	  to	  PrPSc	  it	  may	  be	  a	  possible	  
therapeutic	  target	  in	  the	  treatment	  of	  prion	  disease	  either	  by	  exogenous	  application	  C1	  at	  
the	  site	  of	  infection	  or	  by	  increasing	  the	  levels	  of	  α-­‐cleavage	  through	  manipulating	  of	  the	  
yet	  unknown	  PrP	  secreatase.	  
	  
6.2	  AIMS	  AND	  OBJECTIVES	  
Previous	   chapters	   presented	   data	   showing	   that	   animals	   of	   the	  ARR/ARR	   genotype	   have	  
higher	   average	   levels	   of	   C1	   protein	   compared	   to	   ARQ/ARQ	   and	   VRQ/VRQ	   and	   that	   all	  
variants	  of	  recombinant	  C1	  tested	  can	  form	  amyloid	  fibrils	  in	  vitro,	  although	  C1ARR	  appears	  
to	  have	   a	   reduced	  potential	   to	   do	   so.	   This	   chapter	   aimed	   to	   investigate	   the	   role	   C1	  may	  
play	  in	  the	  conversion	  of	  PrPC	  to	  PrPSc	  using	   in	  vitro	   fibrillisation	  assays	  and	  to	  assess	  the	  
potential	  protective	  effects	  of	  C1	  in	  a	  cell	  culture	  model	  of	  infection.	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6.3	  MATERIALS	  AND	  METHODS	  
6.3.1	  Mixed	  fibrillisation	  assays	  
Fibrillisation	  assays	  were	  performed	  as	  described	  in	  section	  5.3.13	  with	  two	  recombinant	  
proteins.	  For	  1:	  1	  (w/w)	  PrP:	  C1	  reactions	  each	  protein	  was	  at	  a	  final	  concentration	  of	  50	  
µg/ml.	   For	   reactions	   at	   4:	   1	   (w/w)	   PrP:	   C1	   recombinant	   protein	   were	   at	   a	   final	  
concentration	  of	  80	  µg/ml	  and	  20	  µg/ml.	  
	  
6.3.2	  Addition	  of	  fibrils	  to	  cell	  culture	  
Growth	  media	   (Table	   2.6)	  was	   aspirated	   from	  N2a	   or	   SMB	   cells	   24	   hours	   after	   plating.	  
Recombinant	   protein	   fibrils,	   produced	   as	   described	   in	   section	   5.4.6	   in	   sodium	   acetate	  
(10mM,	  pH	  5.5)	  were	   added	   to	   cells	   at	   a	   concentration	  of	  1,	   2	  or	  5μM	   (20μl	   volume)	   in	  
80μl	  of	  cell	  specific	  growth	  media	  along	  with	  sodium	  acetate	  (10mM,	  pH	  5.5)	  only	  and	  α-­‐
helical	  recombinant	  protein	  before	  fibrillisation	  (at	  1,2,	  or	  5	  μM).	  	  Plates	  were	  incubated	  at	  
37°C,	  0.5%	  CO2	  for	  24-­‐72	  hours.	  
	  
6.3.3	  Live/Dead	  cell	  assay	  
To	   measure	   the	   cell	   toxicity	   associated	   with	   addition	   of	   fibrils	   to	   cells	   in	   culture	   fibril	  
suspension	  was	  aspirated	  and	  the	  cells	  were	  then	  washed	  twice	  in	  HBSS	  (Hanks	  Balanced	  
Salt	   Solution).	   Hoechst	   33342	   (Thermo	   Scientific)	   and	   Sytox	   orange	   (Molecular	   Probes)	  
were	  diluted	  in	  H2O	  at	  a	  final	  concentration	  of	  4	  μg/ml	  and	  3	  μM,	  respectively.	  Then	  100	  μl	  
was	  applied	  per	  well	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature.	   	  The	  stain	  was	  
aspirated	   from	   the	   cells	   and	   replaced	  with	  500	  μl	   of	  HBSS.	  Plates	  were	  viewed	  on	  Zeiss	  
Live	  Cell	  Observer	  at	  x10	  and	  two	  images	  taken	  at	  random	  in	  grey	  scale	  for	  each	  well.	  Live	  
and	  dead	  cells	  were	  counted	  using	   image	   J	  and	  results	  were	  exported	   to	  Microsoft	  Excel	  
CHAPTER 6 -  A ROLE FOR C1 IN TSE DISEASE? 
	   157	  
for	   analysis.	   Cell	   viability	  was	   calculated	   as	   the	   percentage	   of	   live	   cells	   in	   the	   total	   cell	  
count.	  
	  
6.3.4	  Isolation	  of	  scrapie	  associated	  fibrils	  (SAF)	  
Natural	  scrapie	  infected	  sheep	  brain	  (1.5g)	  was	  manually	  homogenised	  in	  15ml	  brain	  lysis	  
buffer	  (365	  mM	  N-­‐Sarkosyl,	  0.85mM	  Trisodium	  phosphate,	  pH	  7)	  with	  protease	  inhibitors	  
PMSF	   (1.3	   μM)	   and	   NEM	   (1.3	   μM).	   The	   homogenate	   was	   clarified	   by	   centrifugation	   at	  
13,500rpm	   at	   10	   °C	   for	   30	   minutes	   (R5B	   Ultra	   Centrifuge)	   and	   pellets	   discarded.	   The	  
supernatant	  was	  transferred	  to	  70Ti	  glass	  tubes	  and	  centrifuged	  at	  46000rpm	  at	  10	  °C	  for	  
2.5	  hours	  and	  the	  pellet	  stored	  over	  night	  at	  4	   °C.	  The	  pellet	  was	  resuspended	   in	  ddH2O	  
(6ml/pellet)	  and	  incubated	  at	  37	  °C	  with	  shaking	  for	  30	  minutes.	  An	  equal	  volume	  of	  15	  %	  
Iodine	  HSB	  (0.9	  mM	  Potassium	  iodide,	  6	  μM	  Sodium	  Thiosulfate	  Pentahydrate)	  was	  added	  
and	  the	  suspension	  was	   further	   incubated	  for	  45	  minutes.	  Per	  pellet	  6ml	  of	  10	  %	  Iodine	  
HSB	   (0.6	  mM	  Potassium	   iodide,	   6	  μM	  Sodium	  Thiosulfate	  Pentahydrate)	  was	   added	  and	  
the	   mixture	   was	   over-­‐laid	   on	   a	   20	   %	   sucrose	   bed	   (w/v	   in	   10	   %	   IHSB).	   Tubes	   were	  
centrifuged	  at	  40000rpm	  at	  10	  °C	  for	  1.5	  hours	  and	  the	  supernatant	  removed.	  The	  pellet	  
was	  washed	  with	  ddH2O,	  further	  centrifuged	  at	  50000rpm	  10	  °C	  for	  1	  hour	  and	  stored	  at	  
4°C.	  
	  
6.3.5	  Determining	  SAF	  concentration	  
SAF	   pellets	   were	   resuspended	   in	   ddH2O.	   PK	   was	   added	   to	   a	   small	   sample	   at	   a	   final	  
concentration	   of	   60	   µg/ml	   and	   incubated	   at	   37	   °C	   for	   1	   hour.	   To	   stop	   the	   PK	   reaction	  
Pefabloc	   (Sigma)	   was	   added	   at	   a	   final	   concentration	   of	   25mM.	   	   Several	   dilutions	   of	   PK	  
treated	  SAF	  were	  loaded	  onto	  an	  SDS-­‐PAGE	  gel	  along	  with	  dilutions	  of	  recombinant	  PrPVRQ	  
(100-­‐5	   ng)	   in	   sample	   buffer	   (Invitrogen)	  with	   reducing	   agent	   (Invitrogen)	   and	  western	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blotted	  as	  described	   in	  section	  2.3.1.	  To	  detect	  PrPSc	  monoclonal	  antibody	  P4	  (Biopharm	  
Rhone	  Ltd)	  was	  used	  at	  a	   concentration	  of	  0.2	  µg/ml	   in	  0.5	  %	  blocking	   reagent	   (Roche)	  
and	  incubated	  for	  1	  hour.	  Densitometry	  was	  performed	  as	  described	  in	  section	  2.3.4	  using	  
Kodak	  MI	   software	   and	   PrPSc	   concentration	  was	   calculated	   from	   a	   recombinant	   protein	  
standard	  curve.	  
	  
6.3.6	  Preparation	  of	  sterile	  SSPB/1	  positive	  brain	  homogenate	  
All	  steps	  were	  performed	  in	  a	  biological	  safety	  cabinet.	  Sterile	  brain	  tissue	  from	  a	  SSBP/1	  
infected	  VRQ/VRQ	   sheep	  was	  defrosted	   and	   immediately	  mechanically	   homogenised	   (M	  
protein	   program,	   gentle	   MACs	   disassociator,	   Miltenyl	   Biotec))	   in	   Opti-­‐MEM	   media	  
(Invitrogen)	   to	  make	  a	  10	  %	  (w/v)	  homogenate	  and	  stored	  at	   -­‐20	   °C.	   	  Homogenate	  was	  
diluted	  to	  2.5	  %	  (v/v)	  in	  Rov9	  cell	  growth	  media	  (pre-­‐warmed	  to	  37	  °C,	  Table	  2.6)	  prior	  to	  
application.	  	  
	  
6.3.7	  Testing	  sterility	  of	  brain	  homogenate	  
To	   ensure	   brain	   homogenate	   were	   sterile	   and	   hence	   suitable	   for	   cell	   culture,	   100µl	   of	  
undiluted	  homogenate	  and	  dilutions	  at	  of	  10-­‐1,	  10-­‐2,	  10-­‐3,	  10-­‐4	  and	  10-­‐5	  in	  Opti-­‐MEM	  media	  
(Invitrogen)	  were	  plated	  on	  both	  LB	  agar	  (Roslin	  Institute	  central	  services)	  and	  chocolate	  
agar	   plates	   (E	   and	   O	   Laboratories).	   Plates	  were	   incubated	   at	   37	   °C	   for	  ~	   48	   hours	   and	  
monitored	  for	  growth.	  
	  
6.3.8	  Scrapie	  infection	  of	  Rov9	  cells	  
Rov9	   cells	   were	   cultured	   as	   described	   in	   Table	   2.6,	   in	   a	   12	   well	   plate	   format.	   	   Growth	  
media	   was	   aspirated	   and	   replaced	   with	   500	   μl	   of	   2.5	   %	   SSPB/1	   positive	   homogenate	  
(section	  6.3.6)	  or	  for	  negative	  control	  wells	  growth	  media	  alone	  and	  incubated	  at	  37	  °C	  for	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2	   hours,	   after	   which	   a	   further	   500	   μl	   of	   growth	   media	   was	   added.	   After	   48	   hours	   the	  
homogenate	   was	   aspirated	   from	   the	   cells	   and	   replaced	   with	   normal	   growth	   media.	  
Recombinant	   C1ARR	   	   (5μg/well)	   was	   added	   into	   the	   growth	   media	   at	   24	   hours	   prior	   to	  
infection,	  pre-­‐mixed	  with	  the	  homogenate	  at	  time	  of	  infection	  or	  24	  hours	  post	  infection.	  
The	  wells	   in	  which	  C1ARR	  was	  added	  24	  hours	  post	   infection	  were	  given	   further	  doses	  of	  
C1ARR	  after	  splitting	  and	  re-­‐plating	  at	  day	  2,	  5,	  and	  11.	  
	  
6.3.9	  Lysis	  of	  infected	  cell	  lysate	  
All	  steps	  were	  performed	  in	  a	  biological	  safety	  cabinet.	  Wells	  were	  washed	  with	  cold	  HBSS	  
and	  500	  µl	  of	   lysis	  buffer	   (5	  %	  NP-­‐40	   (v/v),	  12.1	  mM	  Sodium	  deoxycholate	   in	  PBS	  with	  
protease	  inhibitors	  10	  µM	  PMSF,	  10	  µM	  NEM)	  was	  added	  per	  well	  of	  a	  12	  well	  plate.	  The	  
cells	  were	  scraped	  from	  the	  surface.	  The	  suspension	  was	  syringed	  repeatedly	  to	  promote	  
cell	   lysis.	   Suspension	   was	   clarified	   by	   centrifugation	   at	   500rpm	   for	   3	   minutes	   and	   the	  
supernatant	  collected,	  flash	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐20˚C.	  
	  
6.3.10	  PK	  digestion	  of	  infected	  cell	  lysate	  
Cell	   lysate	   (30	   μg	   total	   protein,	   as	  measured	   by	   BCA	   assay)	   in	   an	   equal	   volume	   of	   lysis	  
buffer	  was	  treated	  with	  PK	  (50	  μg/ml)	  and	  incubated	  at	  37	  °C	  with	  shaking	  for	  1.5	  hours.	  
To	  stop	  PK	  reaction	  Pefabloc	  was	  added	  at	  a	  final	  concentration	  of	  25mM.	  To	  precipitate	  
the	   protein,	   5	   x	   volume	   of	   ice-­‐cold	   acetone	   was	   added	   to	   precipitate	   the	   protein	   and	  
incubated	  at	  -­‐20	  °C	  for	  at	  least	  1	  hour.	  	  Protein	  was	  pelleted	  before	  use	  by	  centrifugation	  at	  
13000rpm,	  4	   °C	  and	  air-­‐dried.	  For	  western	  blotting	   the	  pellet	  was	  resuspended	   in	  equal	  
volumes	   of	   sample	   buffer	   and	   dH2O	  with	   reducing	   agent	   and	   denatured	   at	   80	   °C	   for	   10	  
minutes.	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6.3.11	  Dot	  blotting	  for	  detection	  of	  PrPSc	  
PVDF	  membrane	  was	  wetted	  in	  methanol,	  H2O	  and	  soaked	  in	  TBS	  for	  15	  minutes.	  The	  dot	  
blotting	   apparatus	   (Biorad)	   was	   set	   up	   to	   the	   manufacturers	   instructions	   with	   pre-­‐wet	  
PVDF	   membrane.	   TBS	   was	   applied	   to	   all	   wells	   and	   vacuum	   pumped	   through	   the	  
membrane.	  The	  membrane	  was	  re-­‐wet	  with	  TBS	  and	  2.5µg	  of	  cell	   lysate	  was	  applied	  per	  
well	  diluted	  in	  100µl	  TBS	  or	  in	  wells	  with	  no	  sample	  a	  100µl	  of	  TBS	  alone	  was	  added.	  The	  
sample	  was	  allowed	   to	  drip	   through	   the	  membrane	  by	  gravity	   flow	  and	  was	  replaced	  by	  
two	  further	  washes	  with	  TBS.	  The	  membrane	  was	  removed	  from	  the	  apparatus,	  washed	  in	  
TBS	  for	  5	  minutes	  and	  blocked	  using	  0.1	  %	  (v/v)	  blocking	  solution	  (Roche)	  for	  1	  hour	  at	  
room	   temperature	  with	   agitation	   followed	   by	   incubation	  with	   anti-­‐PrP	   antibody	   P4	   at	   a	  
final	   concentration	  of	  0.2µg/ml	  diluted	   in	  0.5	  %	   (v/v)	  blocking	   solution	  under	   the	   same	  
conditions.	  	  Membranes	  were	  washed	  with	  TBST	  (0.1	  %	  Tween	  20	  in	  TBS)	  followed	  by	  0.5	  
%	   (v/v)	   blocking	   solution.	   The	   membranes	   were	   incubated	   in	   horseradish-­‐peroxidase-­‐
conjugated	   rabbit	   anti-­‐mouse	  antibody	   (Stratech,	  UK)	   diluted	   at	   1:10000	   in	   0.5	  %	   (v/v)	  
block	  for	  75	  minutes.	  The	  membranes	  were	  washed	  in	  TBST	  and	  proteins	  were	  visualized	  
using	  activated	  chemiluminescence	  (SuperSignal	  West	  Dura	  Extended	  Duration	  Substrate,	  
Thermo	   Scientific)	   and	   Chemiluminescent	   Detection	   Film	   (Lumi-­‐Film,	   Roche).
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6.4	  RESULTS	  
6.4.1	  Characterisation	  of	  PrPC	  in	  SMB-­‐PS	  and	  N2a	  cell	  lines	  
	  
SMB	   (Scrapie	   Mouse	   Brain)	   cells	   were	   originally	   isolated	   as	   primary	   culture	   from	   the	  
brains	  of	   scrapie	   infected	  mice	  and	   can	   sufficiently	  maintain	   infection	   in	   culture	   (Clarke	  
and	  Haig	   1970).	   The	   cell	   line	   used	   in	   this	   thesis	   has	   been	   cured	   of	   scrapie	   infection	   by	  
treatment	   with	   pentosan	   polysulphate	   (subsequently	   named	   SMB-­‐PS)	   and	   can	   be	   re-­‐
infected	   (Birkett,	   Hennion	   et	   al.	   2001),	   indicating	   this	   could	   be	   an	   excellent	   model	   to	  
investigate	  processing	  prior	  to	  and	  post	  infection.	  	  The	  morphology	  of	  SMB-­‐PS	  cells	  were	  
first	   examined	   by	   ICC,	   stained	   with	   Haematoxylin	   and	   Eosin	   (Figure	   6.1A).	   At	   higher	  
densities	  a	  large	  percentage	  of	  the	  cells	  appeared	  to	  have	  flat	  wide	  cell	  bodies,	  however	  at	  
lower	  densities	  more	  neuronal	  morphology	  can	  be	   seen	  with	  extending	  neurites.	   	  These	  
cells	  were	  stained	  with	  neuronal	  specific	  marker	  MAP-­‐2	  (Figure	  6.1B).	  Reactivity	  is	  varied	  
with	  some	  cells	  expressing	  high	  levels	  of	  microtubule	  associated	  protein,	  while	   in	  others	  
staining	  is	  limited,	  confirming	  this	  may	  be	  a	  mixed	  population.	  
	  
PrPC	  expression	  was	  investigated	  by	  both	  western	  blotting	  and	  ICC	  and	  is	  shown	  in	  Figure	  
6.2.	  The	  most	  prevalent	  form	  of	  PrPC	  in	  these	  SMB-­‐PS	  cells	  is	  di-­‐glycosylated.	  On	  removal	  
of	   N-­‐glycans	   with	   PNGase	   F	   the	   C1	   fragment	   becomes	   visible	   indicating	   that	   PrPC	  
undergoes	  α-­‐cleavage	  in	  these	  cells,	  representing	  20-­‐30	  %	  of	  total	  PrPC	  protein,	  similar	  to	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Figure	   6.1	   –	   SMB	   cell	   morphology.	   A)	   SMB	   cells	   cultured	   on	   glass	   slides	   at	   day	   5	   after	  
plating,	  fixed	  and	  stained	  with	  Haematoxylin	  and	  Eosin.	  Image	  was	  taken	  on	  a	  Nikon	  800E.	  
B)	  SMB	  cells	  days	  6	  after	  plating	  on	  glass	  slides	  were	  stained	  with	  MAP-­‐2	  neuronal	  marker	  
(1:200)	  with	  secondary	  alexa	  fluor	  568	  anti-­‐mouse	  and	  DAPI	  (1:10000).	  Images	  were	  taken	  
on	  Nikon	  EC1	  inverted	  confocal	  microscope	  at	  x20.	  	  
MAP-­‐2	  
Figure	   6.2	   –	   PrP	   Expression	   in	   SMB-­‐PS	   cell	   line.	  A)	   Cells	  were	   lysed,	   treated	  with	   or	  
without	   PNGase	  F	   and	   subjected	   to	  western	  blotting	  with	  BC6	  antibody.	   B)	   SMB	   cells	  
days	   6	   after	   plating	   on	   glass	   slides	   were	   stained	   with	   BC6	   (1:200)	   with	   secondary	  
alexaflour	  568	  anti-­‐mouse	  and	  DAPI	  (1:10000).	  Image	  was	  taken	  on	  Nikon	  EC1	  inverted	  
confocal	  microscope	  at	  x20.	  	  
	  
BC6	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N2a	   cells	   are	   a	   neuroblastoma	   cell	   line	   isolated	   from	  murine	   neuronal	   crest,	   which	   are	  
frequently,	  used	  in	  general	  neurobiology	  research	  and	  in	  the	  TSE	  field	  as	  they	  differentiate	  
into	  cells	  with	  neuronal-­‐like	  morphology	  and	  can	  be	  infected	  with	  prions.	  The	  morphology	  
of	  N2a	  cells	  was	  examined	  by	  ICC,	  stained	  with	  Haemolysin	  and	  Eosin,	  showing	  flattened	  
cell	   bodies	   and	   long	  extensions	   (Figure	  6.3B).	  As	  PrPC	   expression	  has	  been	   shown	   to	  be	  
essential	  for	  PrP	  fibril	  toxicity	  (Novitskaya,	  Bocharova	  et	  al.	  2006)	  and	  N2a	  cell	   lines	  can	  
have	  variable	  levels	  of	  PrPC	  expression	  (Tagliavini,	  Prelli	  et	  al.	  1992)	  PrPC	  expression	  and	  
α-­‐cleavage	  was	  tested	  by	  western	  blotting	  of	  cell	  lysate	  with	  BC6	  antibody	  	  (Figure	  6.3A).	  
This	   showed	   that	   the	  most	   prevalent	   band	   of	   PrPC	   is	   di-­‐glycosylated,	   as	   expected.	   After	  
PNGase	  F	  digest	  C1	  is	  present	  but	  only	  as	  a	  very	  faint	  band,	  indicating	  α-­‐cleavage	  may	  be	  
much	  lower	  in	  the	  N2a	  cell	  line	  compared	  to	  the	  SMB	  cell	  line.	  
	  
Figure	   6.3	   –	   Morphology	   of	   and	   PrP	   expression	   in	   N2a	   cell	   line.	   A)	   Cells	   were	   lysed,	  
treated	  with	  or	  without	  PNGase	  F	  and	  blotted	  with	  BC6	  antibody.	  B)	  N2a	  cells	  days	  3	  after	  
plating	  on	  glass	   slides	  were	  stained	  Haematoxylin	  and	  Eosin.	   Image	  was	   taken	  on	  Nikon	  
800E.	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6.4.2	  Toxicity	  of	  C1	  fibrils	  in	  cell	  culture	  
It	   has	   been	   shown	   that	   fibrils	  made	   up	   of	   full	   length	   PrPC	   are	   toxic	   to	   neuronal	   cells	   in	  
culture	  (Novitskaya,	  Bocharova	  et	  al.	  2006)	  and	  we	  have	  established	  (Chapter	  5)	  that	  all	  
three	  variants	  of	  ovine	  C1	  have	  the	  potential	  to	  form	  amyloid	  fibrils	  in-­‐vitro.	  Although	  it	  in	  
unknown	   whether	   C1	   fibril	   formation	   occurs	   in	   vivo,	   any	   additional	   misfolding	   during	  
disease	  could	  potentially	  add	  to	  neurodegeneration	  and	  toxicity.	  For	  this	  reason,	  C1	  fibril	  
preparations	  were	   tested	   for	  potential	   toxicity	   to	   two	   cells	   lines,	   SMB-­‐PS	   and	  N2a.	  Both	  
cell	  lines	  were	  selected	  as	  they	  both	  express	  PrPC	  but	  showed	  different	  residual	  levels	  of	  α-­‐
cleavage	  (Figures	  6.2	  and	  6.3).	  Along	  with	  recombinant	  C1	   fibril	  preparations	   full	   length	  
PrPC	  fibril	  preparations	  were	  included	  as	  positive	  controls	  against	  which	  C1	  fibril	  toxicity	  
would	  be	  compared	  and	  α-­‐helical	  recombinant	  C1	  or	  buffer	  only	  were	  added	  as	  negative	  
controls.	  	  
	  
Examples	   of	   live/dead	   staining	   with	   Hoechst	   33342	   and	   Sytox	   orange	   of	   SMB-­‐PS	   cells	  
treated	   with	   a	   2μM	   concentration	   of	   fibrils	   or	   α-­‐helical	   C1	   are	   shown	   in	   Figure	   6.4.	  
Recombinant	  protein	  concentrations	  of	  1	  μM,	  2	  μM	  and	  5	  μM	  were	  tested	  with	  incubations	  
of	  24	  hours,	  48	  hours	  and	  72	  hours.	  Cell	  viability	  was	  calculated	  as	  a	  percentage	  of	  buffer	  
only	  control	  wells	  and	  average	  values	  for	  each	  are	  summarised	  in	  Figure	  6.5,	  6.6	  and	  Table	  
6.1.	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At	  24	  hours	  incubation	  at	  1	  μM	  or	  2	  μM	  neither	  full	  length	  PrP	  fibril	  preparations	  nor	  C1	  
fibril	   preparations	   had	   any	   significant	   effect	   on	   cell	   viability	   compared	   to	   buffer	   only	  
controls.	  At	  5	  μM	  concentration	  of	  full	  length	  PrP	  fibril	  preparation	  cell	  viability	  decreased	  
significantly	   compared	   to	   1	   μM	   and	   2	   μM	   concentrations	   (both	   p	   ≤	   0.03).	   No	   such	  
concentration	  dependent	  toxicity	  was	  seen	  with	  C1	  fibril	  preparations	  or	  α-­‐helical	  C1ARR.	  
However,	  decreased	  cell	  viability	  on	  addition	  of	  α-­‐helical	  C1VRQ	  was	  positively	  correlated	  
with	  concentration	  (p	  ≤	  0.0004),	  suggesting	  that	  there	  may	  be	  allotype	  specific	  toxicity	  of	  
α-­‐helical	  C1.	  	  To	  assess	  if	  incubation	  time	  had	  an	  effect	  on	  toxicity	  the	  2	  μM	  concentration	  
was	   selected.	   Full	   length	   PrP	   fibril	   preparations	   appear	   to	   have	   increasing	   toxicity	  with	  
increasing	   incubation	   time.	   In	   the	   case	  of	  PrPARR	  cell	   viability	   at	  72	  hours	   is	   significantly	  
lower	  than	  at	  24	  hours	  and	  48	  hours	  (p	  ≤	  0.007	  and	  p	  ≤	  0.05,	  respectively).	  On	  addition	  of	  
PrPVRQ	  cell	  viability	  at	  72	  and	  48	  hours	  was	  significantly	  lower	  than	  at	  24	  hours	  (p	  ≤	  0.02	  
and	   p	   ≤	   0.001,	   respectively).	   Average	   cell	   viability	   on	   addition	   of	   recombinant	   C1	   fibril	  
preparations	  showed	  no	  significant	  difference	  at	  any	  time	  points	  tested.	  There	  was	  also	  no	  
significant	  difference	  between	  cell	  viability	  on	  incubation	  of	  α-­‐helical	  C1	  variants	  at	  any	  of	  
the	  time	  points	  tested.	  
Figure	   6.4	   –	   Fibril	   toxicity	   in	   SMB	   cell	   line	   by	   live/dead	   staining.	   Fibrils	   or	   α-­‐helical	  
recombinant	  protein	  was	  added	  to	  SMB	  cells	  in	  culture	  at	  2μM	  concentration	  along	  with	  
buffer	  only	  controls.	  After	  incubations	  of	  24-­‐72	  hours	  live	  cells	  were	  stained	  with	  Hoechst	  
33342	  (blue)	  and	  dead	  cells	  were	  stained	  with	  Sytox	  orange	  (red).	  Images	  were	  taken	  on	  
Zeiss	  live	  cell	  observer	  x10.	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Variant	   Concentration	   Incubation	  
Time	  
Repeat	  Wells	   Average	  Cell	  Viability	   SEM	  
PrP	  ARR	  
FIBRILS	  
1μM	   24	   3	   98.2	   0.03	  
	   2μM	   24	   11	   96.1	   2.69	  
	   2μM	   48	   11	   90	   2.45	  
	   2μM	   72	   4	   81.8	   3.38	  
	   5μM	   24	   3	   89.6	   1.7	  
PrP	  VRQ	  
FIBRILS	  
1μM	   24	   2	   98.7	   0.5	  
	   2μM	   24	   11	   98.6	   2.4	  
	   2μM	   48	   12	   88.02	   1.72	  
	   2μM	   72	   7	   80.4	   6	  
	   5μM	   24	   2	   82.7	   2.85	  
C1	  ARR	  
FIBRILS	  
1μM	   24	   3	   97.6	   1.51	  
	   2μM	   24	   11	   100.3	   1.28	  
	   2μM	   48	   11	   95.5	   1.73	  
	   2μM	   72	   4	   93.5	   5.74	  
	   5μM	   24	   3	   97.7	   1.63	  
C1	  VRQ	  
FIBRILS	  
1μM	   24	   2	   97.6	   0.95	  
	   2μM	   24	   11	   99.4	   1.84	  
	   2μM	   48	   12	   96.6	   1.1	  
	   2μM	   72	   7	   94.9	   6.33	  
	   5μM	   24	   3	   96.5	   3.17	  
α	  C1	  ARR	   1μM	   24	   2	   100.2	   0.1	  
	   2μM	   24	   12	   97.2	   2.6	  
	   2μM	   48	   12	   96.1	   1.28	  
	   2μM	   72	   5	   100.8	   2.73	  
	   5μM	   24	   3	   101.7	   1.08	  
α	  C1	  VRQ	   1μM	   24	   3	   99.4	   0.26	  
	   2μM	   24	   10	   93	   3.06	  
	   2μM	   48	   11	   94.5	   1.73	  
	   2μM	   72	   6	   100.6	   3.02	  
	   5μM	   24	   3	   77.4	   1.13	  
Table	  6.1	  –	  Cell	  viability	  of	  SMB	  cells	  with	  addition	  of	  PrP,	  C1	  fibrils	  and	  recombinant	  α-­‐helical	  
C1	  proteins.	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Figure	   6.6	   –	   The	   effect	   of	   incubation	   time	   on	   fibril	   toxicity	   to	   SMB-­‐PS	   cell	   line.	   Graph	  
summarising	   cell	   viability	   for	   fibrils/recombinant	   protein	   2μM	   incubated	   for	   24,	   48	   or	   72	  























Figure	   6.5	   –The	   effect	   of	   fibril	   concentration	   on	   toxicity	   to	   SMB-­‐PS	   cell	   line.	   Graph	  
summarising	  cell	  viability	  for	  concentrations	  of	  fibrils/recombinant	  protein	  of	  1	  μM,	  2	  μM	  
and	  5μM	  incubated	  for	  24	  hours.	  Cell	  viability	  was	  calculated	  as	  a	  percentage	  of	  average	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Examples	  of	  live/dead	  staining	  of	  N2a	  cells	  treated	  with	  2	  μM	  concentration	  of	  fibrils	  or	  α-­‐
helical	   protein	   are	   shown	   in	   Figure	   6.7.	   In	   the	   case	   of	   N2a	   cells	   buffer	   only	   controls	  
showed	  higher	   cell	  death	   in	   comparison	   to	  assays	   in	  SMB-­‐PS	  cells.	  Recombinant	  protein	  
concentrations	  of	  1	  μM	  and	  2	  μM	  were	  tested	  along	  with	  incubations	  of	  24	  hours,	  48	  hours	  
and	   72	   hours.	   Cell	   viability	   was	   calculated	   as	   a	   percentage	   of	   buffer	   only	   controls,	  
represented	  as	  100	  %	  and	  average	  values	  for	  each	  are	  summarised	  in	  Figure	  6.8	  and	  Table	  
6.2.	   There	   was	   no	   significant	   difference	   between	   cell	   viability	   when	   fibrils	   or	   α-­‐helical	  
proteins	  were	  added	  at	  a	  concentration	  of	  1	  μM	  or	  2	  μM	  at	  any	  of	  the	  time	  points	  tested,	  
indicating	  this	  difference	  in	  concentration	  is	  not	  sufficient	  to	  alter	  toxicity	  to	  N2a	  cells.	  At	  
24	  hours	  incubation	  full	  length	  PrP	  fibril	  preparations,	  C1	  fibril	  preparations	  and	  α-­‐helical	  
protein	   controls	   show	   no	   alteration	   in	   cell	   viability.	   At	   48	   hours	   again,	   there	   is	   no	  
reduction	   in	   cell	   viability	   associated	   with	   addition	   of	   full	   length	   PrP	   or	   C1	   fibril	  
preparations.	   At	   72	   hours	   all	   variants	   of	   fibrils	   and	   α-­‐helical	   proteins	   cause	   substantial	  
reduction	  in	  cell	  viability	  compared	  to	  wells	  treated	  with	  buffer	  only.	  
Figure	   6.7	   –	   Fibril	   toxicity	   in	   N2a	   cell	   line	   by	   live/dead	   staining.	   Fibrils	   or	   α-­‐helical	  
recombinant	  protein	  was	  added	   to	  N2a	   cells	   in	  culture	  at	   2μM	  concentration	   along	  with	  
buffer	  only	  controls.	  After	  incubations	  of	  24-­‐72	  hours	  live	  cells	  were	  stained	  with	  Hoechst	  
33342	   (blue)	  and	  dead	   cells	  were	   stained	  with	   Sytox	  orange	   (red).	   Images	  were	   taken	  at	  
random	  on	  Zeiss	  live	  cell	  observer	  x10.	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αC1	  ARR	   αC1	  VRQ	  
1uM	   2uM	  
Figure	  6.8	  –	  Cell	  Viability	  of	  N2a	  cells	  on	  addition	  of	  PrP	  fibrils.	  Graphs	  summarising	  cell	  
viability	  for	  concentrations	  of	  fibrils/recombinant	  protein	  of	  1	  μM,	  and	  2	  μM.	  Cell	  viability	  
was	   calculated	   as	   a	   percentage	   of	   average	   cell	   viability	   of	   buffer	   only	   control	   wells,	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Table	  6.2	   -­‐	  Cell	  viability	  of	  N2a	  cells	  with	  addition	  of	  PrP,	  C1	  fibrils	  and	  recombinant	  α-­‐helical	  
C1	  proteins.	  






Viability	   SEM	  
PrP	  ARR	  
FIBRILS	   1μM	   24	   9	   101	   0.88	  
	  
1μM	   48	   9	   98.9	   1.56	  
	  
1μM	   72	   6	   72.6	   14.15	  
	  
2μM	   24	   9	   101.4	   0.65	  
	  
2μM	   48	   9	   99.6	   1.79	  
	  
2μM	   72	   6	   59.9	   12.68	  
PrP	  VRQ	  
FIBRILS	   1μM	   24	   8	   89.6	   11.33	  
	  
1μM	   48	   9	   93.2	   3.25	  
	  
1μM	   72	   6	   79.8	   12.76	  
	  
2μM	   24	   9	   98.6	   1.23	  
	  
2μM	   48	   9	   100.5	   1.85	  
	  
2μM	   72	   6	   82.1	   10	  
C1	  ARR	  FIBRILS	   1μM	   24	   6	   98.6	   3.23	  
	  
1μM	   48	   9	   95.7	   6.13	  
	  
1μM	   72	   6	   64.9	   9.87	  
	  
2μM	   24	   6	   101.3	   0.82	  
	  
2μM	   48	   8	   97.5	   4.22	  
	  
2μM	   72	   6	   74.2	   7.01	  
C1	  VRQ	  FIBRILS	   1μM	   24	   9	   100.8	   1.33	  
	  
1μM	   48	   9	   96.5	   5.19	  
	  
1μM	   72	   6	   75	   8.58	  
	  
2μM	   24	   9	   101.9	   0.49	  
	  
2μM	   48	   9	   94.7	   3.13	  
	  
2μM	   72	   6	   91.5	   7.18	  
α	  C1	  ARR	   1μM	   24	   6	   100.9	   0.9	  
	  
1μM	   48	   9	   96.5	   4.3	  
	  
1μM	   72	   6	   83.8	   7.77	  
	  
2μM	   24	   6	   97.3	   1.9	  
	  
2μM	   48	   8	   93	   3.86	  
	  
2μM	   72	   6	   80.1	   7.71	  
α	  C1	  VRQ	   1μM	   24	   6	   101.33	   0.57	  
	  
1μM	   48	   9	   91.1	   6.92	  
	  
1μM	   72	   6	   79.8	   11.37	  
	  
2μM	   24	   6	   98.8	   0.46	  
	  
2μM	   48	   9	   80.4	   8.41	  
	  
2μM	   72	   6	   69.2	   13.28	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6.4.3	  The	  effect	  of	  C1	  on	  fibrillisation	  of	  full-­‐length	  PrP	  
All	   sheep	   tested	   during	   the	   preparation	   of	   this	   thesis	   have	   measureable	   levels	   of	   C1	  
protein	  present	  in	  their	  brains.	  Depending	  on	  their	  PRNP	  genotype,	  ovine	  cells	  will	  contain	  
a	   mixture	   of	   full	   length	   PrPC	   molecules	   and	   C1	   fragments	   with	   identical	   or	   different	  
protein	   sequences	   at	   varying	   ratios.	   To	   partially	   mimic	   this	   in	   vivo	   scenario,	   mixed	  
fibrillisation	   assays	   were	   performed	   as	   described	   for	   single	   variants	   alone	   (Chapter	   5)	  
with	  both	  truncated	  and	  full	  length	  recombinant	  proteins	  at	  two	  ratios	  (1:1,	  equivalent	  to	  
50	   %	   C1	   and	   4:1,	   equivalent	   to	   20	   %	   C1),	   representative	   of	   ratios	   found	   in	   vivo.	  
Fibrillisation	   reactions	  were	   repeated	  multiple	   times	   (n)	   and	   typical	   results	   for	   selected	  
reaction	  mixtures	  are	  show	  in	  Figure	  6.9.	  PrPVRQ	  was	  mixed	  at	  a	  1:1	  ratio	  with	  C1ARR	  (n	  =	  
10),	   C1ARQ	  (n	   =	   6)	   or	   C1VRQ	  (n	   =	   10).	   The	   lag	   time	   of	   fibrillisation	   was	   measured	   as	   an	  
indicator	  of	  the	  delay	  in	  nucleation	  along	  with	  the	  growth	  rate	  of	  fibrillisation,	  measured	  
by	   the	   rate	   constant	   of	   the	   elongation	  phase	   (k).	   There	  was	  no	   significant	   change	   in	   lag	  
time	  with	   addition	  of	   C1ARQ	   (5.46	  hours,	   SEM	  ±	  0.67)	   or	  C1VRQ	   (5.13	  hours,	   SEM	  ±	  0.50)	  
compared	   to	   PrPVRQ	   alone	   (Figure	   6.10).	   However,	   C1ARR	   addition	   at	   1:1	   significantly	  
increased	   the	   lag	   time	   of	   fibrillisation	   of	   PrPVRQ	   from	   5.57	   hours	   (SEM	   	   ±	   0.48)	   to	   10.6	  
hours	  (SEM	  	  ±	  1.12)	  (p	  	  =	  5.2	  x	  10-­‐5).	  As	  observed	  with	  fibrillisation	  of	  C1ARR	  alone,	  80	  %	  of	  
the	   mixed	   assays	   did	   not	   result	   in	   full	   fibrillisation	   within	   the	   time	   frame	   of	   the	  
experiment	   and	   therefore	   lag	   times	   could	   not	   be	   calculated	   in	   these	   cases.	   When	   full	  
fibrillisation	  was	   achieved	   reactions	   had	   around	   an	   80	  %	   lower	  maximum	   fluorescence	  
and	  there	  was	  a	  trend	  for	  the	  elongation	  phase	  of	  fibrillisation	  to	  be	  slower	  	  (k	  =	  1.29,	  SEM	  
±	   0.38)	   compared	   to	   PrPVRQ	   alone	   (1.91,	   SEM	   ±	   0.24)	   (Table	   6.3).	   The	   growth	   rate	   is	  
measured	  by	   the	  rate	  constant	  (k)	  and	   is	   independent	  of	  maximum	  fluorescence	  and	   lag	  
time	  of	  fibrillisation	  (Graham,	  Agarwal	  et	  al.	  2010).	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Figure	   6.9	   –	   Fibrillisation	   kinetics	   of	   PrP	   and	   C1	   mixed	   reactions.	   Fibrillisation	   was	  
performed	   as	   described	   in	   sections	   5.3.13	   and	   	   6.3.1.	   Typical	   fibrillisation	   curves	   for	   PrP	  
variants.	  Background	  ThT	  fluorescence	  from	  no	  PrP	  controls	  subtracted	  from	  raw	  data.	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Reactions	  at	  a	  4:1	  PrPVRQ:	  C1ARR	  ratio	  were	  also	  performed	  (n	  =	  7),	  in	  in	  which	  lag	  times	  for	  
fibrillisation	  of	  PrPVRQ	  were	   increased	   to	   an	   average	  of	   6.6	  hours	   (SEM	  ±	  1.36).	   In	   these	  
reactions,	   fibrillisation	   of	   PrPVRQ	  was	   inhibited	   to	   less	   of	   an	   extent	   compared	   to	   the	   1:1	  
reactions.	  Maximum	  fluorescence	  was	  again	  lower	  than	  seen	  with	  full	  length	  protein	  alone,	  




	   	  
Figure	   6.10	   –	   Average	   lag	   times	   for	   mixed	   fibrillisation	   reactions.	   The	   lag	   time	   of	  
fibrillisation	   was	   measured	   for	   each	   well	   repeat	   in	   which	   fibrillisation	   was	   complete	  
within	  the	  time	  frame	  of	  the	  experiment	  and	  an	  average	  was	  calculated.	  A)	  Average	  lag	  
time	  of	  fibrillisation	  for	  PrPARR	   reactions	  with	  C1	  variants	  along	  with	  the	  percentage	  of	  
reactions	  completing	  fibrillisation	  within	  the	  time	  frame	  of	  the	  experiment.	  B)	  Average	  
lag	   time	   of	   fibrillisation	   for	   PrPVRQ	   reactions	   along	   with	   the	   percentage	   of	   reactions	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Mixed	   reactions	  with	   PrPARR	   and	   all	   three	   variants	   of	   C1	   at	   a	   1:1	   ratio	  were	   performed.	  
Addition	  of	  C1ARR	  to	  PrPARR	  (n	  =	  10)	   increased	   the	  average	   lag	   time	  only	  marginally	   from	  
8.3	  (SEM	  ±	  0.69)	  to	  9.0	  (SEM	  ±	  0.41)	  (Figure	  6.10).	  However,	  the	  rate	  of	  fibril	  elongation	  
(k)	  was	  significantly	  decreased	  by	  2.6	  times	  from	  1.60	  (SEM	  ±	  0.22)	  to	  0.45	  (SEM	  ±	  0.10)	  p	  
≤	   3.0-­‐5	  (Table	  6.3),	  which	  was	   similar	   to	   the	   rate	   for	  C1ARR	  alone.	   In	   contrast,	   addition	  of	  
C1VRQ	  or	  C1ARQ	  to	  PrPARR	  shortened	  the	  lag	  time	  of	  fibrillisation	  (Figure	  6.10)	  and	  increased	  
the	  rate	  of	  elongation	  (Table	  6.3).	  The	  early	  ThT	  fluorescence	  increase	  may	  represent	  C1	  
fibrillisation	  and	  mask	  the	  slightly	  later	  fibrillisation	  of	  PrPARR	  or	  the	  addition	  of	  these	  C1	  
variants	  may	  increase	  the	  rate	  of	  nucleation	  and	  elongation	  of	  PrPARR.	  Further	  evidence	  to	  
support	  the	  first	  of	   these	  hypotheses	   is	  the	  observation,	   in	  some	  mixed	  reactions,	  of	   two	  
peaks	  of	  fluorescence,	  illustrated	  in	  the	  PrPVRQ	  +	  C1VRQ	  fibrillisation	  curve	  in	  Figure	  6.9.	  In	  
these	  cases,	  curves	  of	  best	  fit	  could	  not	  be	  produced	  and	  lag	  times	  were	  not	  calculated.	  It	  
appears	   that	   C1ARR	   but	   not	   C1ARQ	   or	   C1VRQ	   can	   inhibit	   fibrillisation	   of	   full	   length	   PrPC	  
variants	   by	   either	   extending	   the	   lag	   time	   of	   fibrillisation	   or	   by	   altering	   the	   elongation	  
stage.	  
	  
The	  presence	  of	  fibrils	  in	  these	  mixed	  assays	  was	  confirmed	  using	  the	  maturation	  assay,	  as	  
described	   in	  Chapter	  5	  and	  shown	   in	  Figure	  6.12.	  Resulting	  gels	   showed	  10	  and	  12	  kDa	  
bands	   as	   described	   for	   full	   length	   PrP	   species	   along	   with	   a	   prominent	   16.6	   kDa	   band	  
associated	  with	  C1	  fibrils	  alone	  after	  maturation.	  The	  16	  kDa	  band	  which	  would	  confirm	  
the	  presence	  of	   full	   length	  PrP	  fibrils	   is	  very	  faint	  when	  compared	  to	  maturation	  and	  PK	  
digestion	   of	   full	   length	   PrP	   alone,	   indicating	   that	   full	   length	   PrPC	   may	   have	   formed	   les	  
amyloid	  fibrils,	  indicating	  that	  mixed	  reactions	  may	  favor	  the	  production	  of	  C1	  fibrils.	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Variant	   Mean	  Rate	  
Constant	  of	  
Elongation	  (k)	  
C1ARR	   0.46	  (SEM	  	  ±	  0.09)	  
PRPARR	   1.6	  (SEM	  	  ±	  0.22)	  
PRPARR	  +C1ARR	  1:1	   0.45	  (SEM	  	  ±	  0.10)	  
PRPARR	  +C1ARR	  4:1	   1.04	  (SEM	  	  ±	  0.10)	  
PRPARR	  +C1ARQ	  1:1	   2.28	  (SEM	  	  ±	  0.09)	  
PRPARR	  +C1VRQ	  1:1	   4.53	  (SEM	  	  ±	  0.71)	  
C1VRQ	   5.78	  (SEM	  	  ±	  0.53)	  
PRPVRQ	   1.91	  (SEM	  	  ±	  0.24)	  
PRPVRQ	  +C1VRQ	  1:1	   3.09	  (SEM	  	  ±	  0.39)	  
PRPVRQ	  +C1VRQ	  4:1	   1.71	  (SEM	  	  ±	  0.84)	  
PRPVRQ	  +C1ARR	  1:1	   1.29	  (SEM	  	  ±	  0.38)	  





























Lag	  Time	  (hours)	  
Figure	  6.11	  –	  The	  relationship	  between	  average	  rate	  constant	  and	  average	  lag	  time	  for	  
fibrillisation	   reactions.	   	   Average	   rate	   constant	   plotted	   against	   average	   lag	   time	   of	  
fibrillisation	   for	   recombinant	   PrP,	   C1	   and	  mixed	   reactions	   at	   a	   ratio	  of	   1:1.	  Error	   bars	  
represent	  SEM.	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It	  was	  investigated	  if	  C1ARR	  could	  also	  inhibit	  fibrillisation	  of	  other	  C1	  variants	  as	  observed	  
for	   full	   length	  PrPC	   variants	   (Figure	  6.13).	  Mixed	   reactions	   at	   a	   1:1	   ratio	  were	   set	   up	   as	  
previously	   described.	   Addition	   of	   C1	  ARR	  to	   C1	  ARQ	  significantly	   increased	   the	   lag	   time	   of	  
fibrillisation	  from	  3.96	  hours	  (SEM	  ±	  0.22)	  to	  12.44	  (SEM	  ±	  0.1)	  (p	  ≤	  2.0-­‐10),	  as	  illustrated	  
in	  Figure	  6.10	  and	  significantly	  reduced	  the	  elongation	  rate	  (k)	  from	  4.14	  (SEM	  ±	  0.34)	  to	  
1.18	  (SEM	  ±	  0.16)	  (p	  ≤	  4.0-­‐7).	  Similar	  inhibition	  was	  also	  observed	  in	  mixed	  reactions	  with	  
C1ARR	  and	   C1VRQ,	   where	   lag	   time	   of	   fibrillisation	   was	   significantly	   increased	   from	   	   	   3.98	  
hours	   (SEM	   ±	   0.34)	   to	   8.99	   hours	   (SEM	   ±	   0.89)	   (p	   ≤	   2.0-­‐5)	   in	   mixed	   reactions	   and	  
elongation	  rate	  was	  decreased	  from	  5.12	  (SEM	  ±	  0.69)	  to	  0.82	  (SEM	  ±	  0.12)	  (p	  ≤	  6.0-­‐6).	  In	  
both	  cases	  75	  %	  of	  mixed	  reactions	  failed	  to	  fibrillise	  within	  the	  24	  hour	  time	  frame	  of	  the	  





Figure	  6.12	  –	  Maturation	  and	  PK	  digest	  of	  PrPVRQ	  and	  C1ARR	  mixed	  reaction.	  Maturation	  
and	  PK	  digestion	  was	  performed	  as	  described	  in	  section	  5.3.14.	  0.5	  µg	  of	  recombinant	  
protein	   was	   untreated	   (Lane	   1),	   PK	   treated	   at	   a	   ratio	   100:1	   of	   PrP:	   PK	   (Lane	   2),	   or	  
matured	  by	  heating	  to	  80°C	  followed	  by	  PK	  treatment	  (Lane	  3).	  Matured	  fibrils	  (Lane	  3)	  
show	  increased	  PK	  resistance	  relative	  to	  non-­‐matured	  fibrils.	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   Frequency	  of	  wells	  fibrillising	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  24	  hours	  (%)	  
Figure	   6.13	   –	   Fibrillisation	   kinetics	   for	   C1	   mixed	   fibrillisation	   reactions.	   A)	   Typical	  
fibrillisation	   curves	   for	   C1ARQ	  and	   C1VRQ	  alone	   and	  with	  C1ARR	  at	   a	   1:1	   ratio.	   B)	   The	   lag	  
time	  of	  fibrillisation	  was	  measured	  for	  each	  repeat	   in	  which	  fibrillisation	  was	  complete	  
within	  the	  time	  frame	  of	  the	  experiment	  and	  an	  average	  was	  calculated	  along	  with	  the	  
percentage	   of	   reactions	   completing	   fibrillisation	   within	   the	   time	   frame	   of	   the	  
experiment.	  	  
0	   5	   10	   15	   20	  
C1	  ARQ	  +	  C1	  ARR	  





CHAPTER  6 – A ROLE FOR C1 IN TSE DISEASE? 




















Does	   C1ARR	  have	   the	   ability	   to	   also	   inhibit	   fibrillisation	   of	  murine	   PrPC?	   This	   question	   is	  
important	  as	  the	  cell	  lines	  used	  to	  assess	  fibril	  toxicity	  (N2a	  and	  SMB-­‐PS)	  were	  of	  mouse	  
origin	  and	  other	   in	  vitro	   conversion	   reactions,	   such	  as	   the	   cell	   free	   conversion	  are	  more	  
effective	  using	  murine	  derived	  PrPC.	  Mixed	  reactions	  with	  either	  C1ARR	  or	  C1VRQ	  were	  set	  
up	  at	  ratios	  of	  1:1	  and	  4:1	  with	  murine	  recombinant	  PrP	  (kindly	  provided	  by	  Fiona	  Lane,	  
0	   2	   4	   6	   8	   10	   12	  
WT	  PrP	  mo	  
WT	  PrP	  mo	  +C1ARR	  1:1	  
WT	  PrP	  mo	  +C1ARR	  4:1	  
WT	  PrP	  mo	  +C1VRQ	  1:1	  
Lag	  Time	  (hours)	  
Figure	   6.14	   –	   Fibrillisation	   kinetics	   for	   murine	   PrP	   with	   ovine	   recombinant	   C1.	   A)	  
Typical	  fibrillisation	  curves	  for	  wild	  type	  murine	  recombinant	  PrP,	  with	  C1ARR	  at	  both	  1:1	  
and	  4:1	  ratios.	  B)	  The	   lag	   time	  of	  fibrillisation	  was	  measured	   for	  each	   repeat	   in	  which	  
fibrillisation	  was	  complete	  within	  the	  time	  frame	  of	  the	  experiment	  and	  an	  average	  was	  
calculated	   along	  with	   the	   percentage	   of	   reactions	   completing	   fibrillisation	   within	   the	  
time	  frame	  of	  the	  experiment.	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The	   Roslin	   Institute).	   Figure	   6.14	   shows	   typical	   fibrillisation	   curves	   for	   these	   reactions	  
along	  with	   the	   average	   lag	   times	   of	   fibrillisation.	  Murine	   PrPC	   alone	   has	   an	   average	   lag	  
time	  of	  4.57	  hours	  (SEM	  ±	  0.52),	  however	  on	  addition	  of	  C1ARR	  at	  a	  1:1	  ratio	  the	  lag	  time	  
was	   significantly	   increased	   to	   9.96	   hours	   (SEM	   ±	   1.25)	   (p	   ≤	   0.003).	   There	   was	   no	  
significant	  difference	   to	   lag	   times	  when	  C1ARR	  was	  added	  at	   a	  4:1	   ratio	  or	  on	  addition	  of	  
C1VRQ	  at	  a	  1:1	  ratio	  the	  rate	  of	  elongation	  (k)	  did	  not	  significantly	  differ	  in	  any	  of	  the	  mixed	  




Inhibition	  of	  lag	  phase	   Inhibition	  of	  growth	  
phase	  
Reduction	  in	  maximum	  
fluorescence	  
PrPARR	   ✗	   ✓ ✓	  
PrPVRQ	   ✓	   ✗ ✓	  
C1ARQ	   ✓	   ✓ ✓	  
C1VRQ	   ✓	   ✓ ✓	  
Murine	  PrP	   ✓	   ✗ ✓	  
Table	  6.4	  –	  Summary	  of	  inhibition	  of	  mixed	  fibrillisation	  reactions	  at	  a	  ratio	  of	  1:1	  by	  C1ARR.	  
 
6.4.4	  Infection	  of	  Rov9	  cells	  with	  SSBP/1	  scrapie	  isolate	  
To	  allow	  for	  the	  inhibitory	  effects	  of	  recombinant	  C1ARR,	  illustrated	  in	  fibrillisation	  assays	  
to	  be	   further	   investigated	   a	   cell	   culture	  model	   of	   infection	  was	   essential.	   Comparison	  of	  
PrP	  expression	  in	  eight	  different	  cell	  lines	  was	  performed	  to	  determine	  the	  line	  expressing	  
highest	   levels	   of	   PrPC	   protein.	   This	   was	   felt	   to	   be	   advantageous	   as	   high	   levels	   of	   PrPC	  
expression	  have	  been	  linked	  to	  susceptibility	  in	  mouse	  models	  (Bueler,	  Aguzzi	  et	  al.	  1993)	  
and	  the	  VRQ	  allotype	  expressed	  by	  these	  cells	  is	  most	  prone	  to	  conversion	  (Sabuncu,	  Petit	  
et	   al.	   2003).	   These	   cells	   have	   also	   been	   successfully	   infected	   with	   scrapie	   on	   several	  
occasions	  (Sabuncu,	  Petit	  et	  al.	  2003,	  Neale,	  Mountjoy	  et	  al.	  2010).	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PrPC	  expression	  was	  quantified	  in	  the	  N2a	  neuroblastoma	  cell	   line	  by	  western	  blotting	  of	  
cell	  lysate	  along	  with	  dilutions	  of	  recombinant	  murine	  wild	  type	  (kindly	  provided	  by	  Fiona	  
Lane,	   The	   Roslin	   Institute).	   Densitometry	   was	   performed	   and	   PrPC	   expression	   was	  
quantified	   in	   N2a	   cells	   using	   a	   recombinant	   protein	   standard	   curve.	   Assuming	   that	   the	  
affinity	   of	   BC6	   was	   similar	   for	   recombinant	   and	   cellular	   murine	   PrPC	   protein	   it	   was	  
estimated	  from	  three	  dilutions	  that	  N2a	  cells	  express	  6.5	  ng	  of	  PrP	  for	  every	  1	  μg	  of	  total	  
protein	   in	   cell	   lysate.	   Cell	   lysates	   from	   other	   cell	   lines	   (gtARQ	   derived,	   Tg338	   derived,	  
SMB-­‐PS,	  Rov9,	  CHOARR,	  CHOARQ	  and	  CHOVRQ)	  were	  then	  subjected	  to	  western	  blotting	  (100	  
μg/	   lane),	   probed	   with	   BC6	   antibody	   along	   with	   alpha	   tubulin	   loading	   control	   and	  
subjected	   to	   densitometry.	   PrPC	   expression	   levels	   relative	   to	   N2a	   cell	   expression	   were	  
used	  to	  calculate	  the	  actual	  quantity	  of	  PrPC	  expressed	  per	  μg	  of	  total	  protein	  (Figure	  6.15).	  
Cell	   lysates	   were	   created	   on	   two	   separate	   occasions	   and	   average	   expression	   of	   PrPC	  
relative	  to	  N2a	  cells	  was	  calculated	  as	  an	  average	  of	  the	  two	  experiments.	  Graphed	  values	  
represent	  the	  average	  calculated	  PrPC	  expression	  for	  each	  cell	  line.	  Rov9	  cells	  express	  the	  
most	  PrP/	  μg	  of	   total	  protein,	  31.2	  ng/μg	  (SEM	  ±	  1.3),	   followed	  by	  CHOVRQ	  at	  22.2	  ng/μg	  
(SEM	  ≠	  0)	   and	  Tg338	  derived	  primary	  neurons	  expressing	  18.9	  ng/μg	   (SEM	  ±	  1.9).	  N2a	  
and	   SMB-­‐PS	   express	   the	   lowest	   levels	   of	   PrP	  per	   μg	   of	   total	   protein	   and	   levels	   are	   very	  
similar	   between	   the	   two	   cells	   lines,	   an	   observation	   also	   reported	   by	   Mays	   et	   al	   (Mays,	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Sterile	   brain	   homogenate	   from	   a	   VRQ/VRQ	   genotype	   SSBP/1	   infected	   sheep	   (final	  
concentration	  of	  2.5	  %	  w/v)	  was	  added	  to	  Rov9	  cells	  48	  hours	  post	  Doxycycline	  induction	  
of	  PrPC	  expression.	  The	  cells	  were	  continually	  passaged	  1:4	  and	  lysed	  at	  2	  (passage	  1),	  5	  
(passage	  2),	  11	  (passage	  3)	  and	  14	  (passage	  4)	  days	  post	   infection.	  To	  confirm	  infection,	  
30	  μg	  of	  cell	  lysate	  was	  treated	  with	  PK	  at	  concentration	  of	  50	  μg/ml	  (Protein:	  PK	  ratio	  of	  
25:1).	  Control	  cells	  show	  no	  PK	  resistant	  protein	  both	  at	  Day	  2	  and	  Day	  14	  (Figure	  6.16).	  
In	  contrast,	  cells	  exposed	  to	  SSBP/1	  homogenate	  had	  bands	  of	  PK	  resistant	  PrPSc	  at	  all	  time	  
points.	   The	   banding	   pattern	   produced	   after	   treatment	   with	   PK	   in	   Rov9	   cells	   is	   slightly	  
different	   to	   that	   characteristically	   observed	   in	   the	   scrapie	   infected	   brain	   with	   the	  
molecular	  weight	  shift	  seen	  primarily	   in	  the	  di-­‐glycosylated	  high	  molecular	  weight	  band.	  
Similar	  band	  patterns	  in	  infected	  Rov9	  cells	  have	  been	  reported	  by	  Vilette	  and	  colleagues	  
(Vilette,	   Andreoletti	   et	   al.	   2001)	   who	   also	   show	   that	   the	   PrPSc	   produced	   by	   Rov9	   cells	  
appears	   to	   be	   a	   lower	  molecular	  weight	  when	   compared	   to	   PrPSc	   from	   scrapie	   infected	  
brain	   homogenate.	   At	   day	   14	   it	   is	   unlikely	   that	   the	   PK	   resistant	   PrPSc	   visible	   is	   residual	  
Figure	  6.15	   –	  Quantification	  of	   PrP	  expression	   in	  cell	   lines	   by	  western	  blotting.	  100μg	  of	  
cell	   lysate	  was	  tested	  by	  western	  blot	  with	  BC6	  and	  anti-­‐alpha	  tubulin	  as	  a	   loading	  control.	  
Densitometry	   was	   performed	   and	   loading	   was	   normalised	   against	   alpha	   tubulin.	   PrP	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infected	  brain	  homogenate	  as	  homogenate	  will	  have	  been	  diluted	  to	  1/64	  of	   the	  original	  







6.4.5	  The	  effect	  of	  C1	  on	  scrapie	  infection	  in	  cell	  culture	  
Following	   confirmation	   that	   in	   our	   hands	   Rov9	   cells	   can	  maintain	   scrapie	   infection	   and	  
produce	  PrPSc	   in	  culture	  it	  was	  explored	  if	  C1ARR	  could	  alter	  or	  inhibit	  PrPSc	  accumulation	  
when	   applied	   exogenously.	   This	   was	   performed	   as	   a	   small-­‐scale	   pilot	   experiment	   to	  
highlight	  a	  potential	  area	  for	  future	  study.	  It	  was	  unknown	  if	  recombinant	  C1ARR	  would	  be	  
up	  taken	  up	  by	  the	  cell	  or	  would	  be	  quickly	  degraded	  in	  the	  cell	  culture	  media.	  Therefore,	  
recombinant	  C1	  was	   added	   to	  Rov9	   cells	   at	  5	  μg/well	   and	   incubated	   for	  24	  hours.	  Both	  
media	   and	   cell	   lysate	   were	   collected,	   acetone	   precipitated	   and	   immunoblotted	   with	   an	  
anti-­‐His-­‐Tag	  monoclonal	  antibody.	  A	  small	  amount	  of	  recombinant	  C1	  seems	  to	  have	  been	  



































Figure	   6.16	   –	   PrPSc	  accumulation	   in	   SSBP/1	   infected	  Rov9	   cells.	  A)	  30µg	  of	  cell	   lysate	  was	  
treated	   with	   or	   without	   PK	   (50µg/ml)	   for	   1.5	   hours	   at	   37	   °C.	   Protein	   was	   acetone	  
precipitated	  and	  separated	  on	  a	  12%	  NuPAGE	  Bis-­‐Tris	  gel	  and	  immunoblotted	  with	  anti-­‐PrP	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Recombinant	   C1ARR	  	   (5µg/well)	  was	   added	   to	   Rov9	   cells	   24	   hours	   before	   infection	  with	  
SSBP/1	  infected	  homogenate	  (n	  =4),	  mixed	  with	  the	  infected	  homogenate	  (n	  =	  4)	  or	  added	  
at	   24	   hours	   post	   infection	   (n	   =	   4).	   The	   wells	   treated	   with	   C1ARR	   post	   infection	   were	  
continually	   treated	   at	   every	   subsequent	   passage.	   Positive	   control	   wells	   without	  
recombinant	  C1	  but	  with	  homogenate	  (n	  =	  4)	  and	  negative	  control	  wells	  with	  media	  only	  
(n	  =	  4)	  were	  also	  included.	  At	  day	  2	  post	  infection	  2	  wells	  from	  each	  were	  passaged	  (1:4).	  
Cell	  lysate	  was	  collected	  from	  the	  remaining	  2	  wells	  and	  pooled.	  This	  was	  repeated	  at	  day	  
5,	   day	   11	   and	   day	   14.	   The	   total	   protein	   concentration	   of	   cell	   lysates	  were	  measured	   by	  
BCA	   assay,	   normalised	   and	   treated	   with	   PK	   (50µg/ml).	   To	   allow	   for	   densitometric	  
comparison	   of	   PrPSc	   levels	   a	   dot	   blotting	   method	   was	   adopted	   as	   described	   in	   section	  
6.3.11.	  	  
	  
Dot	   blotting	  was	   carried	   out	  with	  PK	   treated	   samples	   (2.5μg),	  with	   two	   repeats	   of	   each	  
sample	  included	  (Figure	  6.18).	  In	  control	  wells	  there	  was	  no	  evidence	  of	  PK	  resistant	  PrPSc	  
at	  any	  time	  point.	  At	  day	  2	  all	  samples	  treated	  with	  infected	  homogenate	  have	  evidence	  of	  
PK	  resistant	  PrPSc,	  which	  is	  most	  likely	  residual	  PrPSc	  from	  the	  homogenate.	  By	  the	  second	  
passage	  (day	  5)	  levels	  of	  PK	  resistant	  PrPSc	  are	  reduced,	  corresponding	  with	  the	  removal	  







	  	  	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  
	   Figure	   6.17	   –	   The	   fate	   of	   recombinant	   C1
ARR	   in	  
cell	   media	   after	   24	   hours.	   5µg	   of	   recombinant	  
C1ARR	  was	  added/well	  of	  Rov9	  cells	  and	  incubated	  
for	  24	  hours.	  Lysate	  and	  media	  were	  collected	  and	  
analysed	   by	   immunoblotting	   with	   Anti-­‐His-­‐Tag	  
antibody.	  Lane	  1	  (media),	  Lane	  2(Cell	  lysate).	  
CHAPTER  6 – A ROLE FOR C1 IN TSE DISEASE? 
	   186	  
and	   in	   the	   wells	   that	   had	   been	   treated	   with	   C1ARR	   prior	   to	   infection	   PrPSc	   levels	   are	  
increased	   at	   day	   11	   and	   14	   indicating	   these	   cells	   are	   now	   producing	   misfolded	   PrPSc	  
independent	  of	  the	  initial	  homogenate.	  	  Wells	  that	  had	  been	  treated	  with	  C1ARR	  at	  the	  time	  
of	   infection	   and	   post	   infection	   with	   continued	   application	   with	   every	   passage	   show	   no	  















6.5.1	  C1	  fibril	  preparations	  have	  reduced	  toxicity	  to	  SMB-­‐PS	  cells	  in	  culture	  compared	  
to	  PrPC	  fibril	  preparations	  
It	   is	   unknown	   at	   present	   the	   precise	   form	   of	   misfolded	   PrPC	   responsible	   for	   causing	  
cellular	   toxicity	   during	   disease.	   It	   has	   been	   shown	   that	   oligomers	   and	   pre-­‐fibrillar	  
aggregates	   cause	   neurotoxicity	   to	   cells	   in	   culture	   (Sanghera,	  Wall	   et	   al.	   2008)	   and	   that	  



















Figure	  6.18	  –	  PK	  resistant	  PrPSc	  in	  SSBP/1	  infected	  Rov9	  cells	  in	  the	  presence	  of	  C1ARR.	  
Rov9	   cell	   lysates	   (2.5	  μg)	  were	   treated	  with	   PK	   (50µg/ml),	   subjected	   to	   dot	   blotting	  
and	  probed	  with	  P4	  monoclonal	  antibody	  as	  described	  in	  section	  6.3.11.	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indicating	   that	   perhaps	   it	   is	   a	   smaller	   oligomer	   or	   intermediate	   aggregates	   that	   have	   a	  
prevailing	  toxic	  effect.	  However,	  full-­‐length	  PrP	  fibrils	  are	  also	  toxic	  to	  primary	  neurons	  in	  
culture	   (Novitskaya,	   Bocharova	   et	   al.	   2006).	   In	   previous	   chapters	   we	   have	   shown	   that	  
recombinant	  PrP	  fragments	  equivalent	  to	  naturally	  occurring	  truncated	  PrPC	  proteins	  can	  
form	  amyloid	  fibrils	   in	  vitro	  and	  that	  these	  truncated	  variants	  have	  different	  populations	  
of	   fibrils	   and	   smaller	   aggregates	  when	   compared	   to	   full	   length	   PrPC	   fibril	   preparations.	  
Although	   it	   is	   unknown	   if	   these	   truncated	   proteins	   have	   the	   potential	   to	   misfold	   and	  
aggregate	  in	  vivo	  the	  toxicity	  of	  C1	  fibril	  preparations	  was	  tested	  in	  two	  cell	  culture	  models	  
with	  variable	  results.	  	  
	  
In	  SMB-­‐PS	  cells	  full	  length	  fibrils	  of	  both	  PrPARR	  and	  PrPVRQ	  caused	  a	  significant	  reduction	  in	  
cell	  viability,	  positively	  correlated	  with	  both	  concentration	  and	  incubation	  time	  while	  no	  
reduction	  was	  seen	  with	  either	  of	  the	  C1	  fibril	  preparations.	  Potentially,	  this	  variation	  may	  
be	  attributed	  to	  a	  lower	  number	  of	  toxic	  fibrils	  or	  misfolded	  aggregates	  present	  in	  the	  C1	  
preparations,	  as	  suggested	  by	  the	  data	  collected	  from	  Dynamic	  Light	  Scattering	  (DLS).	  Full	  
length	  variants	  appear	   to	   form	  different	  populations	  of	  smaller	  protein	  aggregates	  when	  
compared	   to	   truncated	   C1,	   perhaps	   with	   the	   higher	   propensity	   to	   form	   stable	   toxic	  
oligomers	  or	  intermediates.	  DLS	  also	  revealed	  that	  polymorphisms	  in	  the	  PrPC	  protein	  had	  
little	  effect	  on	  the	  size	  of	  fibrils	  or	  aggregates	  that	  were	  produced.	  If	  the	  size	  and	  number	  
of	   smaller	   aggregates	   are	   linked	   to	   toxicity	   then	   this	   observation	   correlates	   with	   the	  
similar	  levels	  of	  toxicity	  seen	  on	  addition	  of	  PrPARR	  and	  PrPVRQ	  to	  cell	  culture.	  	  However,	  it	  
has	   also	  been	   suggested	   that	   aggregate	  and	  oligomer	   size	   is	   not	   accountable	   for	   toxicity	  
which	   is	   instead	   determined	   by	   the	   conformation	   and	   folding	   of	   the	   individual	   protein	  
fragments	   (Lee,	   Savtchenko	   et	   al.	   2011).	   It	   may	   be	   a	   combination	   of	   both	   variable	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aggregate	   size	   and	   formation	   of	   different	   small	   intermediate	   oligomers	   and	   aggregates	  
that	  contributes	  to	  the	  variable	  toxicity	  of	  full	  length	  PrP	  and	  C1	  fibril	  preparations.	  	  
	  
At	   the	  highest	  concentration	  of	  α-­‐helical	  C1VRQ	  	  (5µM)	  tested	  cell	  viability	  was	  reduced	  to	  
an	  average	  of	  77.4	  %	  of	  buffer	  only	  control	  wells.	  C1VRQ	  related	  cell	  death	  might	  occur	  in	  a	  
p53	  dependent	  manner	  as	  over-­‐expression	  of	  murine	  C1	  in	  a	  cell	  culture	  has	  been	  shown	  
to	  modulate	   and	   increase	   sensitivity	   to	   p53	  dependent	   apoptosis	   through	   the	   caspase	  3	  
pathway	   (Sunyach,	   Cisse	   et	   al.	   2007).	   Whether	   these	   pathways	   are	   indeed	   activated	   in	  
SMB-­‐PS	  cells	  remains	  to	  be	   investigated,	   for	  example	  by	  monitoring	  caspase	  3	  activity	   in	  
cells	  and	  through	  pharmacologically	  blocking	  of	  the	  p53	  pathway	  in	  cells	  which	  have	  been	  
incubated	  with	  α-­‐helical	  C1VRQ.	  Equally	  important	  would	  be	  to	  test	  the	  toxicity	  of	  C1ARQ	  as	  a	  
PrP	  with	  different	   sequence	   could	   clarify	  whether	   this	   effect	   is	  VRQ	   specific	   or	  whether	  
the	  absence	  of	  toxicity	  from	  ARR	  is	  unique.	  
	  
6.5.2	  Fibril	  toxicity	  is	  cell	  line	  dependent	  
There	  was	  no	  such	  protein	  specific	  fibril	  toxicity	  in	  the	  N2a	  cell	  line	  at	  the	  concentrations	  
used	   in	   this	   study	   and	   high	   proportions	   of	   dead	   cells	  were	   observed	   in	   the	   buffer	   only	  
control	  wells	   compared	   to	   that	   seen	   in	   the	  SMB-­‐PS	   line.	  This	   is	   indicative	   that	  N2a	  cells	  
may	  be	  more	  susceptible	   to	   the	  addition	  of	   sodium	  acetate	  buffer.	   In	  our	  hands	   the	  N2a	  
cell	  line	  naturally	  had	  a	  faster	  cell	  cycle	  when	  compared	  to	  SMB-­‐PS	  and	  perhaps	  increased	  
in	   cell	   death	   in	   control	  wells	   can	  be	   attributed	   to	   dense	   culture	   conditions.	  At	   72	  hours	  
incubation	  addition	  of	  all	  fibril	  variant	  preparations	  and	  α-­‐helical	  recombinant	  protein	  led	  
to	   decreased	   cell	   viability	   as	   a	   percentage	   of	   control	  wells.	   This	   indicates	   that	   PrP	   fibril	  
preparations	  are	  toxic	  to	  N2a	  cells	  and	  that	  unlike	  that	  seen	  with	  SMB-­‐PS	  cells	  C1	  fibrils	  
are	  equally	  toxic	  to	  N2a	  cells.	  Furthermore,	  a	  reduction	  in	  cell	  viability	  is	  seen	  with	  both	  α-­‐
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helical	  C1ARR	  and	  C1VRQ	  proteins,	  in	  contrast	  to	  C1VRQ	  only	  in	  the	  case	  of	  SMB-­‐PS	  cells.	  The	  
mechanisms	  of	  toxicity	  caused	  by	  either	  α-­‐helical	  C1	  and	  fibril	  preparations	  may	  differ.	  If	  
we	   surmise	   that	   after	  72	  hours	  of	   culture	  N2a	   cells,	   as	   a	   result	   of	   their	   faster	   cell	   cycle,	  
become	   stressed	   these	   cells	   will	   be	   more	   sensitive	   to	   p53	   mediated	   apoptosis	   due	   to	  
overcrowding	   and	   lack	   of	   available	   nutrients.	   As	   C1	   expression	   in	   cell	   culture	   has	   been	  
shown	   to	   enhance	   p53	   transcription	   and	   activation	   this	   could	   explain	   why	   these	   cells	  
display	  reduced	  viability	  and	  higher	  sensitivity	  to	  α-­‐helical	  C1	  (Sunyach,	  Cisse	  et	  al.	  2007).	  
	  
Varying	   susceptibility	   of	   cell	   lines	   to	   fibril	   related	   toxicity	   couldn’t	   be	   explained	   by	  
differences	  in	  PrPC	  expression	  as	  SMB-­‐PS	  and	  N2a	  cell	  lines	  both	  expressed	  similar	  levels	  
of	   total	   PrPC.	   However,	   these	   cell	   lines	   do	   have	   different	   levels	   of	  α-­‐cleavage,	   with	   less	  
residual	   C1	   in	   N2a	   cell	   compared	   to	   SMB	   cells.	   It	   is	   possible	   that	   reduced	   levels	   of	   α-­‐
cleavage	  in	  the	  N2a	  cell	   line	  make	  it	  more	  susceptible	  to	  C1	  fibril	   toxicity.	  Cell	   lines	  with	  
low	   residual	   levels	   of	   α-­‐cleavage	   have	   previously	   been	   associated	   with	   cellular	  
susceptibility	   to	   scrapie	   infection	   (Lewis,	   Hill	   et	   al.	   2009).	   Furthermore,	   as	   total	   PrPC	  
expression	  is	  comparable	  in	  both	  cell	  lines	  different	  levels	  of	  α-­‐cleavage	  would	  impact	  on	  
the	  amount	  of	  residual	  cell	  associated	  full	  length	  PrPC.	  	  
	  
6.5.3	  Truncated	  C1ARR	  recombinant	  proteins	  can	  alter	  fibrillisation	  of	  full	  length	  PrPC	  
The	  aim	  of	  this	  chapter	  was	  to	  understand	  the	  role	  of	  C1	  in	  prion	  disease	  and	  explore	  the	  
possible	   dominant	   negative	   inhibitory	   effects	   described	   by	   Westergard	   and	   colleagues	  
(Westergard,	   Turnbaugh	   et	   al.	   2011)	   on	   overexpression	   of	   murine	   C1	   in	   vivo.	   To	  
demonstrate	   if	   these	   inhibitory	   effects	   associated	  with	   C1	   are	   likely	   to	   occur	   in	   normal	  
ovine	   brain	   fibrillisation	   reactions	  were	   performed	   at	   relative	   ratios	   of	   recombinant	   full	  
length	  PrP	  and	  C1	  to	  represent	  a	  situation	  similar	  to	  PRNP	  homozygous	  and	  heterozygous	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brain	  tissue.	  When	  mixed	  with	  other	  protein	  variants	  at	  a	  ratio	  of	  1:1,	  C1ARR	  inhibited	  fibril	  
formation	   of	   both	   PrP	   variants	  whilst	   C1ARQ	  and	  C1VRQ	  did	   not.	   In	   fibrillisation	   reactions	  
with	  a	  PrPC:	  C1	  ratio	  of	  4:1,	  inhibition	  was	  reduced	  suggesting	  that	  the	  PrP:	  C1	  ratio	  could	  
be	  an	   important	   factor	   if	  similar	   inhibitory	  mechanisms	  apply	   in	  vivo	  in	  brain	  during	  the	  
formation	   of	   disease	   associated	   amyloid	   fibrils.	   In	   the	   case	   of	   ovine	   C1	   it	   appears	   that	  
PRNP	  sequence	   is	  an	   important	   factor	   in	   the	   inhibition	  of	   fibril	   formation.	  However,	   it	   is	  
unclear	  if	  PRNP	  sequence	  is	  also	  important	  for	  inhibition	  of	  conversion	  during	  disease	  as	  
mouse	  wild	  type	  C1,	  which	  is	  different	  from	  sheep	  C1ARQ	  by	  only	  nine	  amino	  acid	  changes	  -­‐	  
has	  a	  delaying	  effect	  on	  development	  of	  TSE	  disease	  in	  vivo	  (Westergard,	  Turnbaugh	  et	  al.	  
2011).	  Perhaps,	  if	  the	  amount	  of	  C1ARQ	  and	  C1VRQ	  in	  fibrillisation	  reactions	  were	  increased	  
to	   that	   relative	   to	   the	   ratios	   observed	   in	   overexpressing	  murine	  models	   then	   C1	  would	  
have	  the	  same	  inhibitory	  effects	  on	  fibrillisation	  as	  reported	  on	  conversion.	  It	  also	  remains	  
to	   be	   established	   whether	   this	   variation	   in	   inhibition	   between	   murine	   and	   ovine	   C1	  
indicates	   that	   the	   inhibition	   mechanism	   for	   seeded	   and	   un-­‐seeded	   nucleation	   or	  
elongation	  is	  different	  or	  that	  the	  effects	  of	  C1	  on	  prion	  replication	  are	  amplified	  in	  an	  in	  
vivo	  situation.	  	  	  
	  
The	  dominant	  negative	  inhibitory	  effect	  in	  fibrillisation	  of	  C1ARR	  is	  not	  specific	  to	  ovine	  full-­‐
length	  PrPC,	  but	  crosses	   the	  species	  barrier	   to	  also	  delay	   fibril	   formation	  of	  recombinant	  
mouse	   PrPC.	   Following	   these	   results	   and	   considering	   the	   large	   number	   of	   other	   known	  
polymorphisms	  in	  PrPC	  it	  would	  be	  of	  further	  interest	  to	  produce	  recombinant	  C1	  proteins	  
to	   test	   for	   inhibitory	   characteristics,	   particularly	   with	   other	   species	   specific	   resistance	  
associated	  polymorphisms	   such	  as	  human	  M129V.	  For	   example,	   addition	  of	  different	  C1	  
variants	  into	  reactions	  with	  recombinant	  full	  length	  PrP	  expressing	  129M	  has	  been	  shown	  
previously	  to	  readily	  form	  amyloid	  fibrils	  in	  vitro	  (Lewis,	  Tattum	  et	  al.	  2006).	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6.5.4	  Potential	  mechanisms	  of	  fibril	  inhibition	  
C1	   can	   directly	   inhibit	   the	   formation	   of	   PrP	   amyloid	   fibrils	   in	   the	   absence	   of	   PrPSc.	   Our	  
findings	   suggest	   that	   C1ARR	   can	   either	   inhibit	   the	   initial	   nucleation	   of	   amyloid	   fibrils	   or	  
slow	  the	  elongation	  phase	  of	   fibrillisation	  when	  mixed	  with	   full	   length	  PrPC,	  while	  when	  
mixed	  with	  other	  variants	  of	  C1	  it	  appears	  to	  inhibit	  both	  stages	  of	  fibrillisation.	  Therefore	  
we	  believe	  that	   there	  may	  be	  two	  mechanisms	  explaining	  this	   inhibition	  as	   illustrated	   in	  
Figure	  6.19.	  The	  C1	  protein	  may	  bind	   to	  PrPC	  and	  prevent	   further	   interaction	  with	  other	  
recombinant	   PrPC	   proteins	   thereby	   inhibiting	   the	   formation	   of	   an	   initiating	   nucleus.	  
Alternatively,	  the	  C1	  protein	  may	  become	  incorporated	  into	  amyloid	  fibrils	  of	  PrPC,	  which	  
would	   interfere	   with	   subsequent	   elongation	   of	   the	   fibrils,	   perhaps	   by	   inducing	   the	  
formation	   of	   disordered	   aggregates.	   Knowles	   and	   colleagues	   (Knowles,	   Waudby	   et	   al.	  
2009)	   state	   that	   once	   in	   the	   elongation	   stage	   fibrils	   fragment	   and	   re-­‐nucleate.	  A	   further	  
possible	  mechanism	  leading	  to	  a	  slower	  growth	  rate	  in	  mixed	  C1ARR	  reactions	  would	  be	  the	  
reduced	   potential	   of	   C1ARR	  containing	   fibrils	   to	   fragment.	   It	   appears	   that	   both	   putative	  
mechanisms	   may	   occur	   independently	   and/or	   simultaneously.	   C1ARR	   clearly	   inhibits	  
fibrillisation	   of	   all	   variants	   with	   exception	   of	   full	   length	   PrPARR	   via	   binding	   prior	   to	  
nucleation,	  extending	  the	  lag	  time	  of	  fibrillisation.	  As	  PrPARR	  has	  an	  already	  longer	  relative	  
lag	  time	  and	  hence	  a	  slower	  propensity	  to	  nucleate	  C1	  interactions	  prior	  to	  nucleation	  may	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6.5.5	  A	  cell	  culture	  model	  of	  C1	  related	  inhibition	  of	  conversion	  
Although	  only	   a	   small	   pilot	   study	   this	   experiment	   aimed	   to	   address	   the	   effects	   of	  C1	  on	  
conversion	  in	  a	  physiological	  system.	  The	  major	  challenge	  was	  to	  find	  a	  suitable	  method	  to	  
compare	  PrPSc	  accumulation	  in	  a	   large	  number	  of	   independent	  cultures.	  Western	  blotting	  
and	  dot	  blotting	  were	  adopted	  as	   these	   techniques	  required	   little	  optimisation	  and	  have	  
been	  well	  characterised	  for	  visualising	  infected	  brain	  homogenate.	  On	  reflection	  perhaps	  a	  
different	  assay	  would	  have	  given	  more	  consistent	  results,	  such	  as	   the	  cell	  blotting	  assay,	  
described	  by	  Bosque	  and	  Prusiner	   (Bosque	  and	  Prusiner	  2000).	  A	   further	  problem	  with	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Figure	   6.19	   – Theoretical	   models	   of	   C1ARR	   associated	   inhibition	   of	   in-­‐vitro	  
fibrillisation.	   Diagrammatic	   representation	   of	   possible	   mechanisms	   of	   inhibition,	  
through	   either	   direct	   binding	   to	   PrPC	   prior	   to	   misfolding	   or	   through	   production	   of	  
homogeneous	  aggregates	  or	  pro-­‐fibrils	  which	  then	  bind.	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always	  guaranteed	  to	  affect	  the	  same	  number	  of	  cells	  in	  each	  culture.	  Of	  the	  cells	  that	  are	  
infected	  PrPSc	  production/accumulation	  may	  not	  be	  equivalent.	  To	  address	  this,	  two	  wells	  
were	  pooled	  at	  each	  passage/lysis	  step.	  
	  
Despite	  these	  limitations	  and	  being	  aware	  of	  the	  small	  number	  of	  experiments	  that	  were	  
performed,	   these	  assays	  did	  show	  variable	  PrPSc	  accumulation,	  with	  some	  dependents	   to	  
addition	  of	  C1.	  It	  was	  hypothesised	  from	  fibrillisation	  experiments	  that	  C1ARR	  would	  bind	  
to	  PrPC	  and	   subsequently	  prevent	  dimerisation	   and	  binding	   to	   incoming	  PrPSc.	  However,	  
addition	  of	  C1ARR	  before	  infection	  did	  not	  appear	  to	  effect	  PrPSc	  accumulation.	  It	  appeared	  
that	  application	  of	  C1ARR	  both	  at	  time	  of	  infection	  and	  after	  infection	  and	  at	  every	  passage	  
led	  to	  a	  reduction	  in	  the	  accumulation	  of	  PrPSc	  in	  Rov9	  cells.	  This	  confirms	  the	  hypothesis	  
presented	  earlier	  for	  a	  role	  for	  C1	  in	  binding	  to	  PrPSc	  and	  preventing	  further	  aggregation	  
or	   binding	   to	   PrPC	   and	   suggests	   that	   exogenous	   application	   of	   C1	   may	   be	   a	   possible	  






























Figure	   6.20	   –	  Theoretical	  models	   of	   C1ARR	   associated	   inhibition	  of	  conversion	   in	  Rov9	  
cell	   culture	   model.	  Diagrammatic	   representation	   of	   possible	  mechanisms	   of	   inhibition	  
associated	  with	  addition	  of	  C1ARR	  at	  various	  time	  points.	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6.5.6	  Conclusions	  
This	  chapter	  aimed	  to	   investigate	  the	  role	  C1	  may	  play	   in	  the	  conversion	  of	  PrPC	  to	  PrPSc	  
using	   two	   in	   vitro	   conversion	   assays.	   In	   previous	   chapters	   truncated	   C1	   proteins	   were	  
converted	  to	  amyloid	  fibrils	  in	  vitro.	  These	  fibrils	  were	  shown	  to	  have	  reduced	  toxicity	  to	  
SMB-­‐PS	  cells	  when	  compared	   to	   full	   length	  PrPC	   fibrils	  and	  moreover	   it	  has	  been	  shown	  
that	   cells	   lines	   expressing	   very	   similar	   levels	   of	   PrPC	  but	   different	   levels	   of	   C1	   can	   have	  
different	   susceptibility	   to	   fibril	   toxicity.	   C1ARR	  but	   not	   C1ARQ	   or	   C1VRQ	  could	   inhibit	   fibril	  
formation	  of	  other	  recombinant	  protein	  variants	  by	  at	  least	  two	  independent	  mechanisms.	  
Using	  the	  cell	  free	  conversion	  both	  variants	  of	  C1	  appeared	  to	  reduce	  the	  production	  of	  PK	  
resistant	  PrPSc.	  A	  small	  pilot	  study	  suggested	  that	  addition	  of	  C1ARR	  exogenously	  to	  a	  cell	  
culture	   model	   of	   infection	   had	   the	   potential	   to	   influence	   the	   outcome	   of	   infection	   and	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Primarily,	   this	   thesis	   aimed	   to	   investigate	   cleavage	   of	   PrPC	   in	   the	   sheep	   model	   both	   in	  
health	   and	   with	   the	   goal	   of	   understanding	   if	   it	   is	   a	   contributing	   factor	   in	   the	  
resistance/susceptibility	   to	  prion	  disease.	  The	  experimental	   approach	  was	   to	  use	   in	  vivo	  
investigations	  into	  PrPC	  expression	  and	  processing	  in	  sheep	  brain	  and	  in	  vitro	  modeling	  of	  
misfolding	   and	   cellular	   toxicity.	   There	   were	   no	   significant	   regional	   differences	   in	   PrPC	  
processing	  throughout	  the	  ovine	  brain,	  but	  levels	  of	  both	  α-­‐cleavage	  and	  β-­‐cleavage	  were	  
found	  to	  vary	  significantly	  between	  animals,	  associated	  with	  polymorphisms	  in	  the	  PRNP	  
gene.	  Recombinant	  C1,	  equivalent	   to	   that	  produced	  by	  scrapie	  resistant	  ARR/ARR	  sheep	  
had	   the	   ability	   to	   inhibit	   PrP	   fibrillisation	   and	   production	   of	   PK	   resistant	   PrPSc	   in	   vitro,	  
indicating	   that	  α-­‐cleavage	  may	  be	   a	   defining	   factor	   in	   susceptibility	   to	   scrapie	   in	   sheep.	  
During	   the	   study	   for	   this	   thesis,	   variations	   were	   identified	   in	   antibody	   binding	   to	   PrPC	  
from	  different	  PRNP	  genotypes.	  Novel	  recombinant	  proteins	  were	  produced	  representing	  
variants	  of	  C1,	  C2	  all	  of	  which	  will	  be	  pivotal	  to	  future	  studies.	  	  
	  
Should	   the	   role	   of	   C1	   as	   an	   inhibitor	   of	   conversion	   and	   fibrillisation	   with	   a	   significant	  
genetic	  component	  be	  confirmed	  for	  sheep	  in	  vivo,	  it	  may	  represent	  a	  potential	  therapeutic	  
target	  in	  the	  treatment	  of	  prion	  disease.	  C1	  is	  also	  likely	  to	  have	  important	  roles	  in	  normal	  
cellular	   function	   such	   as	   myelin	   maintenance.	  α-­‐Cleavage	   may	   have	   wider	   implications	  
which	   will	   be	   further	   understood	   as	   the	   function	   and	   role	   of	   PrPC	   in	   other	   diseases	  
becomes	  better	  comprehended.	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7.1.	  SUMMARY	  
This	  thesis	  has	  shown	  that	  levels	  of	  full	  length	  PrPC	  in	  the	  brain	  do	  not	  directly	  correlate	  to	  
susceptibility	   to	   scrapie	   in	   sheep,	   with	   similar	   levels	   of	   PrPC	   expression	   in	   the	   most	  
susceptible	   and	   resistant	   genotypes.	   	   Proteolytic	   processing	   of	   PrPC	   does	   vary	   between	  
these	  genotypes	  with	  both	  higher	  levels	  of	  α-­‐cleavage	  fragment	  C1	  and	  lower	  frequency	  of	  
sheep	   with	   C2	   fragment	   associated	   with	   scrapie	   resistant	   genotype	   ARR/ARR.	   PrPC	  
processing	  and	  expression	   in	  ovine	   transgenic	  mice,	  ovine	  PrPC	  expressing	  cell	   lines	  and	  
primary	  neuronal	  cell	  lines	  produced	  from	  ovine	  transgenic	  mice	  were	  compared	  to	  sheep	  
and	  these	  were	  assessed	  as	  models.	  To	  investigate	  the	  protease	  responsible	  for	  α-­‐cleavage,	  
ADAM	  proteases	  were	  inhibited	  in	  primary	  neuronal	  cells.	  With	  no	  direct	  reduction	  in	  C1	  
levels	   it	   is	   unlikely	   that	   ADAM	  proteases	   are	   directly	   involved	   in	   this	   event	   in	   neurons,	  
although,	   this	   experiment	   does	   not	   rule	   out	   ADAM	   involvement	   in	   other	   cell	   types	   or	  
tissues.	   Novel	   truncated	   recombinant	   C1	   and	   C2	   proteins	   were	   expressed	   in	   bacteria,	  
purified	  and	  characterised.	  It	  has	  been	  shown	  for	  the	  first	  time	  that	  C1	  proteins	  have	  the	  
potential	   to	   form	   amyloid	   fibrils	   in	   vitro.	   These	   C1	   fibrils	   have	   reduced	   toxicity	   to	   SMB	  
cells	  and	  are	  made	  up	  of	  different	  sized	  populations	  of	  smaller	  aggregates,	  when	  compared	  
to	   full	   length	   PrPC.	   All	   PrP	   fibrils	   showed	   no	   toxicity	   to	   N2a	   cells	   indicating	   that	   fibril	  
toxicity	   may	   be	   cell	   type	   specific.	   The	   presence	   of	   171R	   in	   absence	   of	   the	   N-­‐terminal	  
results	  in	  a	  reduced	  potential	  to	  form	  amyloid	  fibrils.	  Addition	  of	  truncated	  proteins	  with	  
171R	  but	  not	  171Q	  to	  fibrillisation	  reactions	  inhibited	  fibrillisation	  of	  full	  length	  PrP,	  both	  
ovine	  and	  murine.	  In	  contrast,	  both	  C1	  171R	  and	  171Q	  inhibited	  in-­‐vitro	  conversion	  of	  full	  
length	   PrPVRQ,	   highlighting	   that	   formation	   of	   amyloid	   fibrils	   and	   the	   conversion	   of	   full	  
length	  PrPC.	  to	  PrPSc	  may	  involve	  separate	  misfolding	  pathways.	  A	  preliminary	  experiment	  
indicated	   that	   application	   of	   C1ARR	   exogenously	   to	   cells	   in	   culture	   may	   reduce	   PrPSc	  
accumulation	  when	  infected	  with	  SSBP/1	  scrapie.	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In	  conclusion,	   this	  work	  has	  emphasised	   the	   importance	  of	  proteolytic	  processing	  of	   the	  
cellular	  prion	  protein	  in	  resistance	  to	  TSE	  disease	  in	  sheep	  and	  shown	  that	  the	  C1	  protein	  
can	  act	  as	  an	  inhibitor	  of	  PrPC	  conversion	  to	  PrPSc	  and	  should	  be	  further	  investigated	  as	  a	  
possible	  therapeutic	  in	  the	  treatment	  of	  prion	  disease.	  
	  
7.2.	  PrPC	  EXPRESSION	  AND	  SUCEPTIBILITY	  TO	  SCRAPIE	  
	  To	  investigate	  PrPC	  expression	  and	  processing	  in	  the	  ovine	  brain,	  seven	  brains	  areas	  were	  
tested.	  	  Due	  to	  both	  physiological	  and	  functional	  regional	  variation	  and	  the	  high	  diversity	  
of	  neuronal	   and	  glial	   cell	   types	   in	   the	  brain,	   it	  was	   speculated	   that	  different	  ovine	  brain	  
regions	  would	  have	  different	   levels	  of	  PrPC	  expression.	  However,	  this	  study	  suggests	  that	  
there	  is	  an	  absence	  of	  correlation	  between	  neural	  cell	  density	  and	  levels	  of	  PrPC,	  indicating	  
that	  both	  neural	  and	  glial	  cell	   types	  express	  similar	   levels	  despite	  probable	  variations	   in	  
mRNA	  expression,	  as	  has	  been	  shown	  for	  mice	  (Ford,	  Burton	  et	  al.	  2002).	  It	  is	  obvious	  that	  
a	   study	   in	   sheep	   of	   the	   transcriptional	   and	   post-­‐transcriptional	   regulation	   of	   PrP	   is	  
required	  to	  investigate	  this	  disconnection	  between	  mRNA,	  protein	  and	  cell	  type.	  
	  
In	   mouse	   models	   PrPC	   expression	   has	   been	   shown	   to	   directly	   positively	   correlate	   to	  
disease	  susceptibility	  (Vilotte,	  Soulier	  et	  al.	  2001).	  However,	  in	  this	  study	  PrPC	  was	  found	  
be	  highest	  in	  the	  cortex,	  with	  lowest	  levels	  found	  in	  the	  pons	  and	  the	  midbrain	  which	  are	  
target	  areas	  of	  prion	  pathology.	  Hence,	  we	  have	  shown	  that	  PrPC	  expression	  alone	  in	  sheep	  
is	   unlikely	   to	   solely	   determine	   the	   pattern	   of	   PrPSc	   deposition	   or	   spread	   of	   disease	  
throughout	   the	   brain	   (Chapter	   4).	   Similarly,	   in	   Alzheimer’s	   disease	   there	   is	   no	   direct	  
correlation	   between	   expression	   and	   areas	   characteristic	   for	   protein	   deposition	   of	   the	  
amyloid	   precursor	   protein	   (APP).	   Instead,	   like	   PrP,	   APP	   is	   expressed	   throughout	   both	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human	   and	   rat	   brains	   at	   similar	   levels	   (Goedert	   1987,	  Mita,	   Schon	   et	   al.	   1989).	   	   If	   PrPC	  
expression	   does	   not	   correlate	   with	   PrPSc	   accumulation	   in	   sheep,	   other	   factors	   must	   be	  
considered.	  As	   the	  cell	   surface	   is	   the	  primary	  site	  of	   conversion	  (Goold,	  Rabbanian	  et	  al.	  
2011),	   perhaps	   there	   are	   differences	   in	   PrPC	   surface	   expression	   between	   neuronal	   cell	  
types	   and/or	   between	   PrPC	  with	   certain	   polymorphisms,	  which	  would	   account	   for	   area	  
specific	   differences	   in	   PrPSc	   accumulation	   and	   genotype	   specific	   susceptibility.	  
Furthermore,	   there	  may	   be	   differences	   in	   PrPC	  glycosylation	   patterns	   between	   both	   cell	  
types	   and	   PrPC	   from	   different	   PRNP	   genotypes.	   Through	   the	   use	   of	   ovine	   glycosylation	  
mutants,	  glycosylation	  has	  been	  shown	   to	  be	   important	   in	   the	   trafficking	  of	  PrPVRQ,	  with	  
the	   majority	   of	   unglycosylated	   PrPC	   remaining	   intracellular.	   These	   cell	   lines	   displayed	  
resistance	   to	   challenge	   with	   scrapie	   suggesting	   that	   cellular	   localisation	   as	   a	   result	   of	  
altered	   glycosylation	   can	   effect	   cellular	   susceptibility	   to	   scrapie	   (Salamat,	   Dron	   et	   al.	  
2011).	  Murine	  models	  expressing	  only	  unglycosylated	  PrPC	  also	  have	  increased	  incubation	  
periods	  when	  experimentally	  infected	  with	  scrapie,	  highlighting	  that	  this	  is	  not	  specific	  to	  
ovine	   PrPC	   (Tuzi,	   Cancellotti	   et	   al.	   2008).	   Along	   with	   a	   detailed	   comparison	   of	   PrPC	  
biochemical	   profiles	   of	   healthy	   sheep	   of	   different	   PRNP	   genotypes	   in	   the	   absence	   of	  
PNGase	  F,	   the	   surface	   expression	  of	  PrPC	  both	   in	  different	  primary	   cell	   types	   and	   in	   the	  
brains	   of	   sheep	   of	   different	   PRNP	   genotypes	   could	   be	   studied	   by	   ICC/IHC	   and/or	  
immunogold	  labeling	  of	  PrPC	  and	  electron	  microscopy.	  Independent	  of	  PrPSc	  accumulation,	  
contrasting	   cellular	   susceptibility	   to	   neurotoxic	   forms	   of	   misfolded	   PrP	   could	   in	   part	  
account	   for	   brain	   area	   specific	   differences	   in	   neuronal	   loss.	   We	   have	   shown	   that	   fibril	  
associated	  neurotoxicity	  may	  be	  cell	  type	  dependent	  (Chapter	  6),	  hence	  varying	  neuronal	  
loss	   during	   disease	   could	   be	   partially	   explained	   by	   host	   cell	   susceptibility	   to	   these	  
misfolded	   aggregates.	   Experiments	   that	   measure	   the	   toxicity	   of	   PrPC	   amyloid	   fibrils	   to	  
different	  primary	  neuronal	  cell	  types	  would	  aid	  in	  deciphering	  variable	  cellular	  toxicity.	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For	  future	  study	  it	  will	  be	  important	  to	  not	  only	  look	  at	  PrPC	  expression	  in	  the	  brain,	  but	  
also	   the	   periphery,	   in	  which	   varied	   levels	   of	   PrPC	   could	   determine	   the	   initial	   success	   of	  
infection	  and	  the	  spread	  of	  PrPSc	  to	  the	  brain.	  Along	  with	  differing	  conversion	  abilities	  of	  
each	   of	   protein	   allotype	   (Bossers,	   Belt	   et	   al.	   1997,	   Sabuncu,	   Petit	   et	   al.	   2003)	   and	  
variations	   in	   levels	   of	   proteolytic	   processing	   (Chapter	   4),	   PRNP	   genotype	   specific	  
expression	   levels	   in	  the	   initial	  sites	  of	   infection	  such	  as	  gastrointestinal	  tract	  and	  spleen,	  
like	   those	   reported	   in	   ovine	   blood	   (Halliday,	   Houston	   et	   al.	   2005)	   may	   play	   a	   part	   in	  
creating	  the	  protective	  effect	  associated	  with	  certain	  PrPC	  alleles.	  	  
	  
7.3.	  PrPC	  PROTEOLYTIC	  PROCESSING	  IN	  THE	  OVINE	  BRAIN	  
7.3.1	  α-­‐Cleavage	  levels	  in	  the	  ovine	  brain	  
We	  have	  shown	  that	  there	  is	  a	  lack	  of	  regional	  variation	  in	  levels	  of	  α-­‐cleavage	  suggesting	  
that	  most	  neural	  cell	  types	  undergo	  α-­‐cleavage	  at	  similar	  levels.	  This	  leads	  us	  to	  speculate	  
that	  the	  C1	  and	  N1	  are	  involved	  in	  general	  cell	  survival,	  rather	  than	  being	  responsible	  for	  a	  
single	  specialised	  function.	  This	  work	  has	  also	  shown	  that	  the	  protease	  responsible	  for	  α-­‐
cleavage	   is	   expressed	   throughout	   the	   ovine	   brain	   and	   in	   neurons	   it	   is	   unlikely	   to	   be	   a	  
member	   of	   the	   ADAM	   protease	   family.	   Other	   enzymes	   have	   been	   suggested	   such	   as	  
plasmin,	  a	  serine	  protease	  which	  can	  cleave	  recombinant	  PrPC	  in-­‐vitro	  (Praus,	  Kettelgerdes	  
et	   al.	   2003)	   and	   also	   has	   a	   role	   in	   regulation	   of	   the	   metalloproteinase	   protein	   family.	  
Calpain	  is	  another	  candidate	  secretase,	  the	  activity	  of	  which	  has	  been	  shown	  as	  essential	  
for	  α-­‐cleavage	  and	  processing	  of	  PrPC	  in	  cell	  culture	  (Hachiya,	  Komata	  et	  al.	  2011).	  In	  order	  
to	   identify	   the	   PrP-­‐secretase	   large-­‐scale	   protease	   studies	   are	   required,	   perhaps	  making	  
use	   of	   tagged	   recombinant	   protein	   models	   in	   an	   ELISA	   style	   assay.	   It	   appears	   that	   α-­‐
cleavage	   of	   PrPC	  is	   not	   a	   simple	   enzymatic	   reaction,	   but	  may	   instead	   involve	   a	   complex	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network	   of	   pathways,	   perhaps	   involving	   many	   of	   the	   discussed	   candidate	   proteases.	  
Moreover,	  if	  the	  production	  of	  C1	  and/or	  N1	  is	  essential	  there	  may	  be	  substitute	  cleavage	  
mechanism(s),	  which	  can	  ‘step	  in’	  when	  one	  or	  more	  of	  these	  pathways	  are	  compromised.	  
	  
Although	  there	  was	  little	  regional	  variation	  of	  C1	  levels	  within	  the	  ovine	  brain	  animal-­‐to-­‐
animal	   variation	  was	   high.	   This	   can	   be	   partly	   explained	   by	   polymorphisms	   in	   the	  PRNP	  
gene,	   specifically	   at	   amino	   acid	   position	   171,	   of	   which	   171R	   is	   associated	   with	   higher	  
residual	   C1.	   The	   higher	   propensity	   for	   PrPARR	   to	   undergo	   α-­‐cleavage	   currently	   remains	  
unexplained.	  However,	  possible	  influencing	  factors	  include:	  greater	  structural	  flexibility	  in	  
comparison	  to	  PrPARQ	  and	  PrPVRQ	  (Rezaei,	  Choiset	  et	  al.	  2002,	  Wong,	  Thackray	  et	  al.	  2004,	  
Bujdoso,	  Burke	  et	  al.	  2005),	   leading	   to	   increased	  presentation	  of	   the	  cleavage	  site	   to	   the	  
PrP-­‐secretase;	  a	  higher	  potential	  to	  form	  protein	  dimers	  as	  homodimerisation	  of	  PrPC	  has	  
been	   shown	   to	   increase	   α-­‐cleavage	   in	   cell	   culture	   (Béland,	   Motard	   et	   al.	   2012);	   varied	  
cellular	   localisation,	   for	   example	   co-­‐localisation	  with	   the	   Golgi	   apparatus	   increasing	   the	  
chance	   of	   interacting	   with	   the	   PrP-­‐secretase.	   In	   agreement	   with	   this	   speculation,	  
glycosylation	  deficient	  transgenic	  mice	  with	  more	  Golgi-­‐associated	  PrPC	  and	  high	  levels	  of	  
C1	  (Kayleigh	  Iremonger,	  Ph.D.	  Thesis,	  University	  of	  Edinburgh)	  are	  more	  resistant	  to	  TSE	  
disease	   than	  both	  wild	   type	  and	  other	  glycosylation	  mutants	   (Cancellotti,	  Bradford	  et	  al.	  
2010).	  	  
	  
Prior	   to	   investigating	  these	  hypotheses,	  cleavage	   levels	  should	  be	  examined	   in	  unrelated	  
ARR	  homozygote	  sheep.	  As	  this	  analysis	  was	  performed	  within	  a	  closed	  flock	  the	  influence	  
of	  other	  heritable	  genetic	   factors	  cannot	  be	  ruled	  out.	   	  Although	  homozygous	   tissue	  was	  
not	  available,	  analysis	  of	  ARR	  heterozygotes	  from	  an	  unrelated	  Norwegian	  flock	  failed	  to	  
show	   the	   elevated	   C1	   levels	   observed	   in	   ARR	   heterozygous	   sheep	   from	   The	   Roslin	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Institute	   flock	   (Wilfred	   Goldmann	   and	  Michael	   Tranulis,	   personal	   communication).	   If	  α-­‐
cleavage	  is,	  in	  fact,	  controlled	  by	  a	  gene	  independent	  of	  PRNP,	  these	  ARR/ARR	  homozygote	  
sheep	  may	   be	   an	   interesting	  model	   for	   gene	   expression	   studies.	   Identification	   of	   such	   a	  
gene	   would	   be	   fundamental	   in	   identifying	   the	   unknown	   PrP-­‐secreatase,	   or	   possible	  
pathways	  that	  could	  be	  targeted	  to	  manipulate	  levels	  of	  α-­‐cleavage.	  	  
Aside	   from	   explaining	   the	   reasons	   for	   such	   variation	   in	   cleavage	   levels,	   differences	   in	  
levels	   of	   PrPC,	   C1	   and	   N1	  may	   have	   important	   functional	   repercussions	   in	   brain	   and	   if	  
consistent,	  also	  the	  periphery.	  Lower	  levels	  of	  full	  length	  PrPC	  in	  brain,	  such	  as	  those	  seen	  
in	   the	   ARQ/ARQ	   genotype,	   may	   affect	   normal	   functions,	   such	   as	   copper	   homeostasis.	  
Although	   in	   vivo	   functions	   associated	   specifically	   and	   exclusively	   with	   truncated	   PrPC	  
proteins	   C1	   and	   C2	   are	   more	   or	   less	   unknown;	   the	   most	   probable	   in	   vivo	   role	   for	   α-­‐
cleavage	   is	   in	  myelin	  maintenance	   in	   the	   peripheral	   nervous	   system.	   Presence	   of	   C1	   on	  
neurons	  is	  essential	  for	  myelin	  trophic	  function,	  driving	  communication	  between	  neurons	  
and	  Schwann	  cells	  involved	  in	  myelin	  maintenance	  (Bremer,	  Baumann	  et	  al.	  2010).	   	  Very	  
low	   natural	   residual	   levels	   of	   C1	   may	   over	   time	   result	   in	   a	   reduction	   in	   myelin	  
maintenance	   and	   in	   the	   development	   of	   peripheral	   neuropathies.	   Correspondingly,	   low	  
levels	   of	   N1	   may	   reduce	   the	   cell’s	   ability	   to	   protect	   against	   p53	   dependent	   apoptosis,	  
leading	  to	  a	  higher	  rate	  of	  neuronal	  loss.	  	  
7.3.2	  β-­‐cleavage	  in	  the	  ovine	  brain	  
Many	  sheep	  tested	  during	  this	  study	  had	  levels	  of	  C2	  representing	  1	  %	  or	  less	  of	  total	  PrPC.	  
β-­‐cleavage,	  the	  production	  of	  C2/N2	  fragments	  occurs	  in	  response	  to	  increases	  in	  reactive	  
oxygen	   species	   (ROS)	   (Watt,	   Taylor	   et	   al.	   2005),	   signifying	   that	   this	   event	   could	   be	  
unregulated	  at	   times	  of	  abnormal	  cellular	  homeostasis.	  Such	   factors	  were	  not	   taken	   into	  
account	   when	   selecting	   this	   data	   set,	   in	   which	   ‘healthy’	   was	   defined	   as	   lack	   of	   scrapie	  
infection.	  Age	  may	  also	  be	  an	  important	  factor	  when	  we	  consider	  that	   levels	  of	  oxidative	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stress	  and	  accumulation	  of	  ROS	  can	  increase	  with	  age	  (Finkel	  and	  Holbrook	  2000).	  C2	  may	  
also	   be	   an	   intermediate	   in	   the	   formation	   of	   PrPSc	   and	   we	   have	   found	   an	   increased	  
frequency	  of	   this	  band	   in	   scrapie	   infected	  ovine	  brain,	   in	  agreement	  with	  others	   (Owen,	  
Rees	   et	   al.	   2007,	  Dron,	  Moudjou	  et	   al.	   2010).	  However,	   it	   is	   unclear	   if	   this	   an	   additional	  
susceptibility-­‐enhancing	   factor,	   or	   produced	   as	   a	   result	   of	   elevated	   levels	   of	  ROS	  during	  
disease,	   as	   shown	  using	  murine	  models	   of	   prion	   infection	   (Guentchev,	  Voigtlander	   et	   al.	  
2000)	  and	  in	  other	  neurodegenerative	  diseases,	  such	  as	  Alzheimer’s	  disease,	  Parkinson’s	  
disease	  and	  Multiple	  Sclerosis	  (Christen	  2000,	  Uttara,	  Singh	  et	  al.	  2009).	  Unlike	  C1	  and	  N1,	  
there	  are	  no	  functions	  associated	  with	  the	  truncated	  fragments	  produced	  by	  β-­‐	  cleavage.	  It	  
is	  speculated	  that	  the	  lack	  of	  known	  function	  in	  comparison	  to	  C1	  is	  unlikely	  to	  be	  a	  result	  
of	  higher	   turnover/degradation	  or	  cellular	   localisation,	  as	  C2	   is	   thought	   to	  reside	  on	   the	  
cell	  surface	  alongside	  C1	  but	  may	  instead	  be	  attributed	  to	  the	  addition	  of	  amino	  acids	  92-­‐
114.	  	  
	  
7.3.3	  α-­‐Cleavage	  and	  susceptibility	  to	  scrapie	  
Higher	   levels	   of	   α-­‐cleavage	   are	   associated	   with	   scrapie	   resistant	   genotypes	   in	   sheep	  
(Chapter	   3)	   and	   cell	   lines	   with	   higher	   levels	   of	   C1	   have	   been	   shown	   to	   have	   enhanced	  
resistance	  to	  infection	  in	  cell	  culture	  compared	  to	  lines	  with	  lower	  levels	  of	  C1	  (Lewis,	  Hill	  
et	  al.	  2009).	  It	  has	  been	  previously	  postulated	  that	  α-­‐cleavage	  could	  be	  linked	  to	  resistance	  
via	  two	  mechanisms.	  Firstly,	  more	  cleavage	  would	  result	  in	  less	  full	  length	  PrPC	  to	  act	  as	  a	  
template	  for	  conversion	  during	  TSE	  infection,	  as	  C1	  cannot	  convert.	  Secondly,	  C1	  can	  act	  as	  
an	   inhibitor	   of	   conversion	   (Chapter	   6),	   (Westergard,	   Turnbaugh	   et	   al.	   2011).	   Work	  
presented	   in	   this	   thesis	   suggests	   that	   the	   first	  may	   not	   necessarily	   be	   true	   in	   sheep,	   as	  
levels	  of	  full	  length	  PrPC	  and	  C1	  were	  not	  found	  to	  be	  directly	  correlated.	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For	  the	  first	  time	  this	  study	  has	  shown	  that	  all	  variants	  of	  C1	  (ARR,	  ARQ	  and	  VRQ)	  and	  C2	  
(ARR	   and	   VRQ)	   have	   potential	   to	   misfold	   and	   form	   amyloid	   fibrils	   under	   certain	  
conditions	  (Chapter	  4).	  The	  N-­‐terminal	  is	  therefore	  not	  essential	  for	  PrP	  fibril	  formation	  in	  
vitro.	   The	   decreased	   potential	   of	   N-­‐terminally	   truncated	   171R	   variants	   to	   form	   amyloid	  
fibrils	   suggests	   the	   primary	   binding	   site	   of	   PrP-­‐to-­‐PrP	   interaction	   is	   situated	   in	   the	   N-­‐
terminal	   of	   the	   protein.	   However,	   in	   the	   absence	   of	   this	   binding	   site,	   for	   example,	   in	  
truncated	   C1	   and	   C2,	   a	   secondary	   binding	   site	   may	   be	   adopted.	   If	   this	   site	   is	   in	   close	  
proximity	   to	  amino	  acid	  171,	   then	  polymorphisms	  at	   this	  position	  could	  be	   important	   in	  
defining	  interaction	  and	  binding.	  	  Returning	  to	  our	  previous	  hypothesis	  (see	  section	  X.X.)	  
that	   171R	   has	   a	   higher	   potential	   to	   form	   homodimers	   due	   to	   its	   comparatively	   flexible	  
structure	  and	  hence	  outwards	  facing	  dimer	  binding	  sites,	  it	  may	  be	  possible	  to	  explain	  the	  
link	  with	  171R	  and	   increased	   lag	   time	  of	   nucleation.	   If	   once	  dimerised	  PrP	  proteins	   are	  
more	   stable	   and	   less	   likely	   to	   misfold,	   so	   ARR	   variants	   which	   readily	   form	   dimers	   in	  
solution	  at	  a	  higher	  rate	  than	  other	  variants	  would	  take	  longer	  to	  nucleate.	  	  
	  
Although	   Westergard	   and	   colleagues	   have	   shown	   that	   expression	   of	   C1	   alone	   is	   not	  
sufficient	   to	  support	  TSE	   infection	   in	  mice	  and	   that	  C1	  can	  act	  as	  an	   inhibitor	  of	  disease	  
(Westergard,	   Turnbaugh	   et	   al.	   2011),	   they	   have	   used	   models	   in	   which	   C1	   is	  
unphysiologically	   overexpressed,	   meaning	   that	   these	   inhibitory	   effects	   may	   be	   greatly	  
exaggerated.	  This	  thesis	  aimed	  to	  determine	  if	  proteolytic	  cleavage	  of	  PrPC	  has	  a	  role	  in	  the	  
conversion	   of	   PrPC	   to	   PrPSc	   during	   TSE	   disease,	   by	   assessing	   the	   potential	   for	   ovine	  
truncated	  proteins	  to	  take	  part	  in	  the	  conversion	  of	  PrPC	  to	  PrPSc,	  using	  in	  vitro	  conversion	  
assays.	  We	  have	  shown	  that	  C1	  can	  act	  as	  an	  inhibitor	  to	  in	  vitro	  conversion	  at	  levels	  found	  
in	  vivo	  and	  reduce	  the	  formation	  of	  toxic	  PrPC	  species	  (Chapter	  6).	  These	  assays	  have	  also	  
shown	   that	   the	   ratio	   of	   C1:	   full	   length	   PrP	   is	   crucial	   for	   successful	   inhibition,	   indicating	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that	  variations	  in	  levels	  of	  C1	  observed	  in	  ovine	  brain	  would	  be	  sufficient	  to	  lead	  to	  altered	  
disease	  prognosis.	  	  
	  
The	   mechanism	   by	   which,	   C1	   can	   inhibit	   the	   conversion	   of	   PrPC	   to	   PrPSc	   is	   currently	  
unknown.	   However,	   this	   work	   has	   shown	   that	   in	   vitro	   it	   likely	   involves	   two	   separate	  
mechanisms,	   occurring	   individually	   or	   in	   unison,	   in	   which	   C1	   binds	   to	   PrPC	   prior	   to	  
misfolding	   and/or	   C1	   binds	   to	   PrPC	   fibrils	   preventing	   further	   extension.	   Furthermore,	   a	  
small	  pilot	  experiment	  in	  cell	  culture	  suggests	  that	  C1	  may	  interact	  with	  PrPSc	  rather	  than	  
PrPC	  on	  the	  cell	  surface,	  inadvertently	  preventing	  both	  binding	  to	  other	  PrPC	  molecules	  and	  
also	  delay	  internalization,	  as	  C1	  in	  absence	  of	  the	  N-­‐terminal	  likely	  has	  a	  longer	  presence	  
at	   the	   cell	  membrane	   as	  we	   known	   that	   the	  N-­‐terminal	   possesses	   the	   ability	   to	   interact	  
with	  a	  variety	  of	  protein	  involved	  in	  endocytosis.	  
	  
High	   levels	   of	   C1,	   although	   appearing	   protective	   against	   conventional	   scrapie	   in	   sheep,	  
may	  not	  play	  the	  same	  role	  during	  atypical	  disease.	  ARR/ARR	  sheep	  resistant	  to	  classical	  
infection	   and	   with	   high	   levels	   of	   C1	   are	   the	  most	   susceptible	   to	   infection	   with	   atypical	  
scrapie	  (Benestad,	  Arsac	  et	  al.	  2008).	  This	  raises	  the	  possibility	  that	  either	  C1	  cannot	  bind	  
atypical	   PrPSc	  due	   to	   conformational	   differences	   in	   the	   misfolded	   protein,	   which	   would	  
nullify	  inhibitory	  effect,	  or	  that	  interaction	  with	  atypical	  PrPSc	  can	  induce	  misfolding	  of	  C1.	  
Currently,	   attempts	   to	   amplify	   atypical	   scrapie	   in	  vitro	   have	   been	   unsuccessful	   (Thorne,	  
Holder	  et	  al.	  2012),	  although	  development	  of	  these	  assays	  would	  allow	  for	  the	  role	  of	  C1ARR	  
to	   be	   investigated	   and	   compared	   to	   the	   inhibitory	   effects	   on	   conversion	   in	   classical	  
disease.	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Until	  now	  it	  had	  been	  assumed	  that	   increased	   incubation	  periods	  of	  heterozygous	  sheep	  
and	   resistance	   of	   homozygous	   sheep	   with	   the	   ARR	   allele	   was	   a	   result	   of	   a	   reduced	  
‘convertibility’	   of	   PrPC	  with	   said	   mutations.	   	   The	   association	   of	   higher	   levels	   of	   C1	   in	  
scrapie	  resistant	  ARR/ARR	  sheep	  and	  the	  enhanced	  inhibitory	  effects	  of	  C1ARR	  suggest	  that	  
α-­‐cleavage	   may	   also	   play	   a	   crucial	   part	   in	   the	   PRNP	   genotype	   associated	   resistance	   in	  
sheep.	  As	  there	  is	  similar	  genetic	  resistance	  in	  other	  TSE	  diseases	  such	  as	  vCJD	  and	  CWD,	  
C1	  levels	  as	  a	  factor	  of	  PRNP	  polymorphisms	  need	  to	  be	  fully	  investigated	  in	  these	  species	  
using	  a	  similar	  approach	  to	  that	  of	  sheep,	  with	  both	  in	  vivo	  analysis	  and	  in	  vitro	  modeling.	  
	  
7.4	  C1	  AS	  A	  POSIBLE	  THERAPUTIC	  IN	  THE	  TREATMENT	  OF	  PRION	  DISEASE	  
This	  work	  has	  revealed	  that	  C1	  has	  the	  ability	  to	  inhibit	  both	  fibrillisation	  and	  conversion	  
of	   full	   length	  PrPC	   in-­‐vitro,	  while	  Westergard	  and	  colleagues	  have	  shown	   that	  C1	  plays	  a	  
similar	   role	   when	   expressed	   in	   vivo	   (Westergard,	   Turnbaugh	   et	   al.	   2011).	   As	   the	   C1	  
protein	   also	   does	   not	   act	   as	   a	   sufficient	   substrate	   for	   conversion	   to	   PK	   resistant	   PrPSc	  
during	   disease,	   it	  may	   be	   a	   possible	   treatment	   for	   prion	   disease	   through	   the	   binding	   to	  
PrPSc,	  preventing	  misfolding	  of	  PrPC.	  Similar	  inhibitory	  effects	  have	  been	  illustrated	  in	  cell	  
culture	  with	  the	  use	  of	  monoclonal	  antibodies	  specific	  to	  cellular	  PrPC,	  which	  bind	  to	  PrPC	  
on	  the	  cell	  surface	  and	  block	  interaction	  and	  binding	  to	  incoming	  PrPSc	  (Peretz,	  Williamson	  
et	  al.	  2001).	  In	  vivo,	  murine	  models	  infected	  intraperitoneally	  showed	  a	  marked	  decrease	  
in	   PrPSc	   accumulation,	   after	   treatment	   with	   PrPC	   conformation	   dependent	   monoclonal	  
antibodies	   (Sigurdsson,	   Sy	   et	   al.	   2003,	   White,	   Enever	   et	   al.	   2003).	   Mice	   infected	  
intracranially	  or	  those	  treated	  after	  the	  onset	  of	  clinical	  signs	  showed	  no	  such	  clearance	  of	  
infection	  (White,	  Enever	  et	  al.	  2003),	  indicating	  that	  monoclonal	  antibodies	  may	  be	  useful	  
in	  the	  clearance	  of	  infection	  from	  the	  periphery.	  However,	  as	  they	  cannot	  cross	  the	  blood	  
brain	  barrier	   they	  are	   inert	   once	   infection	  has	   reached	   the	  brain.	  Although	   they	  may	  be	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considered	   a	   useful	   tool	   treat	   those	   which	   have	   been	   exposed	   to	   a	   known	   risk	   factor,	  
monoclonal	   antibodies	   could	   not	   be	   used	   to	   improve	   prognosis	   for	   those	   with	   clinical	  
prion	   infection.	   It	   is	   for	   this	   reason	   that	   C1	   may	   be	   considered	   as	   an	   alternative	   or	  
combination	  therapy.	  C1	  is	  normally	  expressed	  in	  the	  brain	  and	  over	  expression	  of	  C1	  has	  
been	  shown	  to	  have	  no	  neurotoxic	  effects,	   indicating	  that	  increasing	  the	  amount	  of	  C1	  in	  
the	  brain	  as	  a	  treatment	  is	  unlikely	  to	  have	  negative	  implications	  (Westergard,	  Turnbaugh	  
et	  al.	  2011).	  Furthermore,	  as	  the	  mechanism	  of	  C1	  is	  likely	  to	  involve	  binding	  to	  PrPSc	  and	  
not	  to	  cellular	  PrPC,	  it	  is	  unlikely	  to	  interfere	  with	  cellular	  PrPC	  function	  or	  recycling.	  There	  
are	   several	   possible	   application	   strategies.	   The	   first	   of	   these	   would	   involve	   the	  
identification	  of	  the	  protease	  responsible	  for	  cleavage	  in	  the	  brain	  and	  the	  manipulation	  of	  
activity	   through	   pharmacological	   activation.	   The	  main	   problems	  with	   this	   approach	   are	  
the	  lack	  of	  possible	  protease	  candidates	  and,	  if	  successful,	  the	  possible	  downstream	  effects	  
on	  other	  proteins	   leading	  to	  functional	   implications	   in	  the	  brain.	  The	  second	  option	  is	  to	  
artificially	  introduce	  C1	  into	  the	  brain	  with	  a	  viral	  vector	  such	  as	  lentivirus,	  to	  deliver	  and	  
express	  C1	  in	  brain	  cells.	  This	  has	  been	  a	  successful	  delivery	  system	  for	  PrP	  167R,	  which	  
prolonged	  incubation	  times	  and	  alleviated	  behavioral	  symptoms	  in	  infected	  mouse	  models	  
(Toupet,	  Compan	  et	  al.	  2008).	  	  
	  
A	  scaled	  up	  cell	  culture	  experiment,	  similar	  to	  that	  presented	  in	  this	  thesis,	  in	  which	  cells	  
are	   treated	  with	  C1	  at	  both	  different	  concentrations	  and	  at	  different	   time	  points	  may	  be	  
very	   useful	   to	   determine	   the	   potential	   of	   C1	   as	   a	   therapeutic	   in	   the	   treatment	   of	   prion	  
disease.	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7.4.	  IMPLICATIONS	  OF	  VARYING	  LEVELS	  OF	  PrPC	  FRAGMENTS	  IN	  DEVELOPMENT	  OF	  
DISEASE	  
7.4.1	  Cancer	  
With	   the	  knowledge	   that	   truncated	  PrPC	  proteins	  account	   for	   such	  a	   large	  percentage	  of	  
total	   PrPC	   in	   the	   brain,	   it	   would	   be	   interesting	   to	   measure	   proteolytic	   processing	   in	  
peripheral	  tissues,	  such	  as	  the	  gastrointestinal	  tract	  and	  investigate	  the	  influence	  of	  such	  
fragments	   on	   anti-­‐apoptotic	   functions.	   PrPC	   domain	   function	   in	   carcinogenic	   cellular	  
invasion	   has	   been	   investigated	   through	   the	   production	   of	   deletion	   mutants	   PrPΔ4-­‐90,	  
PrPΔ51-­‐90	   and	  PrPΔ96-­‐230.	  Only	   the	  deletion	  of	   the	  N-­‐terminal	   from	  amino	   acids	  4-­‐90	  
had	  an	  inhibitory	  effect	  on	  the	  invasion	  ability	  of	  these	  cells	  (Pan,	  Zhao	  et	  al.	  2006).	  If	  we	  
assume	  that	  α-­‐cleavage	  occurs	  in	  these	  tissues	  it	  is	  likely	  that	  N1	  expression	  and	  secretion	  
will	  not	  only	  promote	  cellular	  invasion	  but	  also	  have	  a	  anti-­‐apoptotic	  effect,	  similar	  to	  that	  
associated	  with	  expression	  of	  full	  length	  PrPC.	  N1	  has	  been	  shown	  to	  reduce	  staurosporin-­‐
stimulated	   caspase	   activation	   by	   down	   regulating	   p53	   and	   subsequently	   protecting	  
neuronal	  cells	  from	  apoptosis	  (Guillot-­‐Sestier,	  Sunyach	  et	  al.	  2009).	  Furthermore,	  removal	  
of	   the	  PrPC	  octopeptide	  repeat	  and	  C-­‐terminal	  mutations,	  specifically,	  T183A	  and	  D178N,	  
can	  reduce	  or	  ablate	  anti-­‐apoptotic	  function	  in	  neuronal	  cells	  (Bounhar,	  Zhang	  et	  al.	  2001).	  
Speculatively,	   if	   these	   mutations	   in	   the	   C-­‐terminal	   can	   result	   in	   functional	   alterations	  
perhaps	  common	  polymorphisms	  in	  the	  human	  PRNP	  gene	  and	  ovine	  polymorphisms	  such	  
as	   those	   at	   amino	   acid	   positions	   136,	   154	   and	   171	   also	   have	   such	   an	   effect	   on	   anti-­‐
apoptotic	   functions	   and	   subsequently	   have	   a	   determining	   role	   in	   the	   development	   and	  
treatment	  of	  both	  breast	  and	  gastric	  cancers.	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7.4.2	  Alzheimer’s	  disease	  
If	  we	   consider	   the	   amino	   acids	   of	   PrPC	  we	   known	   to	   be	   essential	   to	   involvement	   in	   the	  
development	   of	   Alzheimer’s	   disease	   it	   is	   difficult	   to	   predict	   if	   either	   α-­‐	   or	   β-­‐	   cleavage	  
would	  hinder	  these	  functions.	  Both	  cleavage	  events	  leave	  the	  regions	  essential	  to	  binding	  
intact	  (Figure	  7.1,	  ovine	  amino	  acid	  numbering).	  In	  vitro	  peptides	  encompassing	  the	  region	  
of	   amino	   acids	   96-­‐114	   can	   inhibit	   fibril	   formation	   of	   Aβ	   (Younan,	   Sarell	   et	   al.	   2013)	  
implying	   that	   the	   smaller	   N-­‐terminal	   binding	   site	   is	   not	   required	   in	   unison.	   	   We	   can	  
speculate	   therefore	   that	   N1	   and	   C2	   truncated	   protein	   fragments	   could	   potentially	   be	  
involved	  in	  the	  binding	  of	  misfolded	  Aβ	  peptides	  during	  Alzheimer’s	  Disease.	  In	  fact,	  both	  
Fluharty	  and	  colleagues	  (Fluharty,	  Biasini	  et	  al.	  2013)	  and	  Béland	  and	  colleagues	  (Béland,	  
Motard	  et	  al.	  2012)	  have	  shown	  that	  N1	  can	  bind	  Aβ	  oligomers	  and	  reduce	  Aβ-­‐mediated	  
cell	   death	   and	   toxicity	   both	   in	   cell	   culture	   and	   using	   murine	   models	   of	   Alzheimer’s,	  
perhaps	  through	  down	  regulation	  of	  the	  caspase	  3	  pathway.	  This	  indicates	  that	  α-­‐cleavage	  
not	  only	  plays	  a	  protective	  role	  in	  prion	  disease	  but	  also	  during	  Alzheimer’s	  disease.	  
	  
	  
Figure	  7.1	  –	  PrPC	  domains	  involved	  in	  the	  binding	  to	  Aβ .	   	  A	  linear	  model	  of	  	  ovine	  PrPC	  
with	   both	  α-­‐	   and	  β-­‐	   cleavage	   sites.	   The	   domains	   implicated	   in	   binding	   to	   Aβ	   peptides	  
(numbering	  converted	  from	  murine	  PrP)	  are	  highlighted	  in	  black.	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7.6.	  FUTURE	  DIRECTIONS	  
The	  most	  common	  natural	  route	  of	  infection	  in	  sheep	  is	  through	  oral	  ingestion,	  when	  PrPSc	  
is	   imported	   to	   the	   CNS	   via	   the	   lymphoid	   system.	   Therefore	   α-­‐cleavage	   levels	   may	   be	  
important	   in	  predicting	   the	  outcome	  of	  early	  stages	  of	   infection.	  High	   levels	  of	  C1	   in	   the	  
periphery	   could	   stop	   PrPSc	   accumulation	   and	   infection	   of	   the	   brain.	   Measurement	   of	   α-­‐
cleavage	   in	   the	  periphery	  and	   lymphoid	   system	  of	   sheep	  with	  varying	   resistance	   to	  TSE	  
disease	  would	  identify	  if	  similar	  genotypic	  variations	  are	  present	  as	  identified	  in	  the	  brain.	  	  
A	   correlation	   in	   cleavage	   levels	   between	   the	   periphery	   and	   the	   brain	   would	   allow	   for	  
tissue	  sampling	  and	  molecular	  analysis	   to	  be	  performed	  alongside	  genotyping	   to	  predict	  
the	   susceptibility	   of	   a	   particular	   animal	   to	   scrapie	   infection.	   If	   performed	   prior	   to	  
experimental	   infection,	   the	   influence	   of	   C1	   levels	   in	   parallel	   with	   PRNP	   genotype	   on	  
outcome	   of	   infection	   could	   be	   explored.	   Along	   with	   in	   vivo	   analysis,	   further	   in	   vitro	  
conversion	  assays	  could	  be	  performed	  to	  investigate	  the	  role	  of	  C1	  in	  conversion.	  Further	  
cell	   free	   conversion	   assays	   should	   be	   performed	   in	   which	   C1ARR	   and	   C1	   representing	  
cleavage	   fragments	   with	   resistance	   polymorphisms	   from	   other	   species	   could	   be	   mixed	  
with	   both	   murine	   and	   human	   recombinant	   PrP	   to	   assess	   inhibitory	   effects.	   In	   parallel,	  
PMCA	   could	   also	   be	   implemented.	   PMCA	   uses	   brain	   homogenate	   as	   both	   substrate	   and	  
inoculum,	   meaning	   all	   cellular	   cofactors	   will	   be	   present	   and	   unlike	   both	   cell	   free	  
conversion	   and	   fibrillisation	   reactions,	   PrP	   is	   the	   native,	   mammalian	   expressed	   protein	  
with	  post-­‐translational	  modifications.	  Addition	  of	  C1	  into	  these	  assays	  would	  help	  to	  close	  
the	  current	  gap	  between	  in	  vitro	  and	  in	  vivo	  inhibitory	  functions.	  Following	  on	  from	  these	  
experiments,	   large	  scale	  cell	   infection	  experiments	  could	  be	  set	  up	   to	   further	   investigate	  
whether	   exogenous	   application	   of	   recombinant	   C1,	   post	   infection	   can	   decrease	   PrPSc	  
accumulation.	   If	   findings	  mimic	   the	  outcomes	  of	   the	   small-­‐scale	  preliminary	   experiment	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then	  perhaps	  C1’s	  ability	   to	   inhibit	  conversion	  could	  be	   investigated	   in	  mouse	  models	  of	  
infection.	   Mice	   could	   be	   dosed	   with	   scrapie	   and	   subsequently	   administered	   C1	   directly	  
into	   the	   brain	   at	   different	   time	   points	   post	   infection.	   Both	   PrPSc	  accumulation,	   histology	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